1
00:00:06,840 --> 00:00:07,974
>> GOOD AFTERNOON.

2
00:00:08,041 --> 00:00:12,178
I'M EYE HOLTZ HOLTZ AND I'M THE

3
00:00:12,245 --> 00:00:12,779
DESIGNATED FEDERAL FINANCIAL,

4
00:00:12,846 --> 00:00:17,350
EXECUTIVE SECRETARY -- TIMOTHY

5
00:00:17,417 --> 00:00:17,550
HOLTZ.

6
00:00:17,617 --> 00:00:19,119
THE OFFICE OF THE OARAC.

7
00:00:19,185 --> 00:00:21,221
WELCOME AND THANK YOU FOR YOUR

8
00:00:21,287 --> 00:00:21,654
PARTICIPATION TODAY.

9
00:00:21,721 --> 00:00:24,357
AS A BRIEF REMINDER, OUR COUNCIL

10
00:00:24,424 --> 00:00:27,026
IS GOVERNED BY THE PROVISIONS OF

11
00:00:27,093 --> 00:00:28,328
THE FEDERAL ADVISORY COMMITTEE

12
00:00:28,395 --> 00:00:30,463
AS AMENDED WHICH SETS FORTH

13
00:00:30,530 --> 00:00:31,131
STANDARDS FOR THE FORMATION AND

14
00:00:31,197 --> 00:00:34,901
USE OF ADVISORY COMMITTEES.

15
00:00:34,968 --> 00:00:36,436
MY ROLE AS DESIGNATED FEDERAL

16
00:00:36,503 --> 00:00:37,937
OFFICER IS TO PREPARE MEETING

17
00:00:38,004 --> 00:00:40,240
AGENDAS, ORGANIZE MEETINGS, AND

18
00:00:40,306 --> 00:00:42,842
APPROVE ALL COUNCIL AND

19
00:00:42,909 --> 00:00:43,443
SUBCOMMITTEE MEET AGO, ADJOURN

20
00:00:43,510 --> 00:00:45,011
ANY MEETING WHEN IT'S DETERMINED

21
00:00:45,078 --> 00:00:46,513
TO BE IN THE PUBLIC INTEREST AND

22
00:00:46,579 --> 00:00:48,815
CHAIR MEETINGS WHEN DIRECTED BY

23
00:00:48,882 --> 00:00:56,723
THE NIH DIRECTOR OR OAR DIREC

24
00:00:56,790 --> 00:00:56,990
DIRECTOR.

25
00:00:57,056 --> 00:00:58,825
AS IN PREVIOUS MEETINGS, LET'S

26
00:00:58,892 --> 00:01:00,593
GO OVER GENERAL GUIDELINES FOR

27
00:01:00,660 --> 00:01:01,060
TODAY.

28
00:01:01,127 --> 00:01:02,462
PLEASE ALWAYS STAY MUTED UNLESS

29
00:01:02,529 --> 00:01:03,430
YOU'RE SPEAKING.

30
00:01:03,496 --> 00:01:05,565
PLEASE KEEP YOUR CAMERA ON FOR

31
00:01:05,632 --> 00:01:06,733
MOST OF THE MEETING.

32
00:01:06,800 --> 00:01:08,401
FEEL FREE TO HIDE YOUR CAMERA IF

33
00:01:08,468 --> 00:01:11,004
YOU NEED TO LEAVE MOMENTARILY

34
00:01:11,070 --> 00:01:11,671
AND RETURN.

35
00:01:11,738 --> 00:01:13,540
WHEN YOU LIKE TO PARTICIPATE IN

36
00:01:13,606 --> 00:01:15,074
DISCUSSIONS, WE ASK THAT YOU

37
00:01:15,141 --> 00:01:18,311
PLEASE USE THE ZOOM RAISE HAND

38
00:01:18,378 --> 00:01:18,645
FEATURE.

39
00:01:18,711 --> 00:01:20,713
DR. TURN BULL, THE CHAIRPERSON,

40
00:01:20,780 --> 00:01:23,249
AND I WILL NOTE THOSE WHO WANT

41
00:01:23,316 --> 00:01:26,219
TO CALL ON YOU TO TRY TO AVOID

42
00:01:26,286 --> 00:01:27,320
SPEAKING OVER ONE ANOTHER.

43
00:01:27,387 --> 00:01:29,556
YOU'LL NEED TO LOWER THE ZOOM

44
00:01:29,622 --> 00:01:31,891
HAND FEATURE ONCE YOU MADE YOUR

45
00:01:31,958 --> 00:01:33,026
REMARKS.

46
00:01:33,092 --> 00:01:33,693
FOR THIS MEETING, THE ZOOM CHAT

47
00:01:33,760 --> 00:01:35,929
FEATURE HAS BEEN DISABLED EXCEPT

48
00:01:35,995 --> 00:01:38,832
FOR MESSAGES TO THE MEETING

49
00:01:38,898 --> 00:01:39,032
POSTS.

50
00:01:39,098 --> 00:01:39,866
IF YOU HAVE CONCERNS, PLEASE

51
00:01:39,933 --> 00:01:44,571
CALL OR TEXT ME OR

52
00:01:44,637 --> 00:01:45,672
Ms. STEVENS.

53
00:01:45,738 --> 00:01:46,840
OUR PHONE NUMBERS ARE IN YOUR

54
00:01:46,906 --> 00:01:47,173
E-MAIL.

55
00:01:47,240 --> 00:01:48,541
FOR EVERYONE ON VIDEOCAST, IF

56
00:01:48,608 --> 00:01:50,510
YOU WOULD LIKE TO SEE THE CLOSED

57
00:01:50,577 --> 00:01:51,578
CAPTIONS FOR THE MEETING, CLICK

58
00:01:51,644 --> 00:01:55,915
THE CCI CONON THE BOTTOM -- ICON

59
00:01:55,982 --> 00:01:57,884
ON THE BOTTOM RIGHT-HAND CORNER

60
00:01:57,951 --> 00:01:58,618
OF THE VIDEO.

61
00:01:58,685 --> 00:02:01,888
OUR POLICIES REGARDING CONFLICTS

62
00:02:01,955 --> 00:02:02,655
OF INTEREST.

63
00:02:02,722 --> 00:02:04,023
COUNCIL MEMBERS MAY NOT

64
00:02:04,090 --> 00:02:04,991
PARTICIPATE IN THE REVIEW OR

65
00:02:05,058 --> 00:02:06,659
DISCUSSION OF A SPECIFIC PROGRAM

66
00:02:06,726 --> 00:02:10,430
OR PROJECT FOR WHICH THEY HAD A

67
00:02:10,497 --> 00:02:11,898
REAL OR APPEARED CONFLICT OF

68
00:02:11,965 --> 00:02:12,165
INTEREST.

69
00:02:12,232 --> 00:02:16,736
IF A PROGRAM OR PROJECT IS

70
00:02:16,803 --> 00:02:18,338
DISCUSSED THAT PRESENTS A

71
00:02:18,404 --> 00:02:20,039
CONFLICT FOR YOU, EXCUSE

72
00:02:20,106 --> 00:02:30,817
YOURSELF FROM THEI MEET -- SLID,

73
00:03:13,226 --> 00:03:13,326
PLEASE.

74
00:03:13,393 --> 00:03:15,495
THESE VISIONARIES WERE LEADERS

75
00:03:15,562 --> 00:03:16,729
IN THE HIV SPACE AND MANY HAD

76
00:03:16,796 --> 00:03:20,066
THE HONOR OF WORKING WITH THEM.

77
00:03:20,133 --> 00:03:22,969
A PIONEER IN HIV ACTIVISM BY

78
00:03:23,036 --> 00:03:24,470
EXPOSING THE HIV/AIDS EPIDEMIC

79
00:03:24,537 --> 00:03:26,839
IN CHINA IN THE 1990S AND

80
00:03:26,906 --> 00:03:28,575
THROUGH HER EFFORTS IN HIV

81
00:03:28,641 --> 00:03:29,876
PREVENTION AND ANTI-STIGMA

82
00:03:29,943 --> 00:03:31,411
EDUCATION, WHICH RESULTED IN

83
00:03:31,477 --> 00:03:33,046
RECOGNITION OF HIV AND AIDS IN

84
00:03:33,112 --> 00:03:35,081
CHINA AND POLICIES TO PREVENT

85
00:03:35,148 --> 00:03:40,019
AND CONTROL HIV.

86
00:03:40,086 --> 00:03:42,855
SHE EARNED NATIONAL AND

87
00:03:42,922 --> 00:03:44,257
INTERNATIONAL ACCLAIM AND KEPT

88
00:03:44,324 --> 00:03:45,692
UNDER CLOSED STATE SURVEILLANCE

89
00:03:45,758 --> 00:03:47,627
AND EVENTUALLY FLED TO THE

90
00:03:47,694 --> 00:03:49,395
UNITED STATES.

91
00:03:49,462 --> 00:03:50,863
DR. VICTORIA ANN JOHNSON,

92
00:03:50,930 --> 00:03:51,664
DEPARTMENT OF MADISON AT THE

93
00:03:51,731 --> 00:03:54,367
UNIVERSITY OF ALABAMA AT

94
00:03:54,434 --> 00:03:57,070
BIRMINGHAM, WAS A PIONEER IN HIV

95
00:03:57,136 --> 00:03:57,971
DRUG RESISTANCE RESEARCH AND IN

96
00:03:58,037 --> 00:04:01,240
THE USE OF COMBINATION

97
00:04:01,307 --> 00:04:02,308
ANTI-RETROVIRAL DRUG REGIMENS

98
00:04:02,375 --> 00:04:06,846
STANDARD APPROACHES IN HIV

99
00:04:06,913 --> 00:04:07,180
TREATMENT.

100
00:04:07,246 --> 00:04:10,183
DR. ADAORA ADIMORA WAS AN HIV

101
00:04:10,249 --> 00:04:11,017
RESEARCHER AND PROFESSOR OF

102
00:04:11,084 --> 00:04:13,386
MEDICINE IN EPIDEMIOLOGY AT THE

103
00:04:13,453 --> 00:04:14,153
UNIVERSITY OF NORTH CAROLINA

104
00:04:14,220 --> 00:04:16,255
SCHOOL OF MEDICINE AND GILLINGS

105
00:04:16,322 --> 00:04:17,290
SCHOOL OF GLOBAL PUBLIC HEALTH.

106
00:04:17,357 --> 00:04:19,592
SHE DEDICATED HER CAREER TO

107
00:04:19,659 --> 00:04:22,595
STUDYING EPIDEMIOLOGY OF

108
00:04:22,662 --> 00:04:23,429
HETEROSEXUAL HIV TRANSMISSION

109
00:04:23,496 --> 00:04:24,998
AMONG AFRICAN-AMERICANS, THE

110
00:04:25,064 --> 00:04:26,833
SOCIAL DETERMINANTS OF HEALTH

111
00:04:26,899 --> 00:04:29,002
THAT DRIVE HIV, RACIAL AND

112
00:04:29,068 --> 00:04:31,804
ETHNIC DISPARITIES AND WOMEN IN

113
00:04:31,871 --> 00:04:32,105
HIV.

114
00:04:32,171 --> 00:04:35,008
AND JUST TWO DAYS AGO, SADLY, WE

115
00:04:35,074 --> 00:04:38,144
LOST HYDEIA, AN AIDS ACTIVIST

116
00:04:38,211 --> 00:04:39,912
BORN WITH HIV AND BECAME A

117
00:04:39,979 --> 00:04:41,214
LEADING VOICE IN THE FIGHT

118
00:04:41,280 --> 00:04:43,282
AGAINST THE EPIDEMIC.

119
00:04:43,349 --> 00:04:44,484
ADOPTED AT SIX WEEKS OLD, SHE

120
00:04:44,550 --> 00:04:46,319
WAS ULTIMATELY DIAGNOSED WITH

121
00:04:46,386 --> 00:04:48,321
HIV WHEN SHE WAS THREE, HAVING

122
00:04:48,388 --> 00:04:54,460
CONTRACTED THE DISEASE IN UTERO.

123
00:04:54,527 --> 00:04:54,994
SHE GREATLY EXCEEDED

124
00:04:55,061 --> 00:04:56,696
EXPECTATIONS TO BECOME A

125
00:04:56,763 --> 00:04:57,563
ACTIVIST WHO RAISED AWARENESS

126
00:04:57,630 --> 00:04:59,432
ABOUT THE VIRUS, ESPECIALLY

127
00:04:59,499 --> 00:05:00,700
AMONG YOUNG PEOPLE AND REFUSED

128
00:05:00,767 --> 00:05:03,603
TO LET IT NEGATIVELY DEFINE HER

129
00:05:03,670 --> 00:05:03,903
LIFE.

130
00:05:03,970 --> 00:05:06,406
WHEN I READ THROUGH SOME OF THE

131
00:05:06,472 --> 00:05:08,241
QUOTES YESTERDAY, THE THINGS SHE

132
00:05:08,307 --> 00:05:10,410
SAID, I WAS STRUCK BY ONE IN

133
00:05:10,476 --> 00:05:11,611
PARTICULAR FROM HER BOOK, IN

134
00:05:11,678 --> 00:05:14,414
WHICH SHE SAID, I AM A WARRIOR.

135
00:05:14,480 --> 00:05:16,683
I RAISE EACH DAY WITH PURPOSE

136
00:05:16,749 --> 00:05:21,788
WHILE STILL BEING A WORK IN

137
00:05:21,854 --> 00:05:22,155
PROGRESS.

138
00:05:22,221 --> 00:05:25,525
WE WILL TURN THE MEETING TO THE

139
00:05:25,591 --> 00:05:27,493
CHAIR TO DR. IVY TURNBULL, WHO

140
00:05:27,560 --> 00:05:30,830
WILL BRING THE MEETING TO ORDER.

141
00:05:30,897 --> 00:05:34,333
>> THANK YOU DR. HOLTZ.

142
00:05:34,400 --> 00:05:37,503
AND GOOD AFTERNOON EVERYONE.

143
00:05:37,570 --> 00:05:40,807
THE MEETING OF OFFICE OF AIDS

144
00:05:40,873 --> 00:05:43,042
RESEARCH ADVISORY COUNCIL IS NOW

145
00:05:43,109 --> 00:05:51,017
IN SESSION.

146
00:05:51,084 --> 00:05:55,421
COLLEAGUES, WE WILL NOW CONDUCT

147
00:05:55,488 --> 00:05:58,024
THE ROLL CALL, WHEN I CALL YOUR

148
00:05:58,091 --> 00:06:01,728
NAME, PLEASE STATE YOUR POSITION

149
00:06:01,794 --> 00:06:03,062
AND INSTITUTION.

150
00:06:03,129 --> 00:06:06,833
OARAC VOTING MEMBERS,

151
00:06:06,899 --> 00:06:07,633
DR. KATHLEEN COLLINS.

152
00:06:07,700 --> 00:06:10,136
>> MY NAME IS A WELL COLLEEN:

153
00:06:10,203 --> 00:06:11,604
FROM THE UNIVERSITY OF MICHIGAN

154
00:06:11,671 --> 00:06:15,041
AND I'M PROFESSOR OF INTERNAL

155
00:06:15,108 --> 00:06:18,845
MEDICINE WITH SPECIALTY IN

156
00:06:18,911 --> 00:06:22,949
INFECTIOUS DISEASE.

157
00:06:23,015 --> 00:06:25,151
>> DR. OMAR GALARRAGA.

158
00:06:25,218 --> 00:06:27,053
>> HI, I'M OMAR.

159
00:06:27,120 --> 00:06:28,855
I'M AN ASSOCIATE PROFESSOR IN

160
00:06:28,921 --> 00:06:30,656
THE BROWN UNIVERSITY SCHOOL OF

161
00:06:30,723 --> 00:06:30,990
MR.IC HEALTH.

162
00:06:31,057 --> 00:06:32,959
I'M ALSO THE DIRECTOR OF THE

163
00:06:33,025 --> 00:06:36,062
DOCTORAL PROGRAM IN HEALTH

164
00:06:36,129 --> 00:06:39,532
SERVICES RESEARCH.

165
00:06:39,599 --> 00:06:41,667
>> DR. SHRUTI MEHTA.

166
00:06:41,734 --> 00:06:42,802
>> PROFESSOR AND VICE-CHAIR OF

167
00:06:42,869 --> 00:06:44,570
THE  DEPARTMENT OF EPIDEMIOLOGY

168
00:06:44,637 --> 00:06:47,940
AT JOHNS HOPKINS AND ALSO THE

169
00:06:48,007 --> 00:06:57,183
CO-DIRECTOR OF --

170
00:06:57,250 --> 00:07:02,155
>> DR. SHRUTI MEHTA.

171
00:07:02,221 --> 00:07:08,694
>> I [ INAUDIBLE ]

172
00:07:08,761 --> 00:07:09,095
>> DR. MAG MAG.

173
00:07:09,162 --> 00:07:17,036
>> HI, I'M ALAN MAGILL AND I'M

174
00:07:17,103 --> 00:07:18,838
A -- - MOJGAN NAGHAVI AT

175
00:07:18,905 --> 00:07:23,476
NORTHEASTERN UNIVERSITY.

176
00:07:23,543 --> 00:07:23,810
>> DR. ANN.

177
00:07:23,876 --> 00:07:27,747
>> I'M AN ASSISTANT PROFESSOR IN

178
00:07:27,814 --> 00:07:30,049
PEDIATRICS AT HARVARD MEDICAL

179
00:07:30,116 --> 00:07:32,685
SCHOOL AND INFECTIOUS DISEASES

180
00:07:32,752 --> 00:07:34,921
IN MASS GENERAL HOSPITAL IN

181
00:07:34,987 --> 00:07:36,656
BOSTON.

182
00:07:36,722 --> 00:07:38,691
>> DR. RICARDO.

183
00:07:38,758 --> 00:07:41,194
>> HELLO, EVERYONE.

184
00:07:41,260 --> 00:07:42,061
CLINICAL ASSISTANT PROFESSOR AT

185
00:07:42,128 --> 00:07:45,398
UNIVERSITY OF ILLINOIS,

186
00:07:45,464 --> 00:07:48,000
DEPARTMENT OF FAMILY MEDICINE IN

187
00:07:48,067 --> 00:07:58,377
CHICAGO AND ALSO -- [ INAUDIBLE

188
00:07:58,444 --> 00:07:58,911
>> DR. A SLEETS SLEETS.

189
00:07:58,978 --> 00:08:00,279
>> PROFESSOR AND CHIEF OF

190
00:08:00,346 --> 00:08:03,482
IMMUNOLOGY AT THE UNIVERSITY AND

191
00:08:03,549 --> 00:08:06,853
THE SCIENTIFIC LEADERSHIP GROUP

192
00:08:06,919 --> 00:08:12,792
FOR THE IMPACT.

193
00:08:12,859 --> 00:08:14,861
>> 2022 AD-HOC MEMBERS.

194
00:08:14,927 --> 00:08:16,896
DR. AUDWIN FLETCHER.

195
00:08:16,963 --> 00:08:17,797
>> COURTNEY FLETCHER, PROFESSOR

196
00:08:17,864 --> 00:08:19,999
OF PHARMACY AND INFECTIOUS

197
00:08:20,066 --> 00:08:21,801
DISEASES AT THE UNIVERSITY OF

198
00:08:21,868 --> 00:08:24,470
NEBRASKA MEDICAL CENTER IN

199
00:08:24,537 --> 00:08:25,104
OMAHA.

200
00:08:25,171 --> 00:08:27,807
>> DR. DIANE SANTA MARIA.

201
00:08:27,874 --> 00:08:28,908
>> GOOD MORNING.

202
00:08:28,975 --> 00:08:30,042
I'M HERE AT THE SCHOOL OF

203
00:08:30,109 --> 00:08:31,878
NURSING AT THE UNIVERSITY OF

204
00:08:31,944 --> 00:08:34,847
TEXAS HEALTH SCIENCE CENTER IN

205
00:08:34,914 --> 00:08:37,617
HOUSTON.

206
00:08:37,683 --> 00:08:41,988
>> DR. ANNA MARIA.

207
00:08:42,054 --> 00:08:44,724
>> I'M ANNA, A PROFESSOR OF

208
00:08:44,790 --> 00:08:47,393
PEDIATRICS AT BAYLOR COLLEGE OF

209
00:08:47,460 --> 00:08:50,630
MEDICINE AND TEXAS CHILDREN'S

210
00:08:50,696 --> 00:08:53,833
HOSPITAL WHERE I HELP TO

211
00:08:53,900 --> 00:09:04,443
CODIRECT THE -- AND FOCUS ON HIV

212
00:09:05,144 --> 00:09:09,482
AND SUB-SAHARAN AFRICA.

213
00:09:09,548 --> 00:09:10,082
>> DR. SONIA FLORES.

214
00:09:10,149 --> 00:09:12,618
>> HI, I'M SONIA, AND I'M A

215
00:09:12,685 --> 00:09:13,619
PROFESSOR AND VICE-CHAIR IN THE

216
00:09:13,686 --> 00:09:16,589
DEPARTMENT OF MEDICINE AT THE

217
00:09:16,656 --> 00:09:17,256
MEDICAL CAMPUS AT THE UNIVERSITY

218
00:09:17,323 --> 00:09:20,126
OF COLORADO.

219
00:09:20,192 --> 00:09:22,895
>> AND DR. SARAH SAWYER.

220
00:09:22,962 --> 00:09:24,931
>> GOOD MORNING, EVERYBODY.

221
00:09:24,997 --> 00:09:26,332
I'M SAILORRA SAWYER, PROFESSOR

222
00:09:26,399 --> 00:09:29,435
IN BOLDER, COLORADO AND I'M A

223
00:09:29,502 --> 00:09:31,237
VIROLOGIST AND IMMUNOLOGIST

224
00:09:31,304 --> 00:09:36,142
FOCUSING ON HIV RESEARCH.

225
00:09:36,208 --> 00:09:39,845
>> OARAC EX OFFICIOS.

226
00:09:39,912 --> 00:09:41,547
DR. TARA SCHWETZ.

227
00:09:41,614 --> 00:09:43,416
>> HI, I'M THE NIH DEPUTY

228
00:09:43,482 --> 00:09:44,417
DIRECTOR FOR PROGRAM

229
00:09:44,483 --> 00:09:45,818
COORDINATION, PLANNING AND

230
00:09:45,885 --> 00:09:51,324
STRATEGIC INITIATIVES.

231
00:09:51,390 --> 00:09:51,958
>> DR. JULIE.

232
00:09:52,024 --> 00:09:53,993
>> I'M JULIE THE DIRECTOR OF THE

233
00:09:54,060 --> 00:09:55,428
U.S. MILITARY HIV RESEARCH

234
00:09:55,494 --> 00:10:03,169
PROGRAM AT THE WALTER REED.

235
00:10:03,235 --> 00:10:03,703
>> DR. ROHAN.

236
00:10:03,769 --> 00:10:06,839
>> HI, I'M A PEDIATRIC DISEASE

237
00:10:06,906 --> 00:10:07,473
FISSION AND DIRECTOR OF THE

238
00:10:07,540 --> 00:10:09,141
DIVISION OF EXTRAMURAL RESEARCH

239
00:10:09,208 --> 00:10:11,644
AT NICHD AND I HAVE THE HONOR

240
00:10:11,711 --> 00:10:13,679
AND PRIVILEGE OF HELPING TO TAKE

241
00:10:13,746 --> 00:10:15,548
CARE OF -- WHEN SHE WAS HERE AT

242
00:10:15,614 --> 00:10:17,149
OUR NIH CLINICAL CENTER.

243
00:10:17,216 --> 00:10:19,618
SO REALLY A BIG LOSS FOR THE

244
00:10:19,685 --> 00:10:22,688
PEDIATRIC HIV COMMUNITY.

245
00:10:22,755 --> 00:10:24,357
THANK YOU.

246
00:10:24,423 --> 00:10:28,427
>> AND REAR ADMIRAL JONATHAN

247
00:10:28,494 --> 00:10:34,500
MERMAN.

248
00:10:34,567 --> 00:10:36,535
NO?

249
00:10:36,602 --> 00:10:38,270
OKAY.

250
00:10:38,337 --> 00:10:39,972
WE'LL MOVE -- MAYBE HE WILL JOIN

251
00:10:40,039 --> 00:10:40,673
US LATER.

252
00:10:40,740 --> 00:10:42,575
WE ARE MOVING TO THE ADVISORY

253
00:10:42,641 --> 00:10:47,580
COUNCIL REPRESENTATIVES.

254
00:10:47,646 --> 00:10:48,881
DR. MONICA GANDHI.

255
00:10:48,948 --> 00:10:50,616
>> HI, I'M MONICA, PROFESSOR OF

256
00:10:50,683 --> 00:10:52,585
MEDICINE AT UCSF AND THE

257
00:10:52,651 --> 00:10:57,790
DIRECTOR OF OUR C FAR AND ALSO

258
00:10:57,857 --> 00:11:00,059
OF OUR WARD 86 HIV CLINIC.

259
00:11:00,126 --> 00:11:02,161
THANK YOU.

260
00:11:02,228 --> 00:11:04,096
>> DR. MARGARITA.

261
00:11:04,163 --> 00:11:04,997
>> HELLO.

262
00:11:05,064 --> 00:11:06,832
I'M MARGARITA.

263
00:11:06,899 --> 00:11:09,001
I SERVE AS THE REPRESENTATIVE

264
00:11:09,068 --> 00:11:11,537
FOR NIMH COUNCIL, PROFESSOR AND

265
00:11:11,604 --> 00:11:13,272
ASSOCIATE DEAN FOR RESEARCH AND

266
00:11:13,339 --> 00:11:14,940
DOCTORAL PROGRAMS AT THE SCHOOL

267
00:11:15,007 --> 00:11:16,609
OF PUBLIC HEALTH.

268
00:11:16,675 --> 00:11:18,811
>> AND DR. MELANIE ON THE WILL

269
00:11:18,878 --> 00:11:21,881
BE JOINING US LATER -- OTT.

270
00:11:21,947 --> 00:11:24,784
THE OAR LEADERSHIP AND SPEAKERS.

271
00:11:24,850 --> 00:11:32,291
WE HAVE A FINS FINS.

272
00:11:32,358 --> 00:11:33,959
>> GOOD MORNING.

273
00:11:34,026 --> 00:11:36,729
I'M DEANNA FINSY, THE ACTING

274
00:11:36,796 --> 00:11:37,396
ASSOCIATE DIRECTOR OF AIDS

275
00:11:37,463 --> 00:11:40,466
RESEARCH AND ACTING DIRECTOR OF

276
00:11:40,533 --> 00:11:43,235
THE OFFICE OF AIDS RESEARCH AT

277
00:11:43,302 --> 00:11:49,608
THE NIH.

278
00:11:49,675 --> 00:11:52,244
>> TIMOTHY HOLTZ.

279
00:11:52,311 --> 00:11:53,846
>> I'M A MEDICAL OFFICER WITH

280
00:11:53,913 --> 00:11:55,714
THE U.S. PUBLIC HEALTH SERVICE

281
00:11:55,781 --> 00:11:59,785
AND AT NIH.

282
00:11:59,852 --> 00:12:04,323
>> CAPTAN MARRY GLENN SHAW.

283
00:12:04,390 --> 00:12:05,324
>> MARY GLENSHAW, I LEAD THE

284
00:12:05,391 --> 00:12:07,159
SCIENCE GROUP HERE AT THE NIH

285
00:12:07,226 --> 00:12:13,666
OFFICE OF AIDS RESEARCH.

286
00:12:13,732 --> 00:12:15,501
>> DR. RACHEL ANDERSON.

287
00:12:15,568 --> 00:12:18,838
>> I'M THE SENIOR POLICY ADVISOR

288
00:12:18,904 --> 00:12:22,641
AT OAR.

289
00:12:22,708 --> 00:12:25,211
>> AND Ms. CORETTE BYRD.

290
00:12:25,277 --> 00:12:29,648
>> CORETA WILL BE JOINING US

291
00:12:29,715 --> 00:12:30,015
LATER.

292
00:12:30,082 --> 00:12:30,416
>> THANK YOU.

293
00:12:30,483 --> 00:12:33,119
I'D LIKE TO TAKE THIS

294
00:12:33,185 --> 00:12:37,957
OPPORTUNITY TO GIVE DR. SLEETS

295
00:12:38,023 --> 00:12:39,024
MAN A FEW MOMENTS.

296
00:12:39,091 --> 00:12:40,226
HE HAS A STATEMENT HE WOULD LIKE

297
00:12:40,292 --> 00:12:45,531
TO HAVE READ INTO THE MINUTES.

298
00:12:45,598 --> 00:12:46,699
>> THANK YOU, IVY AND I WON'T

299
00:12:46,765 --> 00:12:47,433
READ THE WHOLE STATEMENT FOR THE

300
00:12:47,500 --> 00:12:48,134
PURPOSE OF REVITY.

301
00:12:48,200 --> 00:12:49,902
I WOULD LIKE TO THANK THE OFFICE

302
00:12:49,969 --> 00:12:54,073
OF THE DIRECTOR OF THE NIH AND

303
00:12:54,140 --> 00:12:56,242
THE OAR FOR ALLOWING ME TO SERVE

304
00:12:56,308 --> 00:12:57,510
ON THE ADVISORY COMMITTEE.

305
00:12:57,576 --> 00:13:00,146
THIS WILL BE MY LAST MEETING.

306
00:13:00,212 --> 00:13:01,514
OVER THE PAST FOUR YEARS IT'S

307
00:13:01,580 --> 00:13:03,716
BEEN AN HONOR TO BE PART OF

308
00:13:03,782 --> 00:13:04,216
THIS.

309
00:13:04,283 --> 00:13:07,953
I WANTED TO GO BACK TO

310
00:13:08,020 --> 00:13:09,321
PRESENTATION THAT TIM HAD FOR US

311
00:13:09,388 --> 00:13:12,091
A FEW MEETINGS AGO WHERE HE

312
00:13:12,158 --> 00:13:13,692
TALKED ABOUT THE INCEPTION OF

313
00:13:13,759 --> 00:13:18,831
THE OARAC AND OAR AND WE LEARNED

314
00:13:18,898 --> 00:13:20,399
ABOUT HOW THIS PARTICULAR OFFICE

315
00:13:20,466 --> 00:13:24,737
HAD BEEN THE TEMPLATE FOR FUTURE

316
00:13:24,803 --> 00:13:26,372
INITIATIVES FOR NIH TO ADDRESS

317
00:13:26,438 --> 00:13:28,340
THE NATIONAL AND GLOBAL HEALTH

318
00:13:28,407 --> 00:13:30,743
CRISIS AND TO THAT EXTENT, I

319
00:13:30,809 --> 00:13:34,847
THINK THE OAR HAS BEEN EXTREMELY

320
00:13:34,914 --> 00:13:35,147
SUCCESSFUL.

321
00:13:35,214 --> 00:13:36,749
THE REASON FOR MY COMMENTS TODAY

322
00:13:36,815 --> 00:13:38,751
IS I WANTED TO RECOGNIZE AND

323
00:13:38,817 --> 00:13:40,786
APPRECIATE THE INCREDIBLE

324
00:13:40,853 --> 00:13:42,054
LEADERSHIP OF MAUREEN.

325
00:13:42,121 --> 00:13:45,858
HER GUIDANCE AS THE DIRECTOR

326
00:13:45,925 --> 00:13:48,427
FORMULATED OUR CURRENT FIVE-YEAR

327
00:13:48,494 --> 00:13:48,794
STRATEGIC PLAN.

328
00:13:48,861 --> 00:13:51,530
SHE ENGAGED IN COMMUNITY

329
00:13:51,597 --> 00:13:53,465
STAKEHOLDER DIRECTLY, LISTENING

330
00:13:53,532 --> 00:13:54,967
SESSIONS AND ENHANCED DIVERSITY

331
00:13:55,034 --> 00:13:57,803
OF INCLUSION WITHIN THE HIV

332
00:13:57,870 --> 00:13:59,572
RESEARCH COMMUNITY.

333
00:13:59,638 --> 00:14:01,373
SHE ENCOURAGED PARTNERSHIPS WITH

334
00:14:01,440 --> 00:14:03,375
INSTITUTES THAT PREVIOUSLY HAD

335
00:14:03,442 --> 00:14:05,177
NOT BEEN GREATLY INVOLVED IN THE

336
00:14:05,244 --> 00:14:07,213
HIV RESEARCH AGENDA SUCH AS

337
00:14:07,279 --> 00:14:10,549
NATIONAL INSTITUTE ON AGING.

338
00:14:10,616 --> 00:14:12,751
AND EXPERTISE INVOLVED IN

339
00:14:12,818 --> 00:14:14,687
EXAMINING THE CO-MORBIDITIES

340
00:14:14,753 --> 00:14:17,056
ASSOCIATED WITH PEOPLE LIVING

341
00:14:17,122 --> 00:14:20,092
WITH HIV AS THEY AGE UP.

342
00:14:20,159 --> 00:14:23,095
IN THIS REGARD, I THINK OAR IS

343
00:14:23,162 --> 00:14:24,463
IN A VERY GOOD PLACE.

344
00:14:24,530 --> 00:14:29,301
I SEE THIS AS A CRITICAL TIME

345
00:14:29,368 --> 00:14:30,803
FOR AIDS RESEARCH BECAUSE OAR

346
00:14:30,869 --> 00:14:32,638
HADS BEEN WITHOUT A PERMANENT

347
00:14:32,705 --> 00:14:35,975
DIRECTOR FOR OVER A YEAR, NOW IN

348
00:14:36,041 --> 00:14:40,479
OUR SECOND INTERIM LEADERSHIP.

349
00:14:40,546 --> 00:14:41,380
I'M CONCERNED THAT SPECIAL

350
00:14:41,447 --> 00:14:42,615
INTERESTS WITH NO CONSTITUENCY

351
00:14:42,681 --> 00:14:45,517
WILL BE ABLE TO INFLUENCE THE

352
00:14:45,584 --> 00:14:48,587
HIV AGENDA WITHOUT STRONG

353
00:14:48,654 --> 00:14:50,923
LEADERSHIP AND PERMANENT

354
00:14:50,990 --> 00:14:51,223
LEADERSHIP.

355
00:14:51,290 --> 00:14:53,892
I'M ALSO CONCERNED ABOUT SMALL

356
00:14:53,959 --> 00:14:56,695
INSTITUTES THAT THE CRITICAL HIV

357
00:14:56,762 --> 00:14:59,898
RESEARCH AND HOPE THAT LARGER

358
00:14:59,965 --> 00:15:01,734
INSTITUTES DO NOT DIVERT THE

359
00:15:01,800 --> 00:15:04,970
FUNDING FROM THESE CRITICAL

360
00:15:05,037 --> 00:15:05,237
MISSIONS.

361
00:15:05,304 --> 00:15:08,173
SO WITH THAT REGARD, I'D LIKE TO

362
00:15:08,240 --> 00:15:09,775
THANK DR. MAUREEN GOODENOW FOR

363
00:15:09,842 --> 00:15:11,210
HER RESEARCH AND I HOPE WE HAVE

364
00:15:11,277 --> 00:15:14,380
A NEW LEADER COMING SOON TO

365
00:15:14,446 --> 00:15:16,215
PRESERVE HER LEGACY.

366
00:15:16,282 --> 00:15:16,482
THANK YOU.

367
00:15:16,548 --> 00:15:19,385
>> THANK YOU VERY MUCH, JOHN.

368
00:15:19,451 --> 00:15:22,288
AS A REMINDER TO EVERYONE, PER

369
00:15:22,354 --> 00:15:25,724
OUR CHARTER AND LEGISLATION, THE

370
00:15:25,791 --> 00:15:28,794
OARAC ADVISES THE OAR DIRECTOR

371
00:15:28,861 --> 00:15:30,929
ONBOARD MATTERS RELATING TO HIV

372
00:15:30,996 --> 00:15:33,732
RESEARCH POLICIES, PRIORITIES

373
00:15:33,799 --> 00:15:35,000
AND STRATEGIC PLANNING,

374
00:15:35,067 --> 00:15:39,905
INCLUDING THE REVIEW OF NIH,

375
00:15:39,972 --> 00:15:41,106
HIV/AIDS PROGRAM.

376
00:15:41,173 --> 00:15:42,808
I WILL NOW PROVIDE A BRIEF

377
00:15:42,875 --> 00:15:45,511
OVERVIEW OF TODAY'S AGENDA,

378
00:15:45,577 --> 00:15:50,916
WHICH INCLUDES A REPORT FROM

379
00:15:50,983 --> 00:15:53,852
DR. MARY GLENSHAW AND RACHEL

380
00:15:53,919 --> 00:15:55,220
ANDERSON ON THE NIH STRATEGIC

381
00:15:55,287 --> 00:15:57,423
PLAN FOR HIV AND HIV-RELATED

382
00:15:57,489 --> 00:15:59,024
RESEARCH.

383
00:15:59,091 --> 00:16:00,926
UPDATES FROM NIH ADVISORY

384
00:16:00,993 --> 00:16:05,931
COUNCIL AND FINALLY UPDATES FROM

385
00:16:05,998 --> 00:16:06,932
THE OARAC HIV CLINICAL

386
00:16:06,999 --> 00:16:07,833
GUIDELINES.

387
00:16:07,900 --> 00:16:10,836
THE AGENDA ALSO INCLUDES TIME

388
00:16:10,903 --> 00:16:13,772
FOR REGISTERED PUBLIC COMMENT.

389
00:16:13,839 --> 00:16:15,040
ANYONE LISTENING IN TODAY WHO

390
00:16:15,107 --> 00:16:18,210
WISHES TO MAKE A PUBLIC COMMENT

391
00:16:18,277 --> 00:16:26,552
SHOULD E-MAIL OARAC INFO@NIH GOV

392
00:16:26,618 --> 00:16:29,788
WITH YOUR NAME, AFFILIATION AND

393
00:16:29,855 --> 00:16:31,557
QUESTION OR COMMENT.

394
00:16:31,623 --> 00:16:36,061
PLEASE VISIT THE NIH OAR WEBSITE

395
00:16:36,128 --> 00:16:36,962
FOR THE FEDERAL REGISTER NOTICE

396
00:16:37,029 --> 00:16:42,968
FOR MORE DETAIL.

397
00:16:43,035 --> 00:16:45,037
BEFORE DR. FINSY PROVIDES THE

398
00:16:45,104 --> 00:16:45,838
DIRECTOR'S REPORT, WE WILL HEAR

399
00:16:45,904 --> 00:16:51,076
A FEW WORDS FROM THE NIH DEPUTY

400
00:16:51,143 --> 00:16:52,444
DIRECTOR OF PROGRAM

401
00:16:52,511 --> 00:16:54,079
COMMUNICATION, PLANNING AND

402
00:16:54,146 --> 00:16:58,851
STRATEGIC INITIATIVES.

403
00:16:58,917 --> 00:16:59,485
WELCOME.

404
00:16:59,551 --> 00:17:00,252
>> HI, EVERYONE.

405
00:17:00,319 --> 00:17:01,653
GOOD AFTERNOON OR GOOD MORNING,

406
00:17:01,720 --> 00:17:03,088
DEPENDING ON WHERE YOU ARE.

407
00:17:03,155 --> 00:17:05,557
I'M REALLY DELIGHTED TO BE HERE

408
00:17:05,624 --> 00:17:07,159
TO JOIN YOU ALL TODAY.

409
00:17:07,226 --> 00:17:11,063
I DO WANT TO TAKE JUST A MOMENT

410
00:17:11,130 --> 00:17:12,965
TO WELCOME DR. IVY TURNBULL IN

411
00:17:13,031 --> 00:17:16,502
HER FIRST MEETING AS OFFICIAL

412
00:17:16,568 --> 00:17:16,902
OARAC CHAIRPERSON.

413
00:17:16,969 --> 00:17:18,070
CONGRATULATIONS AND WELCOME.

414
00:17:18,137 --> 00:17:20,973
AND ALSO, DEANNA FINSY IN HER

415
00:17:21,039 --> 00:17:23,575
FIRST MEETING AS THE ACTING

416
00:17:23,642 --> 00:17:26,211
DIRECTOR OF THE OAR.

417
00:17:26,278 --> 00:17:26,979
I'M DELIGHTED TO HAVE BOTH OF

418
00:17:27,045 --> 00:17:27,946
YOU IN THESE ROLES.

419
00:17:28,013 --> 00:17:30,582
I KNOW IT WAS MENTIONED A FEW

420
00:17:30,649 --> 00:17:32,117
MOMENTS AGO SOMETHING ABOUT THE

421
00:17:32,184 --> 00:17:34,453
ACTING LEADERSHIP OF OAR.

422
00:17:34,520 --> 00:17:37,489
I JUST JOINED IN THIS POSITION

423
00:17:37,556 --> 00:17:39,825
AT NIH, SHIFTED INTO THIS ROLE

424
00:17:39,892 --> 00:17:41,727
ABOUT THREE MONTHS AGO AND I CAN

425
00:17:41,794 --> 00:17:43,562
TELL YOU I'M VERY COMMITTED TO

426
00:17:43,629 --> 00:17:45,697
FINDING PERMANENT LEADERSHIP FOR

427
00:17:45,764 --> 00:17:48,167
THIS AND THE SEARCH IS

428
00:17:48,233 --> 00:17:48,534
PROGRESSING.

429
00:17:48,600 --> 00:17:52,971
AND WE HOPE TO BE ABLE TO HONE

430
00:17:53,038 --> 00:17:55,007
IN ON THE NEXT PERMANENT

431
00:17:55,073 --> 00:17:57,109
LEADERSHIP VERY SOON.

432
00:17:57,176 --> 00:17:58,977
SO JUST TO CLARIFY THAT PIECE

433
00:17:59,044 --> 00:18:02,381
AND GIVE YOU THAT UPDATE.

434
00:18:02,448 --> 00:18:05,684
SPEAKING OF ACTING, SO I WOULD

435
00:18:05,751 --> 00:18:08,320
LIKE TO THANK DR. BILL, WHO LEFT

436
00:18:08,387 --> 00:18:10,222
THE ACTING ROLE AFTER ACCEPTING

437
00:18:10,289 --> 00:18:14,126
A NEW POSITION AT HHS BACK IN

438
00:18:14,193 --> 00:18:14,393
DECEMBER.

439
00:18:14,460 --> 00:18:16,595
GRATEFUL TO HIM FOR HIS

440
00:18:16,662 --> 00:18:17,996
DEDICATED EFFORTS IN LEAD CAN

441
00:18:18,063 --> 00:18:21,033
OAR FOR MUCH OF LAST YEAR.

442
00:18:21,099 --> 00:18:23,502
AND I ALSO LIKE TO THANK

443
00:18:23,569 --> 00:18:28,407
DR. TIMOTHY HOLTZ FOR HIS

444
00:18:28,474 --> 00:18:30,409
CONTRIBUTIONS FOR DEPUTY

445
00:18:30,476 --> 00:18:32,144
DIRECTOR OF OARAC AS HE IS

446
00:18:32,211 --> 00:18:38,217
RETIRING FROM THE PUBLIC HEALTH

447
00:18:38,283 --> 00:18:41,019
SERVICE IN A MONTH OR SO.

448
00:18:41,086 --> 00:18:42,521
NOW, AS I MENTIONED, I HAVE BEEN

449
00:18:42,588 --> 00:18:46,825
IN MY CURRENT ROLE FOR ABOUT

450
00:18:46,892 --> 00:18:49,828
THREE MONTHS AT THE NIH --

451
00:18:49,895 --> 00:18:52,531
DEPUTY DIRECTOR FOR PROGRAM

452
00:18:52,598 --> 00:18:54,199
PLANNING AND STRATEGIC

453
00:18:54,266 --> 00:18:54,500
INITIATIVES.

454
00:18:54,566 --> 00:18:59,204
I SERVICE AS THE DIRECTOR OF THE

455
00:18:59,271 --> 00:19:01,206
DIVISION AS WELL.

456
00:19:01,273 --> 00:19:04,610
AND THAT'S WHERE OAR SITS AND

457
00:19:04,676 --> 00:19:06,211
REALLY HAS EVOLVED OVER TIME TO

458
00:19:06,278 --> 00:19:08,113
HELP IDENTIFY AND ADDRESS THOSE

459
00:19:08,180 --> 00:19:12,584
KNOWLEDGE GAPS AND TO IDENTIFY

460
00:19:12,651 --> 00:19:14,419
EMERGING SCIENTIFIC

461
00:19:14,486 --> 00:19:15,654
OPPORTUNITIES IN THE AREA OF

462
00:19:15,721 --> 00:19:17,322
HIV/AIDS RESEARCH.

463
00:19:17,389 --> 00:19:20,726
NOW, NOWHERE IS THE VALUE OF THE

464
00:19:20,792 --> 00:19:22,728
IMPACT OF THIS NIH-WIDE

465
00:19:22,794 --> 00:19:24,796
COORDINATION BECAUSE THAT REALLY

466
00:19:24,863 --> 00:19:28,100
IS THE BREAD AND BUTTER OF WHAT

467
00:19:28,166 --> 00:19:30,836
WE DO IN DEPI KIPSY IS THAT

468
00:19:30,903 --> 00:19:32,504
COORDINATION, AND NOWHERE IS IT

469
00:19:32,571 --> 00:19:34,339
MORE EVIDENCE OR IMPACTFUL THAN

470
00:19:34,406 --> 00:19:38,310
IN THE AREA OF HIV RESEARCH.

471
00:19:38,377 --> 00:19:40,445
THE BREATH AND THE DEPTH OF HIV

472
00:19:40,512 --> 00:19:42,981
RESEARCH FUNDED AND CONDUCTED BY

473
00:19:43,048 --> 00:19:45,651
NIH IS TRULY INCREDIBLE.

474
00:19:45,717 --> 00:19:47,319
AND NIH PROVIDES THE LARGEST

475
00:19:47,386 --> 00:19:50,856
PUBLIC INVESTMENT IN HIV

476
00:19:50,923 --> 00:19:53,692
RESEARCH IN THE WORLD WITH MORE

477
00:19:53,759 --> 00:19:57,963
THAN 3500 PROJECTS AND 96

478
00:19:58,030 --> 00:19:59,031
COUNTRIES.

479
00:19:59,097 --> 00:19:59,631
AND THE SPANS EVERY AREA OF

480
00:19:59,698 --> 00:20:01,233
MEDICINE AND SCIENTIFIC

481
00:20:01,300 --> 00:20:03,135
INVESTIGATION FROM BASIC SCIENCE

482
00:20:03,201 --> 00:20:04,836
TO IMPLEMENTATION RESEARCH AND

483
00:20:04,903 --> 00:20:05,404
BEYOND.

484
00:20:05,470 --> 00:20:09,741
I'M SURE YOU ALL ARE MUCH MORE

485
00:20:09,808 --> 00:20:11,443
AWARE OF ALL OF THE DIFFERENT

486
00:20:11,510 --> 00:20:16,248
TYPE OF WORK THAT YOU AND I HAVE

487
00:20:16,315 --> 00:20:18,450
IN OAR AND NIH SUPPORTS.

488
00:20:18,517 --> 00:20:22,721
AND THIS INVESTMENT REALLY HAS

489
00:20:22,788 --> 00:20:24,156
YIELDED SOME GROUNDBREAKING

490
00:20:24,222 --> 00:20:25,324
RESEARCH ADVANCES IN THE AREAS

491
00:20:25,390 --> 00:20:28,427
OF TREATMENT PREVENTION AND

492
00:20:28,493 --> 00:20:28,961
CARE.

493
00:20:29,027 --> 00:20:30,362
AND THE BRICK THROUGHS ARE

494
00:20:30,429 --> 00:20:34,199
HELPING TO PREVENT THE HIV

495
00:20:34,266 --> 00:20:35,567
TRANSMISSION, TO HALT HIV

496
00:20:35,634 --> 00:20:37,736
DISEASE PROGRESSION, PROTECT

497
00:20:37,803 --> 00:20:39,938
SEXUAL PARTNERS AND PERSONS WHO

498
00:20:40,005 --> 00:20:43,442
USE DRUGS FROM HIV TRANSMISSION

499
00:20:43,508 --> 00:20:47,379
AND I THINK IMPORTANTLY, AS WELL

500
00:20:47,446 --> 00:20:48,847
ENABLE PEOPLE WITH HIV TO LIVE

501
00:20:48,914 --> 00:20:50,482
HEALTHIER AND LONGER LIVES.

502
00:20:50,549 --> 00:20:53,352
AND WE ARE SEEING THIS NOW IN

503
00:20:53,418 --> 00:20:55,954
THAT THE ISSUE OF HIV AND AGING

504
00:20:56,021 --> 00:20:58,557
IS BECOMING MORE AND MORE

505
00:20:58,624 --> 00:20:59,224
PROMINENT.

506
00:20:59,291 --> 00:21:03,228
THE IMPACT OF THE HIV RESEARCH

507
00:21:03,295 --> 00:21:04,763
PROGRAM HAS ALSO EXTENDED FAR

508
00:21:04,830 --> 00:21:07,065
BEYOND THE FIELD OF HIV ITSELF.

509
00:21:07,132 --> 00:21:10,936
I MEAN, I THINK SO I SPENT TIME

510
00:21:11,003 --> 00:21:13,438
WORKING AT NIAID AND DR. FAUCI

511
00:21:13,505 --> 00:21:15,540
AND I WROTE A COMMENTARY ON THIS

512
00:21:15,607 --> 00:21:18,443
EXACT TOPIC SEVERAL YEARS AGO.

513
00:21:18,510 --> 00:21:19,878
IT'S AMAZING SOME OF THE STUFF

514
00:21:19,945 --> 00:21:22,848
THAT WE HAVE BEEN ABLE TO LEARN

515
00:21:22,914 --> 00:21:24,549
FROM THE WORK OF HIV.

516
00:21:24,616 --> 00:21:26,284
AND WE SAW THIS MOST RECENTLY IN

517
00:21:26,351 --> 00:21:29,287
THE RESPONSE TO THE COVID-19

518
00:21:29,354 --> 00:21:30,956
PANDEMIC WHERE HIV RESEARCH

519
00:21:31,023 --> 00:21:33,859
NETWORKS AND PLATFORMS HELPED TO

520
00:21:33,925 --> 00:21:35,460
ENABLE RAPID DEVELOPMENT OF

521
00:21:35,527 --> 00:21:37,996
TESTING COVID AND TREATMENTS AND

522
00:21:38,063 --> 00:21:38,363
VACCINES.

523
00:21:38,430 --> 00:21:40,265
BUT WE KNOW THAT DESPITE ALL OF

524
00:21:40,332 --> 00:21:41,667
THE ADVANCES THAT HAVE BEEN MADE

525
00:21:41,733 --> 00:21:43,468
OVER THE LAST SEVERAL DECADES, A

526
00:21:43,535 --> 00:21:45,804
LOT OF WORK REMAINS.

527
00:21:45,871 --> 00:21:48,974
THERE ARE KNOWLEDGE GAPS THAT

528
00:21:49,041 --> 00:21:51,209
PERSIST AND THERE IS A CRITICAL

529
00:21:51,276 --> 00:21:54,346
NEED FOR CONTINUED AND EXPANDED

530
00:21:54,413 --> 00:21:56,181
RESEARCH INVESTMENTS IN BASIC

531
00:21:56,248 --> 00:21:58,583
SCIENCE, IN LONGER-LASTING

532
00:21:58,650 --> 00:22:01,653
PROVISION OPTIONS, TREATMENTS,

533
00:22:01,720 --> 00:22:03,288
VACCINE, A CURE AND THE

534
00:22:03,355 --> 00:22:05,757
AGING-RELATED ISSUES I MENTIONED

535
00:22:05,824 --> 00:22:05,991
EARLIER.

536
00:22:06,058 --> 00:22:08,694
AND THIS WORK REQUIRES THAT WE

537
00:22:08,760 --> 00:22:12,397
CONTINUE TO LEVERAGE THE BREADTH

538
00:22:12,464 --> 00:22:14,566
AND DEPTH OF EXPERTISE ACROSS

539
00:22:14,633 --> 00:22:16,968
ALL OF THE INSTITUTES AND

540
00:22:17,035 --> 00:22:20,605
CENTERS AND OFFICES WITHIN NIH.

541
00:22:20,672 --> 00:22:22,741
AND THAT'S WHY THIS ESSENTIAL

542
00:22:22,808 --> 00:22:24,176
WORK OF OFFICE OF AIDS RESEARCH

543
00:22:24,242 --> 00:22:26,011
COMES IN BUT IT'S ALSO WHERE I

544
00:22:26,078 --> 00:22:27,612
THINK YOU ALL PROVIDE A REALLY

545
00:22:27,679 --> 00:22:31,183
GREAT OPPORTUNITY TO HELP US AND

546
00:22:31,249 --> 00:22:32,684
ADVISE US AND GIVE FEEDBACK ON

547
00:22:32,751 --> 00:22:36,688
THE WORK THAT WE'RE DOING ACROSS

548
00:22:36,755 --> 00:22:36,888
NIH.

549
00:22:36,955 --> 00:22:39,591
SO AS YOU KNOW, OAR IS THE

550
00:22:39,658 --> 00:22:41,993
COORDINATING FORCE BEHIND THE

551
00:22:42,060 --> 00:22:43,795
HIV-RELATED SCIENCE THAT DRIVES

552
00:22:43,862 --> 00:22:45,397
INNOVATION AND HELPS IMPROVE

553
00:22:45,464 --> 00:22:47,299
PUBLIC POLICY AND ALSO WORKS TO

554
00:22:47,365 --> 00:22:50,068
ACHIEVE GLOBAL HEALTH SECURITY.

555
00:22:50,135 --> 00:22:51,603
AND LIKE ALL THE OTHER -- MOST

556
00:22:51,670 --> 00:22:56,408
OF THE OTHER OFFICES, OAR WORKS

557
00:22:56,475 --> 00:22:58,110
TO MOVE RESEARCH FORWARD IN NEW

558
00:22:58,176 --> 00:23:00,579
AND SIGNIFICANT WAYS TO HELP

559
00:23:00,645 --> 00:23:02,314
EXPAND AND FORM AND DEVELOP NEW

560
00:23:02,380 --> 00:23:04,716
PARTNERSHIPS AND NEW APPROACHES.

561
00:23:04,783 --> 00:23:08,820
AND ENGAGE EXTERNALLY TO ADDRESS

562
00:23:08,887 --> 00:23:11,623
COMMUNITY NEEDS AND CONCERNS.

563
00:23:11,690 --> 00:23:14,693
OAR ALSO HAS A LOT OF UNIQUE

564
00:23:14,760 --> 00:23:17,162
AUTHORITIES THAT IT CAN LEVERAGE

565
00:23:17,229 --> 00:23:20,766
TO HELP MANAGE THE NIH HIV

566
00:23:20,832 --> 00:23:21,066
ENTERPRISE.

567
00:23:21,133 --> 00:23:23,902
AND ITS EFFORTS, FACILITATE A

568
00:23:23,969 --> 00:23:25,537
UNIFIED RESEARCH APPROACH TO

569
00:23:25,604 --> 00:23:30,709
ADDRESS THE GLOBAL HIV PANDEMIC.

570
00:23:30,776 --> 00:23:35,213
AND THAT'S MADE POSSIBLE IN PART

571
00:23:35,280 --> 00:23:36,648
BY ENGAGEMENT WITH ALL OF YOU

572
00:23:36,715 --> 00:23:40,218
WHO ARE MEMBERS OF THIS COUNCIL.

573
00:23:40,285 --> 00:23:42,854
THROUGHOUT YOUR TENURE, AS OARAC

574
00:23:42,921 --> 00:23:45,423
MEMBERS, WE REALLY LOOK FORWARD

575
00:23:45,490 --> 00:23:49,227
TO YOUR EXPERT INPUT ON HIV

576
00:23:49,294 --> 00:23:50,762
RESEARCH PRIORITIES.

577
00:23:50,829 --> 00:23:51,730
YOUR THOUGHTFUL FEEDBACK ON THE

578
00:23:51,797 --> 00:23:55,901
WORK OF OAR AND THE QUESTIONS

579
00:23:55,967 --> 00:23:58,136
THAT YOU RAISE AND THAT YOU CAN

580
00:23:58,203 --> 00:24:00,405
HELP US TO ASK BY HELPING US

581
00:24:00,472 --> 00:24:02,908
REFINE OUR THINKING AND IDENTIFY

582
00:24:02,974 --> 00:24:05,143
OPPORTUNITIES TO IMPROVE OUR

583
00:24:05,210 --> 00:24:06,144
EFFORTS.

584
00:24:06,211 --> 00:24:07,813
THAT FEEDBACK WE TAKE TO HEART

585
00:24:07,879 --> 00:24:10,816
AND USE THAT TO HELP SHAPE SOME

586
00:24:10,882 --> 00:24:15,487
OF THE WORK THAT WE'RE DOING.

587
00:24:15,554 --> 00:24:16,755
SO, I WILL WRAP UP TODAY.

588
00:24:16,822 --> 00:24:18,056
I KNOW YOU'RE GOING TO HEAR

589
00:24:18,123 --> 00:24:19,624
ABOUT CURRENT AND UPCOMING

590
00:24:19,691 --> 00:24:20,725
ACTIVITY TO ESTABLISH RESEARCH

591
00:24:20,792 --> 00:24:22,260
PRIORITIES AND HELP DEVELOP THE

592
00:24:22,327 --> 00:24:25,363
NEXT NIH STRATEGIC PLAN FOR HIV

593
00:24:25,430 --> 00:24:27,632
AND HIV-RELATED RESEARCH.

594
00:24:27,699 --> 00:24:29,935
AND AS PART OF THIS REALLY

595
00:24:30,001 --> 00:24:33,171
CRITICAL PROCESS, OAR HAS ISSUED

596
00:24:33,238 --> 00:24:35,640
A REQUEST FOR INFORMATION TO

597
00:24:35,707 --> 00:24:37,576
GATHER UP PUT FROM EVERYONE IN

598
00:24:37,642 --> 00:24:39,144
THE COMMUNITY ON THE FRAMEWORK

599
00:24:39,211 --> 00:24:42,013
THAT THEY OUTLINED FOR THE

600
00:24:42,080 --> 00:24:43,048
STRATEGIC PLAN AND SPECIFIC

601
00:24:43,114 --> 00:24:44,983
RESEARCH PRIORITIES.

602
00:24:45,050 --> 00:24:46,952
SO, I'D LIKE TO ASK THAT YOU ALL

603
00:24:47,018 --> 00:24:49,955
SHARE YOUR INPUT AND HELP

604
00:24:50,021 --> 00:24:51,456
DISTRIBUTE THE INFORMATION ABOUT

605
00:24:51,523 --> 00:24:54,793
THIS RFI ACROSS YOUR NETWORKS TO

606
00:24:54,860 --> 00:24:56,795
BE SURE THAT THE NEXT STRATEGIC

607
00:24:56,862 --> 00:24:59,564
PLAN WAS REALLY INFORMED BY

608
00:24:59,631 --> 00:25:03,168
BROAD AND DEEP INPUT, FEEDBACK,

609
00:25:03,235 --> 00:25:04,569
EXPERTISE, ACROSS THE RESEARCH

610
00:25:04,636 --> 00:25:04,836
COMMUNITY.

611
00:25:04,903 --> 00:25:07,172
SO JUST WANTED TO FLAG THAT RFI

612
00:25:07,239 --> 00:25:10,575
IS BEING REALLY IMPORTANT

613
00:25:10,642 --> 00:25:14,846
MECHANISM FOR HARNESSING INPUT.

614
00:25:14,913 --> 00:25:17,849
NOW, WITH THAT, I WILL THANK YOU

615
00:25:17,916 --> 00:25:20,886
FOR YOUR TIME TODAY AND THANK

616
00:25:20,952 --> 00:25:22,687
YOU SO, SO MUCH FOR YOUR SERVICE

617
00:25:22,754 --> 00:25:24,589
ON THIS ADVISORY COUNCIL TO HELP

618
00:25:24,656 --> 00:25:26,992
SUPPORT THE WORK THAT WE DO HERE

619
00:25:27,058 --> 00:25:29,794
AT NIH AND OAR.

620
00:25:29,861 --> 00:25:32,964
AND NOW I WILL TURN THE

621
00:25:33,031 --> 00:25:36,868
MICROPHONE BACK OVER TO DR. IVY

622
00:25:36,935 --> 00:25:37,769
TURNBULL.

623
00:25:37,836 --> 00:25:38,937
>> THANK YOU VERY MUCH FOR THE

624
00:25:39,004 --> 00:25:41,606
WELCOMING REMARKS.

625
00:25:41,673 --> 00:25:47,712
I WILL NOW TURN THE FOCUS TO

626
00:25:47,779 --> 00:25:54,386
DR. JESSI A FINN DIANA FINZI WHL

627
00:25:54,452 --> 00:25:57,355
PROVIDE THE DIRECTOR'S REPORT.

628
00:25:57,422 --> 00:25:58,189
>> THANK YOU.

629
00:25:58,256 --> 00:26:00,692
WELCOME, EVERYONE TO THIS

630
00:26:00,759 --> 00:26:02,527
65th OARAC MEETING AND THANK

631
00:26:02,594 --> 00:26:05,497
YOU VERY MUCH FOR JOINING US

632
00:26:05,563 --> 00:26:05,697
TODAY.

633
00:26:05,764 --> 00:26:07,966
AND THANK YOU TARA FOR YOUR

634
00:26:08,033 --> 00:26:10,568
VERY, VERY THOUGHTFUL REMARKS.

635
00:26:10,635 --> 00:26:15,840
OAR LOOKS FORWARD TO CONTINUING

636
00:26:15,907 --> 00:26:17,509
OUR WORK WITH YOU.

637
00:26:17,575 --> 00:26:21,046
MY REPORT TODAY WILL COVER

638
00:26:21,112 --> 00:26:22,213
LEADERSHIP TRANSITIONS AT THE

639
00:26:22,280 --> 00:26:25,483
OAR AND NIH LEVELS, OARAC MEMBER

640
00:26:25,550 --> 00:26:27,786
UPDATES, OAR SIGNATURE PROGRAMS

641
00:26:27,852 --> 00:26:29,788
AS WELL AS RECENT AND UPCOMING

642
00:26:29,854 --> 00:26:33,892
OAR ENGAGEMENTS AND THE ROLE OF

643
00:26:33,959 --> 00:26:35,694
OAR, OARAC AND THE NEXT

644
00:26:35,760 --> 00:26:38,463
ITERATION OF THE NIH STRATEGIC

645
00:26:38,530 --> 00:26:42,834
PLAN FOR HIV AND HIV-RELATED

646
00:26:42,901 --> 00:26:43,501
RESEARCH.

647
00:26:43,568 --> 00:26:45,637
SO, WITH REGARD TO TRANSITIONS

648
00:26:45,704 --> 00:26:52,444
AT OAR AND AT NIH, AS YOU MAY

649
00:26:52,510 --> 00:26:54,813
KNOW, EFFECTIVE DECEMBER 17 OF

650
00:26:54,879 --> 00:26:57,282
2023, I ASSUMED THE POSITION OF

651
00:26:57,349 --> 00:26:59,784
NIH ACTING ASSOCIATE DIRECTOR

652
00:26:59,851 --> 00:27:01,519
FOR AIDS RESEARCH AND ACTING

653
00:27:01,586 --> 00:27:04,422
DIRECTOR OF OAR WHILE A

654
00:27:04,489 --> 00:27:05,890
NATIONWIDE SEARCH FOR THE NEW

655
00:27:05,957 --> 00:27:09,894
PERMANENT DIRECTOR CONCLUDES.

656
00:27:09,961 --> 00:27:13,331
MANY, MANY THANKS TO DR. BILL

657
00:27:13,398 --> 00:27:15,800
WHO SKILLFULLY HELD THESE

658
00:27:15,867 --> 00:27:17,335
POSITIONS FOR MOST OF 2023.

659
00:27:17,402 --> 00:27:19,971
BILL MOVED TO A NEW POSITION IN

660
00:27:20,038 --> 00:27:22,040
THE BIOMEDICAL ADVANCED RESEARCH

661
00:27:22,107 --> 00:27:23,641
AND DEVELOPMENT AUTHORITY,

662
00:27:23,708 --> 00:27:25,176
OTHERWISE KNOWN AS BARDA, WITHIN

663
00:27:25,243 --> 00:27:29,714
THE HHS ADMINISTRATION FOR

664
00:27:29,781 --> 00:27:32,017
STRATEGIC PREPAREDNESS AND

665
00:27:32,083 --> 00:27:32,817
RESEARCH.

666
00:27:32,884 --> 00:27:35,453
AND WHILE AT OAR, I SERVE AS THE

667
00:27:35,520 --> 00:27:43,128
DIRECTOR OF THE BASIC SCIENCES

668
00:27:43,194 --> 00:27:43,395
PROVISION.

669
00:27:43,461 --> 00:27:47,132
I HAVE BEEN AT NIAID FOR OVER 20

670
00:27:47,198 --> 00:27:49,167
YEARS AND AN IMMUNOLOGIST BY

671
00:27:49,234 --> 00:27:49,467
TRAINING.

672
00:27:49,534 --> 00:27:51,636
MY ENTIRE CAREER HAS BEEN

673
00:27:51,703 --> 00:27:53,438
FOCUSED ON HIV.

674
00:27:53,505 --> 00:27:55,807
ITS INTERACTIONS WITH THE IMMUNE

675
00:27:55,874 --> 00:27:59,944
SYSTEM AND THE PROBLEM OF VIRAL

676
00:28:00,011 --> 00:28:02,847
PERSISTENCE OF HIV IN

677
00:28:02,914 --> 00:28:05,150
LATENTLY-INFECTED CD4 CELLS IN

678
00:28:05,216 --> 00:28:06,217
TREATED INDIVIDUALS.

679
00:28:06,284 --> 00:28:08,920
I ALSO HAVE A MASTER'S DEGREE IN

680
00:28:08,987 --> 00:28:10,255
PUBLIC HEALTH.

681
00:28:10,321 --> 00:28:13,858
AND A TRUE INTEREST IN

682
00:28:13,925 --> 00:28:16,061
TRANSLATING BASIC SCIENCE OF HIV

683
00:28:16,127 --> 00:28:17,996
TO BETTER HEALTH OUTCOMES TO ALL

684
00:28:18,063 --> 00:28:20,665
WHO ARE AFFECTED BY HIV.

685
00:28:20,732 --> 00:28:23,068
THERE IS MORE INFORMATION ON MY

686
00:28:23,134 --> 00:28:24,969
BACKGROUND AND ON THIS

687
00:28:25,036 --> 00:28:35,080
TRANSITION ON OUR OAR WEBSITE.

688
00:28:35,146 --> 00:28:37,682
SO NOW -- OARAC DESIGNATED

689
00:28:37,749 --> 00:28:40,552
FEDERAL OFFICIAL OR DFO, IS

690
00:28:40,618 --> 00:28:42,287
RETIRING FROM THE U.S. PUBLIC

691
00:28:42,353 --> 00:28:44,322
HEALTH SERVICE AND THAT WILL BE

692
00:28:44,389 --> 00:28:46,124
EFFECTIVE ON MARCH 31.

693
00:28:46,191 --> 00:28:48,960
TIM WILL BE LEAVING HIS POSITION

694
00:28:49,027 --> 00:28:50,762
AT OAR AS DEPUTY DIRECTOR AND

695
00:28:50,829 --> 00:28:52,997
WILL BE MOVING TO THE NEXT STEP

696
00:28:53,064 --> 00:28:55,066
IN HIS CAREER IN GLOBAL PUBLIC

697
00:28:55,133 --> 00:28:57,268
HEALTH AS A CIVILIAN.

698
00:28:57,335 --> 00:29:00,905
ON BEHALF OF OAR AND THE NIH,

699
00:29:00,972 --> 00:29:03,508
I'D LIKE TO THANK TIM FOR HIS

700
00:29:03,575 --> 00:29:04,175
OUT STABBING COMMITMENT AND

701
00:29:04,242 --> 00:29:08,680
SERVICE TO OAR AND THE NIH-HIV

702
00:29:08,746 --> 00:29:09,581
RESEARCH PROGRAM.

703
00:29:09,647 --> 00:29:13,084
AND FOR SERVING AS OARAC DFO.

704
00:29:13,151 --> 00:29:16,020
PLEASE JOIN ME IN WISHING HIM

705
00:29:16,087 --> 00:29:21,659
WELL IN HIS NEW POSITION.

706
00:29:21,726 --> 00:29:25,997
WHILE THE NIH CONDUCTS A

707
00:29:26,064 --> 00:29:28,166
PERMANENT OAR DEPUTY DIRECTOR,

708
00:29:28,233 --> 00:29:30,201
MARY GLENSHAW, SENIOR SCIENCE

709
00:29:30,268 --> 00:29:32,804
ADVISER WILL SERVE AS ACTING OAR

710
00:29:32,871 --> 00:29:38,676
DEPUTY DIRECTOR AND AS THE OARAC

711
00:29:38,743 --> 00:29:38,843
DFO.

712
00:29:38,910 --> 00:29:40,612
OARAC MEMBERS WILL RECALL THAT

713
00:29:40,678 --> 00:29:44,816
MARRY SERVED AS OARAC DFO PRIOR

714
00:29:44,883 --> 00:29:45,150
TO DR. HOLTZ.

715
00:29:45,216 --> 00:29:47,418
THANK YOU AGAIN TIM FOR YOUR

716
00:29:47,485 --> 00:29:48,686
SERVICE AND THANK YOU MARY FOR

717
00:29:48,753 --> 00:29:50,788
YOUR WILLINGNESS TO TAKE ON

718
00:29:50,855 --> 00:29:56,995
THESE RESPONSIBILITIES.

719
00:29:57,061 --> 00:29:58,897
SO IN ADDITION TO TARA'S NEW

720
00:29:58,963 --> 00:30:00,498
ROLE, THERE ARE TWO OTHER NIH

721
00:30:00,565 --> 00:30:01,699
LEADERS I WOULD LIKE TO

722
00:30:01,766 --> 00:30:03,301
HIGHLIGHT WHO HAVE TRANSITIONED

723
00:30:03,368 --> 00:30:05,470
INTO NEW POSITIONS.

724
00:30:05,537 --> 00:30:09,707
ON DECEMBER 18 OF 2023, KIM

725
00:30:09,774 --> 00:30:11,442
STARTED AS THE 17th DIRECTOR

726
00:30:11,509 --> 00:30:13,478
OF THE NATIONAL CANCER

727
00:30:13,545 --> 00:30:14,212
INSTITUTE.

728
00:30:14,279 --> 00:30:17,916
SHE CAME TO NCI FROM VANDERBILT

729
00:30:17,982 --> 00:30:22,220
UNIVERSITY MEDICAL CENTER AND IS

730
00:30:22,287 --> 00:30:24,355
A RENOWNED KIDNEY CANCER EXPERT

731
00:30:24,422 --> 00:30:26,691
AND AN INFLUENTIAL LEADER IN

732
00:30:26,758 --> 00:30:29,027
CANCER RESEARCH AS WELL AS IN

733
00:30:29,093 --> 00:30:30,128
PATIENT CARE.

734
00:30:30,195 --> 00:30:31,563
DR. ROTH MEL WAS SELECTED BY

735
00:30:31,629 --> 00:30:37,769
PRESIDENT BIDEN TO SUCCEED

736
00:30:37,835 --> 00:30:38,703
DR. MARTIN WHO LEFT THE POSITION

737
00:30:38,770 --> 00:30:41,439
TO BECOME THE NIH DIRECTOR ON

738
00:30:41,506 --> 00:30:44,909
NOVEMBER 9 OF 2023.

739
00:30:44,976 --> 00:30:45,510
DR. MONICA BERTAGNOLLI IS THE

740
00:30:45,577 --> 00:30:48,313
FIRST SERGEANT AND THE SECOND

741
00:30:48,379 --> 00:30:50,648
WOMAN TO HOLD THIS POSITION.

742
00:30:50,715 --> 00:30:53,151
BEFORE JOINING NCI, SHE

743
00:30:53,218 --> 00:30:56,020
SPECIALIZED IN TREATING AND

744
00:30:56,087 --> 00:30:59,624
RESEARCHING GI CANCERS IN HER

745
00:30:59,691 --> 00:31:02,894
ROLE AS THE PROFESSOR OF SURGERY

746
00:31:02,961 --> 00:31:06,030
AT HARVARD MEDICAL SCHOOL AND

747
00:31:06,097 --> 00:31:08,866
SURGEON AT BRING AM AND WOMEN'S

748
00:31:08,933 --> 00:31:09,500
HOSPITAL AS WELL AS MEMBERS OF

749
00:31:09,567 --> 00:31:12,036
THE GI CANCER TREATMENT AND

750
00:31:12,103 --> 00:31:14,305
SARCOMA CENTERS AT DANA-FARBER

751
00:31:14,372 --> 00:31:17,108
CANCER INSTITUTE.

752
00:31:17,175 --> 00:31:19,911
SO NOW I'D LIKE TO PROVIDE SOME

753
00:31:19,978 --> 00:31:24,015
UPDATES REGARDING COUNCIL

754
00:31:24,082 --> 00:31:24,315
MEMBERS.

755
00:31:24,382 --> 00:31:27,619
OUR AD-HOC OARAC MEMBERS IN

756
00:31:27,685 --> 00:31:28,553
ATTENDANCE INTRODUCED THEMSELVES

757
00:31:28,620 --> 00:31:30,722
AT THE BEGINNING OF OUR MEETING

758
00:31:30,788 --> 00:31:31,089
TODAY.

759
00:31:31,155 --> 00:31:32,724
BUT I'D LIKE TO FORMERLY

760
00:31:32,790 --> 00:31:35,393
RECOGNIZE AND WELCOME THEM HERE.

761
00:31:35,460 --> 00:31:39,731
DR.S COURTNEY FLETCHER, SONIA

762
00:31:39,797 --> 00:31:42,834
FLORES, ANNA, DIANE SANTA MARIA

763
00:31:42,900 --> 00:31:45,270
AND SARAH SAWYER.

764
00:31:45,336 --> 00:31:47,105
THANK YOU FOR SERVING ON OARAC

765
00:31:47,171 --> 00:31:48,806
AND WE REALLY LOOK FORWARD TO

766
00:31:48,873 --> 00:31:50,742
YOUR CONTRIBUTIONS.

767
00:31:50,808 --> 00:31:52,043
WE'LL HAVE MORE FORMAL

768
00:31:52,110 --> 00:31:53,544
INTRODUCTIONS WHEN THEY BECOME

769
00:31:53,611 --> 00:31:58,283
FULL VOTING MEMBERS.

770
00:31:58,349 --> 00:31:59,651
AND TO HAVE AFTER SOME DELAYS,

771
00:31:59,717 --> 00:32:03,021
WE ARE VERY, VERY EXCITED AND

772
00:32:03,087 --> 00:32:05,923
HAPPY TO BE ABLE TO OFFICIALLY

773
00:32:05,990 --> 00:32:11,062
RECOGNIZE DR. IVY TURNBULL AS

774
00:32:11,129 --> 00:32:11,429
OAR CHAIRPERSON.

775
00:32:11,496 --> 00:32:13,131
SHE IS THE DEPUTY EXECUTIVE

776
00:32:13,197 --> 00:32:15,566
DIRECTOR AT THE AIDS ALLIANCE

777
00:32:15,633 --> 00:32:17,168
FOR WOMEN AND CHILDREN, YOUTH

778
00:32:17,235 --> 00:32:18,936
AND FAMILIES.

779
00:32:19,003 --> 00:32:21,673
DR. IVY TURNBULL, THANK YOU FOR

780
00:32:21,739 --> 00:32:22,940
YOUR PATIENCE AND THANK YOU FOR

781
00:32:23,007 --> 00:32:24,609
TAKING ON THIS RESPONSIBILITY.

782
00:32:24,676 --> 00:32:28,046
WE LOOK FORWARD TO YOUR

783
00:32:28,112 --> 00:32:28,846
CONTINUED SUPPORT.

784
00:32:28,913 --> 00:32:30,448
AND I ALSO LIKE TO THANK THE

785
00:32:30,515 --> 00:32:33,017
FOLLOWING MEMBERS WHO HAVE

786
00:32:33,084 --> 00:32:34,419
COMPLETED THEIR TURNS AND HERE

787
00:32:34,485 --> 00:32:39,190
FOR THEIR LAST MEETING.

788
00:32:39,257 --> 00:32:42,360
MILLER, RIVERA AND JOHN

789
00:32:42,427 --> 00:32:42,627
SLEASMAN.

790
00:32:42,694 --> 00:32:44,562
COLLEAGUES, THANK YOU FOR YOUR

791
00:32:44,629 --> 00:32:45,229
SERVICE AS OARAC MEMBERS.

792
00:32:45,296 --> 00:32:49,400
WE WILL CONTINUE TO STAY

793
00:32:49,467 --> 00:32:54,605
CONNECTED THROUGH OUR OARAC

794
00:32:54,672 --> 00:32:54,872
WORK.

795
00:32:54,939 --> 00:32:58,843
AND ONE FINAL ITEM REGARDING

796
00:32:58,910 --> 00:32:59,077
COUNCIL.

797
00:32:59,143 --> 00:32:59,877
DR. MONICA GANDHI HAS BEEN

798
00:32:59,944 --> 00:33:01,979
SERVING AS OUR REPRESENTATIVE

799
00:33:02,046 --> 00:33:12,590
FROM THE NIAID NATIONAL ADVISORY

800
00:33:14,258 --> 00:33:14,759
ALLERGY AND INFECTIOUS DISEASES

801
00:33:14,826 --> 00:33:15,393
COUNCIL FOR THREE YEARS AND SHE

802
00:33:15,460 --> 00:33:15,860
IS NOW ROTATING OFF.

803
00:33:15,927 --> 00:33:17,995
WE WELCOME DR. ABRAMS AS THE NEW

804
00:33:18,062 --> 00:33:20,064
COUNCIL REPRESENTATIVE TO OARAC.

805
00:33:20,131 --> 00:33:23,368
WE VERY MUCH APPRECIATE THE

806
00:33:23,434 --> 00:33:26,504
VALUE THAT OUR ADVISORY COUNCIL

807
00:33:26,571 --> 00:33:27,472
REPRESENTATIVES BRING TO THE

808
00:33:27,538 --> 00:33:29,006
COUNCIL AND THANK THEM FOR

809
00:33:29,073 --> 00:33:31,609
BRINGING ITEMS OF INTEREST FROM

810
00:33:31,676 --> 00:33:34,278
THE ICs THEY REPRESENT TO

811
00:33:34,345 --> 00:33:36,748
OARAC AND FOR SHARING IMPORTANT

812
00:33:36,814 --> 00:33:41,719
OARAC UPDATES WITH THEIR ICs.

813
00:33:41,786 --> 00:33:45,223
SO, NOW I'D LIKE TO SHARE SOME

814
00:33:45,289 --> 00:33:49,327
INFORMATION ON TWO RECENT NIH

815
00:33:49,394 --> 00:33:51,295
OAR ENGAGEMENT AND THE PREVIEW

816
00:33:51,362 --> 00:33:53,097
SOME ACTIVITY TAKING PLACE

817
00:33:53,164 --> 00:33:57,101
BEFORE OUR NEXT MEETING IN JUNE.

818
00:33:57,168 --> 00:34:01,305
MANY OF OAR'S ENGAGEMENTS ARE

819
00:34:01,372 --> 00:34:02,440
DRIVEN DRIVEN BY OUR SIGNATURE

820
00:34:02,507 --> 00:34:02,707
PROGRAMS.

821
00:34:02,774 --> 00:34:05,243
YOU HEARD ABOUT THESE AT PRIOR

822
00:34:05,309 --> 00:34:06,844
OARAC MEETINGS.

823
00:34:06,911 --> 00:34:17,422
THESE SIGNATURE PROGRAMS HAVE

824
00:34:40,478 --> 00:34:42,246
LAST NOVEMBER THE OAR SIGNATURE

825
00:34:42,313 --> 00:34:49,353
PROGRAM ON TECHNOLOGY ADVANCES

826
00:34:49,420 --> 00:34:51,322
ORGANIZED AND HELD A TWO-DAY

827
00:34:51,389 --> 00:34:54,425
COMMUNITY ORIENTED WORKSHOP

828
00:34:54,492 --> 00:34:55,827
FOCUSED ON ADVANCING THE

829
00:34:55,893 --> 00:34:58,529
DEVELOPMENT OF HIV TESTING

830
00:34:58,596 --> 00:34:58,863
TECHNOLOGIES.

831
00:34:58,930 --> 00:35:01,199
THE WORKSHOP'S AGENDA WAS

832
00:35:01,265 --> 00:35:02,533
DEVELOPED IN PARTNERSHIP WITH

833
00:35:02,600 --> 00:35:08,139
THE PREVENTION ACCESS CAMPAIGN.

834
00:35:08,206 --> 00:35:10,541
REGULATORY PARTNERS AND

835
00:35:10,608 --> 00:35:12,777
LEVERAGED THE MOMENTUM GAINED

836
00:35:12,844 --> 00:35:15,713
THROUGH RADx TO PUSH FOR THE

837
00:35:15,780 --> 00:35:17,281
DEVELOPMENT OF BETTER

838
00:35:17,348 --> 00:35:19,217
DIAGNOSTICS AND VIRAL LOAD

839
00:35:19,283 --> 00:35:26,757
MONITORING TESTS AT POINT OF

840
00:35:26,824 --> 00:35:31,529
CARE OR PARTICIPANTS AGREED THAT

841
00:35:31,596 --> 00:35:32,763
ACCESS TO -- AFFORDABLE TESTING

842
00:35:32,830 --> 00:35:36,834
IN VIRAL LOAD MONITORING IS

843
00:35:36,901 --> 00:35:40,938
CRITICAL FOR SUSTAINING THE

844
00:35:41,005 --> 00:35:44,475
SUCCESSFUL, UNDETECTABLE,

845
00:35:44,542 --> 00:35:54,986
UNTRANSMITTABLE CAMPAIGN.

846
00:36:17,508 --> 00:36:18,276
ADDITIONAL INFORMATION IS

847
00:36:18,342 --> 00:36:21,746
AVAILABLE ON OUR WEBSITE.

848
00:36:21,812 --> 00:36:27,285
DECEMBER ONE, 2023, MARKED THE

849
00:36:27,351 --> 00:36:31,122
35th OBSERVANCE OF WORLD

850
00:36:31,188 --> 00:36:32,523
AIDS DAY.

851
00:36:32,590 --> 00:36:43,067
OBSERVANCE OF WORLD AIDS DAY

852
00:36:43,501 --> 00:36:43,901
WITHIN AN EVENT ENTITLED,

853
00:36:43,968 --> 00:36:44,535
ACHIEVING EXCELLENCE AND EQUITY

854
00:36:44,602 --> 00:36:46,637
IN HIV RESEARCH.

855
00:36:46,704 --> 00:36:47,238
THE PROGRAM FEATURED AN UPDATE

856
00:36:47,305 --> 00:36:47,838
ON THE HIV/AIDS STRATEGY FROM

857
00:36:47,905 --> 00:36:49,206
Mr. PHILLIPS AND PERSPECTIVES

858
00:36:49,273 --> 00:36:52,677
FROM DR. BILL AND NIAID

859
00:36:52,743 --> 00:37:02,920
DIRECTOR.

860
00:39:23,094 --> 00:39:23,627
OAR WILL CONTINUE PRIORITIZING

861
00:39:23,694 --> 00:39:24,595
OF COLLUSION OF WOMEN IN

862
00:39:24,662 --> 00:39:25,663
PREVENTION, TREATMENT AND CURE

863
00:39:25,730 --> 00:39:27,364
AS AN ESSENTIAL COMPONENT OF

864
00:39:27,431 --> 00:39:31,602
ENDING THE HIV EPIDEMIC.

865
00:39:31,669 --> 00:39:33,637
AND THEN ON APRIL 24, OAR WILL

866
00:39:33,704 --> 00:39:35,573
HOST ITS THIRD ANNUAL VIRTUAL

867
00:39:35,639 --> 00:39:39,577
WORKSHOP FOR EARLY CAREER

868
00:39:39,643 --> 00:39:40,111
INVESTIGATORS.

869
00:39:40,177 --> 00:39:42,113
WE ANTICIPATE ANOTHER GREAT --

870
00:39:42,179 --> 00:39:44,582
ANOTHER GREAT OUTCOME THIS YEAR

871
00:39:44,648 --> 00:39:46,917
AND LOOK FORWARD TO SHARING NEW

872
00:39:46,984 --> 00:39:51,489
DATA REGARDING THE USEFULNESS OF

873
00:39:51,555 --> 00:39:51,922
THIS RESOURCE.

874
00:39:51,989 --> 00:39:55,693
AND I WILL ADD THAT WE ALREADY

875
00:39:55,760 --> 00:39:57,862
HAVE ABOUT 500 PEOPLE REGISTERED

876
00:39:57,928 --> 00:40:01,065
FOR THIS WORKSHOP.

877
00:40:01,132 --> 00:40:03,801
PLEASE CHECK OUR WEBSITE FOR

878
00:40:03,868 --> 00:40:05,236
ADDITIONAL INFORMATION ON THESE

879
00:40:05,302 --> 00:40:07,138
KEY OPPORTUNITIES TO PARTICIPATE

880
00:40:07,204 --> 00:40:12,076
IN ALL OF THESE UPCOMING OAR

881
00:40:12,143 --> 00:40:12,810
ENGAGEMENTS.

882
00:40:12,877 --> 00:40:14,311
AND NOW, I'LL BRIEFLY DISCUSS

883
00:40:14,378 --> 00:40:18,015
THE ROLE OF OAR ANDO RACK AS

884
00:40:18,082 --> 00:40:20,117
WELL AS OUR PLANS FOR THE NEXT

885
00:40:20,184 --> 00:40:21,986
ITERATION OF THE NIH STRATEGIC

886
00:40:22,052 --> 00:40:25,422
PLAN FOR HIV AND HIV-RELATED

887
00:40:25,489 --> 00:40:25,689
RESEARCH.

888
00:40:25,756 --> 00:40:28,859
FOLLOWING MY PRESENTATION,

889
00:40:28,926 --> 00:40:31,362
CAPTAN MARY GLENSHAW AND OAR

890
00:40:31,428 --> 00:40:34,431
SENIOR POLICY ADVISOR,

891
00:40:34,498 --> 00:40:35,533
DR. RACHEL ANDERSON WILL PROVIDE

892
00:40:35,599 --> 00:40:36,133
OVERVIEW OF THE PROCESS TO

893
00:40:36,200 --> 00:40:39,537
DEVELOP THE PLAN AND SHARE NEW

894
00:40:39,603 --> 00:40:43,474
PROPOSED FRAMEWORKS FOR HIV

895
00:40:43,541 --> 00:40:44,141
RESEARCH PRIORITIES.

896
00:40:44,208 --> 00:40:46,343
THEY'LL OUTLINE NEXT STEPS AND

897
00:40:46,410 --> 00:40:48,612
DESCRIBE THE ROLE OFO RACK IN

898
00:40:48,679 --> 00:40:50,347
SUPPORTING THIS ACTIVITY.

899
00:40:50,414 --> 00:40:52,316
THIS IS AN IMPORTANT TIME FOR

900
00:40:52,383 --> 00:40:55,820
OAR AND WE REALLY DO WELCOME

901
00:40:55,886 --> 00:41:00,691
YOUR ADVICE.

902
00:41:00,758 --> 00:41:03,761
SO, FOR A LITTLE BACKGROUND, OAR

903
00:41:03,828 --> 00:41:06,397
WAS CREATED BY CONGRESS IN 1988

904
00:41:06,463 --> 00:41:11,001
AND HAD ITS MANDATE EXPANDED IN

905
00:41:11,068 --> 00:41:11,635
1993.

906
00:41:11,702 --> 00:41:13,971
THE OFFICE AS YOU HEARD FROM

907
00:41:14,038 --> 00:41:16,040
TARA, AUTHORIZED TO ESTABLISH

908
00:41:16,106 --> 00:41:19,009
HIV RESEARCH PRIORITIES, TO

909
00:41:19,076 --> 00:41:20,511
ENSURE NIH AND HIV/AIDS RESEARCH

910
00:41:20,578 --> 00:41:23,380
IS DIRECTED AT THE HIGHEST

911
00:41:23,447 --> 00:41:26,050
PRIORITY RESEARCH AREAS,

912
00:41:26,116 --> 00:41:26,917
DISSEMINATE INFORMATION ABOUT

913
00:41:26,984 --> 00:41:28,886
THE RESEARCH PORTFOLIO TO THE

914
00:41:28,953 --> 00:41:32,156
PUBLIC AND OVERSEE, COORDINATE

915
00:41:32,223 --> 00:41:36,193
AND MANAGE ALL NIH HIV RESEARCH

916
00:41:36,260 --> 00:41:38,429
ACROSS NIH INSTITUTES, CENTERS

917
00:41:38,495 --> 00:41:43,133
AND OFFICES CONDUCTING HIV

918
00:41:43,200 --> 00:41:43,400
RESEARCH.

919
00:41:43,467 --> 00:41:45,870
SO NOW FOCUSING FOR JUST A

920
00:41:45,936 --> 00:41:48,305
MOMENT ON COORDINATION AND

921
00:41:48,372 --> 00:41:50,007
MANAGEMENT AS WELL AS THE NUMBER

922
00:41:50,074 --> 00:41:54,245
OF INSTITUTES, CENTERS AND

923
00:41:54,311 --> 00:41:58,048
OFFICES INVOLVED IN NIH HIV

924
00:41:58,115 --> 00:41:58,315
RESEARCH.

925
00:41:58,382 --> 00:42:00,084
IT'S EVIDENT THAT LIKE AN

926
00:42:00,150 --> 00:42:02,019
ORCHESTRA, EVERY MEMBER PLAYS A

927
00:42:02,086 --> 00:42:04,088
CRITICAL ROLE.

928
00:42:04,154 --> 00:42:05,055
THE NUMBER OF INSTITUTES,

929
00:42:05,122 --> 00:42:10,094
CENTERS AND OFFICES REFLECTS THE

930
00:42:10,160 --> 00:42:13,464
COMPLEXITY OF THIS DISEASE.

931
00:42:13,530 --> 00:42:15,432
AND NOW WITH THIS SLIDE, I WANT

932
00:42:15,499 --> 00:42:18,869
TO SHARE JUST ONE EXAMPLE OF THE

933
00:42:18,936 --> 00:42:20,604
GREAT BREADTH AND SCOPE OF NIH

934
00:42:20,671 --> 00:42:21,672
HIV RESEARCH.

935
00:42:21,739 --> 00:42:23,274
AND HOW INSTITUTES MAY COME

936
00:42:23,340 --> 00:42:25,809
TOGETHER TO ACHIEVE A COMMON

937
00:42:25,876 --> 00:42:26,076
GOAL.

938
00:42:26,143 --> 00:42:28,245
I WILL USE ACRONYMS TO REFER TO

939
00:42:28,312 --> 00:42:30,414
THE INSTITUTES AS I'M TRYING TO

940
00:42:30,481 --> 00:42:33,918
MAKE THE POINT THAT MANY

941
00:42:33,984 --> 00:42:35,252
INSTITUTES CAN BE INVOLVED AND

942
00:42:35,319 --> 00:42:38,589
ARE INVOLVED IN MOVING US

943
00:42:38,656 --> 00:42:38,956
FORWARD.

944
00:42:39,023 --> 00:42:41,292
ON THE LEFT IS AN IMAGE OF THE

945
00:42:41,358 --> 00:42:43,827
CORE STRUCTURE OF HIV.

946
00:42:43,894 --> 00:42:45,095
RESEARCH ON THIS STRUCTURE

947
00:42:45,162 --> 00:42:47,431
BIOLOGY FUNDED FOR MANY, MANY

948
00:42:47,498 --> 00:42:50,334
YEARS BY NIGMS, RESULTED IN A

949
00:42:50,401 --> 00:42:54,238
DEEP UNDERSTANDING OF HOW

950
00:42:54,305 --> 00:42:57,241
INDIVIDUAL MOLECULES INTERACT

951
00:42:57,308 --> 00:42:58,909
AND THEN COME TOGETHER TO FORM

952
00:42:58,976 --> 00:43:02,813
THIS STRUCTURE COMPOSED OF

953
00:43:02,880 --> 00:43:04,014
HEXAMERS DEPICTURED IN ORANGE

954
00:43:04,081 --> 00:43:07,084
AND PENTAMERS IN YELLOW.

955
00:43:07,151 --> 00:43:09,153
NIAID TOOK OVER THESE GRANTS AND

956
00:43:09,219 --> 00:43:12,423
FURTHER FUNDED STUDIES ON HOW

957
00:43:12,489 --> 00:43:13,657
THE INCORPORATION OF THE

958
00:43:13,724 --> 00:43:16,393
PENTAMERS INTO THE STRUCTURE CAN

959
00:43:16,460 --> 00:43:18,462
BE THWARTED AND THEREBY STOP THE

960
00:43:18,529 --> 00:43:21,365
FORMATION OF THIS STRUCTURE AND

961
00:43:21,432 --> 00:43:24,034
STOP VIRAL PRODUCTION.

962
00:43:24,101 --> 00:43:26,203
A DRUG COMPANY USED THIS

963
00:43:26,270 --> 00:43:29,273
FUNDAMENTAL DISCOVERY, THESE

964
00:43:29,340 --> 00:43:30,240
FUNDAMENTAL DISCOVERIES TO THEN

965
00:43:30,307 --> 00:43:32,810
DEVELOP A FIRST-IN CLASS OR A

966
00:43:32,876 --> 00:43:34,712
FIRST OF ITS TYPE DRUG.

967
00:43:34,778 --> 00:43:37,781
THIS IS A NEW DRUG THAT CAN BE

968
00:43:37,848 --> 00:43:41,151
FORMULATED AS A LONG-ACTING DRUG

969
00:43:41,218 --> 00:43:42,419
AND FOR VARIOUS REASONS, IT MAY

970
00:43:42,486 --> 00:43:45,255
ACTUALLY TURN OUT TO BE MORE

971
00:43:45,322 --> 00:43:46,290
PROMISING THAN OTHER DRUGS THAT

972
00:43:46,357 --> 00:43:50,094
WE HAVE FOR PREVENTION AND

973
00:43:50,160 --> 00:43:50,361
TREATMENT.

974
00:43:50,427 --> 00:43:54,498
SEVERAL NIH ICOs INCLUDING

975
00:43:54,565 --> 00:43:58,435
NIAID, NIDA, NICHD AND THE ORWH,

976
00:43:58,502 --> 00:43:59,803
HAVE ALREADY EXPLORED THE

977
00:43:59,870 --> 00:44:03,140
BENEFITS OF LONG-ACTING DRUGS OR

978
00:44:03,207 --> 00:44:05,009
BIOLOGICALS SUCH AS ANTIBODIES.

979
00:44:05,075 --> 00:44:07,578
THIS NEW DRUG MAY BE INVALUABLE

980
00:44:07,644 --> 00:44:09,480
FOR PEOPLE WHO NEED ALTERNATIVE

981
00:44:09,546 --> 00:44:12,483
OPTIONS TO A DAILY PILL OR

982
00:44:12,549 --> 00:44:17,254
PERHAPS IN PREGNANT WOMEN OR IN

983
00:44:17,321 --> 00:44:18,522
ADOLESCENCE OR CHILDREN.

984
00:44:18,589 --> 00:44:23,060
OF COURSE, SIGNIFICANT CHALLE

985
00:44:23,127 --> 00:44:25,496
CHALLENGES REMAIN, BUT IT IS THE

986
00:44:25,562 --> 00:44:27,164
RESEARCH CARRIED OUT THROUGH

987
00:44:27,231 --> 00:44:29,566
EACH INSTITUTE THAT WILL BE MOST

988
00:44:29,633 --> 00:44:31,769
LIKELY TO BETTER THE LIVES OF

989
00:44:31,835 --> 00:44:35,139
ALL PEOPLE AROUND THE WORLD

990
00:44:35,205 --> 00:44:37,374
AFFECTED BY THIS VIRUS.

991
00:44:37,441 --> 00:44:39,743
SO THAT WAS JUST ONE RECENT

992
00:44:39,810 --> 00:44:42,379
EXAMPLE OF WHICH THERE ARE MANY.

993
00:44:42,446 --> 00:44:45,449
THESE ARE NOT SIMPLE PATHWAYS.

994
00:44:45,516 --> 00:44:47,584
THERE ARE CHALLENGES ALONG THE

995
00:44:47,651 --> 00:44:50,788
WAY FROM BASIC BIOLOGY TO HUMAN

996
00:44:50,854 --> 00:44:53,390
BEHAVIOR, FROM LOCAL STRUCTURAL

997
00:44:53,457 --> 00:44:56,460
DETERMINANTS OF HEALTH TO WORLD

998
00:44:56,527 --> 00:44:56,727
POLITICS.

999
00:44:56,794 --> 00:44:58,962
RESEARCH FROM ACROSS THE NIH IS

1000
00:44:59,029 --> 00:45:03,700
CRITICAL IN HELPING PAVE THE WAY

1001
00:45:03,767 --> 00:45:04,268
FORWARD.

1002
00:45:04,334 --> 00:45:07,004
SO, IT IS WITH THIS PERSPECTIVE

1003
00:45:07,071 --> 00:45:09,907
THAT OAR IS DEVELOPING THE NEXT

1004
00:45:09,973 --> 00:45:14,845
FIVE-YEAR STRATEGIC PLAN

1005
00:45:14,912 --> 00:45:20,551
COVERING FY -- IT'S IMPORTANT TO

1006
00:45:20,617 --> 00:45:21,185
UNDERSTAND HOWO RACK FITS INTO

1007
00:45:21,251 --> 00:45:21,885
THIS PROCESS.

1008
00:45:21,952 --> 00:45:24,188
PART OF THE CHARTER, COUNCIL

1009
00:45:24,254 --> 00:45:26,857
MEMBERS PROVIDE GUIDANCE ON THE

1010
00:45:26,924 --> 00:45:30,260
PLANNING, COORDINATION AND

1011
00:45:30,327 --> 00:45:31,061
EVALUATION OF THE NIH HIV

1012
00:45:31,128 --> 00:45:35,599
RESEARCH PROGRAMS AND RELATED

1013
00:45:35,666 --> 00:45:35,899
ACTIVITIES.

1014
00:45:35,966 --> 00:45:38,802
O RACK ADVISES THE DIRECTOR

1015
00:45:38,869 --> 00:45:39,436
REGARDING HIV RESEARCH

1016
00:45:39,503 --> 00:45:40,037
PRIORITIES AND THE ON THE

1017
00:45:40,104 --> 00:45:48,345
DEVELOPMENT OF A COMPREHENSIVE

1018
00:45:48,412 --> 00:45:55,786
PLAN -- PRIOR DFO APPROVAL.

1019
00:45:55,853 --> 00:45:57,754
AS WE DEVELOP, THE NEXT

1020
00:45:57,821 --> 00:45:59,790
STRATEGIC PLAN, WE ARE REALLY AT

1021
00:45:59,857 --> 00:46:00,491
A CRITICAL MOMENT.

1022
00:46:00,557 --> 00:46:02,826
WE ARE LOOKING TO OARAC AND THE

1023
00:46:02,893 --> 00:46:05,662
BROADER COMMUNITY FOR INPUT AS

1024
00:46:05,729 --> 00:46:07,731
WE WORK TO DETERMINE PRIORITIES,

1025
00:46:07,798 --> 00:46:11,335
GAPS AND AREAS OF FOCUS.

1026
00:46:11,401 --> 00:46:13,003
THIS IS A CHALLENGE AS GREAT

1027
00:46:13,070 --> 00:46:15,005
PROGRESS HAS BEEN MADE BUT THERE

1028
00:46:15,072 --> 00:46:17,875
IS STILL MANY MAJOR GAPS THAT

1029
00:46:17,941 --> 00:46:22,045
PERSIST ACROSS THE ENTIRE

1030
00:46:22,112 --> 00:46:22,312
CONTINUUM.

1031
00:46:22,379 --> 00:46:24,348
THEIR IMPACTFUL DECISIONS TO BE

1032
00:46:24,414 --> 00:46:26,884
MADE AT THIS TIME, PARTICULARLY

1033
00:46:26,950 --> 00:46:29,386
GIVEN THAT WE MAY BE WORKING

1034
00:46:29,453 --> 00:46:31,822
WITHIN THE CONSTRAINTS OF A

1035
00:46:31,889 --> 00:46:35,926
LIMITED -- MORE LIMITED BUDGET.

1036
00:46:35,993 --> 00:46:37,928
THE EVOLUTION OF THE STATE OF

1037
00:46:37,995 --> 00:46:40,197
HIV SCIENCE, FOR EXAMPLE, THE

1038
00:46:40,264 --> 00:46:43,267
RECENT DEVELOPMENT SUCH AS THE

1039
00:46:43,333 --> 00:46:45,602
CONVERGENCE OF PREP AND

1040
00:46:45,669 --> 00:46:47,604
TREATMENT AS WELL AS NEW

1041
00:46:47,671 --> 00:46:49,006
LONG-ACTING FORMULATIONS, HAS

1042
00:46:49,072 --> 00:46:54,077
LED US TO RECONSIDER HOW TO

1043
00:46:54,144 --> 00:46:54,878
FRAME THE PRIORITIES MOVING

1044
00:46:54,945 --> 00:46:55,112
FORWARD.

1045
00:46:55,179 --> 00:46:57,314
THE REALITY OF INCREASINGLY

1046
00:46:57,381 --> 00:46:59,216
CONSTRAINED BUDGETS AND A MORE

1047
00:46:59,283 --> 00:47:01,218
DEFINED FEDERAL AGENDA TO END

1048
00:47:01,285 --> 00:47:05,255
THE HIV EPIDEMIC PROVIDE

1049
00:47:05,322 --> 00:47:07,524
OPPORTUNITIES EXPLORE AS WE LOOK

1050
00:47:07,591 --> 00:47:10,127
AT OUR PRIORITIES.

1051
00:47:10,194 --> 00:47:12,062
WE AIM TO INCREASE THE

1052
00:47:12,129 --> 00:47:13,463
EFFICIENCY BY BRINGING

1053
00:47:13,530 --> 00:47:15,299
INSTITUTES TOGETHER, FOSTERING A

1054
00:47:15,365 --> 00:47:17,701
DEEPER SENSE OF COLLABORATION

1055
00:47:17,768 --> 00:47:19,803
WHENEVER POSSIBLE TO INTEGRATE

1056
00:47:19,870 --> 00:47:22,372
AND COMPLIMENT EACH OTHER'S

1057
00:47:22,439 --> 00:47:22,573
WORK.

1058
00:47:22,639 --> 00:47:28,579
THE FY2026-2030 PLAN WILL

1059
00:47:28,645 --> 00:47:30,480
CONTAIN A REVISED FRAMEWORK

1060
00:47:30,547 --> 00:47:33,183
FOLLOWING THE HIV RESEARCH

1061
00:47:33,250 --> 00:47:34,084
CONTINUUM.

1062
00:47:34,151 --> 00:47:37,354
INCLUDING SPECIFIC RESEARCH

1063
00:47:37,421 --> 00:47:38,255
CAPACITY PRIORITIES.

1064
00:47:38,322 --> 00:47:39,690
YOU'LL HEAR MORE ABOUT THIS IN

1065
00:47:39,756 --> 00:47:41,592
THE NEXT PRESENTATION BUT AT A

1066
00:47:41,658 --> 00:47:44,895
VERY, VERY HIGH LEVEL, THE NEW

1067
00:47:44,962 --> 00:47:47,764
PLAN WILL ALSO FACILITATE AND

1068
00:47:47,831 --> 00:47:49,833
SUPPORT DATA-INFORMED

1069
00:47:49,900 --> 00:47:53,437
PRIORITIZATION FOR DIRECTING

1070
00:47:53,503 --> 00:47:54,838
CONGRESSIONALLY-APPROPRIATED NIH

1071
00:47:54,905 --> 00:47:55,572
HIV FUNDING.

1072
00:47:55,639 --> 00:47:57,908
WHILE ALSO ENABLING TRANSPARENCY

1073
00:47:57,975 --> 00:48:01,478
TO FOSTER EFFICIENCY AND

1074
00:48:01,545 --> 00:48:03,780
COLLABORATION ACROSS AND BETWEEN

1075
00:48:03,847 --> 00:48:06,183
NIH INSTITUTES AND CENTERS.

1076
00:48:06,250 --> 00:48:09,419
SO NOW MOVING FORWARD TO JUST A

1077
00:48:09,486 --> 00:48:13,257
FEW HOUSEKEEPING ITEMS BEFORE I

1078
00:48:13,323 --> 00:48:13,557
CONCLUDE.

1079
00:48:13,624 --> 00:48:15,659
I WANT TO REMIND COUNCIL MEMBERS

1080
00:48:15,726 --> 00:48:18,161
THAT OUR NEXT MEETING IS ON

1081
00:48:18,228 --> 00:48:23,133
THURSDAY JUNE 20, 2024 AND THAT

1082
00:48:23,200 --> 00:48:24,768
MEETING WILL BE HELD IN PERSON.

1083
00:48:24,835 --> 00:48:27,337
AS ALWAYS, THE MEETING WILL ALSO

1084
00:48:27,404 --> 00:48:29,606
BE VIDEOCAST SO THE PUBLIC CAN

1085
00:48:29,673 --> 00:48:29,906
VIEW.

1086
00:48:29,973 --> 00:48:32,409
I WANT TO THANK YOU FOR MAKING

1087
00:48:32,476 --> 00:48:34,544
THESE MEETINGS A PRIORITY IN

1088
00:48:34,611 --> 00:48:37,981
YOUR BUSY SCHEDULES.

1089
00:48:38,048 --> 00:48:41,251
THE REST OF THE AGENDA TODAY

1090
00:48:41,318 --> 00:48:43,220
INCLUDES THE DEEPER DIVE, WHICH

1091
00:48:43,287 --> 00:48:46,056
I MENTIONED, INTO THE

1092
00:48:46,123 --> 00:48:46,723
DEVELOPMENT OF THE NEXT

1093
00:48:46,790 --> 00:48:49,393
STRATEGIC PLAN, UPDATES FROM NIH

1094
00:48:49,459 --> 00:48:51,528
ADVISORY COUNCIL REPRESENTATIVES

1095
00:48:51,595 --> 00:48:54,364
TO OARAC, AND UPDATES FROM THE

1096
00:48:54,431 --> 00:48:57,067
HIV CLINICAL GUIDELINES WORKING

1097
00:48:57,134 --> 00:49:00,537
GROUPS AT OARAC.

1098
00:49:00,604 --> 00:49:02,372
THANK YOU ALL SO MUCH FOR YOUR

1099
00:49:02,439 --> 00:49:03,006
ATTENTION.

1100
00:49:03,073 --> 00:49:05,075
WE NOW HAVE TIME FOR SOME

1101
00:49:05,142 --> 00:49:07,778
QUESTIONS AND FOR SOME

1102
00:49:07,844 --> 00:49:08,078
DISCUSSION.

1103
00:49:08,145 --> 00:49:09,546
BUT I'LL ASK YOU HOLD ANY

1104
00:49:09,613 --> 00:49:11,982
QUESTIONS RELATED TO THE

1105
00:49:12,049 --> 00:49:14,785
STRATEGIC PLAN UNTIL AFTER THE

1106
00:49:14,851 --> 00:49:16,219
NEXT PRESENTATION.

1107
00:49:16,286 --> 00:49:18,188
AND, WE JUST PUT THIS SLIDE UP

1108
00:49:18,255 --> 00:49:21,425
AND WE'LL KEEP IT UP AS IT HAS

1109
00:49:21,491 --> 00:49:26,129
THE QR CODE FOR THE RFI.

1110
00:49:26,196 --> 00:49:30,400
THANK YOU AND BACK OVER TO YOU,

1111
00:49:30,467 --> 00:49:40,711
DR. TURN BULL.

1112
00:49:42,446 --> 00:49:43,613
>> IVY TURNBULL: THANK YOU FOR

1113
00:49:43,680 --> 00:49:46,783
THIS UPDATE.

1114
00:49:46,850 --> 00:49:48,318
WE WILL NOW HAVE TIME FOR

1115
00:49:48,385 --> 00:49:48,652
DISCUSSION.

1116
00:49:48,719 --> 00:49:49,853
BEFORE WE MOVE INTO OUR

1117
00:49:49,920 --> 00:49:51,988
DISCUSSION SESSION, I'D LIKE TO

1118
00:49:52,055 --> 00:49:54,224
ACKNOWLEDGE THAT TWO MEMBERS OF

1119
00:49:54,291 --> 00:49:57,928
THE OARAC EX OFFICIOS JOINED THE

1120
00:49:57,994 --> 00:50:03,667
MEETING AND THAT IS DR. JONATHAN

1121
00:50:03,734 --> 00:50:06,570
MERMIN AND -- SO OARAC MEMBERS,

1122
00:50:06,636 --> 00:50:08,638
PLEASE IF YOU HAVE A QUESTION OR

1123
00:50:08,705 --> 00:50:10,407
COMMENT, PLEASE USE THE RAISE

1124
00:50:10,474 --> 00:50:12,409
YOUR HAND FUNCTION SO THAT WE

1125
00:50:12,476 --> 00:50:22,919
CAN BEGIN OUR DISCUSSION.

1126
00:50:42,072 --> 00:50:44,374
IF YOU DON'T HAVE ANY QUESTIONS

1127
00:50:44,441 --> 00:50:46,910
OR COMMENTS -- I DON'T SEE ANY

1128
00:50:46,977 --> 00:50:49,513
RAISED HANDS.

1129
00:50:49,579 --> 00:50:53,750
WE WILL THEN MOVE --

1130
00:50:53,817 --> 00:50:54,384
>> DR. TURNBULL, I THINK THERE

1131
00:50:54,451 --> 00:50:57,521
IS A HAND UP.

1132
00:50:57,587 --> 00:50:58,955
>> SORRY.

1133
00:50:59,022 --> 00:50:59,389
>> IT'S ALL RIGHT.

1134
00:50:59,456 --> 00:51:03,193
I WANT TO MAKE SURE THAT WE

1135
00:51:03,260 --> 00:51:06,430
WELCOME DR. FINSY AS ACTING

1136
00:51:06,496 --> 00:51:06,696
DIRECTOR.

1137
00:51:06,763 --> 00:51:12,502
I THINK HER EXPERIENCE IN THIS

1138
00:51:12,569 --> 00:51:13,270
AREA REALLY POISES THE OARAC TO

1139
00:51:13,336 --> 00:51:15,405
GOOD HANDS MOVING FORWARD.

1140
00:51:15,472 --> 00:51:16,306
SO THANK YOU FOR ACCEPTING

1141
00:51:16,373 --> 00:51:18,408
TAKING THIS CHARGE.

1142
00:51:18,475 --> 00:51:21,211
AND I THINK IT'S REALLY AN

1143
00:51:21,278 --> 00:51:21,711
EXCITING TIME.

1144
00:51:21,778 --> 00:51:23,380
I'M LOOKING FORWARD TO THE

1145
00:51:23,447 --> 00:51:25,248
STRATEGIC PLAN AND TO THE

1146
00:51:25,315 --> 00:51:26,950
DIFFERENCE WE ARE ALL GOING TO

1147
00:51:27,017 --> 00:51:29,719
MAKE BECAUSE I THINK IT'S REALLY

1148
00:51:29,786 --> 00:51:31,054
TRANSFORMATIONAL PERIOD FOR THE

1149
00:51:31,121 --> 00:51:33,757
HIV RESEARCH EFFORT IN MANY

1150
00:51:33,824 --> 00:51:33,990
FRONTS.

1151
00:51:34,057 --> 00:51:36,927
AND SO I THINK THE FUTURE LOOKS

1152
00:51:36,993 --> 00:51:40,397
VERY GOOD FOR ADVANCEMENTS AND

1153
00:51:40,464 --> 00:51:42,933
FOR GUIDING THIS EFFORT FORWARD.

1154
00:51:42,999 --> 00:51:45,569
BUT I WANTED TO WELCOME YOU AND

1155
00:51:45,635 --> 00:51:49,439
THANK YOU FOR TAKING ON THIS

1156
00:51:49,506 --> 00:51:49,673
CHARGE.

1157
00:51:49,739 --> 00:51:51,408
>> THANK YOU LUIS, I REALLY

1158
00:51:51,475 --> 00:51:55,312
APPRECIATE IT AND I WANT TO

1159
00:51:55,378 --> 00:51:56,313
THANK YOU BACK FOR BEING SO

1160
00:51:56,379 --> 00:51:59,382
SUPPORTIVE AND SO INVOLVED IN

1161
00:51:59,449 --> 00:52:02,118
WORLD AIDS DAY AS WELL AS

1162
00:52:02,185 --> 00:52:04,588
SUPPORTING US AT OAR.

1163
00:52:04,654 --> 00:52:10,293
VERY MUCH APPRECIATE IT.

1164
00:52:10,360 --> 00:52:12,529
THANK YOU.

1165
00:52:12,596 --> 00:52:16,500
>> ANY OTHER COMMENTS OR

1166
00:52:16,566 --> 00:52:22,038
QUESTIONS?

1167
00:52:22,105 --> 00:52:24,341
THANK YOU, EVERYONE.

1168
00:52:24,407 --> 00:52:27,010
SEEING NONE, WE'LL NOW HEAR FROM

1169
00:52:27,077 --> 00:52:31,815
DR. MARY GLENSHAW AND DR. RACHEL

1170
00:52:31,882 --> 00:52:33,783
ANDERSON WHO SERVE AS OAR SENIOR

1171
00:52:33,850 --> 00:52:35,952
SCIENCE ADVISER AND SENIOR

1172
00:52:36,019 --> 00:52:40,423
POLICY VISOR, RESPECTIVELY.

1173
00:52:40,490 --> 00:52:41,291
DR. GLENN SHAW AND DR. ANDERSON,

1174
00:52:41,358 --> 00:52:45,695
PLEASE BEGIN WHEN YOU'RE READY.

1175
00:52:45,762 --> 00:52:46,730
>> THANK YOU AND GOOD AFTERNOON,

1176
00:52:46,796 --> 00:52:46,997
EVERYONE.

1177
00:52:47,063 --> 00:52:50,901
TODAY I'M SPEAKING WITH CAPTAN

1178
00:52:50,967 --> 00:52:51,868
FLOWN SHAW TO SHARE AN UPDATE ON

1179
00:52:51,935 --> 00:52:54,838
BEHALF OF THE NIH OAR STRATEGIC

1180
00:52:54,905 --> 00:52:55,939
PLAN AND NIH RESEARCH PRIORITIES

1181
00:52:56,006 --> 00:52:58,642
WORKING GROUP.

1182
00:52:58,708 --> 00:53:00,043
HERE IS A QUICK OUTLINE OF OUR

1183
00:53:00,110 --> 00:53:00,810
REMARKS TODAY.

1184
00:53:00,877 --> 00:53:03,547
WE WILL START BY PROVIDING SOME

1185
00:53:03,613 --> 00:53:05,649
BACKGROUND AND CONTEXT INCLUDING

1186
00:53:05,715 --> 00:53:08,218
A RATIONAL FOR UPDATING THE

1187
00:53:08,285 --> 00:53:12,923
STRATEGIC PLAN FRAMEWORK.

1188
00:53:12,989 --> 00:53:13,523
DESCRIBE THE UPDATED FRAMEWORK

1189
00:53:13,590 --> 00:53:14,724
AND PROCESS AND THEN WE'LL TALK

1190
00:53:14,791 --> 00:53:16,393
ABOUT THE SOURCES OF INPUT AND

1191
00:53:16,459 --> 00:53:19,062
NEXT STEPS AND THEN FINALLY WE

1192
00:53:19,129 --> 00:53:20,664
WILL DESCRIBE OARAC INVOLVEMENT

1193
00:53:20,730 --> 00:53:27,938
IN MORE DETAIL.

1194
00:53:28,004 --> 00:53:32,075
AS YOU HEARD EARLIER, OAR IS

1195
00:53:32,142 --> 00:53:32,609
LEGISLATIVELY MANDATED TO

1196
00:53:32,676 --> 00:53:36,079
DEVELOP AN UPDATED STRATEGIC

1197
00:53:36,146 --> 00:53:36,813
PLAN FOR HIV RESEARCH ACROSS

1198
00:53:36,880 --> 00:53:36,980
NIH.

1199
00:53:37,047 --> 00:53:40,183
BEYOND FULFILLING THE MANDATE,

1200
00:53:40,250 --> 00:53:40,784
THE STRATEGIC PLAN IS USED TO

1201
00:53:40,850 --> 00:53:42,519
SUPPORT MANY CORE FUNCTIONS OF

1202
00:53:42,586 --> 00:53:42,686
OAR.

1203
00:53:42,752 --> 00:53:46,690
THE PLAN NOT ONLY PROVIDES A

1204
00:53:46,756 --> 00:53:48,325
ROADMAP FOR HIV RESEARCH, IT

1205
00:53:48,391 --> 00:53:50,093
ALSO SERVES AS A GUIDING

1206
00:53:50,160 --> 00:53:52,562
FRAMEWORK FOR OAR'S EDUCATIONAL

1207
00:53:52,629 --> 00:53:56,433
FUNDS TO THE DIFFERENT ICOs TO

1208
00:53:56,499 --> 00:53:57,033
ENSURE INVESTMENT OF RESOURCES

1209
00:53:57,100 --> 00:53:58,935
IN THE HIGHEST SCIENTIFIC

1210
00:53:59,002 --> 00:54:00,737
PRIORITY AREAS.

1211
00:54:00,804 --> 00:54:01,638
THE PLAN ALSO INFORMS

1212
00:54:01,705 --> 00:54:03,840
DEVELOPMENT OF OUR TWO MAJOR

1213
00:54:03,907 --> 00:54:05,208
BUDGET NARRATIVE REPORTS EACH

1214
00:54:05,275 --> 00:54:08,812
YEAR INCLUDING THE CONGRESSIONAL

1215
00:54:08,878 --> 00:54:09,446
JUSTIFICATION OF THE BUDGET AS

1216
00:54:09,512 --> 00:54:10,947
WELL AS THE PROFESSIONAL

1217
00:54:11,014 --> 00:54:12,649
JUDGMENT BUDGET.

1218
00:54:12,716 --> 00:54:14,651
ADDITIONALLY, THE STRATEGIC PLAN

1219
00:54:14,718 --> 00:54:18,755
CAN SERVE AS A TOOL THAT INSURES

1220
00:54:18,822 --> 00:54:19,089
TRANSPARENCY.

1221
00:54:19,155 --> 00:54:19,689
WE SAY WHAT OUR RESEARCH

1222
00:54:19,756 --> 00:54:21,291
PRIORITIES ARE AND THAT'S WHAT

1223
00:54:21,358 --> 00:54:22,392
WE SUPPORT.

1224
00:54:22,459 --> 00:54:24,027
FINALLY, OUR STRATEGIC PLANNING

1225
00:54:24,094 --> 00:54:26,329
PROCESS IS DESIGNED TO MAXIMIZE

1226
00:54:26,396 --> 00:54:31,434
PARTNER INPUT.

1227
00:54:31,501 --> 00:54:33,269
TO PROVIDE SOME HISTORICAL

1228
00:54:33,336 --> 00:54:34,237
CONTEXT, I'LL BRIEFLY OUTLINE

1229
00:54:34,304 --> 00:54:35,672
THE RECENT HISTORY OF THE NIH

1230
00:54:35,739 --> 00:54:38,475
STRATEGIC PLANS FOR HIV

1231
00:54:38,541 --> 00:54:38,808
RESEARCH.

1232
00:54:38,875 --> 00:54:42,112
SINCE ISSUING THE FIRST PLAN IN

1233
00:54:42,178 --> 00:54:43,913
1993, OAR HAS DEVELOPED

1234
00:54:43,980 --> 00:54:45,382
COMPREHENSIVE RESEARCH PLAN EACH

1235
00:54:45,448 --> 00:54:46,850
YEAR THROUGH A COLLABORATIVE

1236
00:54:46,916 --> 00:54:49,886
PROCESS INVOLVING BROAD INPUT

1237
00:54:49,953 --> 00:54:55,458
FROM THE COMMUNITY.

1238
00:54:55,525 --> 00:54:57,994
UNTIL RECENTLY, THESE WERE

1239
00:54:58,061 --> 00:54:58,628
ANNUAL PLANS.

1240
00:54:58,695 --> 00:55:00,363
OLDER STRATEGIC PLANS INCLUDED A

1241
00:55:00,430 --> 00:55:02,599
BROAD LIST OF TOPICAL RESEARCH

1242
00:55:02,666 --> 00:55:04,834
AREAS OF EMPHASIS WHICH WAS

1243
00:55:04,901 --> 00:55:06,002
APPROPRIATE AT THE TIME WHEN

1244
00:55:06,069 --> 00:55:07,804
LITTLE WAS YET KNOWN ABOUT AIDS,

1245
00:55:07,871 --> 00:55:11,307
HIV AND HOW TO MITIGATE THE

1246
00:55:11,374 --> 00:55:12,742
EPIDEMIC AND DURING A TIME WHEN

1247
00:55:12,809 --> 00:55:16,146
THE HIV -- SORRY WHEN THE NIH

1248
00:55:16,212 --> 00:55:16,980
RESEARCH BUDGET DOUBLED.

1249
00:55:17,047 --> 00:55:20,650
THAT WAS FOR 1998-2003.

1250
00:55:20,717 --> 00:55:22,318
OVER TIME, THE STRUCTURE OF THE

1251
00:55:22,385 --> 00:55:25,055
PLANS EVOLVED TO DESCRIBE THE

1252
00:55:25,121 --> 00:55:26,456
BIOMEDICAL AND BEHAVIORAL

1253
00:55:26,523 --> 00:55:27,824
RESEARCH AND TRAINING ACTIVITIES

1254
00:55:27,891 --> 00:55:30,393
NEEDED TO ADDRESS THE HIV

1255
00:55:30,460 --> 00:55:32,696
EPIDEMIC AND TO DEFINE SPECIFIC

1256
00:55:32,762 --> 00:55:34,130
PRIORITIES AS THE SCIENCE AND

1257
00:55:34,197 --> 00:55:36,800
THE EPIDEMIC EVOLVED.

1258
00:55:36,866 --> 00:55:40,503
IN 2013, NIH LEADERSHIP TASKED

1259
00:55:40,570 --> 00:55:44,340
OARAC WITH DEVELOPING A NEW

1260
00:55:44,407 --> 00:55:44,874
BLUEPRINT FOR HIV RESEARCH

1261
00:55:44,941 --> 00:55:45,341
PRIORITIES.

1262
00:55:45,408 --> 00:55:47,677
PRIORITIES THAT WERE BOLD BUT

1263
00:55:47,744 --> 00:55:49,145
ACHIEVABLE AND SIMULTANEOUSLY

1264
00:55:49,212 --> 00:55:51,748
SPECIFIC AND COMPREHENSIVE.

1265
00:55:51,815 --> 00:55:54,551
THIS DEVELOPMENT TOOK TIME AND

1266
00:55:54,617 --> 00:55:55,251
ULTIMATELY RESULTED IN THE

1267
00:55:55,318 --> 00:55:57,220
CONCEPT OF OVERARCHING

1268
00:55:57,287 --> 00:55:57,921
PRIORITIES WHICH WAS FIRST

1269
00:55:57,987 --> 00:56:01,658
INCLUDED WITH THE FISCAL YEAR

1270
00:56:01,725 --> 00:56:04,794
2017 PLAN.

1271
00:56:04,861 --> 00:56:06,496
AS YOU CAN SEE IN THE GRAPHIC ON

1272
00:56:06,563 --> 00:56:09,899
THE RIGHT, THERE WERE FOUR

1273
00:56:09,966 --> 00:56:13,536
OVERARCHING PRIORITIES REDUCING

1274
00:56:13,603 --> 00:56:14,871
INCIDENCE, NEXT GENERATION

1275
00:56:14,938 --> 00:56:16,439
THERAPIES, CURE AND

1276
00:56:16,506 --> 00:56:17,140
CO-MORBIDITIES AS WELL AS

1277
00:56:17,207 --> 00:56:18,775
CROSSCUTTING AREAS DEPICTED IN

1278
00:56:18,842 --> 00:56:23,346
THE ARROW THAT SPANS ACROSS THE

1279
00:56:23,413 --> 00:56:23,546
AREAS.

1280
00:56:23,613 --> 00:56:25,081
THE FOLLOWING YEAR, THE FISCAL

1281
00:56:25,148 --> 00:56:27,550
YEAR 2018 PLAN INCLUDED AN

1282
00:56:27,617 --> 00:56:29,285
EXPANSION OF THESE CROSSCUTTING

1283
00:56:29,352 --> 00:56:31,588
AREAS ACROSS THE FOUR

1284
00:56:31,654 --> 00:56:32,856
OVERARCHING PRIORITIES.

1285
00:56:32,922 --> 00:56:35,258
THESE AREAS INCLUDED BASIC

1286
00:56:35,325 --> 00:56:36,760
RESEARCH, HEALTH DISPARITIES,

1287
00:56:36,826 --> 00:56:39,362
BEHAVIORAL AND SOCIAL SCIENCE

1288
00:56:39,429 --> 00:56:42,532
AND INFORMATION DISSEMINATION.

1289
00:56:42,599 --> 00:56:45,135
IN 2019, THE CURRENT VERSION OF

1290
00:56:45,201 --> 00:56:46,536
THESE PRIORITIES WAS PUBLISHED

1291
00:56:46,603 --> 00:56:49,038
IN THE NOW FAMILIAR GRAPHIC ON

1292
00:56:49,105 --> 00:56:49,739
THE RIGHT.

1293
00:56:49,806 --> 00:56:52,408
SPECIFIC AND CROSSCUTTING AREAS

1294
00:56:52,475 --> 00:56:53,543
WERE FURTHER REFINED.

1295
00:56:53,610 --> 00:56:55,078
THE FIRST FIVE-YEAR PLAN WAS

1296
00:56:55,145 --> 00:56:57,080
RELEASED IN 2021 AND REMAINS IN

1297
00:56:57,147 --> 00:57:00,984
PLACE TO THE END OF FISCAL YEAR

1298
00:57:01,050 --> 00:57:01,451
2025.

1299
00:57:01,518 --> 00:57:04,354
A FIVE-YEAR PLAN FACILITATES

1300
00:57:04,420 --> 00:57:05,088
LONGER-TERM PLANNING AND

1301
00:57:05,155 --> 00:57:06,523
RECOGNIZES THE MULTI-YEAR TIME

1302
00:57:06,589 --> 00:57:09,325
LINES ASSOCIATED WITH MOST NIH

1303
00:57:09,392 --> 00:57:11,494
SUPPORTED RESEARCH PROJECTS.

1304
00:57:11,561 --> 00:57:13,797
FIVE YEARS IS ALSO CONGRUENT

1305
00:57:13,863 --> 00:57:14,697
WITH OTHER PLANS ACROSS NIH

1306
00:57:14,764 --> 00:57:18,968
INCLUDING THE NIH-WIDE STRATEGIC

1307
00:57:19,035 --> 00:57:22,005
PLAN.

1308
00:57:22,071 --> 00:57:25,141
THE FOUR STRATEGIC GOALS AND

1309
00:57:25,208 --> 00:57:26,442
FIVE OVERARCHING PRIORITIES

1310
00:57:26,509 --> 00:57:28,044
FEATURED IN THE CURRENT PLAN ARE

1311
00:57:28,111 --> 00:57:29,579
SHOWN ON THE SLIDE HERE.

1312
00:57:29,646 --> 00:57:32,115
BY DESIGN, THERE IS NO DIRECT

1313
00:57:32,182 --> 00:57:33,316
RELATIONSHIP BETWEEN THE GOALS

1314
00:57:33,383 --> 00:57:35,084
AND PRIORITIES IN THIS PLAN.

1315
00:57:35,151 --> 00:57:37,587
AS A REMINDER, THE CURRENT

1316
00:57:37,654 --> 00:57:41,724
STRATEGIC GOALS ARE TO ADVANCE

1317
00:57:41,791 --> 00:57:42,892
RESEARCH, REMAIN FLEXIBLE AND

1318
00:57:42,959 --> 00:57:45,528
RESPONSIVE TO EMERGING NEEDS, TO

1319
00:57:45,595 --> 00:57:47,463
PROMOTE IMPLEMENTATION AND

1320
00:57:47,530 --> 00:57:49,165
DISSEMINATION OF RESEARCH

1321
00:57:49,232 --> 00:57:50,400
FINDINGS AND TO STRENGTHEN

1322
00:57:50,466 --> 00:57:53,937
WORKFORCE AND INFRASTRUCTURE

1323
00:57:54,003 --> 00:57:54,771
CAPACITY.

1324
00:57:54,838 --> 00:57:55,471
THE PRIORITY AREAS SHOWN HERE

1325
00:57:55,538 --> 00:57:59,008
AGAIN ON THE SLIDE ARE EQUALLY

1326
00:57:59,075 --> 00:57:59,709
BROAD.

1327
00:57:59,776 --> 00:58:01,177
THESE PRIORITY AREAS AS

1328
00:58:01,244 --> 00:58:03,179
CURRENTLY STATED REPRESENT A

1329
00:58:03,246 --> 00:58:05,949
COMBINATION OF TOPICAL AREAS AND

1330
00:58:06,015 --> 00:58:06,950
SCIENTIFIC DISCIPLINES.

1331
00:58:07,016 --> 00:58:08,184
DESPITE THE LABEL, THESE AREAS

1332
00:58:08,251 --> 00:58:10,587
DO NOT ACTUALLY ARTICULATE

1333
00:58:10,653 --> 00:58:13,756
SPECIFIC LEVELS OF FUNDING --

1334
00:58:13,823 --> 00:58:13,957
SORRY.

1335
00:58:14,023 --> 00:58:15,291
SPECIFIC LEVELS OF PRIORITY OF

1336
00:58:15,358 --> 00:58:16,059
RESEARCH AREAS.

1337
00:58:16,125 --> 00:58:18,127
THE REALITY OF INCREASINGLY

1338
00:58:18,194 --> 00:58:20,496
CONSTRAINED BUDGETS REQUIRES

1339
00:58:20,563 --> 00:58:21,431
PRIORITIZATION WITH GREATER

1340
00:58:21,497 --> 00:58:24,067
CLARITY AND SPECIFICITY.

1341
00:58:24,133 --> 00:58:26,703
IN 2023, OAR RECEIVED PERMISSION

1342
00:58:26,769 --> 00:58:28,905
FROM NIH LEADERSHIP TO REVISIT

1343
00:58:28,972 --> 00:58:31,975
HOW THE HIV RESEARCH PRIORITIES

1344
00:58:32,041 --> 00:58:33,843
ARE FRAMED WITHIN THE STRATEGIC

1345
00:58:33,910 --> 00:58:37,881
PLAN.

1346
00:58:37,947 --> 00:58:40,216
WE NOW HAVE THE OPPORTUNITY TO

1347
00:58:40,283 --> 00:58:41,451
REARRANGE THE STRUCTURE

1348
00:58:41,517 --> 00:58:45,521
SOMEWHAT, TO DIRECTLY LINK HIV

1349
00:58:45,588 --> 00:58:47,390
GOALS, HIV RESEARCH GOALS WITH

1350
00:58:47,457 --> 00:58:49,425
CORRESPONDING OBJECTIVES AND

1351
00:58:49,492 --> 00:58:50,593
TOPICAL PRIORITIES.

1352
00:58:50,660 --> 00:58:51,928
UPDATED FRAMEWORK CAN LEVERAGE

1353
00:58:51,995 --> 00:58:54,097
THE INCREASING INTERSECTION OF

1354
00:58:54,163 --> 00:58:59,269
SCIENTIFIC APPROACHES ACROSS HIV

1355
00:58:59,335 --> 00:59:00,270
PREVENTION, TREATMENT,

1356
00:59:00,336 --> 00:59:01,704
CO-MORBIDITIES AND CURE

1357
00:59:01,771 --> 00:59:02,305
RESEARCH.

1358
00:59:02,372 --> 00:59:05,308
THESE CHANGES CAN PROMOTE

1359
00:59:05,375 --> 00:59:06,309
INTERDISCIPLINARY INTEGRATIVE

1360
00:59:06,376 --> 00:59:07,310
RESEARCH AND HIGHLIGHT

1361
00:59:07,377 --> 00:59:08,511
POPULATIONS, SETTINGS AND

1362
00:59:08,578 --> 00:59:11,247
CHALLENGES THAT, MERGE AND SHIFT

1363
00:59:11,314 --> 00:59:11,915
OVER TIME.

1364
00:59:11,981 --> 00:59:13,549
IT'S IMPORTANT TO NOTE THAT THE

1365
00:59:13,616 --> 00:59:15,785
UPDATED FRAMEWORK WILL NOT

1366
00:59:15,852 --> 00:59:17,053
ELIMINATE THE CURRENT PRIORITY

1367
00:59:17,120 --> 00:59:18,888
AREAS BUT WILL HIGHLIGHT THESE

1368
00:59:18,955 --> 00:59:20,990
TOPICS DIFFERENTLY ACROSS THE

1369
00:59:21,057 --> 00:59:24,427
BACKDROP OF THE RESEARCH

1370
00:59:24,494 --> 00:59:26,930
CONTINUUM.

1371
00:59:26,996 --> 00:59:29,499
AS A FIRST STEP IN UPDATING THE

1372
00:59:29,565 --> 00:59:30,833
FRAMEWORK, OUR WORKING GROUP

1373
00:59:30,900 --> 00:59:32,602
ESTABLISHED FOUNDATIONAL

1374
00:59:32,669 --> 00:59:35,571
PRINCIPLES RELEVANT THROUGHOUT

1375
00:59:35,638 --> 00:59:36,239
HIV RESEARCH.

1376
00:59:36,306 --> 00:59:38,074
I'LL DESCRIBE THE PRINCIPLES

1377
00:59:38,141 --> 00:59:38,441
NOW.

1378
00:59:38,508 --> 00:59:42,245
RESEARCH TO IDENTIFY AND ADDRESS

1379
00:59:42,312 --> 00:59:42,845
HIV-RELATED HEALTH DISPARITIES

1380
00:59:42,912 --> 00:59:45,515
IS ESSENTIAL TO ENSURE THAT THE

1381
00:59:45,581 --> 00:59:48,251
BENEFITS OF SCIENTIFIC ADVANCES

1382
00:59:48,318 --> 00:59:49,419
REACH ALL PEOPLE UP AND

1383
00:59:49,485 --> 00:59:50,787
COMMUNITIES AFFECTED BY HIV,

1384
00:59:50,853 --> 00:59:52,088
INCLUDING GROUPS THAT

1385
00:59:52,155 --> 00:59:53,089
HISTORICALLY BEEN UNDER

1386
00:59:53,156 --> 00:59:55,258
REPRESENTED AND UNDERSERVED.

1387
00:59:55,325 --> 00:59:56,893
RESEARCH MUST ALSO ADDRESS THE

1388
00:59:56,960 --> 00:59:59,095
UNIQUE NEEDS OF PEOPLE WITH HIV

1389
00:59:59,162 --> 01:00:01,764
ACROSS THE LIFESPAN,

1390
01:00:01,831 --> 01:00:03,032
PARTICULARLY AS PEOPLE AGE WITH

1391
01:00:03,099 --> 01:00:05,835
THE VIRUS, INCLUDING THOSE BORN

1392
01:00:05,902 --> 01:00:06,369
WITH HIV.

1393
01:00:06,436 --> 01:00:09,272
AND FINALLY, ENGAGEMENT AND

1394
01:00:09,339 --> 01:00:10,873
PARTNERSHIP WITH COMMUNITIES

1395
01:00:10,940 --> 01:00:12,976
AFFECTED BY HIV ARE BOTH

1396
01:00:13,042 --> 01:00:17,146
ESSENTIAL AT EVERY STAGE OF

1397
01:00:17,213 --> 01:00:17,413
RESEARCH.

1398
01:00:17,480 --> 01:00:18,481
WE DEVELOPED THE PROPOSED

1399
01:00:18,548 --> 01:00:20,883
FRAMEWORK TO ALIGN WITH THE NEW

1400
01:00:20,950 --> 01:00:23,386
NIH COMMON TEMPLATE FOR

1401
01:00:23,453 --> 01:00:25,488
STRATEGIC PLANS, AN EFFORT TO

1402
01:00:25,555 --> 01:00:26,823
HARMONIZE STRATEGIC PLANNING

1403
01:00:26,889 --> 01:00:27,590
ACROSS NIH.

1404
01:00:27,657 --> 01:00:29,525
WE ALSO LOOKED TO THE STRUCTURE

1405
01:00:29,592 --> 01:00:32,428
OF THE MOST RECENT PROFESSIONAL

1406
01:00:32,495 --> 01:00:34,063
JUDGMENT BUDGET WHICH FOLLOW

1407
01:00:34,130 --> 01:00:35,932
STAGES OF THE RESEARCH

1408
01:00:35,999 --> 01:00:36,399
CONTINUUM.

1409
01:00:36,466 --> 01:00:39,035
OUR PROPOSED FRAMEWORK INCLUDES

1410
01:00:39,102 --> 01:00:40,103
STRATEGIC -- I'M SORRY.

1411
01:00:40,169 --> 01:00:43,106
OUR PROPOSED FRAMEWORK INCLUDES

1412
01:00:43,172 --> 01:00:44,273
RESEARCH GOALS AND THE CAPACITY

1413
01:00:44,340 --> 01:00:44,540
GOAL.

1414
01:00:44,607 --> 01:00:46,009
THE RESEARCH GOALS HAVE BEEN

1415
01:00:46,075 --> 01:00:48,344
SLIGHTLY MODIFIED FROM THE

1416
01:00:48,411 --> 01:00:50,246
STRATEGIC GOALS OUTLINED IN THE

1417
01:00:50,313 --> 01:00:53,716
CURRENT PLAN AND ARE AS FOLLOWS:

1418
01:00:53,783 --> 01:00:55,651
GOAL 1 IS TO ENHANCE DISCOVERY

1419
01:00:55,718 --> 01:00:58,354
AND ADVANCE HIV SCIENCE THROUGH

1420
01:00:58,421 --> 01:01:00,490
FUNDAMENTAL RESEARCH.

1421
01:01:00,556 --> 01:01:03,259
GOAL 2 IS TO ADVANCE THE

1422
01:01:03,326 --> 01:01:04,193
DEVELOPMENT AND ASSESSMENT OF

1423
01:01:04,260 --> 01:01:05,928
NOVEL INTERVENTIONS FOR HIV

1424
01:01:05,995 --> 01:01:08,498
PREVENTION, TREATMENT AND CURE.

1425
01:01:08,564 --> 01:01:11,067
GOAL 3 IS TO OPTIMIZE THE PUBLIC

1426
01:01:11,134 --> 01:01:13,302
HEALTH IMPACT OF HIV DISCOVERIES

1427
01:01:13,369 --> 01:01:14,904
THROUGH TRANSLATION,

1428
01:01:14,971 --> 01:01:16,172
DISSEMINATION AND IMPLEMENTATION

1429
01:01:16,239 --> 01:01:18,508
OF RESEARCH FINDINGS.

1430
01:01:18,574 --> 01:01:21,577
AND FINALLY, GOAL 4 IS TO BUILD

1431
01:01:21,644 --> 01:01:23,746
RESEARCH WORKFORCE AND

1432
01:01:23,813 --> 01:01:25,381
INFRASTRUCTURE CAPACITY TO

1433
01:01:25,448 --> 01:01:27,884
ENHANCE SUSTAINABILITY OF HIV

1434
01:01:27,950 --> 01:01:31,654
RESEARCH DISCOVERY.

1435
01:01:31,721 --> 01:01:34,123
NOW THIS SLIDE SHOWS YOU HOW WE

1436
01:01:34,190 --> 01:01:36,726
ENVISIONED THE PLAN'S STRUCTURE.

1437
01:01:36,793 --> 01:01:39,729
WITHIN EACH GOAL, OBJECTIVES

1438
01:01:39,796 --> 01:01:41,631
REFLECTING DIFFERENT RESEARCH

1439
01:01:41,697 --> 01:01:44,000
AREAS WILL BE IDENTIFIED.

1440
01:01:44,067 --> 01:01:45,101
SPECIFIC FUNDING PRIORITIES WILL

1441
01:01:45,168 --> 01:01:47,770
THEN BE HIGHLIGHTED WITHIN EACH

1442
01:01:47,837 --> 01:01:49,672
OBJECTIVE.

1443
01:01:49,739 --> 01:01:50,206
FUNDING PRIORITIES WILL BE

1444
01:01:50,273 --> 01:01:52,308
IDENTIFIED TO REFLECT BOTH

1445
01:01:52,375 --> 01:01:54,744
ONGOING RESEARCH AND AREAS WHERE

1446
01:01:54,811 --> 01:01:57,180
ADDITIONAL INVESTIGATION IS

1447
01:01:57,246 --> 01:01:57,547
NEEDED.

1448
01:01:57,613 --> 01:01:59,482
AS WELL AS EMERGING AREAS OF

1449
01:01:59,549 --> 01:02:01,551
RESEARCH AND NEW OPPORTUNITIES.

1450
01:02:01,617 --> 01:02:02,852
PLEASE NOTE THAT THE STRUCTURE

1451
01:02:02,919 --> 01:02:05,188
MAY BE THE SAME FOR EACH GOAL

1452
01:02:05,254 --> 01:02:07,657
BUT THE NUMBER OF OBJECTIVES AND

1453
01:02:07,723 --> 01:02:12,862
PRIORITIES PER GOAL WILL DIFFER.

1454
01:02:12,929 --> 01:02:14,464
TO HELP YOU ENVISION HOW SOME

1455
01:02:14,530 --> 01:02:15,765
RESEARCH TOPICS MIGHT FIT INTO

1456
01:02:15,832 --> 01:02:18,134
THE NEW FRAMEWORK, WE MAPPED OUT

1457
01:02:18,201 --> 01:02:19,268
A FEW EXAMPLES.

1458
01:02:19,335 --> 01:02:21,537
IN THE CURRENT FRAMEWORK ON THE

1459
01:02:21,604 --> 01:02:24,373
RIGHT, RESEARCH ON HIV AND

1460
01:02:24,440 --> 01:02:25,942
SUBSTANCE ABUSE CORRESPONDS WITH

1461
01:02:26,008 --> 01:02:27,844
THE CO-MORBIDITY AREA IN GREEN.

1462
01:02:27,910 --> 01:02:31,147
IN THE NEW STRUCTURE, SUBSTANCE

1463
01:02:31,214 --> 01:02:32,248
USE RESEARCH COULD FALL WITHIN

1464
01:02:32,315 --> 01:02:36,886
ANY OF THE THREE RESEARCH GOALS.

1465
01:02:36,953 --> 01:02:37,353
VACCINE RESEARCH WHICH

1466
01:02:37,420 --> 01:02:38,921
CORRESPONDS TO REDUCING

1467
01:02:38,988 --> 01:02:40,223
INCIDENTS, PRIORITY AREAS SHOWN

1468
01:02:40,289 --> 01:02:42,992
IN ORANGE, IS A SIMILAR EXAMPLE.

1469
01:02:43,059 --> 01:02:46,362
AS IS RESEARCH ON LONG ACTING

1470
01:02:46,429 --> 01:02:47,730
FORMULATIONS CURRENTLY MAPPED TO

1471
01:02:47,797 --> 01:02:50,766
NEXT GENERATIONS THERAPY IN

1472
01:02:50,833 --> 01:02:51,100
PURPLE.

1473
01:02:51,167 --> 01:02:52,702
CURE RESEARCH SHOWN IN RED,

1474
01:02:52,768 --> 01:02:55,738
WOULD LIKELY FIT WITHIN GOALS 1

1475
01:02:55,805 --> 01:02:57,240
AND 2 WHILE HELP COMMUNICATIONS

1476
01:02:57,306 --> 01:02:58,975
RESEARCH PREVIOUSLY ACROSS

1477
01:02:59,041 --> 01:03:01,144
CUTTING AREA WOULD FIT WITHIN

1478
01:03:01,210 --> 01:03:02,078
GOALS 2 AND 3.

1479
01:03:02,145 --> 01:03:05,148
YOU CAN ALSO SEE THE

1480
01:03:05,214 --> 01:03:06,549
CROSSCUTTING AREAS OF

1481
01:03:06,616 --> 01:03:09,018
CONSTRUCTION GRANTS AND TRAINING

1482
01:03:09,085 --> 01:03:11,621
GRANTS WOULD FIT UNDER GOAL 4.

1483
01:03:11,687 --> 01:03:13,322
AS THE SCIENCE EVOLVES, THE

1484
01:03:13,389 --> 01:03:14,724
POSITIONING OF THESE TOPICAL

1485
01:03:14,790 --> 01:03:16,659
AREAS ACROSS GOALS IS

1486
01:03:16,726 --> 01:03:20,863
ANTICIPATED TO SHIFT.

1487
01:03:20,930 --> 01:03:22,031
THIS SLIDE PROVIDES AN OVERVIEW

1488
01:03:22,098 --> 01:03:24,133
OF THE PROCESS TO DEVELOP THE

1489
01:03:24,200 --> 01:03:25,101
NEXT STRATEGIC PLAN.

1490
01:03:25,168 --> 01:03:26,202
WE'LL DESCRIBE EACH OF THESE

1491
01:03:26,269 --> 01:03:28,771
STEPS IN MORE DETAIL IN THE NEXT

1492
01:03:28,838 --> 01:03:30,039
SLIDES.

1493
01:03:30,106 --> 01:03:33,609
BUT FIRST, WE STARTED IN MID

1494
01:03:33,676 --> 01:03:35,878
2023 BY FORMING AN INTERNAL

1495
01:03:35,945 --> 01:03:36,379
WORKING GROUP THAT WAS

1496
01:03:36,445 --> 01:03:37,413
ESTABLISHED IN ORDER TO PROPOSE

1497
01:03:37,480 --> 01:03:42,885
A NEW FRAMEWORK FOR THE PLAN.

1498
01:03:42,952 --> 01:03:43,252
SO HERE WE ARE.

1499
01:03:43,319 --> 01:03:45,588
WE ARE CURRENTLY SEEKING INPUT.

1500
01:03:45,655 --> 01:03:47,757
WE STARTED INTERNALLY WITH OAR

1501
01:03:47,823 --> 01:03:49,292
SCIENCE STAFF AND MEMBERS OF THE

1502
01:03:49,358 --> 01:03:51,827
NIH AIDS EXECUTIVE COMMITTEE.

1503
01:03:51,894 --> 01:03:53,496
AND THAT'S THE COMMITTEE THAT

1504
01:03:53,563 --> 01:03:56,499
REPRESENTS THE INSTITUTES AND

1505
01:03:56,566 --> 01:03:57,133
CENTERS AND OFFICES ACROSS NIH

1506
01:03:57,200 --> 01:03:59,835
WITH THE RELEASE OF OUR RFI

1507
01:03:59,902 --> 01:04:00,303
EARLIER THIS MONTH.

1508
01:04:00,369 --> 01:04:01,637
WE ARE CONTINUING TO SOLICIT

1509
01:04:01,704 --> 01:04:03,806
INPUT INCLUDING FROM WITHIN NIH

1510
01:04:03,873 --> 01:04:06,209
AND FROM THE EXTERNAL COMMUNITY.

1511
01:04:06,275 --> 01:04:08,444
THE COLLECTIVE INPUT WILL INFORM

1512
01:04:08,511 --> 01:04:10,513
THE FRAMEWORK AND GENERATE

1513
01:04:10,580 --> 01:04:12,081
PROPOSED PRIORITIES FOR REVIEW

1514
01:04:12,148 --> 01:04:13,216
AND SYNTHESIS BY THE WORKING

1515
01:04:13,282 --> 01:04:14,650
GROUP AND WILL BE SHARED WITH

1516
01:04:14,717 --> 01:04:16,452
OARAC TASK FORCES.

1517
01:04:16,519 --> 01:04:19,255
WE WILL RELY ON TASK FORCES OF

1518
01:04:19,322 --> 01:04:20,356
OARAC TO PROVIDE RECOMMENDATIONS

1519
01:04:20,423 --> 01:04:22,425
TO THE OAR DIRECTOR.

1520
01:04:22,491 --> 01:04:25,294
WE'LL THEN WORK WITH THESE

1521
01:04:25,361 --> 01:04:26,696
REFINERIES TO WRITE THE PLAN.

1522
01:04:26,762 --> 01:04:29,098
THE PLAN WILL BE SHARED WITH

1523
01:04:29,165 --> 01:04:31,033
OARAC FOR APPROVAL BEFORE GOING

1524
01:04:31,100 --> 01:04:33,636
THROUGH NIH CLEARANCE AND

1525
01:04:33,703 --> 01:04:34,003
PUBLICATION.

1526
01:04:34,070 --> 01:04:37,073
NOW, I'LL HAND IT OVER TO CAPTAN

1527
01:04:37,139 --> 01:04:39,008
GLENN SHAW TO TELL YOU MORE

1528
01:04:39,075 --> 01:04:40,843
ABOUT THE SOURCES OF INPUT THAT

1529
01:04:40,910 --> 01:04:43,679
WILL INFORM DEVELOPMENT OF OUR

1530
01:04:43,746 --> 01:04:51,454
RESEARCH PRIORITIES.

1531
01:04:51,520 --> 01:04:56,359
>> JOE GLINIEWICZ: THANK YADRIE.

1532
01:04:56,425 --> 01:04:59,095
CAN EVERYONE HEAR ME OKAY?

1533
01:04:59,161 --> 01:05:02,798
NEXT SLIDE, PLEASE.

1534
01:05:02,865 --> 01:05:04,100
THERE ARE SIX FUNDAMENTAL

1535
01:05:04,166 --> 01:05:06,369
SOURCES OF INPUT INVOLVED IN THE

1536
01:05:06,435 --> 01:05:07,503
DEVELOPMENT OF THIS STRATEGIC

1537
01:05:07,570 --> 01:05:09,739
PLAN AS YOU CAN SEE HERE.

1538
01:05:09,805 --> 01:05:11,207
INTERNAL NIH SOURCES ARE SHOWN

1539
01:05:11,274 --> 01:05:13,676
ON THE LEFT INCLUDING OAR

1540
01:05:13,743 --> 01:05:15,511
SUBJECT MATTER EXPERTS AND THE

1541
01:05:15,578 --> 01:05:18,347
NAEC AS MENTIONED BY RACHEL.

1542
01:05:18,414 --> 01:05:20,483
DISCUSSIONS AND INPUT AT THESE

1543
01:05:20,549 --> 01:05:22,285
LEVELS LED TO THE REVISED

1544
01:05:22,351 --> 01:05:24,220
FRAMEWORK WE PRESENTED TODAY AND

1545
01:05:24,287 --> 01:05:25,688
INITIAL FEEDBACK REGARDING

1546
01:05:25,755 --> 01:05:27,657
OBJECTIVES AND RESEARCH

1547
01:05:27,723 --> 01:05:28,024
PRIORITIES.

1548
01:05:28,090 --> 01:05:30,092
EXTERNAL SOURCES OF SHOWN IN

1549
01:05:30,159 --> 01:05:32,228
BLUE ON THE RIGHT AND INCLUDE

1550
01:05:32,295 --> 01:05:33,863
OAR LISTENING SESSIONS,

1551
01:05:33,929 --> 01:05:35,698
SIGNATURE PROGRAM AND OTHER

1552
01:05:35,765 --> 01:05:39,168
WORKSHOPS AND PUBLIC INPUT FOR

1553
01:05:39,235 --> 01:05:40,536
REQUESTS FOR INFORMATION.

1554
01:05:40,603 --> 01:05:42,271
THESE SOURCES CAN HELP IDENTIFY

1555
01:05:42,338 --> 01:05:44,940
RESEARCH PRIORITIES, GAPS AND

1556
01:05:45,007 --> 01:05:46,776
OPPORTUNITIES AND COMMON THEMES

1557
01:05:46,842 --> 01:05:48,544
AMONG PARTNERS.

1558
01:05:48,611 --> 01:05:49,445
IMPORTANTLY, THEY ARE ALSO

1559
01:05:49,512 --> 01:05:52,615
OPPORTUNITIES FOR DEVELOPING NEW

1560
01:05:52,682 --> 01:05:52,948
PARTNERSHIPS.

1561
01:05:53,015 --> 01:05:54,684
FINALLY, YOU WILL SEE YOURSELF

1562
01:05:54,750 --> 01:05:57,753
THE OARAC, INCLUDING HHS AND NIH

1563
01:05:57,820 --> 01:05:58,921
LEADERSHIP AS FOUNDATIONAL AT

1564
01:05:58,988 --> 01:06:04,827
THE BASE OF THIS GRAPHIC.

1565
01:06:04,894 --> 01:06:06,629
IT IS IMPORTANT TO RECOGNIZE

1566
01:06:06,696 --> 01:06:08,464
THAT MUCH OF THE WORK TOWARDS

1567
01:06:08,531 --> 01:06:10,766
DEVELOPING THE NIH HIV STRA

1568
01:06:10,833 --> 01:06:12,034
TEAMIC PLAN INVOLVES TWO PRIMARY

1569
01:06:12,101 --> 01:06:13,202
ADVISORY COUNCIL.

1570
01:06:13,269 --> 01:06:16,272
OARAC AND THE NAEC.

1571
01:06:16,339 --> 01:06:17,506
OARAC ADVISES THE OAR DIRECTOR

1572
01:06:17,573 --> 01:06:19,508
IN THE PLANNING, COORDINATION

1573
01:06:19,575 --> 01:06:21,377
AND EVALUATION OF HIV RESEARCH

1574
01:06:21,444 --> 01:06:23,012
AT THE NIH.

1575
01:06:23,079 --> 01:06:25,081
THE COUNCIL REFLECTS NATIONAL

1576
01:06:25,147 --> 01:06:26,248
REPRESENTATION BY MEMBERS FROM A

1577
01:06:26,315 --> 01:06:28,250
WIDE RANGE OF DISCIPLINES.

1578
01:06:28,317 --> 01:06:30,386
THE OARAC CHARTER SPECIFICALLY

1579
01:06:30,453 --> 01:06:32,922
CALLS OUT STRATEGIC PLAN ADVICE

1580
01:06:32,988 --> 01:06:34,123
AS A CORE ROLE.

1581
01:06:34,190 --> 01:06:37,626
THE NAEC IS THE ADVISORY ARM AND

1582
01:06:37,693 --> 01:06:40,029
COORDINATING COMMITTEE FOR NIH

1583
01:06:40,096 --> 01:06:41,530
HIV RESEARCH EFFORTS.

1584
01:06:41,597 --> 01:06:43,733
MEMBERS REPRESENT ICOs WITH

1585
01:06:43,799 --> 01:06:44,533
HIV FUNDING.

1586
01:06:44,600 --> 01:06:46,769
THEY ASSIST AND ADVISE IN

1587
01:06:46,836 --> 01:06:48,437
COORDINATION OF PROGRAM

1588
01:06:48,504 --> 01:06:51,941
INITIATIVES AND INTRA-AGENCY

1589
01:06:52,007 --> 01:06:54,310
COORDINATION.

1590
01:06:54,377 --> 01:06:57,346
A FOUNDATIONAL STEP IN STRATEGIC

1591
01:06:57,413 --> 01:06:59,048
PLAN DEVELOPMENT IS THE INTERNAL

1592
01:06:59,115 --> 01:07:01,450
DISCUSSION AND ANALYSIS OF THE

1593
01:07:01,517 --> 01:07:03,419
HIV PORTFOLIO.

1594
01:07:03,486 --> 01:07:04,987
ANALYSIS ASSESS TRENDS OVER TIME

1595
01:07:05,054 --> 01:07:06,856
ACROSS SEVERAL FACTORS AND CAN

1596
01:07:06,922 --> 01:07:08,090
HELP DETERMINE GAPS AND

1597
01:07:08,157 --> 01:07:11,694
OPPORTUNITIES IN THE PORTFOLIO.

1598
01:07:11,761 --> 01:07:13,629
TOPICAL ANALYSIS SUCH AS THOSE

1599
01:07:13,696 --> 01:07:14,964
LISTED HERE, HELP US RESPOND TO

1600
01:07:15,030 --> 01:07:16,599
PARTNER AND COMMUNITY INQUIRIES,

1601
01:07:16,665 --> 01:07:19,168
SHAPE OUR SIGNATURE PROGRAMS AND

1602
01:07:19,235 --> 01:07:20,703
REFINE RESEARCH PRIORITIES.

1603
01:07:20,770 --> 01:07:22,405
AS PRESENTED TO THE OARAC IN

1604
01:07:22,471 --> 01:07:25,741
JUNE 2023, THERE ARE NEW DATA

1605
01:07:25,808 --> 01:07:26,575
DASHBOARDS PUBLICLY AVAILABLE ON

1606
01:07:26,642 --> 01:07:30,446
THE OAR WEBSITE AS SHOWN ON THE

1607
01:07:30,513 --> 01:07:32,415
UPPER RIGHT.

1608
01:07:32,481 --> 01:07:35,451
NEXT SLIDE, PLEASE.

1609
01:07:35,518 --> 01:07:38,754
AS PREVIOUSLY REPORTED, NIH OAR

1610
01:07:38,821 --> 01:07:39,688
IS HEAVILY INVOLVED IN THE

1611
01:07:39,755 --> 01:07:41,056
ORGANIZATION AND COORDINATION OF

1612
01:07:41,123 --> 01:07:42,124
LISTENING SESSIONS WITH

1613
01:07:42,191 --> 01:07:44,026
DIFFERENT PARTNERS.

1614
01:07:44,093 --> 01:07:46,595
I ENCOURAGE YOU TO SCAN THIS QR

1615
01:07:46,662 --> 01:07:48,431
CODE TO READ REPORTS OF

1616
01:07:48,497 --> 01:07:50,232
LISTENING SESSION FINDINGS, THE

1617
01:07:50,299 --> 01:07:53,402
MOST RECENT PUBLISHED THIS PAST

1618
01:07:53,469 --> 01:07:54,403
DECEMBER.

1619
01:07:54,470 --> 01:07:55,304
ONGOING LISTENING SESSIONS

1620
01:07:55,371 --> 01:07:56,906
INCLUDE ENSURING BROAD AND

1621
01:07:56,972 --> 01:07:59,141
INCLUSIVE INPUT FROM DIVERSE

1622
01:07:59,208 --> 01:08:00,276
PARTNERS AND COMMUNITIES AND

1623
01:08:00,342 --> 01:08:02,278
PROVIDING A FORUM TO COMMUNICATE

1624
01:08:02,344 --> 01:08:04,313
WITH THE NIH FROM LOCAL AND

1625
01:08:04,380 --> 01:08:05,648
REGIONAL PERSPECTIVES,

1626
01:08:05,714 --> 01:08:08,517
PARTICULARLY REGARDING RESEARCH

1627
01:08:08,584 --> 01:08:08,818
PRIORITIES.

1628
01:08:08,884 --> 01:08:10,386
TO DAYLIGHT, OAR CONDUCTED

1629
01:08:10,453 --> 01:08:12,655
NEARLY 60 LISTENING SESSIONS IN

1630
01:08:12,721 --> 01:08:15,357
20 LOCATIONS SHOWN HERE ON THE

1631
01:08:15,424 --> 01:08:19,762
MAP, INCLUDING MANY EAG PRIORITY

1632
01:08:19,829 --> 01:08:23,466
JURISDICTIONS.

1633
01:08:23,532 --> 01:08:24,033
LISTENING SESSIONS PRODUCED

1634
01:08:24,099 --> 01:08:25,401
REOCCURRING THEMES REGARDING

1635
01:08:25,468 --> 01:08:27,636
RESEARCH AREAS SUCH AS THOSE

1636
01:08:27,703 --> 01:08:28,571
LISTED HERE.

1637
01:08:28,637 --> 01:08:30,239
AND ACROSS CUTTING THEMES THAT

1638
01:08:30,306 --> 01:08:32,007
ARE RELEVANT ACROSS TOPICAL

1639
01:08:32,074 --> 01:08:34,176
AREAS, SUCH AS THE IMPORTANCE OF

1640
01:08:34,243 --> 01:08:35,311
COMMUNITY PARTNERSHIP AND

1641
01:08:35,377 --> 01:08:38,914
CULTURAL HUMILITY, INFORMATION

1642
01:08:38,981 --> 01:08:42,318
DISSEMINATION AND SUPPORT OF HIV

1643
01:08:42,384 --> 01:08:45,054
RESEARCH WORKFORCEFRASTRUCTURE

1644
01:08:45,120 --> 01:08:49,492
AND RESOURCE NEEDS.

1645
01:08:49,558 --> 01:08:51,527
OAR HAS RECENTLY REDOUBLED

1646
01:08:51,594 --> 01:08:53,829
EFFORTS IN OUR CONVENING ROLE.

1647
01:08:53,896 --> 01:08:56,599
IN FISCAL YEAR 2023 ALONE, OAR

1648
01:08:56,665 --> 01:09:00,035
LED OR CO-LED 11 WORKSHOPS OF

1649
01:09:00,102 --> 01:09:02,137
WHICH MANY OF WHICH SUPPORT

1650
01:09:02,204 --> 01:09:04,540
NIH-WIDE SIGNATURE PROGRAMS.

1651
01:09:04,607 --> 01:09:05,774
THESE WORKSHOPS INVOLVED OVER

1652
01:09:05,841 --> 01:09:07,710
1200 PARTICIPANTS REPRESENTING

1653
01:09:07,776 --> 01:09:10,279
DOZENS OF ORGANIZATIONS,

1654
01:09:10,346 --> 01:09:12,615
INSTITUTIONS, STATES, NATIONS,

1655
01:09:12,681 --> 01:09:15,718
POPULATIONS AND LEVELS OF TEN

1656
01:09:15,784 --> 01:09:15,951
TENURE.

1657
01:09:16,018 --> 01:09:18,087
KEY FINDING AND INPUT FROM THESE

1658
01:09:18,153 --> 01:09:20,756
WORKSHOPS ARE WELL DOCUMENTED IN

1659
01:09:20,823 --> 01:09:22,558
SUMMARIES, REPORTS, AND

1660
01:09:22,625 --> 01:09:22,892
PUBLICATIONS.

1661
01:09:22,958 --> 01:09:23,859
IN ADDITION, WE ARE IN RECEIPT

1662
01:09:23,926 --> 01:09:26,962
OF DATA FROM A RECENT RFI

1663
01:09:27,029 --> 01:09:28,163
REGARDING RESEARCH OPPORTUNITIES

1664
01:09:28,230 --> 01:09:30,766
RELATED TO HIV AND WOMEN'S

1665
01:09:30,833 --> 01:09:33,202
HEALTH CO-ISSUED BY THE OAR AND

1666
01:09:33,269 --> 01:09:34,637
NIH OFFICE ON RESEARCH FOR

1667
01:09:34,703 --> 01:09:35,504
WOMEN'S HEALTH.

1668
01:09:35,571 --> 01:09:36,772
INPUT FROM ALL OF THESE

1669
01:09:36,839 --> 01:09:38,007
ACTIVITIES WILL BE INCORPORATED

1670
01:09:38,073 --> 01:09:42,077
INTO THE NEXT STRATEGIC PLAN.

1671
01:09:42,144 --> 01:09:43,479
THE FINAL EXTERNAL SOURCE OF

1672
01:09:43,546 --> 01:09:45,514
INPUT IS A FORMAL OUTREACH

1673
01:09:45,581 --> 01:09:47,483
METHOD TO EXTERNAL PARTNERS

1674
01:09:47,550 --> 01:09:50,119
THROUGH AN RFI OR REQUEST FOR

1675
01:09:50,185 --> 01:09:50,452
INFORMATION.

1676
01:09:50,519 --> 01:09:53,389
THIS WEB-BASED REQUEST ENABLES

1677
01:09:53,455 --> 01:09:55,958
WRITTEN FEEDBACK USING ONLINE

1678
01:09:56,025 --> 01:09:56,158
FORUM.

1679
01:09:56,225 --> 01:09:57,760
YOU SEEN IT BEFORE BUT FEEL FREE

1680
01:09:57,826 --> 01:10:00,195
TO SCAN THE QR CODE HERE TO SEE

1681
01:10:00,262 --> 01:10:02,197
THE RFI ON LINE AND PLEASE

1682
01:10:02,264 --> 01:10:03,999
CONSIDER SHARING YOUR INPUT

1683
01:10:04,066 --> 01:10:11,874
BEFORE IT CLOSES ON MARCH 28.

1684
01:10:11,941 --> 01:10:12,474
FEEDBACK FREQUENTLY INTERESTED

1685
01:10:12,541 --> 01:10:14,710
CONSTITUENTS SUCH AS THOSE SHOWN

1686
01:10:14,777 --> 01:10:18,347
HERE ARE INVITED TO PROPOSE

1687
01:10:18,414 --> 01:10:19,014
RESEARCH PRIORITIES FOR GREATEST

1688
01:10:19,081 --> 01:10:21,083
POTENTIAL TO ADVANCE HIV SCIENCE

1689
01:10:21,150 --> 01:10:24,687
AND IMPACT HIV ASSOCIATED PUBLIC

1690
01:10:24,753 --> 01:10:28,290
HEALTH ACROSS THE FOUR RESEARCH

1691
01:10:28,357 --> 01:10:29,925
CAPACITY BUILDING ROLES.

1692
01:10:29,992 --> 01:10:31,226
WE ALSO LOVE ADDITIONAL FEEDBACK

1693
01:10:31,293 --> 01:10:37,199
ON THE UPDATED FRAMEWORK.

1694
01:10:37,266 --> 01:10:42,171
NOW WE'LL MOVE TO SPECIFIC

1695
01:10:42,237 --> 01:10:42,838
INFORMATION REGARD OTHER OARAC

1696
01:10:42,905 --> 01:10:44,473
IN THIS PROCESS.

1697
01:10:44,540 --> 01:10:47,042
OARAC INPUT IS ESSENTIAL TO

1698
01:10:47,109 --> 01:10:48,744
DEVELOP A REPRESENTATIVE AND

1699
01:10:48,811 --> 01:10:51,013
ROBUST STRATEGIC PLAN.

1700
01:10:51,080 --> 01:10:55,184
THUS, OAR WILL INITIATE SHORT

1701
01:10:55,250 --> 01:10:56,185
TERM MULTISECTORIAL TASK FORCES

1702
01:10:56,251 --> 01:10:57,987
WITH OARAC MEMBERS AND INVITED

1703
01:10:58,053 --> 01:10:59,788
PARTICIPANTS TO REVIEW AND

1704
01:10:59,855 --> 01:11:01,890
SYNTHESIZE INPUT FROM THE MANY

1705
01:11:01,957 --> 01:11:03,492
SOURCES DISCUSSED TODAY.

1706
01:11:03,559 --> 01:11:04,393
TASK FORCE PARTICIPANTS WILL ADD

1707
01:11:04,460 --> 01:11:06,729
THEIR OWN IMPRESSIONS AND AREAS

1708
01:11:06,795 --> 01:11:07,863
TO CONSIDER ALONG WITH

1709
01:11:07,930 --> 01:11:10,265
RECOMMENDATIONS TO THE OAR

1710
01:11:10,332 --> 01:11:10,532
DIRECTOR.

1711
01:11:10,599 --> 01:11:12,835
THESE TASK FORCES ARE CONCEIVED

1712
01:11:12,901 --> 01:11:14,203
TO BE SIMILAR TO THE

1713
01:11:14,269 --> 01:11:15,270
COORDINATING COMMITTEES THAT

1714
01:11:15,337 --> 01:11:18,807
SUPPORTED STRATEGIC PLAN

1715
01:11:18,874 --> 01:11:21,110
DEVELOPMENT IN THE PAST.

1716
01:11:21,176 --> 01:11:22,044
THE TASK FORCES WILL BE ASKED TO

1717
01:11:22,111 --> 01:11:24,513
DEVELOP CRITERIA TO CATEGORIZE

1718
01:11:24,580 --> 01:11:26,949
INPUT BY TYPE, SUCH AS TOPICAL

1719
01:11:27,016 --> 01:11:30,019
AREAS, METHODS AND APPROACHES,

1720
01:11:30,085 --> 01:11:31,553
AND BI-LEVEL SUCH AS HIGH,

1721
01:11:31,620 --> 01:11:33,322
MEDIUM AND LOW.

1722
01:11:33,389 --> 01:11:35,591
THE TASK FORCES WILL BE ASKED TO

1723
01:11:35,658 --> 01:11:37,493
ASSESS THE INPUT RECEIVED

1724
01:11:37,559 --> 01:11:40,095
INCLUDING ANY FROM THE TASK

1725
01:11:40,162 --> 01:11:41,130
FORCE MEMBERS ITSELF.

1726
01:11:41,196 --> 01:11:43,632
AND ESTABLISH CONSENSUS ON

1727
01:11:43,699 --> 01:11:45,467
PRIORITY AREAS AND DOCUMENT ANY

1728
01:11:45,534 --> 01:11:47,503
OUTLIERS OR AREAS THAT LACK

1729
01:11:47,569 --> 01:11:47,770
CONSENSUS.

1730
01:11:47,836 --> 01:11:49,872
AND FINALLY, REPORT THEIR

1731
01:11:49,938 --> 01:11:52,708
FINDINGS TO THE OAR DIRECTOR.

1732
01:11:52,775 --> 01:11:54,977
ON THE RIGHT YOU'LL SEE A BRIEF

1733
01:11:55,044 --> 01:11:56,378
PROPOSED STRUCTURE FOR HOW THESE

1734
01:11:56,445 --> 01:12:01,016
TASK FORCES MAY BE COMPOSED.

1735
01:12:01,083 --> 01:12:02,718
CO-CHAIRS INCLUDE ONE OARAC

1736
01:12:02,785 --> 01:12:05,220
MEMBER AND ONE NIH SME OR

1737
01:12:05,287 --> 01:12:06,922
SUBJECT MATTER EXPERT.

1738
01:12:06,989 --> 01:12:11,660
MEMBERS WOULD BE INVITED FROM

1739
01:12:11,727 --> 01:12:13,662
NAEC AND NON FEDERAL PARTNERS

1740
01:12:13,729 --> 01:12:17,533
AND REPRESENT MULTIDISCIPLINARY

1741
01:12:17,599 --> 01:12:20,969
EXPERTISE, INCLUDING LIVED

1742
01:12:21,036 --> 01:12:21,270
EXPERIENCE.

1743
01:12:21,336 --> 01:12:23,706
WE'LL REVIEW THE STAGES OF PLAN

1744
01:12:23,772 --> 01:12:26,408
DEVELOPMENT AND THE ANTICIPATED

1745
01:12:26,475 --> 01:12:26,875
TIMELINE.

1746
01:12:26,942 --> 01:12:28,610
AS YOU CAN SEE HERE, THE

1747
01:12:28,677 --> 01:12:30,612
PREPARATION STAGE JUST CONCLUDED

1748
01:12:30,679 --> 01:12:31,947
WHICH INVOLVED PERFORMING

1749
01:12:32,014 --> 01:12:34,016
INTERNAL WORKING GROUP AT THE

1750
01:12:34,083 --> 01:12:37,986
OAR, DRAFTING NEW FRAMEWORK AND

1751
01:12:38,053 --> 01:12:43,926
COORDINATING INTERNAL NIH INPUT.

1752
01:12:43,992 --> 01:12:44,993
WE ARE CURRENTLY HERE IN THE

1753
01:12:45,060 --> 01:12:46,595
CONVENING ENGAGING STAGE.

1754
01:12:46,662 --> 01:12:48,397
THIS STAGE WILL LAST THROUGH THE

1755
01:12:48,464 --> 01:12:50,532
CURRENT FISCAL YEAR AND INVOLVES

1756
01:12:50,599 --> 01:12:52,968
SIN SIZING INPUT FROM SEVERAL

1757
01:12:53,035 --> 01:12:55,237
SOURCES SUCH AS RFI LISTENING

1758
01:12:55,304 --> 01:12:56,371
SESSIONS AND STANDING UP THE

1759
01:12:56,438 --> 01:12:58,774
SHORT TERM MULTISECTORIAL TASK

1760
01:12:58,841 --> 01:13:01,643
FORCES I JUST MENTIONED.

1761
01:13:01,710 --> 01:13:03,545
LOOKING AHEAD, WE ANTICIPATE

1762
01:13:03,612 --> 01:13:05,714
RECEIVING RECOMMENDATIONS FROM

1763
01:13:05,781 --> 01:13:07,583
OARAC LATER THIS YEAR WHEN WE

1764
01:13:07,649 --> 01:13:10,986
START FORMERLY DEVELOPING THE

1765
01:13:11,053 --> 01:13:12,354
PLAN FOR NIH CLEARANCE.

1766
01:13:12,421 --> 01:13:15,023
FINAL REVIEWS MAY TAKE THE FIRST

1767
01:13:15,090 --> 01:13:19,495
HALF OF FISCAL YEAR 2025.

1768
01:13:19,561 --> 01:13:21,964
AND FINALLY, WE ARE AGING TO

1769
01:13:22,030 --> 01:13:23,332
PROMOTE AND LAUNCH THE NEW PLAN

1770
01:13:23,398 --> 01:13:27,302
NEXT SUMMER BEFORE THE START OF

1771
01:13:27,369 --> 01:13:29,037
FISCAL YEAR 2026.

1772
01:13:29,104 --> 01:13:32,141
IN CONCLUSION, WE INVITE YOUR

1773
01:13:32,207 --> 01:13:33,542
FEEDBACK, OVER ALL IMPRESSIONS

1774
01:13:33,609 --> 01:13:34,009
AND QUERIES.

1775
01:13:34,076 --> 01:13:36,912
ANY SPECIFIC RECOMMENDATIONS OR

1776
01:13:36,979 --> 01:13:42,151
FEEDBACK FOR THE SECTORS IS

1777
01:13:42,217 --> 01:13:43,318
WELCOME.

1778
01:13:43,385 --> 01:13:43,986
IDEAS ON TASK FORCE ORGANIZATION

1779
01:13:44,052 --> 01:13:46,121
AND THE TIMELINE WOULD ALSO BE

1780
01:13:46,188 --> 01:13:46,488
APPRECIATED.

1781
01:13:46,555 --> 01:13:49,024
RACHEL AND I WOULD ESPECIALLY

1782
01:13:49,091 --> 01:13:50,826
LIKE TO THANK OAR AND NIH

1783
01:13:50,893 --> 01:13:52,027
COLLEAGUES PARTICULARLY THE

1784
01:13:52,094 --> 01:13:55,564
STRATEGIC PLAN AND HIV RESEARCH

1785
01:13:55,631 --> 01:13:56,198
PRIORITIES WORKING GROUP FOR THE

1786
01:13:56,265 --> 01:14:02,971
DEVELOPMENT OF THIS PRESENTA

1787
01:14:03,038 --> 01:14:03,305
PRESENTATION.

1788
01:14:03,372 --> 01:14:09,745
THANK YOU.

1789
01:14:09,812 --> 01:14:11,914
>> THANK YOU DR. FLOWN SHAW AND

1790
01:14:11,980 --> 01:14:12,247
DR. ANDERSON.

1791
01:14:12,314 --> 01:14:17,886
WE NOW HAVE TIME FOR DISCUSSION.

1792
01:14:17,953 --> 01:14:19,988
ANY MEMBERS WHO HAVE ANY

1793
01:14:20,055 --> 01:14:22,324
QUESTIONS OR COMMENTS, PLEASE

1794
01:14:22,391 --> 01:14:25,828
REMEMBER TO USE THE RAISE HAND

1795
01:14:25,894 --> 01:14:33,735
FUNCTION SO I CAN SEE YOU.

1796
01:14:33,802 --> 01:14:37,472
>> I SEE JOHN SLEASMAN AND

1797
01:14:37,539 --> 01:14:37,806
OTHERS.

1798
01:14:37,873 --> 01:14:38,407
>> THANK YOU.

1799
01:14:38,473 --> 01:14:42,978
I DON'T SEE ANY OF THAT.

1800
01:14:43,045 --> 01:14:43,412
THANK YOU VERY MUCH.

1801
01:14:43,478 --> 01:14:45,848
IN THAT ORDER.

1802
01:14:45,914 --> 01:14:49,685
>> LADIES FIRST.

1803
01:14:49,751 --> 01:14:50,118
>> OKAY.

1804
01:14:50,185 --> 01:14:53,388
>> THANKS VERY MUCH.

1805
01:14:53,455 --> 01:14:54,990
DR. ANDERSON AND CAPTAN GLENN

1806
01:14:55,057 --> 01:14:55,190
SHAW.

1807
01:14:55,257 --> 01:14:56,525
CAN YOU TALK MORE ABOUT THE ROLE

1808
01:14:56,592 --> 01:14:58,894
AND TIMELINE OF THE PORTFOLIO

1809
01:14:58,961 --> 01:15:02,164
ANALYSIS COMPONENT?

1810
01:15:02,231 --> 01:15:04,533
AND HOW THE RESULTS OF THAT

1811
01:15:04,600 --> 01:15:05,834
PORTFOLIO ANALYSIS WILL EITHER

1812
01:15:05,901 --> 01:15:07,569
BE FOLDED INTO A REPORT OR INTO

1813
01:15:07,636 --> 01:15:09,004
THE SPECIFIC TASK FORCES?

1814
01:15:09,071 --> 01:15:15,911
THANK YOU VERY MUCH.

1815
01:15:15,978 --> 01:15:17,880
>> SURE, I'M HAPPY TO TAKE THAT.

1816
01:15:17,946 --> 01:15:21,049
THESE ANALYSIS AND REPORTS ARE

1817
01:15:21,116 --> 01:15:21,350
CONTINUOUS.

1818
01:15:21,416 --> 01:15:24,720
WE CONTINUALLY ANALYZE DIFFERENT

1819
01:15:24,786 --> 01:15:27,089
ASPECTS OF THE PORTFOLIO AND TRY

1820
01:15:27,155 --> 01:15:31,293
OUT NEW METHODOLOGIES FOR

1821
01:15:31,360 --> 01:15:35,697
ANALYSIS AND WE ANTICIPATE USING

1822
01:15:35,764 --> 01:15:37,399
THIS TOOL TO SORT OF HELP REFINE

1823
01:15:37,466 --> 01:15:40,736
THE INPUT THAT WE'RE GETTING SO

1824
01:15:40,802 --> 01:15:43,038
WE DON'T HAVE SORT OF A PRE-SET

1825
01:15:43,105 --> 01:15:45,874
PLAN FOR THESE NEW ANALYSIS.

1826
01:15:45,941 --> 01:15:47,342
IT WILL DEPEND ON THE INPUT WE

1827
01:15:47,409 --> 01:15:49,878
ARE GETTING.

1828
01:15:49,945 --> 01:15:54,816
AND ONE EXAMPLE WOULD BE IF A

1829
01:15:54,883 --> 01:15:58,053
PRIORITY AREA IS NOTED THAT WE

1830
01:15:58,120 --> 01:16:00,722
DON'T HAVE A GREAT SENSE FOR HOW

1831
01:16:00,789 --> 01:16:02,024
MUCH RESEARCH HAS BEEN DONE IN

1832
01:16:02,090 --> 01:16:04,760
THAT AREA IN THE PAST, WE COULD

1833
01:16:04,826 --> 01:16:07,029
LOOK AT THE LEVELS OF

1834
01:16:07,095 --> 01:16:09,331
INVESTMENT, TYPES OF GRANTS, THE

1835
01:16:09,398 --> 01:16:10,832
DIFFERENT INSTITUTES THAT FUND

1836
01:16:10,899 --> 01:16:13,902
THAT TYPE OF RESEARCH, HOW IT'S

1837
01:16:13,969 --> 01:16:15,604
GROWN OR SHRUNK OR CHANGED OVER

1838
01:16:15,671 --> 01:16:18,040
TIME, TO REALLY HELP DETERMINE

1839
01:16:18,106 --> 01:16:25,881
HOW MUCH OF A GAP THIS PRIORITY

1840
01:16:25,948 --> 01:16:26,114
IS.

1841
01:16:26,181 --> 01:16:27,716
DOES THAT HELP.

1842
01:16:27,783 --> 01:16:29,551
>> YES IT DOES. I WAS WONDERING

1843
01:16:29,618 --> 01:16:32,821
WERE THERE GAPS IDENTIFIED WHERE

1844
01:16:32,888 --> 01:16:34,690
THE PORTFOLIO ANALYSIS DIDN'T

1845
01:16:34,756 --> 01:16:36,124
NECESSARILY MAP TO THE PRIOR

1846
01:16:36,191 --> 01:16:37,025
STRATEGIC PLANNING?

1847
01:16:37,092 --> 01:16:39,795
WERE THERE ANY INSIGHTS GARNERED

1848
01:16:39,861 --> 01:16:41,063
FROM THAT PROCESS?

1849
01:16:41,129 --> 01:16:43,432
BUT IT SOUNDS LIKE THIS IS MORE

1850
01:16:43,498 --> 01:16:47,202
OF A TOOL TO IDENTIFY HOW

1851
01:16:47,269 --> 01:16:49,271
SPECIFIC AREAS ARE FUNDED BY

1852
01:16:49,338 --> 01:16:53,408
SPECIFIC INSTITUTES AND FUNDING.

1853
01:16:53,475 --> 01:16:53,642
THANKS.

1854
01:16:53,709 --> 01:16:55,344
>> AMONG OTHERS, YES.

1855
01:16:55,410 --> 01:16:59,448
AND TRULY LOOKING MORE

1856
01:16:59,514 --> 01:17:05,487
PROSPECTIVELY AT THIS POINT.

1857
01:17:05,554 --> 01:17:09,091
>> DR. JOHN SLEASMAN.

1858
01:17:09,157 --> 01:17:09,791
>> THANK YOU THANK YOU.

1859
01:17:09,858 --> 01:17:11,360
I LOVE THE SLIDES.

1860
01:17:11,426 --> 01:17:15,497
I DEPENDENT HEAR MUCH ABOUT

1861
01:17:15,564 --> 01:17:16,631
PARTNERSHIPS WITH THE OTHER

1862
01:17:16,698 --> 01:17:19,701
FEDERAL AGENCIES THAT ARE

1863
01:17:19,768 --> 01:17:22,938
INVOLVED IN HIV AND PARTICULARLY

1864
01:17:23,005 --> 01:17:25,007
INVOLVING THE COMMUNITY OUTREACH

1865
01:17:25,073 --> 01:17:31,313
SPECIFICALLY THINKING ABOUT

1866
01:17:31,380 --> 01:17:40,088
INTERACTIONS BETWEEN -- AS WE

1867
01:17:40,155 --> 01:17:43,258
START TO THINK ABOUT UNDERSERVED

1868
01:17:43,325 --> 01:17:45,994
POPULATIONS AND HEALTH CARE

1869
01:17:46,061 --> 01:17:49,031
DISPARITIES, WHICH ARE REALLY A

1870
01:17:49,097 --> 01:17:50,899
BIG THING FOR A LOT OF US.

1871
01:17:50,966 --> 01:17:52,000
ONE OTHER THING.

1872
01:17:52,067 --> 01:17:55,103
SO A LOT OF THE TIMES THE RFIs

1873
01:17:55,170 --> 01:17:58,974
HAVE ONLY BEEN ENGAGED ACADEMIC

1874
01:17:59,041 --> 01:17:59,574
CENTERS AND I THINK WE HAVE TO

1875
01:17:59,641 --> 01:18:02,344
BE CAREFUL THAT WE GET THE FULL

1876
01:18:02,411 --> 01:18:04,346
SCOPE OF THE PEOPLE THAT ARE

1877
01:18:04,413 --> 01:18:08,383
AFFECTED BY HIV AND AIDS THAT

1878
01:18:08,450 --> 01:18:13,989
ARE OUTSIDE OF THE ACADEMIC

1879
01:18:14,056 --> 01:18:14,222
CENTERS.

1880
01:18:14,289 --> 01:18:16,858
>> THANK YOU DR. JOHN SLEASMAN.

1881
01:18:16,925 --> 01:18:17,192
GREAT ADVICE.

1882
01:18:17,259 --> 01:18:18,760
I THINK REACHEL HAS SOME

1883
01:18:18,827 --> 01:18:19,628
THOUGHTS AS WELL.

1884
01:18:19,694 --> 01:18:24,533
>> I WANTED TO ADD THAT WE ARE

1885
01:18:24,599 --> 01:18:26,435
DEFINITELY ENGAGING WITH OUR

1886
01:18:26,501 --> 01:18:28,136
COLLEAGUES AT -- WE INCLUDED

1887
01:18:28,203 --> 01:18:30,839
THEM IN PART OF OUR OUTREACH AND

1888
01:18:30,906 --> 01:18:32,274
PROMOTIONAL PLAN FOR THIS RFI

1889
01:18:32,340 --> 01:18:33,108
RELEASE.

1890
01:18:33,175 --> 01:18:35,077
SO, WE ARE SHARING THIS REQUEST

1891
01:18:35,143 --> 01:18:37,946
WITH THEM AND WE ALSO ENGAGE

1892
01:18:38,013 --> 01:18:41,049
WITH HIV.GOV TO COORDINATE

1893
01:18:41,116 --> 01:18:44,519
DISTRIBUTION OF THIS REQUEST

1894
01:18:44,586 --> 01:18:49,157
ACROSS THE GOVERNMENT.

1895
01:18:49,224 --> 01:18:54,329
>> I WANTED TO REITERATE, JOHN,

1896
01:18:54,396 --> 01:18:57,132
RACHEL IS OUR NEWLY-PROMOTED

1897
01:18:57,199 --> 01:18:58,934
SUPERVISOR OF THE POLICY

1898
01:18:59,000 --> 01:18:59,901
LEGISLATIVE COMMUNICATIONS AND

1899
01:18:59,968 --> 01:19:00,502
ENGAGEMENT TEAMS.

1900
01:19:00,569 --> 01:19:04,639
THIS IS VERY MUCH PART OF OUR

1901
01:19:04,706 --> 01:19:10,545
OAR STRUCTURE.

1902
01:19:10,612 --> 01:19:10,846
>> THANKS.

1903
01:19:10,912 --> 01:19:13,148
>> THANKS AND REGARDING THE

1904
01:19:13,215 --> 01:19:14,683
ACADEMIC CENTERS AS WELL, WE DO

1905
01:19:14,749 --> 01:19:17,319
HAVE A NUMBER OF OUTREACH

1906
01:19:17,385 --> 01:19:20,555
OPPORTUNITIES WITH NON-ACADEMIC

1907
01:19:20,622 --> 01:19:22,023
PARTNERS AND WE TAKE THOSE VERY,

1908
01:19:22,090 --> 01:19:24,159
VERY SERIOUSLY AND WILL BE

1909
01:19:24,226 --> 01:19:25,026
CONTINUING THOSE.

1910
01:19:25,093 --> 01:19:28,730
AND WE ALSO HAVE A NUMBER OF

1911
01:19:28,797 --> 01:19:32,667
ONGOING FEDERAL TO FEDERAL

1912
01:19:32,734 --> 01:19:35,036
ENGAGEMENTS, FOR EXAMPLE, NIH

1913
01:19:35,103 --> 01:19:36,571
AND CDC MEET QUARTERLY TO

1914
01:19:36,638 --> 01:19:39,908
DISCUSS TOPICAL EVENTS AND

1915
01:19:39,975 --> 01:19:40,509
ACTIVITIES.

1916
01:19:40,575 --> 01:19:42,043
WE MEET WITH OUR PARTNERS

1917
01:19:42,110 --> 01:19:42,677
FREQUENTLY AS WELL.

1918
01:19:42,744 --> 01:19:44,479
SO WE'LL BE PROMOTING THIS

1919
01:19:44,546 --> 01:19:50,752
THROUGH BOTH FORMAL AND KIND OF

1920
01:19:50,819 --> 01:19:55,724
ROUTINE CHANNELS.

1921
01:19:55,790 --> 01:19:56,992
>> THANK YOU.

1922
01:19:57,058 --> 01:19:58,960
DR. LUIS MONTANER.

1923
01:19:59,027 --> 01:20:01,396
>> YES, THANK YOU.

1924
01:20:01,463 --> 01:20:03,999
SO I THINK THIS PLAN IS REALLY

1925
01:20:04,065 --> 01:20:05,333
SETS THE TONE FOR HOW WE ARE

1926
01:20:05,400 --> 01:20:08,170
GOING TO ENGAGE THE FOLLOWING

1927
01:20:08,236 --> 01:20:10,772
PRIORITIES MOVING FORWARD.

1928
01:20:10,839 --> 01:20:11,640
ONLY TWO POINTS.

1929
01:20:11,706 --> 01:20:15,076
ONE TO JUST SORT OF FOLLOW-UP ON

1930
01:20:15,143 --> 01:20:16,845
THE -- GETTING INPUT FROM THE

1931
01:20:16,912 --> 01:20:18,613
OUTSIDE AND WE TALKED ABOUT THE

1932
01:20:18,680 --> 01:20:19,748
ROLE OF COMMUNITY HEALTH CENTERS

1933
01:20:19,814 --> 01:20:22,117
AND THE NETWORKS WITHIN THESE

1934
01:20:22,184 --> 01:20:25,253
CLINICS THAT CARE FOR A LOT OF

1935
01:20:25,320 --> 01:20:28,790
INDIVIDUALS WITH HIV THAT THEIR

1936
01:20:28,857 --> 01:20:30,292
VOICE WILL MEET THAT ARE MORE

1937
01:20:30,358 --> 01:20:31,193
OPERATIONAL WILL BE REALLY

1938
01:20:31,259 --> 01:20:33,061
IMPORTANT TO TAKE INTO ACCOUNT.

1939
01:20:33,128 --> 01:20:36,665
THE RCMI NETWORKS ALSO THAT ARE

1940
01:20:36,731 --> 01:20:38,233
DEALING WITH ENVIRONMENTS THAT

1941
01:20:38,300 --> 01:20:40,435
WE WANT TO LOOK INTO IS ANOTHER

1942
01:20:40,502 --> 01:20:41,036
ONE.

1943
01:20:41,102 --> 01:20:42,604
SO I WOULD JUST ENCOURAGE YOU TO

1944
01:20:42,671 --> 01:20:44,973
TRY TO REACH OUT OUTSIDE OF THE

1945
01:20:45,040 --> 01:20:46,641
COMFORT ZONE OF ACADEMIC

1946
01:20:46,708 --> 01:20:48,643
STANDARDS AGGRESSIVELY.

1947
01:20:48,710 --> 01:20:51,479
MY SECOND POINT IS THAT WHEN IT

1948
01:20:51,546 --> 01:20:52,480
COMES TO STRATEGIC PLAN, WE ALL

1949
01:20:52,547 --> 01:20:55,217
WANT TO THINK ABOUT

1950
01:20:55,283 --> 01:20:56,484
OPERATIONALLY REDUCING TO VERY

1951
01:20:56,551 --> 01:20:57,519
SPECIFIC ACTIONS BUT OBVIOUSLY

1952
01:20:57,586 --> 01:20:58,954
AT THIS POINT, WE ARE TALKING

1953
01:20:59,020 --> 01:21:02,824
ABOUT MUCH BROADER THEMES AND

1954
01:21:02,891 --> 01:21:03,124
PRIORITIES.

1955
01:21:03,191 --> 01:21:06,294
SO I WANT TO ENCOURAGE WHEN YOU

1956
01:21:06,361 --> 01:21:08,997
DEFINE TASK FORCE, THAT YOU

1957
01:21:09,064 --> 01:21:10,398
DEFINE SOME OF THESE TASK FORCES

1958
01:21:10,465 --> 01:21:12,767
TO BE MORE INQUISITIVE ABOUT THE

1959
01:21:12,834 --> 01:21:12,968
GAPS.

1960
01:21:13,034 --> 01:21:14,636
LIKE FOR EXAMPLE, WE TALKED

1961
01:21:14,703 --> 01:21:17,105
ABOUT HOW TO REACH GREATER

1962
01:21:17,172 --> 01:21:18,773
COMMUNITY-BASED RESEARCH OR HOW

1963
01:21:18,840 --> 01:21:21,243
TO BREAKTHROUGH OUR STUDY

1964
01:21:21,309 --> 01:21:22,844
SECTIONS ON COMMUNITIES THAT ARE

1965
01:21:22,911 --> 01:21:24,279
TRYING TO DEVELOP RESEARCH

1966
01:21:24,346 --> 01:21:25,914
INITIATIVES BUT THEY BASICALLY

1967
01:21:25,981 --> 01:21:27,549
DIE ON THE STUDY SECTION.

1968
01:21:27,616 --> 01:21:28,950
AND THERE IS THE GOAL AND THERE

1969
01:21:29,017 --> 01:21:30,685
IS THE OPERATIONAL PROCESS TO

1970
01:21:30,752 --> 01:21:32,821
GET THE GOAL IMPLEMENTED.

1971
01:21:32,887 --> 01:21:34,656
AND TO THE POINT THAT THE

1972
01:21:34,723 --> 01:21:37,792
PRIORITIES COULD TRY TO CHIP

1973
01:21:37,859 --> 01:21:39,628
AWAY AT TRYING TO ACKNOWLEDGE

1974
01:21:39,694 --> 01:21:42,464
THAT WE DO NEED TO DO BETTER

1975
01:21:42,530 --> 01:21:43,732
THAN JUST GO AFTER THE TOPICS.

1976
01:21:43,798 --> 01:21:46,568
WE NEED TO ALSO LOOK AT THE

1977
01:21:46,635 --> 01:21:48,069
OPERATIONAL PROCESS BY WHICH WE

1978
01:21:48,136 --> 01:21:49,471
SUPPORT OUR RESEARCH STRUCTURE,

1979
01:21:49,537 --> 01:21:54,409
BECAUSE I THINK THAT THERE IS

1980
01:21:54,476 --> 01:21:55,443
SOME REALIGNMENT THAT COULD

1981
01:21:55,510 --> 01:21:56,444
POTENTIALLY OPEN UP FOR MORE

1982
01:21:56,511 --> 01:21:58,046
REPRESENTATION IN THE RESEARCH

1983
01:21:58,113 --> 01:21:59,881
EFFORT ACROSS-THE-BOARD AND

1984
01:21:59,948 --> 01:22:00,915
BY - EYE UNDERSTAND THE BARRIERS

1985
01:22:00,982 --> 01:22:02,584
ARE IMPORTANT BECAUSE OF THE

1986
01:22:02,651 --> 01:22:03,918
GOALS BUT WE ALSO HAVE TO

1987
01:22:03,985 --> 01:22:05,787
ACKNOWLEDGE THE PROCESS OF

1988
01:22:05,854 --> 01:22:07,656
GETTING THOSE GOALS IS ALSO

1989
01:22:07,722 --> 01:22:07,989
IMPORTANT.

1990
01:22:08,056 --> 01:22:10,859
SO I DON'T KNOW TO WHAT EXTENT

1991
01:22:10,925 --> 01:22:12,460
WE COULD INTRODUCE OPERATIONAL

1992
01:22:12,527 --> 01:22:14,796
RESEARCH SUPPORT,

1993
01:22:14,863 --> 01:22:15,330
COMMUNITY-BASED RESEARCH

1994
01:22:15,397 --> 01:22:18,166
OPPORTUNITIES, AND HOW THESE

1995
01:22:18,233 --> 01:22:19,301
PRIORITIES WILL ACKNOWLEDGE THAT

1996
01:22:19,367 --> 01:22:21,202
THAT IS SOMETHING THAT WE WANT

1997
01:22:21,269 --> 01:22:27,108
TO DO BETTER IN THE FUTURE.

1998
01:22:27,175 --> 01:22:27,409
>> THANKS.

1999
01:22:27,475 --> 01:22:29,511
IF I MAY, IT SOUNDS LIKE YOU

2000
01:22:29,577 --> 01:22:30,745
REALLY ARE SUPPORTING THE NOTION

2001
01:22:30,812 --> 01:22:33,715
OF NOT ONLY ELUCIDATING RESEARCH

2002
01:22:33,782 --> 01:22:36,184
PRIORITIES BUT PATHWAYS TO REACH

2003
01:22:36,251 --> 01:22:37,185
THOSE PRIORITIES.

2004
01:22:37,252 --> 01:22:37,519
>> CORRECT.

2005
01:22:37,585 --> 01:22:40,355
I THINK THE PATHWAY IS WHERE WE

2006
01:22:40,422 --> 01:22:43,758
LOSE A LOT IN THE PROCESS.

2007
01:22:43,825 --> 01:22:44,125
>> ABSOLUTELY.

2008
01:22:44,192 --> 01:22:45,894
AND JUST IF IT WASN'T CLEAR

2009
01:22:45,960 --> 01:22:47,395
REGARDING THE TASK FORCES, WE

2010
01:22:47,462 --> 01:22:50,065
WILL ABSOLUTELY BE INVITING

2011
01:22:50,131 --> 01:22:52,100
COMMUNITY MEMBERS, NON-ACADEMIC

2012
01:22:52,167 --> 01:22:55,904
COMMUNITY MEMBERS TO THESE TASK

2013
01:22:55,970 --> 01:22:57,706
FORCES AS WELL.

2014
01:22:57,772 --> 01:23:02,510
>> THANK YOU BOTH.

2015
01:23:02,577 --> 01:23:02,744
DR. AKE.

2016
01:23:02,811 --> 01:23:04,679
>> I HAD TWO COMMENTS.

2017
01:23:04,746 --> 01:23:10,752
ONE WAS JUST TO REALLY COMMEND

2018
01:23:10,819 --> 01:23:16,691
THE PRESENTATION FOR SEPARATELY

2019
01:23:16,758 --> 01:23:21,062
IDENTIFYING AND BY COROLLARY,

2020
01:23:21,129 --> 01:23:23,932
PRIORITIZING FOR RESOURCES,

2021
01:23:23,998 --> 01:23:28,837
EFFORTS FOR CAPACITY BUILDING,

2022
01:23:28,903 --> 01:23:30,372
TRAINING GRANTS IN THAT

2023
01:23:30,438 --> 01:23:30,705
PRESENTATION.

2024
01:23:30,772 --> 01:23:32,240
AND THOSE ARE REALLY IMPORTANT

2025
01:23:32,307 --> 01:23:34,843
EFFORTS TO SUSTAINABILITY OF HIV

2026
01:23:34,909 --> 01:23:37,979
RESEARCH, REALLY ACROSS THE

2027
01:23:38,046 --> 01:23:40,014
SPECTRUM OF THE WORK THAT IS

2028
01:23:40,081 --> 01:23:40,448
DONE.

2029
01:23:40,515 --> 01:23:42,150
AND EVEN ADDRESSING THE

2030
01:23:42,217 --> 01:23:44,252
DISPARITIES WITHIN THE RESEARCH

2031
01:23:44,319 --> 01:23:47,222
COMMUNITY, ARE GOING TO

2032
01:23:47,288 --> 01:23:48,022
REACQUIRE A FOCUSED ATTENTION ON

2033
01:23:48,089 --> 01:23:48,823
THAT VERY ISSUE.

2034
01:23:48,890 --> 01:23:52,327
SO I REALLY WANTED TO COMMEND

2035
01:23:52,394 --> 01:23:55,764
THE PRESENTATION AND EARLY PLANS

2036
01:23:55,830 --> 01:23:57,399
FOR CALLING THAT OUT.

2037
01:23:57,465 --> 01:23:58,533
THE COMMENT I'D LIKE TO MAKE

2038
01:23:58,600 --> 01:24:00,769
ABOUT THAT IS IT IS MOST USEFUL

2039
01:24:00,835 --> 01:24:02,036
WHEN THOSE CAPACITY-BUILDING

2040
01:24:02,103 --> 01:24:04,906
EFFORTS ARE REALLY INTEGRATED

2041
01:24:04,973 --> 01:24:06,941
INTO THE PRIMARY RESEARCH

2042
01:24:07,008 --> 01:24:08,143
EFFORTS THAT ARE DESCRIBED.

2043
01:24:08,209 --> 01:24:09,644
LIKE A TRAINING GRANT IS NOT

2044
01:24:09,711 --> 01:24:10,445
HELPFUL IF SOMEONE DOESN'T HAVE

2045
01:24:10,512 --> 01:24:12,580
A RESEARCH PROJECT THAT GIVES

2046
01:24:12,647 --> 01:24:16,684
THEM DATA OR AN ANALYSIS THAT

2047
01:24:16,751 --> 01:24:17,986
THEY ARE ABLE TO WORK ON FOR

2048
01:24:18,052 --> 01:24:20,088
THEIR TRAINING.

2049
01:24:20,155 --> 01:24:21,489
AND DISSERTATION.

2050
01:24:21,556 --> 01:24:23,491
SO, YOU MIGHT WANT TO CONSIDER

2051
01:24:23,558 --> 01:24:28,630
WAYS THAT YOU MIGHT BE ABLE TO

2052
01:24:28,696 --> 01:24:30,832
VISUALLY SHOW OR THROUGH THE

2053
01:24:30,899 --> 01:24:35,203
WRITING OF THE PLAN, SHOWING HOW

2054
01:24:35,270 --> 01:24:37,071
EACH OF THE BASIC SCIENCE TOOL

2055
01:24:37,138 --> 01:24:40,775
DEVELOPMENT AND IMPLEMENTATION

2056
01:24:40,842 --> 01:24:44,279
SCIENCE COMPONENTS OF THE

2057
01:24:44,345 --> 01:24:46,881
RESEARCH PILLARS COULD EACH

2058
01:24:46,948 --> 01:24:48,850
INCORPORATE SOME OF THOSE

2059
01:24:48,917 --> 01:24:51,152
CAPACITY-BUILDING

2060
01:24:51,219 --> 01:24:52,554
CONSIDERATIONS.

2061
01:24:52,620 --> 01:24:59,027
THANK YOU VERY MUCH.

2062
01:24:59,093 --> 01:25:01,763
>> THANK YOU.

2063
01:25:01,830 --> 01:25:02,063
DR. GANDHI.

2064
01:25:02,130 --> 01:25:06,267
>> I JUST WANT TO SAY I SO

2065
01:25:06,334 --> 01:25:06,901
APPRECIATE THE FOURTH GOAL BEING

2066
01:25:06,968 --> 01:25:08,570
ALL ABOUT CAPACITY.

2067
01:25:08,636 --> 01:25:10,472
I THINK THAT'S AMAZING BECAUSE I

2068
01:25:10,538 --> 01:25:12,440
THINK WHAT COULD GET LOST IN THE

2069
01:25:12,507 --> 01:25:14,142
PRIOR ITERATION WAS THAT IT WAS

2070
01:25:14,209 --> 01:25:16,544
A CROSSCUTTING PRIORITY.

2071
01:25:16,611 --> 01:25:22,116
BUT TO HAVE A DISTINCTIVE GOAL

2072
01:25:22,183 --> 01:25:23,618
FOR CAPACITY BUILDING AND

2073
01:25:23,685 --> 01:25:25,453
TRAINING BIOMEDICAL RESEARCH

2074
01:25:25,520 --> 01:25:26,354
WORKFORCE, I THINK DISTINGUISHES

2075
01:25:26,421 --> 01:25:28,389
IT AND MAKES IT SO MEANINGFUL IN

2076
01:25:28,456 --> 01:25:29,891
TERMS OF WHAT THE NIH IS TRYING

2077
01:25:29,958 --> 01:25:32,794
TO DO TO BUILD THE WORKFORCE.

2078
01:25:32,861 --> 01:25:34,863
AS YOU KNOW IN INFECTIOUS

2079
01:25:34,929 --> 01:25:37,832
DISEASE, WE HAD REDUCTIONS IN ID

2080
01:25:37,899 --> 01:25:38,833
MATCHES, AT LEAST TWO YEARS AGO,

2081
01:25:38,900 --> 01:25:42,337
AND THIS IS JUST CRITICAL TO

2082
01:25:42,403 --> 01:25:43,404
BUILDUP THE CAPACITY AND

2083
01:25:43,471 --> 01:25:44,873
TRAINING WORKFORCE.

2084
01:25:44,939 --> 01:25:47,008
SO I LOVE THAT SO MUCH.

2085
01:25:47,075 --> 01:25:48,776
AND I JUST WANTED TO GIVE THAT

2086
01:25:48,843 --> 01:25:51,446
FEEDBACK THAT I THOUGHT THAT WAS

2087
01:25:51,513 --> 01:25:52,146
FANTASTIC.

2088
01:25:52,213 --> 01:25:53,815
>> THANK YOU FOR SHARING THAT.

2089
01:25:53,882 --> 01:25:55,383
AND I'LL ADD TO THE COMMENT THAT

2090
01:25:55,450 --> 01:25:58,820
THIS IS REALLY AN NIH-WIDE

2091
01:25:58,887 --> 01:26:01,322
INTEREST IN HAVING A SPECIFIC

2092
01:26:01,389 --> 01:26:03,491
FOCUS AND A SEPARATELY CALLING

2093
01:26:03,558 --> 01:26:06,294
OUT CAPACITY.

2094
01:26:06,361 --> 01:26:09,163
AND SO, THIS WAS PART OF THE NIH

2095
01:26:09,230 --> 01:26:11,299
COMMON TEMPLATE FOR STRATEGIC

2096
01:26:11,366 --> 01:26:13,868
PLANS WHERE THE EXPECTATION IS

2097
01:26:13,935 --> 01:26:17,038
NOW THAT ALL STRATEGIC PLANS

2098
01:26:17,105 --> 01:26:18,606
ACROSS NIH WILL KIND OF

2099
01:26:18,673 --> 01:26:21,776
SEPARATELY ADDRESS THE RESEARCH

2100
01:26:21,843 --> 01:26:22,710
QUESTIONS VERSUS THE CAPACITY

2101
01:26:22,777 --> 01:26:24,012
INFRASTRUCTURE AND TRAINING

2102
01:26:24,078 --> 01:26:24,512
NEEDS.

2103
01:26:24,579 --> 01:26:32,820
SO THANKS FOR YOUR COMMENT.

2104
01:26:32,887 --> 01:26:35,256
>> ANY OTHER COMMENTS OR

2105
01:26:35,323 --> 01:26:39,394
QUESTIONS?

2106
01:26:39,460 --> 01:26:42,497
>> IF I MAY, JUST TO REITERATE

2107
01:26:42,564 --> 01:26:44,532
THAT WE WILL BE CALLING YOU TO

2108
01:26:44,599 --> 01:26:49,437
JOIN THESE TASK FORCES VERY SO

2109
01:26:49,504 --> 01:26:49,637
SOON.

2110
01:26:49,704 --> 01:26:51,873
SO, WE WILL BE IN TOUCH VIA

2111
01:26:51,940 --> 01:26:52,340
E-MAIL.

2112
01:26:52,407 --> 01:26:53,775
WE'LL BE GETTING YOUR

2113
01:26:53,841 --> 01:26:55,376
AVAILABILITY BUT WE ARE THINKING

2114
01:26:55,443 --> 01:26:57,312
SORT OF LATE SPRING, EARLY

2115
01:26:57,378 --> 01:27:07,221
SUMMER FOR SOME INTENSIVE WORK

2116
01:27:07,288 --> 01:27:08,156
AND SERIAL MEETINGS, MAYBE 3-4,

2117
01:27:08,222 --> 01:27:10,058
AND THESE WILL NOT BE PUBLIC

2118
01:27:10,124 --> 01:27:10,325
MEETINGS.

2119
01:27:10,391 --> 01:27:14,228
THESE ARE CLOSED TASK FORCE

2120
01:27:14,295 --> 01:27:14,495
MEETINGS.

2121
01:27:14,562 --> 01:27:17,765
BUT THE ACTIVITIES OF EACH OF

2122
01:27:17,832 --> 01:27:21,869
THE GROUPS WILL BE COLLATED AND

2123
01:27:21,936 --> 01:27:23,438
REPORTED OUT AT THE JUNEAU RACK

2124
01:27:23,504 --> 01:27:25,640
AND AT THE OCTOBER OARAC LATER

2125
01:27:25,707 --> 01:27:26,774
THIS YEAR.

2126
01:27:26,841 --> 01:27:29,010
SO STAY TUNED AND THANK YOU VERY

2127
01:27:29,077 --> 01:27:34,816
MUCH FOR THE FEEDBACK.

2128
01:27:34,882 --> 01:27:35,283
>> THANK YOU.

2129
01:27:35,350 --> 01:27:39,020
ALL RIGHT, I DON'T SEE ANYMORE

2130
01:27:39,087 --> 01:27:39,354
RAISED HANDS.

2131
01:27:39,420 --> 01:27:42,256
SO I'D LIKE TO TAKE THE

2132
01:27:42,323 --> 01:27:43,625
OPPORTUNITY TO THANK YOU, TO ALL

2133
01:27:43,691 --> 01:27:47,695
OF OUR PRESENTERS AND OARAC

2134
01:27:47,762 --> 01:27:48,262
MEMBERS FOR SUCH A FRUITFUL

2135
01:27:48,329 --> 01:27:48,563
DISCUSSION.

2136
01:27:48,630 --> 01:27:50,632
WE WILL NOW TAKE A 15-MINUTE

2137
01:27:50,698 --> 01:27:51,165
BREAK.

2138
01:27:51,232 --> 01:27:54,102
WE'LL RETURN PROMPTLY AT 2:00.

2139
01:27:54,168 --> 01:27:55,503
PLEASE DO NOT LOG OUT OF YOUR

2140
01:27:55,570 --> 01:27:58,773
ZOOM MEETING, BUT DO MUTE YOUR

2141
01:27:58,840 --> 01:27:59,674
LINE AND PLEASE HIDE YOUR

2142
01:27:59,741 --> 01:28:00,775
CAMERA.

2143
01:28:00,842 --> 01:28:08,483
SEE YOU ALL BACK IN 15.

2144
01:28:08,549 --> 01:28:09,951
>> WELCOME BACK FROM THE BREAK,

2145
01:28:10,018 --> 01:28:10,218
EVERYONE.

2146
01:28:10,284 --> 01:28:13,588
WE WILL NOW HEAR A BRIEFLY

2147
01:28:13,655 --> 01:28:15,556
UPDATE FROM OTHER NIH ADVISORY

2148
01:28:15,623 --> 01:28:17,091
COUNCILS AND THE NATIONAL AIDS

2149
01:28:17,158 --> 01:28:18,593
EXECUTIVE COMMITTEE.

2150
01:28:18,660 --> 01:28:21,929
I WOULD LIKE TO INVITE

2151
01:28:21,996 --> 01:28:23,231
DR. MONICA GANDHI,

2152
01:28:23,297 --> 01:28:27,168
DR. MARGUERITA LIGHTFOOT.

2153
01:28:27,235 --> 01:28:28,536
>> DR. MELANIE OTT AND

2154
01:28:28,603 --> 01:28:32,106
Ms. CORETTE BYRD, TO PROVIDE

2155
01:28:32,173 --> 01:28:33,374
SUMMARIES OF RECENT MEETINGS OF

2156
01:28:33,441 --> 01:28:37,745
THE AIDS RESEARCH ADVISORY

2157
01:28:37,812 --> 01:28:38,346
COUNCIL, NATIONAL ADVISORY

2158
01:28:38,413 --> 01:28:39,380
MENTAL HEALTH COUNCIL, NATIONAL

2159
01:28:39,447 --> 01:28:42,717
ADVISORY COUNCIL ON DRUG ABUSE

2160
01:28:42,784 --> 01:28:47,021
AND THE NIH HIV/AIDS EXECUTIVE

2161
01:28:47,088 --> 01:28:48,489
COMMITTEE.

2162
01:28:48,556 --> 01:28:51,826
DR. MONICA GANDHI IS ALSO

2163
01:28:51,893 --> 01:28:52,560
WELL-KNOWN TO THE OARAC AS A

2164
01:28:52,627 --> 01:28:54,328
PRIOR CHAIR.

2165
01:28:54,395 --> 01:28:56,030
SHE SERVED AS PROFESSOR OF

2166
01:28:56,097 --> 01:29:00,535
MEDICINE AND ASSOCIATE DIVISION

2167
01:29:00,601 --> 01:29:02,236
CHIEF WITH THE DIVISION OF HIV,

2168
01:29:02,303 --> 01:29:04,038
INFECTIOUS DISEASE AND GLOBAL

2169
01:29:04,105 --> 01:29:08,242
MEDICINE AT UCSF SAN FRANCISCO

2170
01:29:08,309 --> 01:29:09,644
GENERAL HOSPITAL.

2171
01:29:09,711 --> 01:29:11,512
DR. MARGUERITA LIGHTFOOT SERVES

2172
01:29:11,579 --> 01:29:17,552
AS SORT DEAN FOR RESEARCH AND A

2173
01:29:17,618 --> 01:29:20,254
PROFESSOR AND HEALTH EQUITY AT

2174
01:29:20,321 --> 01:29:23,191
THE OREGON HEALTH AND SCIENCE

2175
01:29:23,257 --> 01:29:26,194
UNIVERSITY AND PORTLAND STATE

2176
01:29:26,260 --> 01:29:28,062
UNIVERSITY SCHOOL OF PUBLIC

2177
01:29:28,129 --> 01:29:28,329
HEALTH.

2178
01:29:28,396 --> 01:29:30,465
DR. MELANIE OTT SERVES AS

2179
01:29:30,531 --> 01:29:32,300
DIRECTOR AND SENIOR INVESTIGATOR

2180
01:29:32,366 --> 01:29:36,137
AT THE GLAD STONE INSTITUTE OF

2181
01:29:36,204 --> 01:29:36,804
VIROLOGY AND MIMINOLOGIY AND

2182
01:29:36,871 --> 01:29:39,273
PROFESSOR OF MEDICINE AT THE

2183
01:29:39,340 --> 01:29:42,210
UNIVERSITY OF CALIFORNIA SAN

2184
01:29:42,276 --> 01:29:42,877
FRANCISCO.

2185
01:29:42,944 --> 01:29:45,179
AND Ms. CORETTE BYRD SERVES AS

2186
01:29:45,246 --> 01:29:48,983
A HEALTH SCIENCE POLICY ANALYST

2187
01:29:49,050 --> 01:29:51,919
MEETING OAR, HIV INFO AND

2188
01:29:51,986 --> 01:29:54,722
CLINICAL GUIDELINES ACTIVITIES

2189
01:29:54,789 --> 01:29:59,060
AND OTHER COURSE CUTTING OAR AND

2190
01:29:59,127 --> 01:29:59,427
NIH ACTIVITIES.

2191
01:29:59,494 --> 01:30:01,896
DR. GANDHI, WE WILL BEGIN WITH

2192
01:30:01,963 --> 01:30:02,063
YOU.

2193
01:30:02,130 --> 01:30:02,597
>> THANK YOU VERY MUCH.

2194
01:30:02,663 --> 01:30:05,266
SO THIS IS REALLY A REPORT ABOUT

2195
01:30:05,333 --> 01:30:09,837
NIAID ADVISORY COUNCIL AND ARAC.

2196
01:30:09,904 --> 01:30:11,239
NEXT SLIDE, PLEASE.

2197
01:30:11,305 --> 01:30:16,310
SO ONE THING THAT STARTED OUT

2198
01:30:16,377 --> 01:30:18,179
EVERY MEETING AT THE MOMENT IS

2199
01:30:18,246 --> 01:30:20,815
THIS DISTRESSING SLIDE OF THE

2200
01:30:20,882 --> 01:30:22,283
POTENTIAL HOUSE CUTS TO NIAID

2201
01:30:22,350 --> 01:30:25,586
THAT SEEMS TO TARGET NIAID

2202
01:30:25,653 --> 01:30:25,920
SPECIFICALLY.

2203
01:30:25,987 --> 01:30:28,256
THIS HAS BEEN A SLIDE THAT IS

2204
01:30:28,322 --> 01:30:30,658
REALLY BEEN CIRCULATING FOR A

2205
01:30:30,725 --> 01:30:31,292
WHILE NOW.

2206
01:30:31,359 --> 01:30:34,228
BUT LUCKILY, WITH CONTINUING

2207
01:30:34,295 --> 01:30:38,866
RESOLUTIONS, AND HOPEFULLY

2208
01:30:38,933 --> 01:30:39,500
ADVOCACY IN CONGRESS, THIS WILL

2209
01:30:39,567 --> 01:30:40,635
NOT COME TO PASS.

2210
01:30:40,701 --> 01:30:43,237
BUT THIS IS HOW THINGS START OUT

2211
01:30:43,304 --> 01:30:45,540
AT THE NIAID ADVISORY COUNCIL

2212
01:30:45,606 --> 01:30:48,810
MEETINGS FOR THE LAST SEVERAL

2213
01:30:48,876 --> 01:30:50,144
MEETINGS.

2214
01:30:50,211 --> 01:30:52,814
SO, ON THE PLUS SIDE, AFTER

2215
01:30:52,880 --> 01:30:55,016
SEEING THAT SLIDE WE ALL HATE,

2216
01:30:55,082 --> 01:30:57,251
THIS IS THIS INCREASED FUNDING

2217
01:30:57,318 --> 01:30:59,187
TO NIAID THAT HAS BEEN QUITE

2218
01:30:59,253 --> 01:31:00,321
AGGRESSIVE OVER THE YEARS,

2219
01:31:00,388 --> 01:31:01,989
INCLUDING IN THE CONTINUING

2220
01:31:02,056 --> 01:31:03,791
RESOLUTION OF THE REALLY FLAT

2221
01:31:03,858 --> 01:31:08,095
FUNDING FROM 2023-2024 AND THEN

2222
01:31:08,162 --> 01:31:10,231
THIS SLIDE AT THE BOTTOM RIGHT

2223
01:31:10,298 --> 01:31:12,633
THAT SHOWS US HOW THE FUNDING AT

2224
01:31:12,700 --> 01:31:17,438
NIAID IS DIVIDED INTO HIV VERSUS

2225
01:31:17,505 --> 01:31:19,540
NON-HIV PRIORITIES, REALLY BIG

2226
01:31:19,607 --> 01:31:22,176
EMPHASIS ON ANTIMICROBIAL

2227
01:31:22,243 --> 01:31:24,145
RESISTANCE WHICH IS INCREDIBLY

2228
01:31:24,212 --> 01:31:25,847
IMPORTANT AND THEN EMERGING

2229
01:31:25,913 --> 01:31:27,014
INFECTIOUS DISEASES GET PULLED

2230
01:31:27,081 --> 01:31:29,617
INTO ALL OF THAT, ACTUALLY.

2231
01:31:29,684 --> 01:31:31,586
NEXT SLIDE.

2232
01:31:31,652 --> 01:31:34,822
SO, THEN THE REMAINDER OF THE

2233
01:31:34,889 --> 01:31:38,059
DAY WAS A REPORT BACK FROM FOUR

2234
01:31:38,125 --> 01:31:39,827
PROGRAMS AND THAT WAS SUCH A

2235
01:31:39,894 --> 01:31:42,930
GOOD DAY TO HEAR REALLY

2236
01:31:42,997 --> 01:31:45,099
COMPREHENSIVE WAY WHAT'S BEEN

2237
01:31:45,166 --> 01:31:47,435
HAPPENING BIOMEDICAL,

2238
01:31:47,501 --> 01:31:48,236
BIOBEHAVIORAL, SOCIAL

2239
01:31:48,302 --> 01:31:50,838
BEHAVIORAL, SCIENCE AND BASIC

2240
01:31:50,905 --> 01:31:52,006
TRANSLATIONAL RESEARCH ACROSS

2241
01:31:52,073 --> 01:31:52,240
NIAID.

2242
01:31:52,306 --> 01:31:53,841
IT'S SO INCREDIBLY EXCITING.

2243
01:31:53,908 --> 01:31:56,978
SO THESE WERE THE FOUR REPORT

2244
01:31:57,044 --> 01:31:57,178
BACKS.

2245
01:31:57,245 --> 01:31:58,713
AND THE FOUR LEADERS OF THOSE

2246
01:31:58,779 --> 01:32:00,615
PROGRAMS THAT PRESENTED THOSE

2247
01:32:00,681 --> 01:32:02,550
FOUR REPORT BACKS.

2248
01:32:02,617 --> 01:32:03,184
NEXT SLIDE.

2249
01:32:03,251 --> 01:32:04,585
SO TO GIVE THE HIGHLIGHTS FROM

2250
01:32:04,652 --> 01:32:06,153
THE THERAPEUTICS RESEARCH

2251
01:32:06,220 --> 01:32:09,557
PROGRAM PRESENTED BY DR. KIM,

2252
01:32:09,624 --> 01:32:10,291
THERAPEUTICS RESEARCH PROGRAM IS

2253
01:32:10,358 --> 01:32:11,826
TO INCLUDE THE HEALTH OF PEOPLE

2254
01:32:11,893 --> 01:32:15,162
LIVING WITH HIV BUT THAT

2255
01:32:15,229 --> 01:32:17,231
INCLUDES TB TREATMENT, HEPATITIS

2256
01:32:17,298 --> 01:32:19,367
TREATMENT AND PANDEMIC RESPONSES

2257
01:32:19,433 --> 01:32:24,105
IS IN THAT, BECAUSE OF THE COVID

2258
01:32:24,171 --> 01:32:24,972
AND M POX RESPONSE GOT FOLDED

2259
01:32:25,039 --> 01:32:26,841
INTO A LOT OF THE HIV CLINICAL

2260
01:32:26,908 --> 01:32:28,743
TRIAL NETWORKS.

2261
01:32:28,809 --> 01:32:31,679
AND SO, REALLY A DIVISION

2262
01:32:31,746 --> 01:32:34,782
DR. KIM TALKED TO US ABOUT FOUR

2263
01:32:34,849 --> 01:32:36,250
LONG-TERM GOALS, NEW AND

2264
01:32:36,317 --> 01:32:37,919
IMPROVED TREATMENTS AND

2265
01:32:37,985 --> 01:32:39,587
STRATEGIES WHICH FOLDS NICELY

2266
01:32:39,654 --> 01:32:41,622
INTO THE NEW PRIORITIES THAT WE

2267
01:32:41,689 --> 01:32:43,958
JUST WENT OVER, NIH HIV

2268
01:32:44,025 --> 01:32:46,193
PRIORITIES, POINT OF CARE AND

2269
01:32:46,260 --> 01:32:49,230
HOME BASED BIOG NOSTICS AND WE

2270
01:32:49,297 --> 01:32:49,864
HAVE DONE A LOT OF STRATEGIES ON

2271
01:32:49,931 --> 01:32:50,598
CURE AND ADDRESSING KEY

2272
01:32:50,665 --> 01:32:51,832
MORBIDITIES THROUGH STRATEGIES

2273
01:32:51,899 --> 01:32:54,035
FOR COOPERATION IN THESE REALLY

2274
01:32:54,101 --> 01:32:57,271
KEY MOMENTS WITH TB AND

2275
01:32:57,338 --> 01:33:01,409
HEPATITIS.

2276
01:33:01,475 --> 01:33:03,210
AND THEN HIGHLIGHTED SOME VERY

2277
01:33:03,277 --> 01:33:04,578
MAJOR ADVANCES THAT CAME

2278
01:33:04,645 --> 01:33:07,281
ABSOLUTELY DIRECTLY OUT OF THE

2279
01:33:07,348 --> 01:33:08,649
THERAPEUTICS RESEARCH PROGRAM

2280
01:33:08,716 --> 01:33:09,483
OVER THE LAST YEAR.

2281
01:33:09,550 --> 01:33:12,386
WHAT I THINK HAS BEEN EXTREMELY

2282
01:33:12,453 --> 01:33:13,921
EXCITING IS NOT ONLY THE

2283
01:33:13,988 --> 01:33:16,257
RESEARCH ON LONG ACTING

2284
01:33:16,324 --> 01:33:16,891
FORMULATIONS AND YESTERDAY THERE

2285
01:33:16,958 --> 01:33:19,493
WAS A PRESS RELEASE FROM NIAID

2286
01:33:19,560 --> 01:33:21,829
ON THE STUDY SHOWING THAT LONG

2287
01:33:21,896 --> 01:33:24,832
ACTING ART IS SUPERIOR TO ORAL

2288
01:33:24,899 --> 01:33:26,434
ART IN PARTICIPANTS WITH

2289
01:33:26,500 --> 01:33:27,435
ADHERENCE CHALLENGES, THAT WAS

2290
01:33:27,501 --> 01:33:31,038
VERY EXCITING TO SEE THAT

2291
01:33:31,105 --> 01:33:31,305
YESTERDAY.

2292
01:33:31,372 --> 01:33:34,542
BUT THEN IN TERMS OF THE

2293
01:33:34,608 --> 01:33:35,109
CO-MORBIDITIES ASPECT, THIS

2294
01:33:35,176 --> 01:33:37,311
MAJOR PUBLICATION FROM ACTG

2295
01:33:37,378 --> 01:33:39,947
WHICH WAS THE REPRIEVE STUDY

2296
01:33:40,014 --> 01:33:42,049
PUBLISHED IN AUGUST HAS CHANGED

2297
01:33:42,116 --> 01:33:43,818
CLINICAL CARE ALREADY, THE USE

2298
01:33:43,884 --> 01:33:45,987
OF STATENS IN THOSE WHO ARE LOW

2299
01:33:46,053 --> 01:33:47,655
TO MODERATE RISK OF

2300
01:33:47,722 --> 01:33:48,856
CARDIOVASCULAR DISEASE IN PEOPLE

2301
01:33:48,923 --> 01:33:49,857
LIVING WITH HIV.

2302
01:33:49,924 --> 01:33:52,560
AND REALLY SHOWED THAT IN A

2303
01:33:52,626 --> 01:33:55,062
RANDOMIZED WAY A STATEN IS GOING

2304
01:33:55,129 --> 01:33:56,897
TO PREVENT CARDIOVASCULAR

2305
01:33:56,964 --> 01:33:57,832
DISEASE OUTCOMES.

2306
01:33:57,898 --> 01:34:00,434
THIS IS SO PIVOTAL TO HOW WE ARE

2307
01:34:00,501 --> 01:34:03,804
CHANGING OUR CARE YESTERDAY AND

2308
01:34:03,871 --> 01:34:05,906
WE JUST AUTOMATED THIS SO WE

2309
01:34:05,973 --> 01:34:07,641
REALLY HAVE TO MAKE AN EXCUSE

2310
01:34:07,708 --> 01:34:10,311
WHY YOU'RE NOT PUTTING YOUR

2311
01:34:10,378 --> 01:34:13,147
PATIENT ON A STAT IN.

2312
01:34:13,214 --> 01:34:16,117
SO THEN THEN IT WAS PREVENTION

2313
01:34:16,183 --> 01:34:16,884
SCIENCE PRIORITIES AND AN

2314
01:34:16,951 --> 01:34:19,487
AMAZING PORTFOLIO OF NEW

2315
01:34:19,553 --> 01:34:21,322
PREVENTION PRODUCTS.

2316
01:34:21,389 --> 01:34:22,957
A LOT ON ENGAGING KEY

2317
01:34:23,024 --> 01:34:24,759
POPULATIONS AND SOCIAL BASIC

2318
01:34:24,825 --> 01:34:27,094
SCIENCE, HOW IMPORTANT ADHERENCE

2319
01:34:27,161 --> 01:34:29,730
IS TO ANYTHING THAT INVOLVES

2320
01:34:29,797 --> 01:34:30,031
PREVENTION.

2321
01:34:30,097 --> 01:34:32,867
SO THIS WAS THE ROUND PORTFOLIO

2322
01:34:32,933 --> 01:34:34,402
AND THEN HIGHLIGHTED, NEXT

2323
01:34:34,468 --> 01:34:37,638
SLIDE, WAS REALLY NEXT SLIDE.

2324
01:34:37,705 --> 01:34:40,474
WAS REALLY SHOWING FOUR MAJOR

2325
01:34:40,541 --> 01:34:41,842
ACCOMPLISHMENTS THAT I THINK ARE

2326
01:34:41,909 --> 01:34:44,412
IMPORTANT TO JUST BRIEFLY

2327
01:34:44,478 --> 01:34:44,645
MENTION.

2328
01:34:44,712 --> 01:34:46,447
ONE IS A FOCUS FROM NIAID ON

2329
01:34:46,514 --> 01:34:47,882
DEVELOPMENT OF PEDIATRIC

2330
01:34:47,948 --> 01:34:49,717
FORMULATIONS AS WE ARE LOOKING

2331
01:34:49,784 --> 01:34:51,185
AT LONG ACTING FORMULATIONS, WE

2332
01:34:51,252 --> 01:34:52,586
DO NEED TO INCLUDE CHILDREN IN

2333
01:34:52,653 --> 01:34:55,056
THAT, ESPECIALLY WITH THE LOWER

2334
01:34:55,122 --> 01:34:57,858
RATES OF BOTH ACCESS AND

2335
01:34:57,925 --> 01:34:58,793
VIROLOGICAL SUPPRESSION IN

2336
01:34:58,859 --> 01:34:59,060
CHILDREN.

2337
01:34:59,126 --> 01:35:01,195
SO THINKING ABOUT PREVENTION

2338
01:35:01,262 --> 01:35:02,363
PRODUCTS FOR CHILDREN THAT ARE

2339
01:35:02,430 --> 01:35:03,464
PATCHES, SHOTS, SOMETHING THAT

2340
01:35:03,531 --> 01:35:06,000
CAN BE REALLY EASILY TAKEN.

2341
01:35:06,067 --> 01:35:07,401
THE SECOND WAS PREVENTION AND

2342
01:35:07,468 --> 01:35:12,440
TREATMENT FOR PREGNANT WOMEN AND

2343
01:35:12,506 --> 01:35:13,674
HIGHLIGHTING THE VAGINAL RING IN

2344
01:35:13,741 --> 01:35:15,576
PREGNANT WOMEN TO PREVENT HIV

2345
01:35:15,643 --> 01:35:16,310
DURING THAT TIME PERIOD.

2346
01:35:16,377 --> 01:35:18,279
THE THIRD IS THE DEVELOPMENT OF

2347
01:35:18,345 --> 01:35:20,881
NEW HIV PREVENTION TRIALS, OF

2348
01:35:20,948 --> 01:35:24,785
COURSE NIAID WAS PIVOTAL IN THAT

2349
01:35:24,852 --> 01:35:28,823
STUDY SHOWING SUPERIORITY -- AND

2350
01:35:28,889 --> 01:35:31,492
THEN FINALLY, REALLY A FOCUS ON

2351
01:35:31,559 --> 01:35:33,427
CHILDREN WITH BOTH PREVENTION

2352
01:35:33,494 --> 01:35:35,830
BUT ALSO TREATMENT WHICH I THINK

2353
01:35:35,896 --> 01:35:40,201
IS TERRIBLY IMPORTANT GIVEN THE

2354
01:35:40,267 --> 01:35:40,868
DISPARATE OUTCOMES ESPECIALLY IN

2355
01:35:40,935 --> 01:35:43,104
VERY YOUNG CHILDREN.

2356
01:35:43,170 --> 01:35:43,404
NEXT SLIDE.

2357
01:35:43,471 --> 01:35:47,341
THE THIRD FOCUS WAS ON THE BASIC

2358
01:35:47,408 --> 01:35:48,242
SCIENCES PROGRAM.

2359
01:35:48,309 --> 01:35:48,809
ALSO REALLY EXCITING.

2360
01:35:48,876 --> 01:35:52,446
I DO HAVE TO SAY IT WAS DIVIDED

2361
01:35:52,513 --> 01:35:53,147
INTO TWO THINGS.

2362
01:35:53,214 --> 01:35:56,016
ONE IS BASIC PIVOTAL WORK ON

2363
01:35:56,083 --> 01:35:56,717
CURE RESEARCH.

2364
01:35:56,784 --> 01:35:59,720
THE SECOND WAS BROADLY

2365
01:35:59,787 --> 01:36:00,354
NEUTRALIZING ANTIBODIES AND THE

2366
01:36:00,421 --> 01:36:01,355
PROMISE OF THOSE.

2367
01:36:01,422 --> 01:36:04,492
THERE WILL BE A LOT ON BONDING

2368
01:36:04,558 --> 01:36:05,392
NEUTRALIZING ANTIBODIES FOR

2369
01:36:05,459 --> 01:36:07,294
PREVENTION, TREATMENT AND CURE.

2370
01:36:07,361 --> 01:36:10,197
AND THEN FOCUS THROUGH THE BASIC

2371
01:36:10,264 --> 01:36:12,199
SCIENCES PROGRAM ON SCIENCE

2372
01:36:12,266 --> 01:36:14,335
WORKFORCE DIVERSITY.

2373
01:36:14,401 --> 01:36:15,536
NEXT SLIDE.

2374
01:36:15,603 --> 01:36:16,270
SO SOMETHING TO HIGHLIGHT THAT

2375
01:36:16,337 --> 01:36:17,738
REALLY PRIMARY AREAS OF FOCUS IN

2376
01:36:17,805 --> 01:36:20,674
THIS AREA WERE REALLY

2377
01:36:20,741 --> 01:36:22,276
MECHANISTIC WORK AROUND CURE,

2378
01:36:22,343 --> 01:36:24,812
SMALL MOLECULES, BIOLOGICS

2379
01:36:24,879 --> 01:36:28,115
ALREADY THERAPEUTICS, THIRD IS

2380
01:36:28,182 --> 01:36:29,250
IDENTIFYING THROUGH SURVEILLANCE

2381
01:36:29,316 --> 01:36:31,185
APPROACHES, THE CLINICAL OUTCOME

2382
01:36:31,252 --> 01:36:32,887
TO STUDY, BASIC SCIENCE

2383
01:36:32,953 --> 01:36:33,187
APPROACHES.

2384
01:36:33,254 --> 01:36:36,223
AND THEN FOURTH REALLY FOCUS ON

2385
01:36:36,290 --> 01:36:37,424
IMPLEMENTATION RESEARCH TO

2386
01:36:37,491 --> 01:36:38,792
COLLABORATE BETWEEN DIFFERENT

2387
01:36:38,859 --> 01:36:40,561
FEDERAL AGENCIES TO END THE HIV

2388
01:36:40,628 --> 01:36:40,828
EPIDEMIC.

2389
01:36:40,895 --> 01:36:44,765
SO REALLY BROAD SCOPE OF THE

2390
01:36:44,832 --> 01:36:45,232
BASIC SCIENCE PROGRAM.

2391
01:36:45,299 --> 01:36:46,700
AND THEN THE NEXT SLIDE SHOWS

2392
01:36:46,767 --> 01:36:50,971
THE LAST PRIMARY FOCUS, WHICH

2393
01:36:51,038 --> 01:36:53,607
WAS VACCINE PROGRAM.

2394
01:36:53,674 --> 01:36:57,311
WE HAD MAJOR SETBACKS EVEN

2395
01:36:57,378 --> 01:36:59,213
RECENTLY IN THAT MAJOR VACCINE

2396
01:36:59,280 --> 01:37:00,548
FILES BUT I THINK WE ARE STILL

2397
01:37:00,614 --> 01:37:03,317
REALLY HOPEFUL THAT THERE ARE

2398
01:37:03,384 --> 01:37:04,585
TRANSLATIONAL APPROACHES,

2399
01:37:04,652 --> 01:37:06,520
INCLUDING mRNA VACCINES THAT

2400
01:37:06,587 --> 01:37:09,456
COULD BE USEFUL FOR HIV.

2401
01:37:09,523 --> 01:37:10,891
AND SO THERE IS NOT ONLY FOCUS

2402
01:37:10,958 --> 01:37:13,961
ON NEW VACCINE STRATEGIES BUT ON

2403
01:37:14,028 --> 01:37:14,862
BROADLY NEUTRALIZING ANTIBODIES

2404
01:37:14,929 --> 01:37:18,098
FOR VACCINE AND THEN FINALLY,

2405
01:37:18,165 --> 01:37:20,367
VACCINE ADJUVANTS AND HOW TO

2406
01:37:20,434 --> 01:37:21,001
DESIGN THE ADJUVANTS AND REALLY

2407
01:37:21,068 --> 01:37:23,170
EXCITING TO SEE THE mRNA

2408
01:37:23,237 --> 01:37:25,639
VACCINE GET THE NOBEL PRIZE.

2409
01:37:25,706 --> 01:37:28,943
AND THEN THE LAST SLIDE

2410
01:37:29,009 --> 01:37:30,878
HIGHLIGHTED THAT THE OARAC

2411
01:37:30,945 --> 01:37:31,545
TALKED ABOUT THIS COMMUNITY PATH

2412
01:37:31,612 --> 01:37:34,848
ON SELF TESTING.

2413
01:37:34,915 --> 01:37:36,050
SO THANK YOU VERY MUCH.

2414
01:37:36,116 --> 01:37:38,986
>> THANK YOU, DR. GANDHI.

2415
01:37:39,053 --> 01:37:44,758
DR. MARGUERITA LIGHTFOOT OPEN TO

2416
01:37:44,825 --> 01:37:44,925
YOU.

2417
01:37:44,992 --> 01:37:45,326
>> THANK YOU.

2418
01:37:45,392 --> 01:37:46,560
SO NEXT SLIDE, PLEASE.

2419
01:37:46,627 --> 01:37:50,931
I'M HOPING TO GIVE YOU ALL

2420
01:37:50,998 --> 01:37:52,800
HIGH-LEVEL INFORMATION ON THINGS

2421
01:37:52,866 --> 01:37:56,103
THAT ARE HAPPENING ON NIMH AND

2422
01:37:56,170 --> 01:37:57,171
SOME SPECIFIC THAT WOULD BE OF

2423
01:37:57,238 --> 01:38:00,407
INTEREST TO THOSE CONDUCTING HIV

2424
01:38:00,474 --> 01:38:00,674
RESEARCH.

2425
01:38:00,741 --> 01:38:02,009
IN TERMS OF THE OVERARCHING NEW

2426
01:38:02,076 --> 01:38:05,613
NEWS HAPPENING IN NIMH, THERE IS

2427
01:38:05,679 --> 01:38:06,313
A NEW DIVISION REPLACING THE

2428
01:38:06,380 --> 01:38:09,049
FORMER OFFICE OF TECHNOLOGY

2429
01:38:09,116 --> 01:38:10,084
DEVELOPMENT AND COORDINATION.

2430
01:38:10,150 --> 01:38:13,954
SO THAT IS THE DIVISION OF DATA

2431
01:38:14,021 --> 01:38:14,588
SCIENCE AND TECHNOLOGY.

2432
01:38:14,655 --> 01:38:16,857
THIS NEW DIVISION IS GOING TO

2433
01:38:16,924 --> 01:38:19,526
PROVIDE VALUABLE SUPPORT TO NIMH

2434
01:38:19,593 --> 01:38:20,327
INVESTIGATORS, INCLUDING

2435
01:38:20,394 --> 01:38:22,429
LARGE-SCALE SEQUENCING, BRAIN

2436
01:38:22,496 --> 01:38:25,532
AND TISSUE BANK, DATA ARCHIVES,

2437
01:38:25,599 --> 01:38:29,637
NON-HUMAN PRIMATE RESOURCES AND

2438
01:38:29,703 --> 01:38:30,004
INSTRUMENTATION.

2439
01:38:30,070 --> 01:38:30,904
ALSO THIS DIVISION WILL SUPPORT

2440
01:38:30,971 --> 01:38:31,939
THE DEVELOPMENT OF NEW TOOLS,

2441
01:38:32,006 --> 01:38:35,009
TECHNOLOGIES AND APPROACHES FOR

2442
01:38:35,075 --> 01:38:36,010
BRAIN AND BEHAVIORAL RESEARCH

2443
01:38:36,076 --> 01:38:36,777
AND PROVIDE INFRASTRUCTURE

2444
01:38:36,844 --> 01:38:40,014
RELATED TO DATA MANAGEMENT.

2445
01:38:40,080 --> 01:38:43,050
SO THE DIRECTOR OF DST IS GREG

2446
01:38:43,117 --> 01:38:43,484
FARBER.

2447
01:38:43,550 --> 01:38:45,786
NIMH AS I MENTIONED LAST TIME,

2448
01:38:45,853 --> 01:38:49,790
IT'S CONTINUING ITS 75TH

2449
01:38:49,857 --> 01:38:50,924
ANNIVERSARY.

2450
01:38:50,991 --> 01:38:52,293
NEW THINGS TO NOTE IS THAT WE

2451
01:38:52,359 --> 01:38:55,029
LAUNCHED A NEW PODCAST SERIES

2452
01:38:55,095 --> 01:38:55,663
FOR THE ANNIVERSARY.

2453
01:38:55,729 --> 01:38:56,997
IT'S CALLED MENTAL HEALTH

2454
01:38:57,064 --> 01:38:59,933
MATTERS AND IT'S HOSTED BY

2455
01:39:00,000 --> 01:39:01,235
DR. GORDON, THE DIRECTOR.

2456
01:39:01,302 --> 01:39:02,469
THEY ALSO LAUNCHED A SOCIAL

2457
01:39:02,536 --> 01:39:06,240
MEDIA CAMPAIGN CALLED, I AM NIMH

2458
01:39:06,307 --> 01:39:09,576
AND IT SHOWCASING MEMBERS OF THE

2459
01:39:09,643 --> 01:39:10,711
DIVERSITY GROUP OF INDIVIDUALS

2460
01:39:10,778 --> 01:39:14,014
THAT WORK AT NIMH AND JUST

2461
01:39:14,081 --> 01:39:14,748
SHOWING THE PASSION AND THE

2462
01:39:14,815 --> 01:39:17,818
DIVERSITY OF WORK THAT IS

2463
01:39:17,885 --> 01:39:19,720
HAPPENING AROUND NIMH AND THE

2464
01:39:19,787 --> 01:39:22,856
WORK IT'S DOING.

2465
01:39:22,923 --> 01:39:25,926
NIMH ALSO IS HEAVILY PARTNERED

2466
01:39:25,993 --> 01:39:28,729
AND INVESTED IN SUICIDE

2467
01:39:28,796 --> 01:39:29,029
PREVENTION.

2468
01:39:29,096 --> 01:39:32,766
SO THEY RECENTLY PARTNERED WITH

2469
01:39:32,833 --> 01:39:33,934
SAMHSA AND RECENTLY AWARDING

2470
01:39:34,001 --> 01:39:36,370
ABOUT 230 MILLION DOLLARS IN

2471
01:39:36,437 --> 01:39:37,771
GRANTS FOR SUICIDE PREVENTION

2472
01:39:37,838 --> 01:39:39,373
AND BEHAVIORAL HEALTH FOR

2473
01:39:39,440 --> 01:39:41,942
MARGINALIZED COMMUNITIES.

2474
01:39:42,009 --> 01:39:45,879
AND SO NIMH HAS A COUPLE OF

2475
01:39:45,946 --> 01:39:47,548
NOTICES OUT RIGHT NOW FUNDING

2476
01:39:47,614 --> 01:39:48,615
MECHANISMS, THAT ARE SUPPORTING

2477
01:39:48,682 --> 01:39:53,053
THIS WORK ON SUICIDE PREVENTION.

2478
01:39:53,120 --> 01:39:56,357
NIMH IS ALSO VERY MUCH INVESTED

2479
01:39:56,423 --> 01:39:57,624
IN BRAIN RESEARCH.

2480
01:39:57,691 --> 01:40:00,394
SO RESEARCHERS FROM THE BRAIN

2481
01:40:00,461 --> 01:40:01,295
INITIATIVE -- SOMETHING I WANTED

2482
01:40:01,362 --> 01:40:04,331
TO HIGHLIGHT IS WE HEARD ABOUT

2483
01:40:04,398 --> 01:40:07,668
THESE SUCCESSES FROM THIS

2484
01:40:07,735 --> 01:40:07,901
FUNDING.

2485
01:40:07,968 --> 01:40:09,303
ONE OF THE THINGS WE HEARD ABOUT

2486
01:40:09,370 --> 01:40:10,738
WERE THE RESEARCHERS FROM THE

2487
01:40:10,804 --> 01:40:13,240
BRAIN INITIATIVE CELL CENSUS

2488
01:40:13,307 --> 01:40:15,743
NETWORK, THERE ARE TWO MAJOR

2489
01:40:15,809 --> 01:40:16,110
ACCOMPLISHMENTS.

2490
01:40:16,176 --> 01:40:17,845
SO THEY DETAILED CELL MAPS TO

2491
01:40:17,911 --> 01:40:20,314
THE HUMAN BRAIN AND THE

2492
01:40:20,381 --> 01:40:21,148
NON-HUMAN PRIMATE BRAIN RECENTLY

2493
01:40:21,215 --> 01:40:22,649
IN A SERIES OF PUBLICATIONS.

2494
01:40:22,716 --> 01:40:25,252
AND SO IT REALLY SHOWCASED

2495
01:40:25,319 --> 01:40:27,154
EXCEPTIONALLY COMPLEXED

2496
01:40:27,221 --> 01:40:27,988
DIVERSITY OF CELLS HAPPENING IN

2497
01:40:28,055 --> 01:40:29,456
THE BRAIN AND HOPEFULLY IT WILL

2498
01:40:29,523 --> 01:40:33,360
LEAD TO A NEW GENERATION OF

2499
01:40:33,427 --> 01:40:34,895
TREATMENTS.

2500
01:40:34,962 --> 01:40:38,198
IN TERMS OF SOME ALSO HIGH-LEVEL

2501
01:40:38,265 --> 01:40:43,737
CHANGES IN PERSONNEL, ANN

2502
01:40:43,804 --> 01:40:45,739
HOUSTON WHO WAS THE NIMH DEPUTY

2503
01:40:45,806 --> 01:40:47,841
DIRECTOR OF MANAGEMENT AND THE

2504
01:40:47,908 --> 01:40:49,143
EXECUTIVE OFFICER.

2505
01:40:49,209 --> 01:40:53,247
SHE RECENTLY RETIRED.

2506
01:40:53,313 --> 01:40:54,815
THIS PARTICULAR POSITION

2507
01:40:54,882 --> 01:40:56,884
PROVIDED STRATEGIC DIRECTION AND

2508
01:40:56,950 --> 01:40:58,719
MANAGEMENT OF THE ADMINISTRATIVE

2509
01:40:58,786 --> 01:41:01,522
FUNCTIONS WHICH INCLUDED

2510
01:41:01,588 --> 01:41:02,089
OVERSILENT OF THE BUDGET AND

2511
01:41:02,156 --> 01:41:03,891
OVER 1600 STAFF, CONTRACTORS AND

2512
01:41:03,957 --> 01:41:04,258
STUDENTS.

2513
01:41:04,324 --> 01:41:05,793
A REPLACEMENT HAS NOT BEEN FOUND

2514
01:41:05,859 --> 01:41:07,261
YET FOR THAT POSITION BUT SHE

2515
01:41:07,327 --> 01:41:09,797
HAD BEEN THERE FOR OVER 30

2516
01:41:09,863 --> 01:41:10,798
YEARS.

2517
01:41:10,864 --> 01:41:13,434
RELEVANT TO THIS GROUP, TO OARAC

2518
01:41:13,500 --> 01:41:15,669
AND HIV RESEARCHERS, NIMH

2519
01:41:15,736 --> 01:41:17,104
ANNOUNCED THE APPOINTMENT OF

2520
01:41:17,171 --> 01:41:18,672
GREG GREENWOOD AS THE DEPUTY

2521
01:41:18,739 --> 01:41:20,541
DIRECTOR OF THE NIMH DIVISION OF

2522
01:41:20,607 --> 01:41:22,242
AIDS RESEARCH.

2523
01:41:22,309 --> 01:41:23,644
AND SO AS DEPUTY DIRECTOR, HE IS

2524
01:41:23,710 --> 01:41:25,078
GOING TO OVERSEE THE

2525
01:41:25,145 --> 01:41:27,281
DEVELOPMENT, DIRECTION AND

2526
01:41:27,347 --> 01:41:29,249
COORDINATION AND EVALUATION OF

2527
01:41:29,316 --> 01:41:29,883
DAR PROGRAMS.

2528
01:41:29,950 --> 01:41:31,752
THE DIVISION OF AIDS RESEARCH

2529
01:41:31,819 --> 01:41:33,220
PROGRAMS AND ACTIVITIES.

2530
01:41:33,287 --> 01:41:35,222
HE WILL ALSO CONTINUE TO SERVE

2531
01:41:35,289 --> 01:41:36,290
AS THE BRANCH CHIEF OF THE

2532
01:41:36,356 --> 01:41:37,458
DEVELOPMENTAL AND CLINICAL

2533
01:41:37,524 --> 01:41:38,992
NEUROSCIENCE OF HIV PREVENTION

2534
01:41:39,059 --> 01:41:41,295
AND TREATMENT BRANCH.

2535
01:41:41,361 --> 01:41:43,764
SO, GREG IS SUCCEEDS TIM

2536
01:41:43,831 --> 01:41:45,299
BROWERS, WHO I HAD MENTIONED AT

2537
01:41:45,365 --> 01:41:47,734
THE LAST MEETING, RETIRED IN

2538
01:41:47,801 --> 01:41:53,040
FEDERAL SERVICE IN 2023.

2539
01:41:53,106 --> 01:41:55,943
IN TERMS OF FUNDING, SIMILAR TO

2540
01:41:56,009 --> 01:41:57,377
NIAID, WE ALSO GO OVER THE

2541
01:41:57,444 --> 01:42:00,013
FUNDING FOR NIMH AT EVERY

2542
01:42:00,080 --> 01:42:01,682
COUNCIL MEETING AND FUNDING

2543
01:42:01,748 --> 01:42:01,915
LEVELS.

2544
01:42:01,982 --> 01:42:05,085
SO AS YOU CAN SEE HERE, NIMH

2545
01:42:05,152 --> 01:42:08,255
AWARDED 579 NEW GRANTS AND

2546
01:42:08,322 --> 01:42:09,590
COMPETING RESEARCH PROJECTS IN

2547
01:42:09,656 --> 01:42:10,691
FISCAL YEAR 23.

2548
01:42:10,757 --> 01:42:13,193
SO THAT REFLECTS AN OVERALL

2549
01:42:13,260 --> 01:42:18,131
SUCCESS RATE OF ABOUT 22%.

2550
01:42:18,198 --> 01:42:21,001
NIMH AWARDS MORE THAN 85% OF THE

2551
01:42:21,068 --> 01:42:23,303
RO1 APPLICATIONS SCORING IN THE

2552
01:42:23,370 --> 01:42:25,339
20th PERCENTILE OR BETTER.

2553
01:42:25,405 --> 01:42:27,441
HERE IS A GRAPH LOOKING AT

2554
01:42:27,508 --> 01:42:28,342
FUNDING OVER TIME.

2555
01:42:28,408 --> 01:42:31,111
SO FROM FISCAL YEAR 10 TO FISCAL

2556
01:42:31,178 --> 01:42:36,049
YEAR 23, NIMH RECEIVED INFLATION

2557
01:42:36,116 --> 01:42:37,818
ADJUSTED BUDGET OF ABOUT 18%.

2558
01:42:37,885 --> 01:42:39,586
THAT IS GOOD NEWS.

2559
01:42:39,653 --> 01:42:44,491
BUT ON THE MORE SIMILAR TO WHAT

2560
01:42:44,558 --> 01:42:45,125
DR. GANDHI TALKED ABOUT WHEN WE

2561
01:42:45,192 --> 01:42:46,760
LOOK AT THE CONTINUING

2562
01:42:46,827 --> 01:42:48,195
RESOLUTION, NIMH IS CURRENTLY

2563
01:42:48,262 --> 01:42:49,696
OPERATING UNDER THAT CONTINUING

2564
01:42:49,763 --> 01:42:52,599
RESOLUTION THROUGH MARCH OF

2565
01:42:52,666 --> 01:42:54,535
2024.

2566
01:42:54,601 --> 01:42:55,469
SO, WHILE UNDER THAT CONTINUING

2567
01:42:55,536 --> 01:42:56,570
RESOLUTION, NON-COMPETING GRANTS

2568
01:42:56,637 --> 01:42:59,706
WILL BE AWARDED AT LEVELS BELOW

2569
01:42:59,773 --> 01:43:01,608
THE COMMITTED AMOUNTS, TYPICALLY

2570
01:43:01,675 --> 01:43:02,509
AT ABOUT 90%.

2571
01:43:02,576 --> 01:43:06,079
AND AS YOU ALL KNOW, ON JANUARY

2572
01:43:06,146 --> 01:43:08,448
7, THERE WAS A AGREEMENT ON THE

2573
01:43:08,515 --> 01:43:11,018
FISCAL YEAR TOP LINE FUNDING

2574
01:43:11,084 --> 01:43:15,656
LEVELS WHICH WAS 772 BILLION FOR

2575
01:43:15,722 --> 01:43:16,890
NON DEFENSE PROGRAMS.

2576
01:43:16,957 --> 01:43:18,325
SO, THIS AGREEMENT REFLECTS A

2577
01:43:18,392 --> 01:43:21,695
FLAT BUDGET FOR MANY NON-DEFENSE

2578
01:43:21,762 --> 01:43:26,266
PROGRAMS, INCLUDING NIMH.

2579
01:43:26,333 --> 01:43:26,600
NEXT SLIDE.

2580
01:43:26,667 --> 01:43:28,068
THERE ARE A NUMBER OF FUNDING

2581
01:43:28,135 --> 01:43:28,936
OPPORTUNITIES THAT I THOUGHT

2582
01:43:29,002 --> 01:43:30,771
WOULD BE OF INTEREST TO THIS

2583
01:43:30,837 --> 01:43:31,371
AUDIENCE.

2584
01:43:31,438 --> 01:43:34,575
THE FIRST ONE IS LOOKING AT

2585
01:43:34,641 --> 01:43:37,110
INTERVENTIONS TO REDUCE SUICIDE

2586
01:43:37,177 --> 01:43:38,412
AMONG YOUNG PEOPLE AND

2587
01:43:38,478 --> 01:43:39,446
UNDERSERVED POPULATIONS.

2588
01:43:39,513 --> 01:43:40,647
THIS INITIATIVE WILL SUPPORT

2589
01:43:40,714 --> 01:43:42,115
REACH TO TEST THE EFFECTIVENESS

2590
01:43:42,182 --> 01:43:44,117
OF COMBINED STRATEGIES TO BOTH

2591
01:43:44,184 --> 01:43:46,353
THE TECH AND INTERVENE TO REDUCE

2592
01:43:46,420 --> 01:43:48,355
THE RISK OF SUICIDE, SUICIDE

2593
01:43:48,422 --> 01:43:50,023
IDEATION AND BEHAVIOR.

2594
01:43:50,090 --> 01:43:55,028
AND/OR NON-SUICIDAL SELF HARM,

2595
01:43:55,095 --> 01:43:57,064
AMONG CHILDREN AND ADOLESCENCE

2596
01:43:57,130 --> 01:43:58,899
FROM UNDERSERVED POPULATIONS.

2597
01:43:58,966 --> 01:44:01,034
THE SECOND HERE IS A

2598
01:44:01,101 --> 01:44:02,002
STREAMLINING MENTAL HEALTH

2599
01:44:02,069 --> 01:44:04,237
INTERVENTIONS FOR YOUTH LIVING

2600
01:44:04,304 --> 01:44:06,440
WITH HIV AND LMICs.

2601
01:44:06,506 --> 01:44:07,641
THE PURPOSE OF THIS INITIATIVE

2602
01:44:07,708 --> 01:44:10,210
IS TO USE NOVEL METHODS TO

2603
01:44:10,277 --> 01:44:11,078
STREAMLINE EVIDENCE-BASED MENTAL

2604
01:44:11,144 --> 01:44:12,412
HEALTH INTERVENTIONS FOR YOUTH

2605
01:44:12,479 --> 01:44:13,213
LIVING WITH HIV.

2606
01:44:13,280 --> 01:44:16,450
SO THEY REQUIRE FEWER RESOURCES

2607
01:44:16,516 --> 01:44:18,018
WHILE STILL LEADING TO

2608
01:44:18,085 --> 01:44:19,519
CLINICALLY MEANING IMPROVEMENTS

2609
01:44:19,586 --> 01:44:20,754
IN MENTAL HEALTH AND HIV

2610
01:44:20,821 --> 01:44:21,421
OUTCOMES.

2611
01:44:21,488 --> 01:44:23,423
AND THEN THE LAST ONE HERE SEEKS

2612
01:44:23,490 --> 01:44:24,925
TO ADVANCE DATA SCIENCE RESEARCH

2613
01:44:24,992 --> 01:44:25,559
IN HIV.

2614
01:44:25,626 --> 01:44:27,127
AND IT'S INTENDED TO ENCOURAGE

2615
01:44:27,194 --> 01:44:31,098
THE GENERATION OF CUTTING-EDGE

2616
01:44:31,164 --> 01:44:32,766
SYNTHETIC DATASETS, ARTIFICIAL

2617
01:44:32,833 --> 01:44:33,266
INTELLIGENCE AND MACHINE

2618
01:44:33,333 --> 01:44:35,035
LEARNING APPROACHES TO EXPAND

2619
01:44:35,102 --> 01:44:36,637
CAPACITY TO ADDRESS THE DYNAMIC

2620
01:44:36,703 --> 01:44:39,139
COMPLEX AND EVOLVING HIV

2621
01:44:39,206 --> 01:44:39,539
EPIDEMIC.

2622
01:44:39,606 --> 01:44:40,941
SO TEAM SCIENCE APPROACHES WHERE

2623
01:44:41,008 --> 01:44:43,310
THE STRENGTH AND EXPERTISE OF

2624
01:44:43,377 --> 01:44:44,645
MULTIPLE INDIVIDUALS ACROSS DATA

2625
01:44:44,711 --> 01:44:47,180
AND COMPUTATIONAL SCIENCES,

2626
01:44:47,247 --> 01:44:49,583
BIOSTATS, BEHAVIORAL AND SOCIAL

2627
01:44:49,650 --> 01:44:51,118
SCIENCES, COMPUTER SCIENCE AND

2628
01:44:51,184 --> 01:44:53,387
HIV PREVENTION AND CARE IS WHAT

2629
01:44:53,453 --> 01:44:54,655
IS REALLY STRONGLY ENCOURAGED

2630
01:44:54,721 --> 01:44:55,255
FOR THIS.

2631
01:44:55,322 --> 01:44:58,425
AND I ALSO LISTED THE NUMBERS

2632
01:44:58,492 --> 01:45:01,094
HERE FOR THOSE CALLS.

2633
01:45:01,161 --> 01:45:03,096
NEXT SLIDE.

2634
01:45:03,163 --> 01:45:07,034
WE HEARD -- COUNCIL HEARD AND

2635
01:45:07,100 --> 01:45:08,468
APPROVED TWO CONCEPT CLEARANCES

2636
01:45:08,535 --> 01:45:10,737
THAT WERE RELATED TO HIV THIS

2637
01:45:10,804 --> 01:45:11,071
ROUND.

2638
01:45:11,138 --> 01:45:17,411
SO THE FIRST WAS PRESENTED BY

2639
01:45:17,477 --> 01:45:20,514
DR. LORI SHELTON, GENERATIVE

2640
01:45:20,580 --> 01:45:21,148
ARTIFICIAL INTELLIGENCE,

2641
01:45:21,214 --> 01:45:22,449
OPPORTUNITIES AND CHALLENGES FOR

2642
01:45:22,516 --> 01:45:23,183
HIV CLINICAL CARE.

2643
01:45:23,250 --> 01:45:25,252
SO THE GOAL OF THIS CONCEPT WAS

2644
01:45:25,318 --> 01:45:28,588
TO ENCOURAGE THE USE OF

2645
01:45:28,655 --> 01:45:30,557
MULTI-MODAL AI TO ACCELERATE

2646
01:45:30,624 --> 01:45:31,758
DIAGNOSIS, PREVENTION AND

2647
01:45:31,825 --> 01:45:32,025
TREATMENT.

2648
01:45:32,092 --> 01:45:34,861
SO THE CONCEPT IS CONSISTENT

2649
01:45:34,928 --> 01:45:38,365
WITH THE HHS-AI STRATEGY.

2650
01:45:38,432 --> 01:45:39,966
SO MORE SPECIFICALLY THIS

2651
01:45:40,033 --> 01:45:40,834
CONCEPT AIMS TO ENCOURAGE THE

2652
01:45:40,901 --> 01:45:46,006
USE OF MULTI-MODAL AI IN

2653
01:45:46,073 --> 01:45:48,175
CLINICAL CARE THAT CAN EXPAND

2654
01:45:48,241 --> 01:45:49,543
OUR CAPACITY TO ADDRESS THE

2655
01:45:49,609 --> 01:45:52,079
DYNAMIC COMPLEX AND EVOLVING HIV

2656
01:45:52,145 --> 01:45:53,980
EPIDEMIC AND IT HAS THREE MAIN

2657
01:45:54,047 --> 01:45:54,915
GOALS.

2658
01:45:54,981 --> 01:45:56,650
THE FIRST IS DEVELOPMENT,

2659
01:45:56,717 --> 01:45:58,552
ADAPTATION AND USE OF ACCURATE,

2660
01:45:58,618 --> 01:46:00,754
SAFE AND EFFICIENT AND UNBIASED

2661
01:46:00,821 --> 01:46:02,589
AI MODELS TO SUPPORT DIVERSE

2662
01:46:02,656 --> 01:46:04,491
RANGE OF HIV APPLICATIONS.

2663
01:46:04,558 --> 01:46:06,993
THE SECOND IS THE CREATION OF

2664
01:46:07,060 --> 01:46:10,764
KNOWLEDGE GRAPHS TO STRENGTHEN,

2665
01:46:10,831 --> 01:46:12,199
MODAL INTERPRETATION AND

2666
01:46:12,265 --> 01:46:13,266
EXPLAINABILITY OF APPLICATIONS

2667
01:46:13,333 --> 01:46:16,336
OF AI APPLICATIONS IN HIV

2668
01:46:16,403 --> 01:46:16,970
RESEARCH CLINICAL CARE AND

2669
01:46:17,037 --> 01:46:17,738
PUBLIC HEALTH.

2670
01:46:17,804 --> 01:46:21,842
AND THE THIRD IS EXPLORATION OF

2671
01:46:21,908 --> 01:46:23,477
SINNER GEANISTIC INTEGRATION OF

2672
01:46:23,543 --> 01:46:25,612
KNOWLEDGE GRAPHS AND MODELS FOR

2673
01:46:25,679 --> 01:46:27,414
MORE RECISE MODEL OUTPUTS AND

2674
01:46:27,481 --> 01:46:30,484
INCREASE USE OF HIV CLINICAL

2675
01:46:30,550 --> 01:46:31,384
CARE.

2676
01:46:31,451 --> 01:46:33,820
THE SECOND CONCEPT CLEARANCE WAS

2677
01:46:33,887 --> 01:46:36,423
PRESENTED BY DR. JOSEPH AT DAR.

2678
01:46:36,490 --> 01:46:40,060
THE GOAL OF THIS CONCEPT WAS TO

2679
01:46:40,127 --> 01:46:41,995
ENCOURAGE RESEARCH TO DEFINE THE

2680
01:46:42,062 --> 01:46:44,197
MECHANISMS AND ROLES OF T-CELLS

2681
01:46:44,264 --> 01:46:46,967
AND HIV AND CNS RESERVOIR

2682
01:46:47,033 --> 01:46:49,770
SEEDING AND PERSISTENCE IN

2683
01:46:49,836 --> 01:46:50,170
NEUROPATHOGENESIS.

2684
01:46:50,237 --> 01:46:51,338
SO THIS RESEARCH WILL BE

2685
01:46:51,404 --> 01:46:52,839
CRITICAL IN DEVELOPING

2686
01:46:52,906 --> 01:46:54,641
THERAPEUTIC STRATEGIES FOR

2687
01:46:54,708 --> 01:46:58,311
TARGETING CNS RESERVOIRS AND

2688
01:46:58,378 --> 01:46:58,979
ONGOING NEUROINFLAMMATION THAT

2689
01:46:59,045 --> 01:47:01,281
DRIVES CNS CO-MORBIDITIES.

2690
01:47:01,348 --> 01:47:05,418
SO, THEY ARE LOOKING FOR --

2691
01:47:05,485 --> 01:47:08,088
LOOKING AT THIS BEING ABLE TO

2692
01:47:08,155 --> 01:47:09,890
DEFINE MECHANISMS OF

2693
01:47:09,956 --> 01:47:12,058
NEUROINVASION OF HIV INFECTED

2694
01:47:12,125 --> 01:47:14,060
T-CELLS AND ACUTE AND CHRONIC

2695
01:47:14,127 --> 01:47:15,762
BASES OF INFECTION, TO ADDRESS

2696
01:47:15,829 --> 01:47:18,198
THE ROLE OF T-CELLS AND CNS

2697
01:47:18,265 --> 01:47:19,599
SEEDING AND PERSISTENCE.

2698
01:47:19,666 --> 01:47:22,702
TO DEFINE T-CELL CONTRIBUTION TO

2699
01:47:22,769 --> 01:47:23,737
CNS HIV CLEARANCE,

2700
01:47:23,804 --> 01:47:24,938
NEUROINFLAMMATION AND

2701
01:47:25,005 --> 01:47:26,540
NEUROPATHOGENESIS AND TO DEVELOP

2702
01:47:26,606 --> 01:47:30,677
THERAPEUTIC STRATEGIES TO TARGET

2703
01:47:30,744 --> 01:47:31,278
T-CELL NEUROINVASION RESERVOIR

2704
01:47:31,344 --> 01:47:33,580
MAINTENANCE AND

2705
01:47:33,647 --> 01:47:33,980
NEUROPATHOGENESIS.

2706
01:47:34,047 --> 01:47:37,083
NEXT SLIDE, PLEASE.

2707
01:47:37,150 --> 01:47:39,786
WE ALSO HEARD HIV-RELATED

2708
01:47:39,853 --> 01:47:41,588
RESEARCH HIGHLIGHT.

2709
01:47:41,655 --> 01:47:43,223
SO THIS WAS HIGHLIGHTING SOME

2710
01:47:43,290 --> 01:47:45,091
RESEARCH THAT IS CURRENTLY BEING

2711
01:47:45,158 --> 01:47:47,194
FUNDED BY NIMH.

2712
01:47:47,260 --> 01:47:50,630
SO THIS AS WE KNOW, CURRENT

2713
01:47:50,697 --> 01:47:52,132
ANTI-RETROVIRAL THERAPY DOESN'T

2714
01:47:52,199 --> 01:47:53,500
COMPLETELY ELIMINATE HIV FROM

2715
01:47:53,567 --> 01:47:54,367
THE NERVOUS SYSTEM.

2716
01:47:54,434 --> 01:47:56,837
AND HIV CAN LIE DORMANT WITHIN

2717
01:47:56,903 --> 01:47:58,238
BRAIN RESERVOIRS FOR MANY YEARS

2718
01:47:58,305 --> 01:48:00,674
WHERE IT CAN INTEGRATE INTO THE

2719
01:48:00,740 --> 01:48:02,375
GENOME OF THE HOST CELLS AND

2720
01:48:02,442 --> 01:48:06,213
CONTRIBUTE TO HIV-ASSOCIATED

2721
01:48:06,279 --> 01:48:08,315
NEUROLOGICAL DISORDERS.

2722
01:48:08,381 --> 01:48:09,883
SO THIS GROUP AT GEORGE MASON

2723
01:48:09,950 --> 01:48:11,618
UNIVERSITY IS SEEKING TO TEST A

2724
01:48:11,685 --> 01:48:14,287
HIGHLY INNOVATIVE MODULAR

2725
01:48:14,354 --> 01:48:16,623
APPROACH TO PRODUCING LONG TERM

2726
01:48:16,690 --> 01:48:17,123
STABLE SILENCING OF HIV

2727
01:48:17,190 --> 01:48:19,125
TRANSCRIPTION BY DELIVERING

2728
01:48:19,192 --> 01:48:22,295
ANTIVIRAL MODALITIES THROUGH

2729
01:48:22,362 --> 01:48:22,963
EXTRACELLULAR VESICLES TO

2730
01:48:23,029 --> 01:48:24,231
HIV-INFECTED CELLS.

2731
01:48:24,297 --> 01:48:27,100
SO THESE BRAIN DERIVED

2732
01:48:27,167 --> 01:48:28,368
EXTRACELLULAR VESICLES ARE NOVEL

2733
01:48:28,435 --> 01:48:32,772
AND THEY CAN CARRY LARGE TARGET

2734
01:48:32,839 --> 01:48:33,673
HIV-INFECTED CELLS AND THE

2735
01:48:33,740 --> 01:48:39,379
INVESTIGATOR WILL TEST THIS

2736
01:48:39,446 --> 01:48:40,714
METHOD TO PRESS EXPRESSION LONG

2737
01:48:40,780 --> 01:48:42,949
TERM IN THE BRAIN AND ULTIMATELY

2738
01:48:43,016 --> 01:48:44,751
INHIBITING HIV NEUROLOGICAL

2739
01:48:44,818 --> 01:48:45,018
DISORDERS.

2740
01:48:45,085 --> 01:48:47,020
SO THIS APPROACH CAN OFFER NEW

2741
01:48:47,087 --> 01:48:49,522
PLATFORMS FOR DELIVERY

2742
01:48:49,589 --> 01:48:51,224
THERAPEUTICALLY RELEVANT RNAs

2743
01:48:51,291 --> 01:48:54,394
TO TARGET CELLS AND MAY

2744
01:48:54,461 --> 01:48:54,995
ELIMINATE HIV IN INDIVIDUALS.

2745
01:48:55,061 --> 01:48:59,099
I BELIEVE THAT IS MY LAST SLIDE.

2746
01:48:59,165 --> 01:49:09,009
THANK YOU VERY MUCH.

2747
01:49:09,075 --> 01:49:11,311
>> THANK YOU DR. LIGHT FOOT.

2748
01:49:11,378 --> 01:49:14,948
DR. OTT, OVER TO YOU.

2749
01:49:15,015 --> 01:49:16,249
>> THANK YOU VERY MUCH HELLO,

2750
01:49:16,316 --> 01:49:17,484
EVERYBODY.

2751
01:49:17,550 --> 01:49:20,053
I'M GOING TO GIVE YOU THREE

2752
01:49:20,120 --> 01:49:25,392
HIGHLIGHTS FROM THE CURRENT NIDA

2753
01:49:25,458 --> 01:49:27,027
PORTFOLIO HIGHLIGHTING SOME OF

2754
01:49:27,093 --> 01:49:30,030
THE UNIQUE ASPECTS OF THE

2755
01:49:30,096 --> 01:49:33,099
RESEARCH DONE AT NIDA.

2756
01:49:33,166 --> 01:49:34,334
NEXT SLIDE, PLEASE.

2757
01:49:34,401 --> 01:49:36,603
THE FIRST ONE IS A NIDA FUNDED

2758
01:49:36,670 --> 01:49:41,474
STUDY THAT HAS LOOKED AT

2759
01:49:41,541 --> 01:49:44,778
OVERDOSE DEATH AMONG PEOPLE WITH

2760
01:49:44,844 --> 01:49:45,946
HIV IN NEW YORK CITY.

2761
01:49:46,012 --> 01:49:49,816
AND THEY HAVE COMPARED THAT RATE

2762
01:49:49,883 --> 01:49:54,421
SPECIFICALLY AMONG PEOPLE WITH

2763
01:49:54,487 --> 01:49:55,588
HIV COMPARED TO THE OVERALL

2764
01:49:55,655 --> 01:49:58,024
DEATH RATE BASED ON OVERDOSES

2765
01:49:58,091 --> 01:49:59,759
AND FOUND THAT THE RATE IS

2766
01:49:59,826 --> 01:50:03,396
ACTUALLY DOUBLE IN PEOPLE WITH

2767
01:50:03,463 --> 01:50:03,563
HIV.

2768
01:50:03,630 --> 01:50:06,833
AND THEN THEY DUG DEEPER AND

2769
01:50:06,900 --> 01:50:11,104
LOOKED AT WHETHER PEOPLE WITH

2770
01:50:11,171 --> 01:50:13,840
HIV DIVIDED ON THE LEFT SIDE AND

2771
01:50:13,907 --> 01:50:16,343
ACCIDENTAL OVERDOSE DEATH OR ON

2772
01:50:16,409 --> 01:50:20,113
THE RIGHT SIDE INTENTIONAL

2773
01:50:20,180 --> 01:50:22,215
OVERDOSE DEATH, WERE ACTUALLY IN

2774
01:50:22,282 --> 01:50:26,353
CLINICAL CARE AND FOUND THAT

2775
01:50:26,419 --> 01:50:31,091
MOST OF THEM HAD BEEN RETAINED

2776
01:50:31,157 --> 01:50:34,828
IN A RELATIVELY HIGH LEVEL OF

2777
01:50:34,894 --> 01:50:37,630
CLINICAL CARE, INDICATING THERE

2778
01:50:37,697 --> 01:50:40,467
WERE PLENTY OF OPPORTUNITIES TO

2779
01:50:40,533 --> 01:50:41,501
POTENTIALLY PREVENT THESE

2780
01:50:41,568 --> 01:50:42,469
OVERDOSES.

2781
01:50:42,535 --> 01:50:46,506
AND HIGHLIGHTING REALLY AN

2782
01:50:46,573 --> 01:50:48,675
IMPORTANT WINDOW OF OPPORTUNITY

2783
01:50:48,742 --> 01:50:54,614
HERE THAT OBVIOUSLY WAS MISSED.

2784
01:50:54,681 --> 01:50:59,819
THE SECOND IS A VERY PRACTICAL

2785
01:50:59,886 --> 01:51:01,321
ONE.

2786
01:51:01,388 --> 01:51:05,291
IT IS A MOBILE VAN THAT WAS

2787
01:51:05,358 --> 01:51:15,402
ESTABLISHED BY A RECENT ADJUVANT

2788
01:51:15,468 --> 01:51:17,003
GUARD AT YALE UNIVERSITIY.

2789
01:51:17,070 --> 01:51:22,108
SHE IS AN M.D., PH.D. AND HAS

2790
01:51:22,175 --> 01:51:24,077
ESTABLISHED THIS COMBINED RETAIL

2791
01:51:24,144 --> 01:51:28,048
PHARMACY AND CLINIC VAN ON

2792
01:51:28,114 --> 01:51:30,483
WHEELS THAT IS SPECIFICALLY

2793
01:51:30,550 --> 01:51:33,086
TARGETED TO PEOPLE WITH HIV, HEP

2794
01:51:33,153 --> 01:51:36,356
C AND SUBSTANCE USE DISORDERS.

2795
01:51:36,423 --> 01:51:39,192
AND HER REASONING IS THAT PEOPLE

2796
01:51:39,259 --> 01:51:44,230
IN THAT CATEGORY OFTEN HAVE A

2797
01:51:44,297 --> 01:51:46,099
LOT ON THEIR PLATE INCLUDING

2798
01:51:46,166 --> 01:51:48,101
UNSAFE HOUSING AND OTHER THINGS

2799
01:51:48,168 --> 01:51:50,703
SO THAT HEALTH CARE COMES REALLY

2800
01:51:50,770 --> 01:51:54,874
LAST ON THE LIST OF THEIR NEEDS.

2801
01:51:54,941 --> 01:51:58,511
AND BRINGING IT DIRECTLY TO THEM

2802
01:51:58,578 --> 01:52:03,550
IS THE APPROACH HERE TO REALLY

2803
01:52:03,616 --> 01:52:05,685
IMPROVE CARE FOR PEOPLE

2804
01:52:05,752 --> 01:52:06,386
AFFLICTED WITH THESE DISORDERS.

2805
01:52:06,453 --> 01:52:09,155
AND I THINK THERE IS A LOT OF

2806
01:52:09,222 --> 01:52:10,990
ENTHUSIASM ABOUT THE APPROACH

2807
01:52:11,057 --> 01:52:13,126
AND A LOT OF FIRST SUCCESSES AND

2808
01:52:13,193 --> 01:52:15,295
WE ARE LOOKING REALLY FORWARD TO

2809
01:52:15,361 --> 01:52:17,230
SEEING HOW THIS IS PANNING OUT

2810
01:52:17,297 --> 01:52:21,334
AS A POTENTIAL MODEL.

2811
01:52:21,401 --> 01:52:22,569
NEXT SLIDE.

2812
01:52:22,635 --> 01:52:27,674
AND THE THIRD ONE IS SHINING

2813
01:52:27,740 --> 01:52:31,277
LIGHT ON CLIMATE CHANGE AND HOW

2814
01:52:31,344 --> 01:52:34,380
THIS EFFECTS MORTALITY OF HIV

2815
01:52:34,447 --> 01:52:35,315
INFECTED PEOPLE.

2816
01:52:35,381 --> 01:52:37,584
THE POINT IS HERE THAT THERE WAS

2817
01:52:37,650 --> 01:52:43,556
A LARGE COHORT STUDY IN AFRICA

2818
01:52:43,623 --> 01:52:50,230
WHO LOOKED AT THE INDIVIDUAL

2819
01:52:50,296 --> 01:52:51,998
RESEARCH RESULTS FROM THESE

2820
01:52:52,065 --> 01:52:54,567
CENTERS, SPECIFICALLY MORTALITY,

2821
01:52:54,634 --> 01:52:59,239
IN THESE CENTERS, COMPARED TO

2822
01:52:59,305 --> 01:53:01,007
RELATIVE RAINFALL DECREASE.

2823
01:53:01,074 --> 01:53:05,278
AND FOUND THAT ACTUALLY, A

2824
01:53:05,345 --> 01:53:06,980
DECREASE OR SHORTAGE OF RAINFALL

2825
01:53:07,046 --> 01:53:09,949
TRANSLATED, ESPECIALLY IN RURAL

2826
01:53:10,016 --> 01:53:10,617
AREAS, TO A SIGNIFICANT INCREASE

2827
01:53:10,683 --> 01:53:13,052
IN MORTALITY.

2828
01:53:13,119 --> 01:53:16,322
IT DID NOT CHANGE CD4 COUNTS OR

2829
01:53:16,389 --> 01:53:18,658
VIRAL LOADS OR EVEN LARGER THAN

2830
01:53:18,725 --> 01:53:19,826
12 MONTH GAPS IN CARE.

2831
01:53:19,893 --> 01:53:26,032
BUT IT LED TO LESS SIGNIFICANTLY

2832
01:53:26,099 --> 01:53:27,300
LESS VISITS INTO THE CENTERS,

2833
01:53:27,367 --> 01:53:31,004
POTENTIALLY TRANSLATING INTO

2834
01:53:31,070 --> 01:53:33,406
TREATMENT AND CARE UPDATES OR

2835
01:53:33,473 --> 01:53:41,281
LACK OF THOSE.

2836
01:53:41,347 --> 01:53:42,982
AND DISTURBING  INCREASE IN

2837
01:53:43,049 --> 01:53:44,150
MORTALITY DIRECTLY LINKED OR

2838
01:53:44,217 --> 01:53:48,421
LINKED TO A DECREASE IN RAINFALL

2839
01:53:48,488 --> 01:53:50,290
AND RESULTING FROM CLIMATE

2840
01:53:50,356 --> 01:53:52,959
CHANGE.

2841
01:53:53,026 --> 01:53:54,994
NEXT SLIDE.

2842
01:53:55,061 --> 01:53:58,131
THERE ARE A COUPLE -- A SERIES

2843
01:53:58,198 --> 01:54:02,268
OF VERY INTERESTING HIV FUNDING

2844
01:54:02,335 --> 01:54:04,304
OPPORTUNITIES PUBLISHED BY NIDA.

2845
01:54:04,370 --> 01:54:07,974
AND THEY RANGE FROM A VERY

2846
01:54:08,041 --> 01:54:13,680
INTERESTING -- ADDRESSING REALLY

2847
01:54:13,746 --> 01:54:15,248
SOCIOECONOMIC CHARACTERISTICS IN

2848
01:54:15,315 --> 01:54:18,751
THE NIDA PORTFOLIO RANGING FROM

2849
01:54:18,818 --> 01:54:23,389
SEXUAL AND GENDER MINORITIES TO

2850
01:54:23,456 --> 01:54:24,757
PSYCHOSOCIAL STRESS, PSYCHIATRIC

2851
01:54:24,824 --> 01:54:28,561
DISORDERS, SEXUAL VIOLENCE AND

2852
01:54:28,628 --> 01:54:30,563
TRAFFICKING, TO MORE BASIC

2853
01:54:30,630 --> 01:54:34,033
RESEARCH TOPICS, ALSO TARGETING

2854
01:54:34,100 --> 01:54:37,003
HIV CURE BY MODULATING HIV

2855
01:54:37,070 --> 01:54:39,038
TRANSCRIPTION WITH SPECIFICALLY

2856
01:54:39,105 --> 01:54:45,311
CHEMICAL PROBES TO STUDYING THE

2857
01:54:45,378 --> 01:54:46,246
AUTOPHAGY AND INTERPLAY WITH

2858
01:54:46,312 --> 01:54:50,383
CELL DEATH AND HIV PATHOGENESIS.

2859
01:54:50,450 --> 01:54:51,718
AND SPECIFICALLY THE EFFECT OF

2860
01:54:51,784 --> 01:54:56,656
HIV AND SUBSTANCE USE

2861
01:54:56,723 --> 01:54:59,959
CO-MORBIDITIES ON THE MATERNAL

2862
01:55:00,026 --> 01:55:00,193
OUTCOME.

2863
01:55:00,260 --> 01:55:04,430
FOR THE FUTURE, NEXT SLIDE,

2864
01:55:04,497 --> 01:55:10,503
COUNCIL APPROVED THE FOLLOWING

2865
01:55:10,570 --> 01:55:12,305
CONCEPTS WHERE RESEARCH TO

2866
01:55:12,372 --> 01:55:14,540
ADDRESS MULTI-LEVEL BARRIERS AND

2867
01:55:14,607 --> 01:55:17,577
FACILITATORS TO IMPROVE PrEP

2868
01:55:17,644 --> 01:55:19,612
IS SPECIFICALLY HIGHLIGHTED

2869
01:55:19,679 --> 01:55:22,181
TOGETHER WITH ADVANCING RESEARCH

2870
01:55:22,248 --> 01:55:24,517
ON MOLECULAR TARGETS, MECHANISMS

2871
01:55:24,584 --> 01:55:26,152
THAT INFLUENCE INTERPLAY BETWEEN

2872
01:55:26,219 --> 01:55:28,254
SEX HORMONES, ADDICTED

2873
01:55:28,321 --> 01:55:31,124
SUBSTANCES AND HIV INFECTION.

2874
01:55:31,190 --> 01:55:31,991
MITOCHONDRIAL-ASSOCIATED

2875
01:55:32,058 --> 01:55:34,160
MECHANISMS OF NEUROPATHOLOGICAL

2876
01:55:34,227 --> 01:55:35,461
AND IMMUNODEFICIENT AGING IN THE

2877
01:55:35,528 --> 01:55:38,965
CONTEXT OF HIV AND SUBSTANCE USE

2878
01:55:39,032 --> 01:55:39,966
DISORDER.

2879
01:55:40,033 --> 01:55:41,301
WASTE NOT, WANT NOT.

2880
01:55:41,367 --> 01:55:43,269
EXPLORING INTERACTIONS BETWEEN

2881
01:55:43,336 --> 01:55:44,070
BRAIN WASTE CLEARANCE AND

2882
01:55:44,137 --> 01:55:47,540
RENEWAL SYSTEMS WITH HIV AND

2883
01:55:47,607 --> 01:55:47,807
ADDICTION.

2884
01:55:47,874 --> 01:55:50,009
AND MECHANISM OF CELL-TO-CELL

2885
01:55:50,076 --> 01:55:52,745
INTERACTIONS AND COMMUNICATION

2886
01:55:52,812 --> 01:55:54,981
IN CENTRAL NERVOUS SYSTEM HIV

2887
01:55:55,048 --> 01:55:55,515
REPLICATION.

2888
01:55:55,581 --> 01:55:57,850
SO I THINK ALSO LEARNING SOME OF

2889
01:55:57,917 --> 01:55:59,952
THE SORT OF COMMON THEMES WITH

2890
01:56:00,019 --> 01:56:02,255
THE OTHER INSTITUTES WHERE I

2891
01:56:02,322 --> 01:56:05,224
THINK REPLICATION IN THE BRAIN

2892
01:56:05,291 --> 01:56:08,061
COMBINED WITH AGING AND

2893
01:56:08,127 --> 01:56:10,196
SPECIFICALLY SEX-SPECIFIC

2894
01:56:10,263 --> 01:56:13,132
ASPECTS ARE REALLY PRIORITIZED

2895
01:56:13,199 --> 01:56:13,333
HERE.

2896
01:56:13,399 --> 01:56:15,468
WITH THIS, I WILL STOP AND HAND

2897
01:56:15,535 --> 01:56:19,939
OVER TO THE NEXT SPEAKER.

2898
01:56:20,006 --> 01:56:22,742
>> THANK YOU DR. OTT.

2899
01:56:22,809 --> 01:56:27,146
NOW WE'RE GOING TO GO TO

2900
01:56:27,213 --> 01:56:28,348
Ms. CORETTE BYRD.

2901
01:56:28,414 --> 01:56:30,583
>> THANK YOU VERY MUCH,

2902
01:56:30,650 --> 01:56:30,917
DR. TURNBULL.

2903
01:56:30,983 --> 01:56:32,251
GOOD AFTERNOON AND GOOD MORNING.

2904
01:56:32,318 --> 01:56:34,454
I THINK IT'S SAFE TO SAY FOR

2905
01:56:34,520 --> 01:56:35,488
THOSE ON THE WEST COAST AS WELL

2906
01:56:35,555 --> 01:56:36,856
AS HAPPY NEW YEAR.

2907
01:56:36,923 --> 01:56:39,325
IT IS NICE TO SEE MANY OF YOU

2908
01:56:39,392 --> 01:56:41,761
AGAIN, AND TODAY I WILL PROVIDE

2909
01:56:41,828 --> 01:56:44,197
A BRIEF OVERVIEW OF A FEW

2910
01:56:44,263 --> 01:56:47,700
ADDITIONAL HIV CONCEPTS AND

2911
01:56:47,767 --> 01:56:48,368
RE-ISSUED CONCEPTS SINCE THE

2912
01:56:48,434 --> 01:56:50,069
OCTOBER OARAC MEETING BY THE

2913
01:56:50,136 --> 01:56:52,472
INSTITUTE CENTERS AND OFFICES

2914
01:56:52,538 --> 01:56:55,541
HERE AT NIH.

2915
01:56:55,608 --> 01:56:57,043
SO HERE SAY SUMMARY OF ALL NEW

2916
01:56:57,110 --> 01:57:00,680
AND RE-ISSUED CLEARED CONCEPTS.

2917
01:57:00,747 --> 01:57:03,616
AND AS YOU CAN SEE, THERE ARE 12

2918
01:57:03,683 --> 01:57:05,518
NEW AND FOUR RE-ISSUED CONCEPTS

2919
01:57:05,585 --> 01:57:09,021
FOR A TOTAL OF 16.

2920
01:57:09,088 --> 01:57:10,990
THE NATIONAL INSTITUTE ON

2921
01:57:11,057 --> 01:57:12,358
ALLERGY AND INFECTIOUS DISEASE

2922
01:57:12,425 --> 01:57:14,160
HAS THREE NEW CONCEPTS.

2923
01:57:14,227 --> 01:57:17,230
AND THE NATIONAL INSTITUTE OF

2924
01:57:17,296 --> 01:57:19,265
NEUROLOGICAL DISORDERS HAS ONE

2925
01:57:19,332 --> 01:57:22,001
NEW CLEAR CONCEPT.

2926
01:57:22,068 --> 01:57:26,506
NIAID, THEIR FIRST CONCEPT

2927
01:57:26,572 --> 01:57:28,141
RESOURCE RELATED RESEARCH TO

2928
01:57:28,207 --> 01:57:29,008
SUPPORT COLLABORATIVE

2929
01:57:29,075 --> 01:57:30,543
IMPLEMENTATION SCIENCE TO END

2930
01:57:30,610 --> 01:57:33,780
HIV EPIDEMIC IS A NOTICE OF

2931
01:57:33,846 --> 01:57:35,314
SPECIAL INTEREST TO SOLICIT

2932
01:57:35,381 --> 01:57:37,383
PROPOSALS FOR RESOURCE-RELATED

2933
01:57:37,450 --> 01:57:39,385
RESEARCH PROJECTS, INCLUDING A

2934
01:57:39,452 --> 01:57:41,220
COORDINATION, CONSULTATION AND

2935
01:57:41,287 --> 01:57:44,657
DATA MANAGEMENT CENTER.

2936
01:57:44,724 --> 01:57:45,925
AND REGIONAL CONSULTATION HUBS

2937
01:57:45,992 --> 01:57:48,361
TO SUPPORT ONGOING

2938
01:57:48,428 --> 01:57:49,028
IMPLEMENTATION SCIENCE RESEARCH

2939
01:57:49,095 --> 01:57:52,331
THAT ADDRESSES THE GOALS OF

2940
01:57:52,398 --> 01:57:54,600
ENDING THE HIV EPIDEMIC IN THE

2941
01:57:54,667 --> 01:57:55,034
U.S.

2942
01:57:55,101 --> 01:57:57,837
THE NEW DRUG CLASSES WITH NOVEL

2943
01:57:57,904 --> 01:58:01,541
MECHANISMS OF ACTION FOR HIV,

2944
01:58:01,607 --> 01:58:03,709
HEPATITIS B AND TUBERCULOSIS,

2945
01:58:03,776 --> 01:58:05,111
SUPPORTS SMALL BUSINESSES IN THE

2946
01:58:05,178 --> 01:58:08,114
DEVELOPMENT OF NEW DRUG CLASSES

2947
01:58:08,181 --> 01:58:11,684
FOR HIV, HPV OR TUBERCULOSIS

2948
01:58:11,751 --> 01:58:12,952
THERAPY, WITH A DIFFERENT MODE

2949
01:58:13,019 --> 01:58:15,321
OF ACTION THAN FDA-APPROVED

2950
01:58:15,388 --> 01:58:16,556
DRUGS CURRENTLY IN USE.

2951
01:58:16,622 --> 01:58:19,459
AND THE THIRD DEVICES AND

2952
01:58:19,525 --> 01:58:20,293
MATERIALS-BASED PLATFORMS FOR

2953
01:58:20,359 --> 01:58:23,296
THE DELIVERY OF BROADLY

2954
01:58:23,362 --> 01:58:25,298
NEUTRALIZING ANTIBODIES SUPPORTS

2955
01:58:25,364 --> 01:58:26,065
SMALL BUSINESSES IN A

2956
01:58:26,132 --> 01:58:28,768
DEVELOPMENT OF DEVICES AND/OR

2957
01:58:28,835 --> 01:58:33,005
MATERIALS FOR ADMINISTRATION OF

2958
01:58:33,072 --> 01:58:34,874
THE DERIVATIVES RESULTING IN

2959
01:58:34,941 --> 01:58:37,577
INCREASED PROTECTION FROM

2960
01:58:37,643 --> 01:58:38,277
INFECTION.

2961
01:58:38,344 --> 01:58:41,547
FOR NINDS, THE NEXT GENERATION

2962
01:58:41,614 --> 01:58:46,085
PRE-CLINICAL MODELS OF NEUROHIV

2963
01:58:46,152 --> 01:58:48,187
IN THE CART ERA, SOLICITS

2964
01:58:48,254 --> 01:58:49,655
APPLICATIONS FOR THE DEVELOPMENT

2965
01:58:49,722 --> 01:58:53,493
AND EARLY STAGE VALIDATION OF

2966
01:58:53,559 --> 01:58:55,361
NEXT GENERATION HUMAN AND SMALL

2967
01:58:55,428 --> 01:58:58,898
ANIMAL MODELS AND/OR HUMAN

2968
01:58:58,965 --> 01:59:00,199
CELLULAR MICROPHYSIOLOGICAL

2969
01:59:00,266 --> 01:59:03,302
SYSTEMS THAT IMPROVE THE

2970
01:59:03,369 --> 01:59:04,770
TRANSLATIONAL RELEVANCE OF

2971
01:59:04,837 --> 01:59:06,272
NEUROHIV MODELS.

2972
01:59:06,339 --> 01:59:08,307
SPECIFICALLY IN THE CONTEXT OF

2973
01:59:08,374 --> 01:59:10,743
CHRONIC HIV INFECTION OF THE

2974
01:59:10,810 --> 01:59:16,148
CENTRAL NERVOUS SYSTEM AND THE

2975
01:59:16,215 --> 01:59:16,749
MODERN ANTI-RETROVIRAL THERAPY

2976
01:59:16,816 --> 01:59:20,019
ERA UNDER CONDITIONS OF VIRAL

2977
01:59:20,086 --> 01:59:21,220
SUPPRESSION.

2978
01:59:21,287 --> 01:59:23,489
THESE ARE THE FIVE NEWLY CLEARED

2979
01:59:23,556 --> 01:59:28,561
CONCEPTS FROM NIDA.

2980
01:59:28,628 --> 01:59:31,764
AND ON THIS SLIDE, THE NATIONAL

2981
01:59:31,831 --> 01:59:33,900
INSTITUTE OF DENTAL AND

2982
01:59:33,966 --> 01:59:35,635
CRANIOFACIAL RESEARCH HAS ONE

2983
01:59:35,701 --> 01:59:37,637
NEW CLEAR CONCEPT AND THE

2984
01:59:37,703 --> 01:59:38,504
NATIONAL INSTITUTE OF MENTAL

2985
01:59:38,571 --> 01:59:40,940
HEALTH HAS TWO NEWLY-CLEARED

2986
01:59:41,007 --> 01:59:41,941
CONCEPTS WHICH HAVE BEEN

2987
01:59:42,008 --> 01:59:43,676
DISCUSSED BY DR. LIGHT FOOT.

2988
01:59:43,743 --> 01:59:49,582
FOR NIDCR, ADVANCING HIV/AIDS

2989
01:59:49,649 --> 01:59:50,683
AND ORAL HEALTH RESEARCH SEEKS

2990
01:59:50,750 --> 01:59:53,219
TO SOLICIT INNOVATIVE AND

2991
01:59:53,286 --> 01:59:54,787
MULTI-DISCIPLINARY BASIC,

2992
01:59:54,854 --> 01:59:57,089
TRANSLATIONAL AND CLINICAL

2993
01:59:57,156 --> 01:59:58,925
RESEARCH ON HIV/AIDS THAT IS

2994
01:59:58,991 --> 02:00:04,697
RELEVANT TO DENTAL, ORAL AND

2995
02:00:04,764 --> 02:00:05,464
CRANIOFACIAL HEALTH.

2996
02:00:05,531 --> 02:00:09,101
IN TERMS OF CONCEPTS FOR

2997
02:00:09,168 --> 02:00:12,338
RE-ISSUANCE, THE NATIONAL

2998
02:00:12,405 --> 02:00:12,905
INSTITUTE OF ALLEY JEER AND

2999
02:00:12,972 --> 02:00:14,774
INFECTIOUS DISEASE RE-ISSUED TWO

3000
02:00:14,840 --> 02:00:15,975
CONCEPTS AND THE NATIONAL

3001
02:00:16,042 --> 02:00:17,476
INSTITUTE OF CHILD HEALTH AND

3002
02:00:17,543 --> 02:00:19,278
DEVELOPMENT AND THE NATIONAL

3003
02:00:19,345 --> 02:00:20,279
INSTITUTE OF DRUG ABUSE EACH

3004
02:00:20,346 --> 02:00:24,784
HAVE RE-ISSUED ONE CONCEPT.

3005
02:00:24,850 --> 02:00:26,552
NIAID'S RAPID DIAGNOSTIC ASSAYS

3006
02:00:26,619 --> 02:00:29,555
FOR SELF-MONITORING OF ACUTE OR

3007
02:00:29,622 --> 02:00:33,326
REBOUND HIV-1 INFECTION AIMS TO

3008
02:00:33,392 --> 02:00:34,927
DEVELOP LOW-COST RAPID

3009
02:00:34,994 --> 02:00:39,065
DIAGNOSTIC ASSAYS TO ENABLE

3010
02:00:39,131 --> 02:00:39,899
UNTRAINED INDIVIDUALS TO TEST

3011
02:00:39,966 --> 02:00:41,534
FOR HIV-1 INFECTION.

3012
02:00:41,601 --> 02:00:45,104
DURING THE EARLIEST STAGES OF

3013
02:00:45,171 --> 02:00:46,272
INITIAL FINNECTION OR DURING

3014
02:00:46,339 --> 02:00:49,108
LOSS OF VIRAL SUPPRESSION IN

3015
02:00:49,175 --> 02:00:50,509
CHRONIC TREATED INFECTION, A

3016
02:00:50,576 --> 02:00:52,712
TIME WHEN ANTIBODY RESPONSES ARE

3017
02:00:52,778 --> 02:00:54,580
NOT AN ACCURATE SURROGATE FOR

3018
02:00:54,647 --> 02:00:56,349
VIRAL LOAD.

3019
02:00:56,415 --> 02:00:59,819
FOR NICHD'S PEDIATRIC HIV/AIDS

3020
02:00:59,885 --> 02:01:02,254
COHORT STUDY, SUPPORTS RESEARCH

3021
02:01:02,321 --> 02:01:04,490
ON A DEVELOPMENTAL AND CLINICAL

3022
02:01:04,557 --> 02:01:08,194
COURSE OF PERIFATALITY ACQUIRED

3023
02:01:08,260 --> 02:01:09,261
HIV.

3024
02:01:09,328 --> 02:01:13,032
THE TRANSITION TO ADULTHOOD WITH

3025
02:01:13,099 --> 02:01:15,167
PERRY NATALY ACQUIRED HIV,

3026
02:01:15,234 --> 02:01:15,635
PROVIDES AN IMPORTANT

3027
02:01:15,701 --> 02:01:16,936
OPPORTUNITY TO UNDERSTAND A HOST

3028
02:01:17,003 --> 02:01:20,339
OF SIGNIFICANT HEALTH OUTCOMES

3029
02:01:20,406 --> 02:01:22,775
INCLUDING REPRODUCTION, ORAL,

3030
02:01:22,842 --> 02:01:24,744
COGNITIVE, NEURODEVELOPMENTAL,

3031
02:01:24,810 --> 02:01:28,080
MENTAL HEALTH, SUBSTANCE USE,

3032
02:01:28,147 --> 02:01:30,116
BEHAVIORAL, EMOTIONAL, ACADEMIC

3033
02:01:30,182 --> 02:01:35,187
AND SOCIAL OUTCOMES.

3034
02:01:35,254 --> 02:01:41,527
FOR NIAIDA'S SEEKS TO STIMULATE

3035
02:01:41,594 --> 02:01:42,995
OBSERVATIONAL OR INTERVENTIONAL

3036
02:01:43,062 --> 02:01:45,498
RESEARCH ON STRUCTURAL FACTORS,

3037
02:01:45,564 --> 02:01:47,867
ORGANIZATIONAL PRACTICES,

3038
02:01:47,933 --> 02:01:49,502
POLICIES AND OTHER SOCIAL,

3039
02:01:49,568 --> 02:01:51,737
CULTURAL AND CONTEXTURAL

3040
02:01:51,804 --> 02:01:54,507
INFLUENCES THAT LEAD TO

3041
02:01:54,573 --> 02:01:56,075
INEQUITIES AT THE INTERSECTION

3042
02:01:56,142 --> 02:01:59,679
OF HIV AND SUBSTANCE USE AMONG

3043
02:01:59,745 --> 02:02:01,113
UNDERSERVED, RACIAL AND/OR

3044
02:02:01,180 --> 02:02:03,549
ETHNIC MINORITY POPULATIONS

3045
02:02:03,616 --> 02:02:06,786
AFFECTED BY PERSISTENT HIV

3046
02:02:06,852 --> 02:02:07,086
DISPARITIES.

3047
02:02:07,153 --> 02:02:10,589
AND LASTLY, SCORCH, THE SINGLE

3048
02:02:10,656 --> 02:02:12,892
CELL OPIOID RESPONSES IN THE

3049
02:02:12,958 --> 02:02:16,395
CONTEXT OF HIV PROGRAM SUPPORTS

3050
02:02:16,462 --> 02:02:18,664
DATA-MINING ON SINGLE CELL

3051
02:02:18,731 --> 02:02:22,635
DATASETS TO IDENTIFY CELL TYPES,

3052
02:02:22,702 --> 02:02:24,303
TRANSCRIPTS, ENHANCERS OR

3053
02:02:24,370 --> 02:02:25,304
TRANSCRIPTIONAL NETWORKS THAT

3054
02:02:25,371 --> 02:02:30,376
PLAY A ROLE IN HIV, ART OR

3055
02:02:30,443 --> 02:02:31,944
SUBSTANCE USE DISORDER RELEVANT

3056
02:02:32,011 --> 02:02:34,246
MOLEC LARRY RESPONSES.

3057
02:02:34,313 --> 02:02:36,048
AND TO SUPPORT FUNCTIONAL

3058
02:02:36,115 --> 02:02:39,585
VALIDATION STUDIES SUCH AS

3059
02:02:39,652 --> 02:02:39,985
EPIGENOMIC.

3060
02:02:40,052 --> 02:02:41,854
TO CONFIRM OR DENY A BIOLOGICAL

3061
02:02:41,921 --> 02:02:45,224
ROLE FOR ONE OR MORE OF THE DATA

3062
02:02:45,291 --> 02:02:48,394
CELL TRANSCRIPTS ENHANCERS OR

3063
02:02:48,461 --> 02:02:49,428
TRANSCRIPTIONAL NETWORKS IN HIV

3064
02:02:49,495 --> 02:02:52,631
AND ART AND SUBSTANCE USE

3065
02:02:52,698 --> 02:03:03,275
DISORDERS, MOLEC LARRY RESPONSE.

3066
02:03:14,520 --> 02:03:17,056
>> WE ARE NOW OPEN FOR

3067
02:03:17,123 --> 02:03:17,356
DISCUSSION.

3068
02:03:17,423 --> 02:03:21,227
ONCE AGAIN, FEEL FREE TO USE THE

3069
02:03:21,293 --> 02:03:26,766
RAISE HAND OPTION IN THE CHAT.

3070
02:03:26,832 --> 02:03:28,167
DR. HOLTZ IF YOU CAN SEE

3071
02:03:28,234 --> 02:03:29,135
ANYBODY'S HAND RAISED, THAT I

3072
02:03:29,201 --> 02:03:34,774
CAN'T SEE, LET ME KNOW.

3073
02:03:34,840 --> 02:03:38,511
>> I SEE JONATHAN MERMIN.

3074
02:03:38,577 --> 02:03:39,378
>> THANK YOU.

3075
02:03:39,445 --> 02:03:43,182
WHAT A FANTASTIC SET OF

3076
02:03:43,249 --> 02:03:43,516
PRESENTATIONS.

3077
02:03:43,582 --> 02:03:44,350
IT'S GREAT TO WELCOME ALL THE

3078
02:03:44,416 --> 02:03:46,685
NEW PEOPLE TO OARAC.

3079
02:03:46,752 --> 02:03:48,454
I THINK I HAVE ONE SMALL AND

3080
02:03:48,521 --> 02:03:53,959
THEN A BIGGER KIND OF BIGGER

3081
02:03:54,026 --> 02:03:54,226
QUESTION.

3082
02:03:54,293 --> 02:03:56,896
I THINK THE IDEA OF HAVING SOME

3083
02:03:56,962 --> 02:03:59,064
KIND OF NUCLEIC ACID TEST FOR

3084
02:03:59,131 --> 02:04:01,233
SELF TESTING FOR HIV IS

3085
02:04:01,300 --> 02:04:01,567
TREMENDOUS.

3086
02:04:01,634 --> 02:04:05,838
AND I WANTED TO MENTION THAT NOT

3087
02:04:05,905 --> 02:04:07,006
ONLY ALL THOSE OTHER REASONS YOU

3088
02:04:07,072 --> 02:04:08,607
MENTIONED, BUT WE HAVE A LOT OF

3089
02:04:08,674 --> 02:04:11,577
TROUBLE FROM PEOPLE ON PrEP.

3090
02:04:11,644 --> 02:04:13,479
AND OUR CURRENT RECOMMENDATIONS

3091
02:04:13,546 --> 02:04:16,348
ARE QUITE CONSTRAINING ON WHAT

3092
02:04:16,415 --> 02:04:18,317
KIND OF TESTS ARE AVAILABLE.

3093
02:04:18,384 --> 02:04:23,289
AND IF YOU COULD DO HOME TESTING

3094
02:04:23,355 --> 02:04:25,491
FOR NUKE LAKE ACID ON PrEP,

3095
02:04:25,558 --> 02:04:26,325
THEN YOU COULD ESSENTIALLY NOT

3096
02:04:26,392 --> 02:04:29,595
HAVE TO VISIT A CLINIC.

3097
02:04:29,662 --> 02:04:32,631
JUST GET YOUR MEDS.

3098
02:04:32,698 --> 02:04:33,899
SO EVEN A BIGGER OPPORTUNITY FOR

3099
02:04:33,966 --> 02:04:34,266
THAT.

3100
02:04:34,333 --> 02:04:36,235
SO IT'S GREAT THAT YOU'RE

3101
02:04:36,302 --> 02:04:37,703
THINKING ABOUT THOSE THINGS.

3102
02:04:37,770 --> 02:04:39,038
THEN THE OTHER QUESTION I HAD

3103
02:04:39,104 --> 02:04:40,906
WAS JUST THAT THERE IS SO MUCH

3104
02:04:40,973 --> 02:04:43,108
GOOD WORK ON THE NEW STRATEGIC

3105
02:04:43,175 --> 02:04:47,513
PLAN, IT SEEMS TO BE REFRAMING

3106
02:04:47,580 --> 02:04:48,280
THE AREAS FOR FOCUS.

3107
02:04:48,347 --> 02:04:50,482
BUT ONE OF THE QUESTIONS THAT

3108
02:04:50,549 --> 02:04:54,486
COMES UP IS, IT'S TRULY ABOUT

3109
02:04:54,553 --> 02:04:57,356
SHIFTING RESOURCES TO DIFFERENT

3110
02:04:57,423 --> 02:05:00,593
AMOUNTS FOR EACH OF THOSE FOCIS.

3111
02:05:00,659 --> 02:05:02,962
SO, HOW MUCH OF THE MONEY THAT

3112
02:05:03,028 --> 02:05:07,199
COMES TO OAR AND THEN FOR HIV

3113
02:05:07,266 --> 02:05:08,234
RESEARCH IN GENERAL SHOULD BE

3114
02:05:08,300 --> 02:05:12,338
GOING TO COINJECTIONS VERSUS A

3115
02:05:12,404 --> 02:05:14,106
CURE, VERSUS OTHER FOCI?

3116
02:05:14,173 --> 02:05:15,708
AND I'M JUST THINKING BECAUSE

3117
02:05:15,774 --> 02:05:18,110
ALL OF THE RESEARCH STUDIES ARE

3118
02:05:18,177 --> 02:05:19,979
IMPORTANT AND INTERESTING.

3119
02:05:20,045 --> 02:05:24,049
SOME MAY HAVE -- MAY BE MORE

3120
02:05:24,116 --> 02:05:25,851
POWERFULLY ALONG THE LOGIC MODEL

3121
02:05:25,918 --> 02:05:28,053
TOWARDS THOSE GOALS OF A CURE OR

3122
02:05:28,120 --> 02:05:31,757
A LONG-ACTING TREATMENT.

3123
02:05:31,824 --> 02:05:33,525
BUT I WONDER HOW THAT HAPPENS?

3124
02:05:33,592 --> 02:05:35,294
IS THAT SOMETHING THAT OAR DOES?

3125
02:05:35,361 --> 02:05:36,762
IS IT SOMETHING YOU WORK WITH

3126
02:05:36,829 --> 02:05:47,206
THE INSTITUTES TO DO?

3127
02:05:47,640 --> 02:05:50,075
>> THAT'S A REALLY GREAT

3128
02:05:50,142 --> 02:05:50,342
QUESTION.

3129
02:05:50,409 --> 02:05:51,310
AND I DON'T HAVE AN ANSWER FOR

3130
02:05:51,377 --> 02:05:53,679
YOU AT THIS MOMENT BUT IT IS

3131
02:05:53,746 --> 02:05:55,848
CERTAINLY SOMETHING THAT I CAN

3132
02:05:55,915 --> 02:05:57,783
LOOK INTO AND TO GET BACK TO YOU

3133
02:05:57,850 --> 02:05:59,585
ON THAT.

3134
02:05:59,652 --> 02:06:03,956
SO, THANK YOU VERY MUCH FOR THAT

3135
02:06:04,023 --> 02:06:12,631
QUESTION.

3136
02:06:12,698 --> 02:06:14,166
>> EXCELLENT PRESENTATIONS.

3137
02:06:14,233 --> 02:06:17,970
MY QUESTION, I JUST WOULD LIKE

3138
02:06:18,037 --> 02:06:21,206
TO ASK DR. LIGHT FOOT, THAT WAS

3139
02:06:21,273 --> 02:06:25,411
REALLY INNOVATIVE, MOLECULAR

3140
02:06:25,477 --> 02:06:29,348
APPROACH TO PRODUCE THIS -- TO

3141
02:06:29,415 --> 02:06:32,318
CHOOSE THIS EXTRACELLULAR

3142
02:06:32,384 --> 02:06:32,584
VESICLES.

3143
02:06:32,651 --> 02:06:34,453
SO THE VESICLES, THAT WOULD

3144
02:06:34,520 --> 02:06:37,723
SPECIFICALLY TARGET THE MAIN

3145
02:06:37,790 --> 02:06:40,793
RESERVOIR WHICH ARE MICROGLIA'S

3146
02:06:40,859 --> 02:06:41,126
IN THE BRAIN?

3147
02:06:41,193 --> 02:06:44,363
I WOULD JUST LIKE TO KNOW IF

3148
02:06:44,430 --> 02:06:54,907
THAT WOULD BE THE APPROACH?

3149
02:07:05,818 --> 02:07:08,854
>> IS DR. LIGHT FOOT STILL ON?

3150
02:07:08,921 --> 02:07:19,164
MAYBE ON MUTE?

3151
02:07:19,398 --> 02:07:20,566
>> NO WORRIES.

3152
02:07:20,632 --> 02:07:24,003
I CAN FIGURE OUT THE

3153
02:07:24,069 --> 02:07:24,336
APPLICATIONS.

3154
02:07:24,403 --> 02:07:27,439
>> I DON'T SEE THAT SHE IS STILL

3155
02:07:27,506 --> 02:07:28,774
ON LINE.

3156
02:07:28,841 --> 02:07:36,415
APOLOGIES ABOUT THAT.

3157
02:07:36,482 --> 02:07:36,949
>> THANK YOU.

3158
02:07:37,016 --> 02:07:42,788
PERHAPS WE CAN FIGURE OUT HOW

3159
02:07:42,855 --> 02:07:43,655
DR. LIGHTFOOT HAS AN OPPORTUNITY

3160
02:07:43,722 --> 02:07:47,993
TO RESPOND TO DR. MOJGAN

3161
02:07:48,060 --> 02:07:50,662
NAGHAVI'S QUESTION.

3162
02:07:50,729 --> 02:07:53,232
DR. LUIS MONTANER.

3163
02:07:53,298 --> 02:07:55,634
>> IN THE CAPACITY OF THE

3164
02:07:55,701 --> 02:07:56,235
ADVISORY ROLE OF THIS GROUP, I

3165
02:07:56,301 --> 02:07:57,302
WANT TO SPEAK ABOUT CURE AND AS

3166
02:07:57,369 --> 02:07:59,738
ONE OF THE AREAS THAT NEEDS TO

3167
02:07:59,805 --> 02:08:01,707
GROW IN THE PORTFOLIO AS FAR AS

3168
02:08:01,774 --> 02:08:03,976
INVESTMENT AND RELATIVE TO THE

3169
02:08:04,043 --> 02:08:04,276
PRIORITIES.

3170
02:08:04,343 --> 02:08:06,612
AND I WOULD LIKE TO SUGGEST THAT

3171
02:08:06,678 --> 02:08:11,250
WE ARE MAYBE ENCOURAGING MAYBE

3172
02:08:11,316 --> 02:08:12,951
IN AID PARTICULARLY TO CONSIDER

3173
02:08:13,018 --> 02:08:15,087
A SMALL PHASE I OR PROOF OF

3174
02:08:15,154 --> 02:08:16,321
PRINCIPLE STUDIES.

3175
02:08:16,388 --> 02:08:22,461
I SIT IN THE CURE TSG AS WELL AS

3176
02:08:22,528 --> 02:08:24,830
THE LABORATORY, AND THE

3177
02:08:24,897 --> 02:08:26,198
COLABORATORIES ARE REALLY

3178
02:08:26,265 --> 02:08:28,901
GENERATING A LARGE NUMBER OF

3179
02:08:28,967 --> 02:08:31,036
INITIATIVES THAT ARE REALLY IN

3180
02:08:31,103 --> 02:08:32,738
THE NEED OF PROOF-OF-CONCEPT

3181
02:08:32,805 --> 02:08:34,406
CLINICALLY BUT A LOT OF THE

3182
02:08:34,473 --> 02:08:35,674
TRIALS THAT ARE BEING PROPOSED

3183
02:08:35,741 --> 02:08:37,910
ARE KIND OF LIKE LARGER

3184
02:08:37,976 --> 02:08:39,545
INITIATIVES THAT LOOK FOR SORT

3185
02:08:39,611 --> 02:08:41,346
OF AN IMPACT ON THE RESERVOIR

3186
02:08:41,413 --> 02:08:45,417
AND IMPACT ON THE REBOUND WITH

3187
02:08:45,484 --> 02:08:47,686
SORT OF EXPECTATIONS THAT THE

3188
02:08:47,753 --> 02:08:50,022
APPROACHES WOULD WORK IN-VIVO,

3189
02:08:50,089 --> 02:08:51,256
WHEREAS IF WE HAD A SYSTEM THAT

3190
02:08:51,323 --> 02:08:56,061
HAD LIKE A SMALLER PHASE I TYPE

3191
02:08:56,128 --> 02:08:58,363
OF PROOF OF PRINCIPLE, SHORT

3192
02:08:58,430 --> 02:09:01,700
INVESTMENT AND SHORT DURATION,

3193
02:09:01,767 --> 02:09:02,868
THEN MAYBE WE COULD POTENTIALLY

3194
02:09:02,935 --> 02:09:06,672
CREATE A PIPELINE FOR MORE HUMAN

3195
02:09:06,738 --> 02:09:08,874
STUDIES THAT COULD LEVERAGE SOME

3196
02:09:08,941 --> 02:09:10,542
OF THESE PROOF OF PRINCIPLE

3197
02:09:10,609 --> 02:09:10,843
INITIATIVES.

3198
02:09:10,909 --> 02:09:14,146
AND RIGHT NOW, THERE IS THE CURE

3199
02:09:14,213 --> 02:09:17,749
INITIATIVE THAT THE ACDG IS

3200
02:09:17,816 --> 02:09:19,952
OFFERING BUT THESE AS WELL

3201
02:09:20,018 --> 02:09:22,321
PROPOSED SORT OF VERY SORT OF

3202
02:09:22,387 --> 02:09:22,921
COMPREHENSIVE TRIALS HAVE BEEN

3203
02:09:22,988 --> 02:09:25,190
WAITING TO DEVELOP.

3204
02:09:25,257 --> 02:09:25,791
SO I'M NOT SUGGESTING THEY ARE

3205
02:09:25,858 --> 02:09:26,158
NOT WARRANTED.

3206
02:09:26,225 --> 02:09:26,425
THEY ARE.

3207
02:09:26,492 --> 02:09:28,527
BUT I THINK THAT THERE IS ROOM

3208
02:09:28,594 --> 02:09:31,263
FOR A LOT OF MORE GROWTH IN

3209
02:09:31,330 --> 02:09:33,298
SMALLER INITIATIVES THAT

3210
02:09:33,365 --> 02:09:34,633
POTENTIALLY COULD TAKE ADVANTAGE

3211
02:09:34,700 --> 02:09:36,168
OF ALL OF THESE STRATEGIES THAT

3212
02:09:36,235 --> 02:09:39,771
ARE EMERGING THROUGH THE

3213
02:09:39,838 --> 02:09:45,978
COLLABORATORIES.

3214
02:09:46,044 --> 02:09:48,447
>> THANK YOU.

3215
02:09:48,514 --> 02:09:48,747
DR. COLLINS.

3216
02:09:48,814 --> 02:09:52,184
>> THANK YOU FOR TAKING MY

3217
02:09:52,251 --> 02:09:52,484
QUESTION.

3218
02:09:52,551 --> 02:09:56,588
I GUESS ON A RELATED THEME OF

3219
02:09:56,655 --> 02:09:58,857
MOVING THINGS TO THE CLINIC,

3220
02:09:58,924 --> 02:10:00,492
EVEN BEFORE PHASE I TRIALS IT

3221
02:10:00,559 --> 02:10:03,462
CAN BE CHALLENGING FOR

3222
02:10:03,529 --> 02:10:04,897
INVESTORS -- INVESTIGATORS TO

3223
02:10:04,963 --> 02:10:07,432
MOVE FROM SMALL-MOLECULE

3224
02:10:07,499 --> 02:10:10,302
CANDIDATES TO THE NEXT STAGE

3225
02:10:10,369 --> 02:10:14,540
BECAUSE EFFICACY IS HARD TO

3226
02:10:14,606 --> 02:10:16,875
REALLY ESTABLISH IN SMALL-MODELS

3227
02:10:16,942 --> 02:10:18,911
THAT CURRENTLY EXIST FOR HIV

3228
02:10:18,977 --> 02:10:21,013
DISEASE, ESPECIALLY FOR NEED

3229
02:10:21,079 --> 02:10:26,451
IMMUNE RESPONSE AND YOU NEED

3230
02:10:26,518 --> 02:10:27,152
ANTI-RETROVIRAL THERAPY AND

3231
02:10:27,219 --> 02:10:29,421
EVERYTHING AND FOR THE ANIMAL TO

3232
02:10:29,488 --> 02:10:32,824
LIVE LONG ENOUGH FOR A THOROUGH

3233
02:10:32,891 --> 02:10:33,091
TEST.

3234
02:10:33,158 --> 02:10:36,061
ANIMAL MODELS ARE SUPER TRICKY.

3235
02:10:36,128 --> 02:10:37,763
AND SO I THINK SOME HELP WITH

3236
02:10:37,829 --> 02:10:39,665
INVESTIGATORS IN MOVING

3237
02:10:39,731 --> 02:10:42,000
CANDIDATE SMALL MOLECULES FOR

3238
02:10:42,067 --> 02:10:45,571
COMPLEX IMMUNOLOGIC FUNCTIONS

3239
02:10:45,637 --> 02:10:48,307
FROM THE BENCH INTO MAYBE LARGER

3240
02:10:48,373 --> 02:10:49,675
MODELS, EVEN BEFORE PHASE I IS

3241
02:10:49,741 --> 02:10:53,879
AN AREA THAT I THINK MANY PEOPLE

3242
02:10:53,946 --> 02:10:57,182
COULD GET SOME HELP WITH TO KIND

3243
02:10:57,249 --> 02:10:58,984
OF MOVE FORWARD THE CURIOUS

3244
02:10:59,051 --> 02:11:02,254
STRATEGIES THAT ARE EXPERIMENTAL

3245
02:11:02,321 --> 02:11:07,893
AT THIS POINT.

3246
02:11:07,960 --> 02:11:10,996
>> THANK YOU DR. COLLINS.

3247
02:11:11,063 --> 02:11:13,465
ANY OTHER HANDS?

3248
02:11:13,532 --> 02:11:14,566
DR. HOLTZ DO YOU SEE ANY HANDS

3249
02:11:14,633 --> 02:11:17,169
ON YOUR SIDE?

3250
02:11:17,236 --> 02:11:23,041
>> I WANTED TO QUICKLY JUST

3251
02:11:23,108 --> 02:11:24,576
RESPOND TO A QUESTION.

3252
02:11:24,643 --> 02:11:26,144
I WAS HAVING TOGGLING ISSUES ON

3253
02:11:26,211 --> 02:11:27,112
MY MUTE BUTTON.

3254
02:11:27,179 --> 02:11:32,584
THE ANSWER IS ESSENTIALLY BOTH.

3255
02:11:32,651 --> 02:11:34,253
WE FOLLOW THE BUDGET AND WE HAVE

3256
02:11:34,319 --> 02:11:35,153
A LEGISLATIVE TEAM THAT FOLLOWS

3257
02:11:35,220 --> 02:11:36,455
THE BUDGET AND WHAT IS HAPPENING

3258
02:11:36,521 --> 02:11:38,624
WITH THE BUDGET ON THE HILL VERY

3259
02:11:38,690 --> 02:11:40,158
CLOSELY WITH OUR TEAM AND WE

3260
02:11:40,225 --> 02:11:41,994
WORK WITH THAT INFORMATION ABOUT

3261
02:11:42,060 --> 02:11:44,029
WHAT THE POSSIBLE BUDGET CUTS

3262
02:11:44,096 --> 02:11:45,864
WILL BE.

3263
02:11:45,931 --> 02:11:46,398
OF COURSE IT ISN'T IN THE

3264
02:11:46,465 --> 02:11:47,532
APPROPRIATIONS USUALLY, SPECIFIC

3265
02:11:47,599 --> 02:11:50,202
PRIORITY AREAS, BUT WE TRY TO

3266
02:11:50,269 --> 02:11:51,670
MAKE SURE THAT IT'S BALANCED AND

3267
02:11:51,737 --> 02:11:53,272
IF THERE IS AN INCREASE OR

3268
02:11:53,338 --> 02:11:56,141
DECREASE, THAT WE HAVE RESEARCH

3269
02:11:56,208 --> 02:11:56,908
PRIORITIES IN MIND.

3270
02:11:56,975 --> 02:12:00,812
THE OAR DIRECTOR OR ACTING

3271
02:12:00,879 --> 02:12:02,648
DIRECTOR HAS DIRECT LINK TO ALL

3272
02:12:02,714 --> 02:12:04,416
THE IC DIRECTORS WITHIN OUR

3273
02:12:04,483 --> 02:12:05,684
AGENCY AND IS IN CONTACT WITH

3274
02:12:05,751 --> 02:12:08,987
THEM REGARDING ANY CHANGES IN

3275
02:12:09,054 --> 02:12:11,990
THE BUDGET AND WE ALSO DISCUSS

3276
02:12:12,057 --> 02:12:14,826
THIS AT THE NIH AIDS EXECUTIVE

3277
02:12:14,893 --> 02:12:25,070
COMMITTEE.

3278
02:12:25,971 --> 02:12:26,872
>> THANK YOU.

3279
02:12:26,938 --> 02:12:29,574
THANK YOU FOR SUCH A LIVELY

3280
02:12:29,641 --> 02:12:29,875
DISCUSSION.

3281
02:12:29,941 --> 02:12:32,144
OUR FINAL UPDATE FOR TODAY WILL

3282
02:12:32,210 --> 02:12:35,280
COME FROM THE HIV CLINICAL

3283
02:12:35,347 --> 02:12:37,382
GUIDELINES WORKING GROUP OF

3284
02:12:37,449 --> 02:12:37,749
OARAC.

3285
02:12:37,816 --> 02:12:40,319
THESE INCLUDE BOTH GUIDELINES

3286
02:12:40,385 --> 02:12:41,987
AND PANEL UPDATES.

3287
02:12:42,054 --> 02:12:52,564
WE HAVE FOUR PRESENTERS TODAY.

3288
02:12:56,802 --> 02:12:58,637
DR. AMAZE MAS, DR. A POW POW,

3289
02:12:58,704 --> 02:13:01,306
DR. NAHIDA CHAKTOURA,

3290
02:13:01,373 --> 02:13:06,912
DR. FRANKLIN YATES.

3291
02:13:06,978 --> 02:13:07,879
>> DR. CHRISTINE MIASKOWSKI IS

3292
02:13:07,946 --> 02:13:10,415
THE FOUNDING THE TORAND LEAD OF

3293
02:13:10,482 --> 02:13:13,085
GUIDELINES FOR MANAGEMENT OF

3294
02:13:13,151 --> 02:13:14,653
OPPORTUNISTIC INFECTION IN

3295
02:13:14,720 --> 02:13:15,921
ADOLESCENCE WITH HIV.

3296
02:13:15,987 --> 02:13:19,391
-- DR. HENRY PASUR.

3297
02:13:19,458 --> 02:13:20,859
DR. PAU IS A CRITICAL MEMBER OF

3298
02:13:20,926 --> 02:13:23,929
THE ADULT AND ADOLESCENCE

3299
02:13:23,995 --> 02:13:26,431
ANTI-RETROVIRAL GUIDELINES PANEL

3300
02:13:26,498 --> 02:13:28,700
SINCE 1998 AND BECAME THE

3301
02:13:28,767 --> 02:13:30,369
EXECUTIVE SECRETARY OF THE PANEL

3302
02:13:30,435 --> 02:13:32,938
IN 2003.

3303
02:13:33,004 --> 02:13:35,741
SHE IS A CO-ED TORE OF THE PANEL

3304
02:13:35,807 --> 02:13:38,110
ON TREATMENT AND PREVENTION OF

3305
02:13:38,176 --> 02:13:39,611
OPPORTUNISTIC INFECTION AND THE

3306
02:13:39,678 --> 02:13:44,049
LEAD UP OF THE FORMS OF THESE

3307
02:13:44,116 --> 02:13:44,349
GUIDELINES.

3308
02:13:44,416 --> 02:13:48,120
DR. NAHIDA CHAKTOURA IS THE

3309
02:13:48,186 --> 02:13:48,720
CHIEF MEDICAL OFFICER IN THE

3310
02:13:48,787 --> 02:13:52,958
PEDIATRIC INFECTION DISEASE

3311
02:13:53,024 --> 02:13:54,259
BRANCH AT THE EUNICE KENNEDY

3312
02:13:54,326 --> 02:13:56,628
DRIVER NATIONAL INSTITUTE OF

3313
02:13:56,695 --> 02:13:58,397
OF CHILD HEALTH AND HUMAN

3314
02:13:58,463 --> 02:13:59,865
DEVELOPMENT.

3315
02:13:59,931 --> 02:14:02,534
SHE OVERSEES VARIOUS HIV/AIDS

3316
02:14:02,601 --> 02:14:04,970
RELATED CLINICAL TRIALS AND

3317
02:14:05,036 --> 02:14:08,106
ADOLESCENCE EVENTS WITHIN THE

3318
02:14:08,173 --> 02:14:11,343
INTERNATIONAL PEDIATRIC

3319
02:14:11,410 --> 02:14:13,678
ADOLESCENT CLINICAL TRIAL

3320
02:14:13,745 --> 02:14:14,045
NETWORK.

3321
02:14:14,112 --> 02:14:16,047
DR. FRANKLIN YATES IS A MEDICAL

3322
02:14:16,114 --> 02:14:18,450
OFFICER IN THE MATERNAL AND

3323
02:14:18,517 --> 02:14:20,619
PEDIATRIC INFECTIOUS DISEASE

3324
02:14:20,685 --> 02:14:23,588
BRANCH AT THE EUNICE KENNEDY

3325
02:14:23,655 --> 02:14:24,890
DRIVER NATIONAL INSTITUTE

3326
02:14:24,956 --> 02:14:28,160
OF CHILD HEALTH AND DEVELOPMENT.

3327
02:14:28,226 --> 02:14:31,096
HIS RESEARCH INCLUDES HIV

3328
02:14:31,163 --> 02:14:31,730
PREVENTION STRATEGY AMONG YOUTH

3329
02:14:31,797 --> 02:14:34,566
AND ADOLESCENTS AND EVALUATING

3330
02:14:34,633 --> 02:14:38,270
TOOLS FOR CARE NAVIGATION AND

3331
02:14:38,336 --> 02:14:41,006
MANAGEMENT OF HIV AND VIRAL

3332
02:14:41,072 --> 02:14:43,375
HEPATITIS AND THEIR

3333
02:14:43,442 --> 02:14:47,846
CO-MORBIDITIES IN LOW-RESOURCED

3334
02:14:47,913 --> 02:14:51,216
SETTINGS.

3335
02:14:51,283 --> 02:14:52,217
DR. MASUR, WE WILL START WITH

3336
02:14:52,284 --> 02:14:52,384
YOU.

3337
02:14:52,451 --> 02:14:53,518
>> THANK YOU FOR THAT

3338
02:14:53,585 --> 02:14:55,520
INTRODUCTION.

3339
02:14:55,587 --> 02:15:05,997
TO START WITH THE -- TWO

3340
02:15:15,740 --> 02:15:17,042
QUESTIONS I WANT TO ADDRESS.

3341
02:15:17,108 --> 02:15:19,377
ONE IS, ARE THESE GUIDELINES

3342
02:15:19,444 --> 02:15:20,011
STILL NEEDED AND USED?

3343
02:15:20,078 --> 02:15:22,080
NUMBER 2, WHAT ARE WE DOING WITH

3344
02:15:22,147 --> 02:15:23,315
THE GUIDELINES?

3345
02:15:23,381 --> 02:15:26,151
SO WE CAN SEE THE NEXT SLIDE.

3346
02:15:26,218 --> 02:15:30,422
IF YOU LOOK AT THE NUMBER OF --

3347
02:15:30,489 --> 02:15:33,525
OVER THE LAST FEW YEARS, WE HAVE

3348
02:15:33,592 --> 02:15:38,463
HAD ABOUT 500,000.

3349
02:15:38,530 --> 02:15:39,998
THIS SUGGESTS THAT EVEN THOUGH

3350
02:15:40,065 --> 02:15:42,968
IT WAS UP-TO-DATE WITH ON LINE

3351
02:15:43,034 --> 02:15:44,569
RESOURCES, PEOPLE STILL RELY ON

3352
02:15:44,636 --> 02:15:46,371
THIS BECAUSE THEY SEE IT -- I

3353
02:15:46,438 --> 02:15:50,709
THINK AS AN AUTHORITATIVE AND

3354
02:15:50,775 --> 02:15:53,512
NEEDED ACCESSORY SOURCE.

3355
02:15:53,578 --> 02:15:55,447
IF YOU LOOK AT THE TOTAL NUMBER

3356
02:15:55,514 --> 02:15:59,518
FROM LAST YEAR, IT'S ABOUT THE

3357
02:15:59,584 --> 02:15:59,751
SAME.

3358
02:15:59,818 --> 02:16:00,785
IT'S INTERESTING TO LOOK AT WHAT

3359
02:16:00,852 --> 02:16:02,120
PEOPLE REALLY WANT TO KNOW

3360
02:16:02,187 --> 02:16:02,687
ABOUT.

3361
02:16:02,754 --> 02:16:04,189
AND IF YOU LOOK AT THE LEFT SIDE

3362
02:16:04,256 --> 02:16:07,692
OF THIS, THE RED IS 2022, THE

3363
02:16:07,759 --> 02:16:10,595
BLUE IS 2023.

3364
02:16:10,662 --> 02:16:13,765
REALLY THE 5 OR 6OIs IMPORTANT

3365
02:16:13,832 --> 02:16:24,309
IN LATE 1980S ARE STILL THE SA

3366
02:16:24,376 --> 02:16:25,644
SAME.

3367
02:16:25,710 --> 02:16:27,445
BUT IF YOU LOOK AT THE

3368
02:16:27,512 --> 02:16:29,481
RIGHT-HAND SIDE, WHILE VERY FEW

3369
02:16:29,548 --> 02:16:33,718
PEOPLE RELATIVELY LOOK AT THESE,

3370
02:16:33,785 --> 02:16:36,421
WE SEE THOSE AS ALMOST EQUALLY

3371
02:16:36,488 --> 02:16:38,023
VALUABLE BECAUSE FOR MOST OF US,

3372
02:16:38,089 --> 02:16:41,927
WE SEE A PATIENT WITH HIV, WE

3373
02:16:41,993 --> 02:16:52,537
REALLY DO NEED EXPERT ADVICE IF

3374
02:16:59,844 --> 02:17:02,013
YOU WANT TO KNOW WHO ACCESSES

3375
02:17:02,080 --> 02:17:03,148
THESE, MUCH THESE COME FROM THE

3376
02:17:03,214 --> 02:17:03,715
UNITED STATES.

3377
02:17:03,782 --> 02:17:04,950
THE OTHER COUNTRIES THAT YOU SEE

3378
02:17:05,016 --> 02:17:09,621
HERE LISTED ARE PROBABLY NOT

3379
02:17:09,688 --> 02:17:10,889
SURPRISING, AND THIS IS USED IN

3380
02:17:10,956 --> 02:17:12,891
ASIA, USED IN EUROPE AND THIS IS

3381
02:17:12,958 --> 02:17:15,794
USED IN LATIN AMERICA.

3382
02:17:15,860 --> 02:17:19,164
NOT SURPRISING THAT THESE HAVE A

3383
02:17:19,230 --> 02:17:21,333
WIDE VIEWERSHIP.

3384
02:17:21,399 --> 02:17:23,401
BUT WE SEE THAT OUR MANDATE IS

3385
02:17:23,468 --> 02:17:26,838
REALLY TO ADDRESS THE UNITED

3386
02:17:26,905 --> 02:17:27,072
STATES.

3387
02:17:27,138 --> 02:17:30,842
SO WE MAINTAIN WE HAVE THE

3388
02:17:30,909 --> 02:17:34,279
AGENCIES OR THE ABILITY TO

3389
02:17:34,346 --> 02:17:44,689
HANDLE OPPORTUNIES.

3390
02:17:48,360 --> 02:17:50,528
WE HANDLE OPPORTUNISTIC

3391
02:17:50,595 --> 02:17:51,396
INFECTIONS AS THEY WOULD BE

3392
02:17:51,463 --> 02:17:55,066
DEALT WITH IN OTHER HEALTH CARE

3393
02:17:55,133 --> 02:17:55,300
SYSTEMS.

3394
02:17:55,367 --> 02:17:56,635
IF YOU WANT SOME IDEA OF THE

3395
02:17:56,701 --> 02:17:58,703
RANGE OF THINGS WE UPDATE, WE

3396
02:17:58,770 --> 02:18:00,472
MAKE A EFFORT TO TRY TO KEEP

3397
02:18:00,538 --> 02:18:03,008
THESE GUIDELINES CURRENT AND WE

3398
02:18:03,074 --> 02:18:05,110
TURN OUT AS MANY UPDATES PER

3399
02:18:05,176 --> 02:18:07,779
YEAR AS WE THINK ARE

3400
02:18:07,846 --> 02:18:08,079
APPROPRIATE.

3401
02:18:08,146 --> 02:18:09,114
AND JUST TAKING A QUICK LOOK,

3402
02:18:09,180 --> 02:18:11,116
YOU CAN SEE HERE THAT THERE ARE

3403
02:18:11,182 --> 02:18:13,718
QUITE A FEW SECTIONS THAT

3404
02:18:13,785 --> 02:18:18,056
RECENTLY WE HAVE MADE UP.

3405
02:18:18,123 --> 02:18:20,425
WHAT DO THESE UPDATES LOOK LIKE?

3406
02:18:20,492 --> 02:18:23,361
IF YOU LOOK AT SYPHILIS AS AN

3407
02:18:23,428 --> 02:18:26,665
EXAMPLE, WE INCLUDE SOME

3408
02:18:26,731 --> 02:18:29,834
CLINICAL INFORMATION ABOUT

3409
02:18:29,901 --> 02:18:32,137
WHAT'S NOT SO NEW BUT MORE

3410
02:18:32,203 --> 02:18:34,005
OCULAR SYPHILIS BEING SEEN.

3411
02:18:34,072 --> 02:18:35,907
ALTHOUGH WE ARE NOT

3412
02:18:35,974 --> 02:18:37,842
COMPREHENSIVE, WE DO UPDATE

3413
02:18:37,909 --> 02:18:41,312
INFORMATION ABOUT DIAGNOSTICS,

3414
02:18:41,379 --> 02:18:43,248
PARTICULARLY THE TWO DIFFERENT

3415
02:18:43,314 --> 02:18:44,749
DIAGNOSTIC APPROACHES.

3416
02:18:44,816 --> 02:18:48,019
WE DON'T GIVE A SPECIFIC

3417
02:18:48,086 --> 02:18:51,523
RECOMMENDATION FOR DOXYBUT WE

3418
02:18:51,589 --> 02:18:55,326
MENTION IT BECAUSE IT IS A

3419
02:18:55,393 --> 02:18:59,364
RECOMMENDATION AND THE

3420
02:18:59,431 --> 02:19:01,633
SYPHILIS -- AND WE ADDRESS WHAT

3421
02:19:01,700 --> 02:19:04,069
THE OPTIONS ARE IN TERMS OF

3422
02:19:04,135 --> 02:19:06,371
PENICILLIN SHORTAGES, AND THAT

3423
02:19:06,438 --> 02:19:09,874
PROBABLY NEEDS TO BE UPDATED

3424
02:19:09,941 --> 02:19:10,075
AGAIN.

3425
02:19:10,141 --> 02:19:12,277
SOME OF THE UPDATES ARE MORE

3426
02:19:12,343 --> 02:19:13,712
MINOR BUT STILL IMPORTANT.

3427
02:19:13,778 --> 02:19:17,982
HEPATITIS B, FOR INSTANCE, HEP I

3428
02:19:18,049 --> 02:19:19,384
WILL SAF, THE ADJUVANT VACCINE

3429
02:19:19,451 --> 02:19:23,488
FOR HEPATITIS B HAS BEEN MOVED

3430
02:19:23,555 --> 02:19:25,056
UP AND NOW CONSIDERED THE FIRST

3431
02:19:25,123 --> 02:19:27,726
LINE VACCINE.

3432
02:19:27,792 --> 02:19:33,064
UPDATES ARE CURRENT FOR INSTANCE

3433
02:19:33,131 --> 02:19:34,499
MEN I THINK COCKAL VACCINE AND

3434
02:19:34,566 --> 02:19:36,334
THESE ARE HARMONIZED WITH CDC

3435
02:19:36,401 --> 02:19:38,937
AND EVERYTHING GETS REVIEWED AND

3436
02:19:39,003 --> 02:19:41,372
APPROVED BY CDC BEFORE IT GOES

3437
02:19:41,439 --> 02:19:41,840
OUT.

3438
02:19:41,906 --> 02:19:45,110
AND THEN FOR MONKEY POX, THAT

3439
02:19:45,176 --> 02:19:47,579
HAS HAD ITS UPS AND DOWNS

3440
02:19:47,645 --> 02:19:49,047
EPIDEMIOLOGICALLY AND WE TRY TO

3441
02:19:49,114 --> 02:19:53,918
KEEP THE CURRENT CLINICAL

3442
02:19:53,985 --> 02:19:54,919
EXPERIENCE AT LEAST SUMMARIZED

3443
02:19:54,986 --> 02:19:56,888
WITH REFERENCES AND AS THERE ARE

3444
02:19:56,955 --> 02:19:58,957
CHANGES IN PREVENTION OR

3445
02:19:59,023 --> 02:20:01,226
THERAPY, THOSE WILL BE CHANGED

3446
02:20:01,292 --> 02:20:02,026
AS WELL.

3447
02:20:02,093 --> 02:20:05,663
THERE IS SOME CONTROVERSIAL

3448
02:20:05,730 --> 02:20:05,897
ISSUES.

3449
02:20:05,964 --> 02:20:06,664
THERE ARE PEOPLE ON THIS PANEL

3450
02:20:06,731 --> 02:20:09,367
WHO KNOW A LOT MORE ABOUT HPV

3451
02:20:09,434 --> 02:20:09,634
THAN I DO.

3452
02:20:09,701 --> 02:20:11,436
ONE OF THE THINGS WE STRUGGLED

3453
02:20:11,503 --> 02:20:18,409
WITH IS THE INTERNATIONAL ANAL

3454
02:20:18,476 --> 02:20:19,477
NEOPLASIA STUDY ISSUED NEW

3455
02:20:19,544 --> 02:20:20,945
GUIDELINES THIS PAST YEAR AND

3456
02:20:21,012 --> 02:20:23,782
THEY WERE BASED ON NEW ENGLAND

3457
02:20:23,848 --> 02:20:28,286
JOURNAL OF MEDICINE SAYING THAT

3458
02:20:28,353 --> 02:20:29,020
THE GAPLESS KEY, ALSO ON OUR

3459
02:20:29,087 --> 02:20:30,221
PANEL WHO IS THE LEADER AUTHOR

3460
02:20:30,288 --> 02:20:36,327
ON, AND THAT REALLY IS THE FIRST

3461
02:20:36,394 --> 02:20:40,765
DATA THAT OBJECTIVELY SHOWS THE

3462
02:20:40,832 --> 02:20:41,666
SCREENING EARLY INTERVENTION ARE

3463
02:20:41,733 --> 02:20:44,335
IMPORTANT IN TERMS OF REDUCING

3464
02:20:44,402 --> 02:20:46,271
ANAL CANCER, AT LEAST IN ONE

3465
02:20:46,337 --> 02:20:47,872
POPULATION.

3466
02:20:47,939 --> 02:20:49,908
WE HAVE SEVERAL PROBLEMS.

3467
02:20:49,974 --> 02:20:52,377
ONE IS WE HAVE TO MAKE SURE WE

3468
02:20:52,443 --> 02:20:54,112
AGREE ON WHAT THE CONTENT IS AND

3469
02:20:54,179 --> 02:20:55,480
WHAT IS EVIDENCE-BASED AND WHAT

3470
02:20:55,547 --> 02:20:57,916
IS BASED ON EXPERT OPINION.

3471
02:20:57,982 --> 02:20:59,818
AND OF COURSE IN MOST

3472
02:20:59,884 --> 02:21:00,785
RECOMMENDATIONS AND THE

3473
02:21:00,852 --> 02:21:02,520
GUIDELINES, DON'T HAVE DATA.

3474
02:21:02,587 --> 02:21:04,589
THEY HAVE EXPERT PERSON, WHICH

3475
02:21:04,656 --> 02:21:08,593
WE THINK IS USEFUL BUT IT'S JUST

3476
02:21:08,660 --> 02:21:09,594
A DIFFERENT LEVEL OF WHAT IS

3477
02:21:09,661 --> 02:21:12,297
BEING RECOMMENDED.

3478
02:21:12,363 --> 02:21:14,799
A SECOND PROBLEM IS IN TERMS OF

3479
02:21:14,866 --> 02:21:16,935
MAKING THE INFORMATION

3480
02:21:17,001 --> 02:21:17,502
UNDERSTANDABLE.

3481
02:21:17,569 --> 02:21:20,538
WE HAVE BEEN THROUGH A COUPLE OF

3482
02:21:20,605 --> 02:21:23,508
ITERATIONS OF THIS SECTION

3483
02:21:23,575 --> 02:21:23,808
OURSELVES.

3484
02:21:23,875 --> 02:21:28,246
WE LOOKED AT WHAT THE

3485
02:21:28,313 --> 02:21:30,014
INTERNATIONAL ANAL NEOPLASIA

3486
02:21:30,081 --> 02:21:31,449
SOCIETY HAS, AND IT IS VERY HARD

3487
02:21:31,516 --> 02:21:33,885
TO UNDERSTAND THE TABLES AND THE

3488
02:21:33,952 --> 02:21:36,788
TEXT IF YOU'RE A CLINICIAN

3489
02:21:36,855 --> 02:21:37,422
TRYING TO FIGURE OUT WHAT TO DO.

3490
02:21:37,488 --> 02:21:39,324
AND WE ARE WORKING ON TRYING TO

3491
02:21:39,390 --> 02:21:42,126
MAKE THAT UNDERSTANDABLE WITH

3492
02:21:42,193 --> 02:21:44,829
MORE FLOW DIAGRAMS AND BETTER

3493
02:21:44,896 --> 02:21:47,031
TABLES, BUT GIVEN THE DATA, THAT

3494
02:21:47,098 --> 02:21:47,932
ISN'T EASY.

3495
02:21:47,999 --> 02:21:50,401
WE ALSO WANT TO HARMONIZE

3496
02:21:50,468 --> 02:21:55,173
EVERYTHING WITH ACOG AND THE

3497
02:21:55,240 --> 02:21:56,374
NEOPLASIA SOCIETY CLINICIANS IF

3498
02:21:56,441 --> 02:21:58,476
POSSIBLE, AND NOT CONFRONT WITH

3499
02:21:58,543 --> 02:22:00,511
DIFFERENT TABLES AND DIFFERENT

3500
02:22:00,578 --> 02:22:00,879
RECOMMENDATIONS.

3501
02:22:00,945 --> 02:22:03,214
AGAIN THERE MAY BE SOME SLIDE

3502
02:22:03,281 --> 02:22:04,616
DIFFERENCES BUT WE UNDERSTAND

3503
02:22:04,682 --> 02:22:06,017
THAT THERE ARE A LOT OF PEOPLE

3504
02:22:06,084 --> 02:22:07,552
WHO THINK WE NEED TO GET THESE

3505
02:22:07,619 --> 02:22:07,986
GUIDELINES OUT.

3506
02:22:08,052 --> 02:22:09,554
WE WANT TO MAKE SURE WE CAN

3507
02:22:09,621 --> 02:22:11,956
STAND BY THE CONTENT AND THAT

3508
02:22:12,023 --> 02:22:14,859
THE PRESENTATION IS

3509
02:22:14,926 --> 02:22:22,600
UNDERSTANDABLE.

3510
02:22:22,667 --> 02:22:27,038
BY THE TIME UPDATES GET REVIEWED

3511
02:22:27,105 --> 02:22:30,541
BY ALL AFTER THE DEVELOPMENT, IT

3512
02:22:30,608 --> 02:22:33,177
DOES TAKE TIME FOR THESE

3513
02:22:33,244 --> 02:22:36,114
VOLUNTEER GROUPS TO REVIEW

3514
02:22:36,180 --> 02:22:36,547
THESE.

3515
02:22:36,614 --> 02:22:37,882
WE TRY TO SPEED THIS UP AS MUCH

3516
02:22:37,949 --> 02:22:39,684
AS POSSIBLE, AND TO MAKE SURE

3517
02:22:39,751 --> 02:22:43,087
THAT THESE KEEP MOVING ALONG.

3518
02:22:43,154 --> 02:22:44,756
WE ARE ALSO VERY AWARE OF THE

3519
02:22:44,822 --> 02:22:49,727
FACT THAT WE NEED TO MAKE SURE

3520
02:22:49,794 --> 02:22:53,631
THAT OUR MEMBERSHIP IS

3521
02:22:53,698 --> 02:22:55,600
REPRESENTATIVE AND THAT THERE IS

3522
02:22:55,667 --> 02:22:56,768
WIDE ACCESS TO BEING ON THE

3523
02:22:56,834 --> 02:22:57,335
PANEL.

3524
02:22:57,402 --> 02:23:00,905
WE HAVE OVER 100 MEMBERS IN OUR

3525
02:23:00,972 --> 02:23:02,206
VARIOUS GROUPS ON THE PANEL.

3526
02:23:02,273 --> 02:23:05,143
PEOPLE SERVE A FOUR-YEAR TERM.

3527
02:23:05,209 --> 02:23:07,779
WE DO ADVERTISE BUT REMEMBER WE

3528
02:23:07,845 --> 02:23:09,514
ALSO SOLICIT FOR MEMBERS WHO

3529
02:23:09,580 --> 02:23:11,716
RECOMMEND OTHERS AND THERE IS

3530
02:23:11,783 --> 02:23:14,118
SOME ROTATION IN THE SUBJECT

3531
02:23:14,185 --> 02:23:16,087
GROUP LEADS AND THE MEMBERS EACH

3532
02:23:16,154 --> 02:23:16,287
YEAR.

3533
02:23:16,354 --> 02:23:19,057
AND AGAIN, WE ARE COGNIZANT OF

3534
02:23:19,123 --> 02:23:21,426
WHAT THE PROFILE OF OUR

3535
02:23:21,492 --> 02:23:23,061
PANELISTS ARE.

3536
02:23:23,127 --> 02:23:24,562
SO, YOU CAN STOP THE SLIDES.

3537
02:23:24,629 --> 02:23:26,731
THAT'S REALLY A SUMMARY OF WHERE

3538
02:23:26,798 --> 02:23:28,232
WE ARE.

3539
02:23:28,299 --> 02:23:29,100
AND YOU CAN DECIDE WHAT YOU WANT

3540
02:23:29,167 --> 02:23:30,835
TO TAKE QUESTIONS AT THE END OF

3541
02:23:30,902 --> 02:23:32,670
EACH PRESENTATION OR WAIT UNTIL

3542
02:23:32,737 --> 02:23:36,607
THE END OF ALL OF THEM.

3543
02:23:36,674 --> 02:23:38,042
THANK YOU.

3544
02:23:38,109 --> 02:23:39,610
>> THANK YOU.

3545
02:23:39,677 --> 02:23:41,079
ARE WE ARE GOING TO WAIT AND

3546
02:23:41,145 --> 02:23:42,914
TAKE THE QUESTIONS AFTER

3547
02:23:42,981 --> 02:23:44,716
EVERYBODY MAKES THEIR

3548
02:23:44,782 --> 02:23:45,516
PRESENTATION.

3549
02:23:45,583 --> 02:23:48,252
DR. PAU OVER TO YOU.

3550
02:23:48,319 --> 02:23:48,619
>> THANK YOU.

3551
02:23:48,686 --> 02:23:50,888
THANK YOU EVERYONE FOR INVITING

3552
02:23:50,955 --> 02:23:52,924
ME TO GIVE YOU A PRESENTATION OF

3553
02:23:52,991 --> 02:23:54,892
WHAT HAPPENED SINCE THE LAST

3554
02:23:54,959 --> 02:23:55,994
TIME WE REPORTED.

3555
02:23:56,060 --> 02:23:59,097
IF I CAN HAVE THE NEXT SLIDE,

3556
02:23:59,163 --> 02:23:59,330
PLEASE.

3557
02:23:59,397 --> 02:24:01,065
SO, WE HAD AN UPDATE IN DECEMBER

3558
02:24:01,132 --> 02:24:06,571
OF 2023.

3559
02:24:06,637 --> 02:24:08,306
WE MAINLY FOCUSED ON TWO

3560
02:24:08,373 --> 02:24:10,174
DIFFERENT TOPICS AT THAT TIME.

3561
02:24:10,241 --> 02:24:13,077
ONE IS HIV 2 AND THE OTHER IS AN

3562
02:24:13,144 --> 02:24:15,580
UPDATE ON THE EARLY ACUTE OR

3563
02:24:15,646 --> 02:24:18,649
RECENT HIV INFECTION.

3564
02:24:18,716 --> 02:24:20,084
HIV-2, WE USUALLY UPDATE THAT

3565
02:24:20,151 --> 02:24:21,085
PROBABLY EVERY TWO OR THREE

3566
02:24:21,152 --> 02:24:24,222
YEARS OR SO AND AS THEY ARE NOT

3567
02:24:24,288 --> 02:24:28,092
AS MUCH NEW DATA AVAILABLE AND

3568
02:24:28,159 --> 02:24:30,728
ALSO IS NOT AS RELEVANT,

3569
02:24:30,795 --> 02:24:33,398
HOWEVER, WE DO RECOGNIZE THAT WE

3570
02:24:33,464 --> 02:24:35,333
HAVE INDIVIDUALS THAT ARE IN THE

3571
02:24:35,400 --> 02:24:37,468
U.S. COMING FROM COUNTRIES

3572
02:24:37,535 --> 02:24:40,338
ENDEMIC WITH HIV-2 AND NOTING

3573
02:24:40,405 --> 02:24:42,373
THAT A COUPLE OF IMPORTANT

3574
02:24:42,440 --> 02:24:44,142
ISSUES THAT WE WANT TO ADDRESS.

3575
02:24:44,208 --> 02:24:46,377
ONE OF WHICH IS THE FACT THAT WE

3576
02:24:46,444 --> 02:24:49,180
ALL KNOW THAT IT IS

3577
02:24:49,247 --> 02:24:50,882
INTRINSICALLY CONSISTENT TO

3578
02:24:50,948 --> 02:24:55,386
NNRTIs AND BECAUSE OF THAT,

3579
02:24:55,453 --> 02:24:58,523
NOW BECAUSE OF THIS REGIMEN

3580
02:24:58,589 --> 02:25:00,525
SWITCHING IN MOST COUNTRIES

3581
02:25:00,591 --> 02:25:01,559
AROUND THE WORLD, THAT IS NO

3582
02:25:01,626 --> 02:25:03,327
LONGER AS MUCH OF AN ISSUE,

3583
02:25:03,394 --> 02:25:05,763
HOWEVER, WE DO RECOGNIZE THAT

3584
02:25:05,830 --> 02:25:06,731
SOME PEOPLE MAY NOT BE THINKING

3585
02:25:06,798 --> 02:25:12,036
ABOUT THE USE OF LONG-ACTING --

3586
02:25:12,103 --> 02:25:13,604
IN THE CASE OF PATIENTS WHO

3587
02:25:13,671 --> 02:25:17,508
EITHER HIV-2 OR HAS CO-INFECTION

3588
02:25:17,575 --> 02:25:19,577
WITH HIV-1 AND 2.

3589
02:25:19,644 --> 02:25:23,614
SO WE MORE EXPLICITLY PUT OUT A

3590
02:25:23,681 --> 02:25:24,649
RECOMMENDATION THAT IN PATIENTS

3591
02:25:24,715 --> 02:25:26,184
WHO HAVE BEEN DIAGNOSED WITH

3592
02:25:26,250 --> 02:25:31,722
HIV-2, THE USE OF LONG ACTING --

3593
02:25:31,789 --> 02:25:34,692
IS NOT RECOMMENDED.

3594
02:25:34,759 --> 02:25:36,294
RECOGNIZING THAT VERY FEW

3595
02:25:36,360 --> 02:25:38,863
INDIVIDUALS WITH MULTIDRUG

3596
02:25:38,930 --> 02:25:41,799
RESISTANT HIV-2 INFECTION IN

3597
02:25:41,866 --> 02:25:47,472
VITRO DATA HAS SHOWN THAT BOTH

3598
02:25:47,538 --> 02:25:49,740
THESE DRUGS HAVE GAINS IN HIV-2

3599
02:25:49,807 --> 02:25:52,243
AND POTENTIALLY USED IN THE CASE

3600
02:25:52,310 --> 02:25:52,844
WHERE THERE ARE PATIENTS THAT

3601
02:25:52,910 --> 02:25:54,712
HAS MULTIPLE DRUG RESISTANT

3602
02:25:54,779 --> 02:25:54,979
INFECTION.

3603
02:25:55,046 --> 02:25:56,781
AND LASTLY, THERE ARE NOW MORE

3604
02:25:56,848 --> 02:25:59,450
CLINICAL DATA TO LOOK AT THE

3605
02:25:59,517 --> 02:26:02,320
EFFICACY OF DOLUTEGRAVIR IN THE

3606
02:26:02,386 --> 02:26:04,422
TREATMENT OF HIV-2 SO WE ARE

3607
02:26:04,489 --> 02:26:05,957
MORE CONFIDENT IT WILL BE AN

3608
02:26:06,023 --> 02:26:06,624
EFFECTIVE REGIMEN TO BE USED IN

3609
02:26:06,691 --> 02:26:09,460
THAT SETTING.

3610
02:26:09,527 --> 02:26:11,596
THE OTHER THING WE TRY TO UPDATE

3611
02:26:11,662 --> 02:26:15,766
IS WITH REGARDS TO EARLY HIV

3612
02:26:15,833 --> 02:26:17,068
INFECTION AND THAT IS PRIMARILY

3613
02:26:17,135 --> 02:26:21,606
BY UPDATING THE DATA THAT WERE

3614
02:26:21,672 --> 02:26:25,776
REPORTED FROM EXTENDED ANALYSIS

3615
02:26:25,843 --> 02:26:31,883
FROM HPTN0 A LITTLE 3 TO LOOK AT

3616
02:26:31,949 --> 02:26:34,185
CAB-LA FOR PrEP VERSUS

3617
02:26:34,252 --> 02:26:34,418
PLACEBO.

3618
02:26:34,485 --> 02:26:36,220
THERE ARE A NUMBER OF REPORTS OF

3619
02:26:36,287 --> 02:26:38,823
CASES OF HIV OCCURRING WHILE THE

3620
02:26:38,890 --> 02:26:40,925
PATIENT WAS SUPPOSED TO BE

3621
02:26:40,992 --> 02:26:43,227
RECEIVING KABLA INCLUDING THOSE

3622
02:26:43,294 --> 02:26:46,664
ON LINE INJECTIONS ON TIME

3623
02:26:46,731 --> 02:26:47,565
INJECTIONS.

3624
02:26:47,632 --> 02:26:48,733
THEY ALSO, BECAUSE OF THE FACT

3625
02:26:48,799 --> 02:26:50,935
THAT THEY MIGHT HAVE LOW-LEVEL

3626
02:26:51,002 --> 02:26:54,639
OF HIV, IT MAY CAUSE DELAY IN

3627
02:26:54,705 --> 02:26:54,906
DIAGNOSIS.

3628
02:26:54,972 --> 02:26:55,940
AND AS WELL AS THE FACT THAT

3629
02:26:56,007 --> 02:26:58,176
THERE ARE A NUMBER OF CASES THAT

3630
02:26:58,242 --> 02:26:59,644
ARE REPORTED EACH THOUGH THE

3631
02:26:59,710 --> 02:27:01,979
NUMBERS ARE SMALL, OF

3632
02:27:02,046 --> 02:27:03,714
INDIVIDUALS AFTER THEY HAD BEEN

3633
02:27:03,781 --> 02:27:05,950
DIAGNOSED WITH HIV HAVE FOUND TO

3634
02:27:06,017 --> 02:27:09,353
HAVE MAJOR INSTI-RELATED

3635
02:27:09,420 --> 02:27:10,054
RESISTANT MUTATIONS.

3636
02:27:10,121 --> 02:27:13,357
AND BASICALLY THESE DATA

3637
02:27:13,424 --> 02:27:14,192
REINFORCED THE FACT IT'S

3638
02:27:14,258 --> 02:27:17,061
IMPORTANT TO TAKE THE HISTORY OF

3639
02:27:17,128 --> 02:27:18,296
A PATIENT WITH NEWLY DIAGNOSED

3640
02:27:18,362 --> 02:27:21,432
HIV TO NOTE THAT IF SOMEONE HAS

3641
02:27:21,499 --> 02:27:25,336
BEEN ON PRIOR HISTORY OF CAB-LA

3642
02:27:25,403 --> 02:27:28,339
USE FOR PrEP, THE GENOTYPE

3643
02:27:28,406 --> 02:27:31,442
SHOULD BE DONE AND ONE MAY NOT

3644
02:27:31,509 --> 02:27:34,378
WANT TO USE A REGIMEN UNTIL WE

3645
02:27:34,445 --> 02:27:37,381
KNOW FOR SURE THAT A PATIENT

3646
02:27:37,448 --> 02:27:40,218
DOES NOT HAVE -- RESISTANT

3647
02:27:40,284 --> 02:27:41,419
MUTATIONS.

3648
02:27:41,485 --> 02:27:43,421
NEXT SLIDE, PLEASE.

3649
02:27:43,487 --> 02:27:51,162
NOW THIS IS THE EXCITING PART.

3650
02:27:51,229 --> 02:27:51,696
THERE WERE REPRIEVE STUDY

3651
02:27:51,762 --> 02:27:56,901
PUBLISHED IN JULY 2023, HAS

3652
02:27:56,968 --> 02:27:58,536
SHOWN THERE WAS BENEFIT AS

3653
02:27:58,603 --> 02:28:00,371
PRIMARY PREVENTION OF

3654
02:28:00,438 --> 02:28:00,871
CARDIOVASCULAR DISEASES,

3655
02:28:00,938 --> 02:28:02,473
ESPECIALLY IN THE PATIENTS WITH

3656
02:28:02,540 --> 02:28:06,277
LOW TO MODERATE TENURED ASCVD

3657
02:28:06,344 --> 02:28:06,477
RISKS.

3658
02:28:06,544 --> 02:28:09,280
WE HAVE A LOT OF DEBATES WHERE

3659
02:28:09,347 --> 02:28:10,448
THIS BELONGS TO MAINLY BECAUSE

3660
02:28:10,514 --> 02:28:14,018
WE ARE THE ANTI-RETROVIRAL

3661
02:28:14,085 --> 02:28:15,019
TREATMENT GUIDELINES.

3662
02:28:15,086 --> 02:28:17,221
WE ALSO RECOGNIZE THE LIMITATION

3663
02:28:17,288 --> 02:28:20,024
OF OUR PANEL MEMBERS THAT WE

3664
02:28:20,091 --> 02:28:23,094
EVEN THOUGH WE ARE GENERAL

3665
02:28:23,160 --> 02:28:24,262
INTERNISTS, THIS WAS INFECTIOUS

3666
02:28:24,328 --> 02:28:27,164
DISEASES SPECIALISTS, WE REALIZE

3667
02:28:27,231 --> 02:28:28,833
THAT WE ARE NOT SPECIALISTS IN

3668
02:28:28,899 --> 02:28:29,133
CARDIOLOGY.

3669
02:28:29,200 --> 02:28:30,568
SO WE DON'T FEEL TOTALLY

3670
02:28:30,635 --> 02:28:32,670
COMFORTABLE IN MAKING OUR

3671
02:28:32,737 --> 02:28:35,039
RECOMMENDATION WITHOUT

3672
02:28:35,106 --> 02:28:36,407
CONSULTING EXPERTS IN THE AREA.

3673
02:28:36,474 --> 02:28:39,043
SO IN NOVEMBER OF 2023, WE

3674
02:28:39,110 --> 02:28:41,078
DECIDED THAT WE DO NEED TO MAKE

3675
02:28:41,145 --> 02:28:44,048
SOME RECOMMENDATION, EACH THOUGH

3676
02:28:44,115 --> 02:28:46,083
WE ARE ANTI-RETROVIRAL THERAPY

3677
02:28:46,150 --> 02:28:46,384
GUIDELINES.

3678
02:28:46,450 --> 02:28:50,154
WE HAVE CONSULTED WITH THE TWO

3679
02:28:50,221 --> 02:28:52,757
MAJOR ORGANIZATION, AMERICAN

3680
02:28:52,823 --> 02:28:53,357
COLLEGE OF CARDIOLOGY AND

3681
02:28:53,424 --> 02:28:55,126
AMERICAN HEART ASSOCIATION.

3682
02:28:55,192 --> 02:28:57,828
WE ALSO WORK WITH DRIVING HIV

3683
02:28:57,895 --> 02:29:00,298
MA, ESPECIALLY THOSE WRITING THE

3684
02:29:00,364 --> 02:29:01,232
PRIMARY CARE GUIDELINES AND ALSO

3685
02:29:01,299 --> 02:29:02,400
IN THE PROCESS OF TRYING TO

3686
02:29:02,466 --> 02:29:03,968
FIGURE OUT WHAT TO DO WITH THE

3687
02:29:04,035 --> 02:29:04,335
DATA.

3688
02:29:04,402 --> 02:29:07,371
AND TO TRY TO CREATE THE RAPID

3689
02:29:07,438 --> 02:29:09,674
COMMUNICATION ON THE USE OF STAT

3690
02:29:09,740 --> 02:29:10,074
IN WITH HIV.

3691
02:29:10,141 --> 02:29:11,575
SO WE FINALLY DEVELOPED THE

3692
02:29:11,642 --> 02:29:14,078
DOCUMENT AND THE DATE THAT I PUT

3693
02:29:14,145 --> 02:29:15,880
ON HERE FEBRUARY 29, WHICH IS

3694
02:29:15,946 --> 02:29:17,348
NEXT THURSDAY, IS NOT GOING TO

3695
02:29:17,415 --> 02:29:17,948
BE THE DATE.

3696
02:29:18,015 --> 02:29:22,019
WE TRIED TO MOVE IT UP TO NEXT

3697
02:29:22,086 --> 02:29:23,254
TUESDAY FOR RELEASE THAT WILL

3698
02:29:23,321 --> 02:29:23,921
COME OUT.

3699
02:29:23,988 --> 02:29:27,224
AND THIS DOCUMENT HAS BEEN

3700
02:29:27,291 --> 02:29:28,693
WRITTEN AS WELL AS ENDORSED BY

3701
02:29:28,759 --> 02:29:29,427
ALL THREE OF THE ORGANIZATIONS

3702
02:29:29,493 --> 02:29:32,330
ON TOP OF OUR PANEL.

3703
02:29:32,396 --> 02:29:36,067
SO AS I MENTIONED, IT WILL BE

3704
02:29:36,133 --> 02:29:36,934
RELEASED ON FEBRUARY 27.

3705
02:29:37,001 --> 02:29:38,135
NEXT SLIDE, PLEASE.

3706
02:29:38,202 --> 02:29:41,772
THIS IS A PREVIEW OF OUR DRAFT

3707
02:29:41,839 --> 02:29:43,541
RECOMMENDATIONS.

3708
02:29:43,607 --> 02:29:46,344
THIS IS WE DIVIDE THEM BASED ON

3709
02:29:46,410 --> 02:29:47,278
INDIVIDUAL RISKS.

3710
02:29:47,345 --> 02:29:49,046
THERE ARE MORE INFORMATION ABOUT

3711
02:29:49,113 --> 02:29:51,048
THOSE INDIVIDUALS WITH LESS THAN

3712
02:29:51,115 --> 02:29:55,553
20 -- GREATER THAN 20% RISK.

3713
02:29:55,619 --> 02:29:57,822
AND WE ALSO NEED READERS TO USE

3714
02:29:57,888 --> 02:30:01,258
THE CALCULATOR IN DETERMINING

3715
02:30:01,325 --> 02:30:02,126
THE RISK OF THE INDIVIDUAL

3716
02:30:02,193 --> 02:30:02,360
PATIENT.

3717
02:30:02,426 --> 02:30:07,264
AND THEN DIVIDE BY AGE 40-75

3718
02:30:07,331 --> 02:30:09,433
VERSUS LESS THAN ANAL 40 YEARS

3719
02:30:09,500 --> 02:30:11,569
OF AGE.

3720
02:30:11,635 --> 02:30:13,237
40-75 IS THE AGE RANGE IN WHICH

3721
02:30:13,304 --> 02:30:14,538
THE STUDY WAS BEING DONE.

3722
02:30:14,605 --> 02:30:17,641
AS WELL AS THAT IS THE AGE RANGE

3723
02:30:17,708 --> 02:30:21,245
IN WHICH THE AHAACC LIPID

3724
02:30:21,312 --> 02:30:24,348
GUIDELINES RECOMMENDATIONS CAME

3725
02:30:24,415 --> 02:30:24,982
FROM.

3726
02:30:25,049 --> 02:30:26,784
SO, WHEN INDIVIDUALS WHO ARE

3727
02:30:26,851 --> 02:30:30,287
BETWEEN AGE 40-75, WITH A 5-LESS

3728
02:30:30,354 --> 02:30:33,224
THAN 20% RISK, THE PANEL

3729
02:30:33,290 --> 02:30:38,028
RECOMMENDS AT LEAST A MODERATE

3730
02:30:38,095 --> 02:30:39,397
INTENSITY STAT IN WITH AN A ONE

3731
02:30:39,463 --> 02:30:39,964
RECOMMENDATION.

3732
02:30:40,030 --> 02:30:43,534
SO THIS IS A STRONG

3733
02:30:43,601 --> 02:30:43,901
RECOMMENDATION.

3734
02:30:43,968 --> 02:30:47,304
RECOGNIZING THAT THE STUDY

3735
02:30:47,371 --> 02:30:49,707
REPRIEVE WAS USING STAT IN, ALSO

3736
02:30:49,774 --> 02:30:52,877
RECOGNIZED THE FACT THAT NOT ALL

3737
02:30:52,943 --> 02:30:54,178
INSTITUTES HAVE THIS STAT IN IN

3738
02:30:54,245 --> 02:30:56,680
THE FORMULARY.

3739
02:30:56,747 --> 02:30:57,281
WE PROVIDED THE INFORMATION ON

3740
02:30:57,348 --> 02:31:03,220
THE USE OF TWO OTHER STAT INS

3741
02:31:03,287 --> 02:31:04,688
INCLUDING -- THESE INDIVIDUAL

3742
02:31:04,755 --> 02:31:07,224
STATINS THAT HAS SOME OTHER DATA

3743
02:31:07,291 --> 02:31:10,127
RATHER THAN LARGE RANDOMIZED

3744
02:31:10,194 --> 02:31:11,896
CONTROL TRIAL TO SHOW THEY HAVE

3745
02:31:11,962 --> 02:31:12,329
BENEFITS IN REDUCING

3746
02:31:12,396 --> 02:31:13,431
INFLAMMATION AND POTENTIALLY

3747
02:31:13,497 --> 02:31:16,167
HAVE SIMILAR BENEFITS AS SEEN

3748
02:31:16,233 --> 02:31:17,301
WITH TAPA STAT IN.

3749
02:31:17,368 --> 02:31:19,937
FOR INDIVIDUALS WITH LESS THAN

3750
02:31:20,004 --> 02:31:23,841
5% RISK, WOO INDICATED WE FAVOR

3751
02:31:23,908 --> 02:31:25,342
INITIATING A MODERATE IN DENSITY

3752
02:31:25,409 --> 02:31:29,079
STAT IN WITH A WEAKER

3753
02:31:29,146 --> 02:31:29,880
RECOMMENDATION.

3754
02:31:29,947 --> 02:31:31,749
NOTING THAT THE ABSOLUTE RISK IN

3755
02:31:31,816 --> 02:31:33,017
THESE -- THE BENEFITS FROM THE

3756
02:31:33,083 --> 02:31:35,019
STAT IN IS MODEST IN THIS

3757
02:31:35,085 --> 02:31:37,621
POPULATION BASED ON THE NUMBER

3758
02:31:37,688 --> 02:31:39,423
NEEDED TO TREAT FOR FIVE YEARS

3759
02:31:39,490 --> 02:31:40,458
IN THE REPRIEVE DATA.

3760
02:31:40,524 --> 02:31:43,260
AND BECAUSE OF THAT, THE

3761
02:31:43,327 --> 02:31:44,261
POSITION FOR INITIATING SHOULD

3762
02:31:44,328 --> 02:31:45,329
TAKE INTO ACCOUNT THE PRESENCE

3763
02:31:45,396 --> 02:31:48,499
OR ABSENCE OF OTHER HIV-RELATED

3764
02:31:48,566 --> 02:31:51,702
FACTORS THAT CAN INCREASE CBD

3765
02:31:51,769 --> 02:31:52,002
RISK.

3766
02:31:52,069 --> 02:31:53,070
BECAUSE OF THE FACT THAT THE

3767
02:31:53,137 --> 02:31:54,872
STUDY DID NOT STUDY INDIVIDUALS

3768
02:31:54,939 --> 02:31:56,841
FOR LESS THAN 40 YEARS OF AGE,

3769
02:31:56,907 --> 02:31:59,510
WE INDICATED THAT THE DATA I

3770
02:31:59,577 --> 02:32:02,279
BELIEVE SUFFICIENTLY WAS TO MAKE

3771
02:32:02,346 --> 02:32:02,880
RECOMMENDATION OR AGAINST THE

3772
02:32:02,947 --> 02:32:04,048
USE OF STATINS PRIMARY

3773
02:32:04,114 --> 02:32:07,184
PREVENTION IN THESE PATIENTS.

3774
02:32:07,251 --> 02:32:08,118
THE OTHER IMPORTANT INFORMATION

3775
02:32:08,185 --> 02:32:11,088
IS LIFESTYLE MODIFICATIONS

3776
02:32:11,155 --> 02:32:11,789
RECOMMENDED FOR THESE

3777
02:32:11,856 --> 02:32:13,390
INDIVIDUALS ESPECIALLY FOR THOSE

3778
02:32:13,457 --> 02:32:15,759
WHO HAVE OTHER RISK FACTORS FOR

3779
02:32:15,826 --> 02:32:16,927
CARDIOVASCULAR DISEASE.

3780
02:32:16,994 --> 02:32:17,761
NEXT SLIDE.

3781
02:32:17,828 --> 02:32:19,597
SO AS I MENTIONED BEFORE, THIS

3782
02:32:19,663 --> 02:32:21,165
WILL NOT HAVE BEEN DONE AND WE

3783
02:32:21,232 --> 02:32:22,700
WOULD NOT FEEL AS COMFORTABLE IN

3784
02:32:22,766 --> 02:32:23,667
MAKING OUR RECOMMENDATIONS

3785
02:32:23,734 --> 02:32:25,202
WITHOUT THE HELP OF OUR

3786
02:32:25,269 --> 02:32:28,606
COLLEAGUES FROM ACC, AHA AND HIV

3787
02:32:28,672 --> 02:32:29,740
MA.

3788
02:32:29,807 --> 02:32:31,909
I WANT TO ACKNOWLEDGE A NUMBER

3789
02:32:31,976 --> 02:32:33,177
OF OUR CONSULTANTS

3790
02:32:33,244 --> 02:32:34,445
REPRESENTATIVES FROM THOSE

3791
02:32:34,512 --> 02:32:36,480
ORGANIZATIONS THAT PARTICIPATED

3792
02:32:36,547 --> 02:32:37,181
IN A LOT OF PHONE CALLS WITH US

3793
02:32:37,248 --> 02:32:40,985
AND A LOT OF RECONCILING THE

3794
02:32:41,051 --> 02:32:44,522
DIFFERENT REGIMENS, DIFFERENT

3795
02:32:44,588 --> 02:32:45,689
DOCUMENTS THAT WE HAVE.

3796
02:32:45,756 --> 02:32:46,724
NEXT SLIDE, PLEASE.

3797
02:32:46,790 --> 02:32:48,692
ON TOP OF THATTINGS, WE ARE

3798
02:32:48,759 --> 02:32:51,862
REALLY WORKING VERY CLOSELY WITH

3799
02:32:51,929 --> 02:32:54,798
OUR PANEL TO UPDATE OTHER

3800
02:32:54,865 --> 02:32:55,699
SECTIONS OF THE GUIDELINES

3801
02:32:55,766 --> 02:32:56,600
WITHIN ANTICIPATION THAT NEW

3802
02:32:56,667 --> 02:32:58,569
UPDATES WILL COME OUT IN LATE

3803
02:32:58,636 --> 02:33:00,771
SPRING TO EARLY SUMMER AND THAT

3804
02:33:00,838 --> 02:33:02,506
INCLUDES A BRAND NEW SECTION ON

3805
02:33:02,573 --> 02:33:05,576
HIV AND TRANSPLANT WITH FOCUS ON

3806
02:33:05,643 --> 02:33:09,246
HOW TO MANAGE THE PATIENT

3807
02:33:09,313 --> 02:33:10,981
PRE AND POST TRANSPLANT NOTING

3808
02:33:11,048 --> 02:33:12,650
INTERACTIONS AND OTHER FACTORS.

3809
02:33:12,716 --> 02:33:15,319
OTHER SECTIONS TO BE UPDATED

3810
02:33:15,386 --> 02:33:17,288
INCLUDE WHAT TO START OPTIMIZING

3811
02:33:17,354 --> 02:33:20,090
ERT, HIV IN OLDER PEOPLE, IN

3812
02:33:20,157 --> 02:33:22,693
WOMEN, IN HEPATITIS B

3813
02:33:22,760 --> 02:33:25,496
CO-INFECTION, SUBSTANCE USE,

3814
02:33:25,563 --> 02:33:28,933
ADHERENCE, DRUG-DRUG

3815
02:33:28,999 --> 02:33:30,000
INTERACTIONS AND RENAL DOSING.

3816
02:33:30,067 --> 02:33:32,736
THAT IS ALL I HAVE.

3817
02:33:32,803 --> 02:33:33,037
THANK YOU.

3818
02:33:33,103 --> 02:33:35,039
>> THANK YOU VERY MUCH DR. PAU.

3819
02:33:35,105 --> 02:33:38,208
DR. NAHIDA CHAKTOURA.

3820
02:33:38,275 --> 02:33:39,076
>> THANK YOU VERY MUCH.

3821
02:33:39,143 --> 02:33:40,711
ON BEHALF OF MY EXCELLENT PANEL

3822
02:33:40,778 --> 02:33:43,981
OF VOLUNTEER EXPERTS AND

3823
02:33:44,048 --> 02:33:44,949
CO-CHAIRS I'M PRESENTING THE

3824
02:33:45,015 --> 02:33:46,350
UPDATES FROM THE PERINATAL

3825
02:33:46,417 --> 02:33:52,222
GUIDELINES THAT WERE RECENTLY

3826
02:33:52,289 --> 02:33:54,458
PUBLISHED IN JANUARY OF THIS

3827
02:33:54,525 --> 02:33:55,492
YEAR, JANUARY 31.

3828
02:33:55,559 --> 02:33:59,730
NEXT SLIDE, PLEASE.

3829
02:33:59,797 --> 02:34:05,536
SO AS I MENTIONED, THE -- I KEEP

3830
02:34:05,603 --> 02:34:06,870
GETTING A THING SAYING YOU WANT

3831
02:34:06,937 --> 02:34:09,807
ME TO START MY VIDEO.

3832
02:34:09,873 --> 02:34:15,879
I'M GOING TO TRY TO -- SO WE

3833
02:34:15,946 --> 02:34:18,048
HAVE FOUR CHAIRED SECTIONS WITH

3834
02:34:18,115 --> 02:34:21,185
OUR PEDIATRIC PANEL

3835
02:34:21,251 --> 02:34:23,487
COLLABORATORS AND SO WE HAVE

3836
02:34:23,554 --> 02:34:25,322
PUBLISHED ONE OF THE FOUR

3837
02:34:25,389 --> 02:34:26,523
SECTIONS AND THEN THE OTHER

3838
02:34:26,590 --> 02:34:30,561
THREE WILL BE PUBLISHED LATER ON

3839
02:34:30,628 --> 02:34:34,198
IN THE SPRING OF THE SO THE

3840
02:34:34,264 --> 02:34:35,432
UPDATE TO THE PREGNANCY AND

3841
02:34:35,499 --> 02:34:37,801
POSTPARTUM HIV TESTING AND

3842
02:34:37,868 --> 02:34:41,772
IDENTIFICATION OF THE PERINATAL

3843
02:34:41,839 --> 02:34:45,142
AND POSTNATAL EXPOSURE WAS

3844
02:34:45,209 --> 02:34:45,376
UPDATED.

3845
02:34:45,442 --> 02:34:45,976
THE OTHER THREE SUBSES WILL BE

3846
02:34:46,043 --> 02:34:46,977
UPDATED IN THE SPRING.

3847
02:34:47,044 --> 02:34:50,180
NEXT SLIDE, PLEASE.

3848
02:34:50,247 --> 02:34:51,448
SO THERE ARE MINOR REVISIONS

3849
02:34:51,515 --> 02:34:53,250
MADE TO INCORPORATE OR CONTINUE

3850
02:34:53,317 --> 02:34:55,686
TO INCORPORATE GENDER INCLUSIVE

3851
02:34:55,753 --> 02:34:57,521
LANGUAGE WHERE APPROPRIATE AND

3852
02:34:57,588 --> 02:34:59,523
WHERE APPROPRIATE ALSO IN LINE

3853
02:34:59,590 --> 02:35:02,860
WITH ALICE'S GUIDELINES OF THE

3854
02:35:02,926 --> 02:35:06,997
ADULT AND ADDS LES ENT PANEL.

3855
02:35:07,064 --> 02:35:11,235
AND WE ALSO MADE CLARIFICATIONS

3856
02:35:11,301 --> 02:35:15,272
AROUND THE TIMING OF EXPOSURE IN

3857
02:35:15,339 --> 02:35:16,740
PREGNANCY SO CLEARLY DEFINED.

3858
02:35:16,807 --> 02:35:18,442
THIS WAS AN INTRODUCTION

3859
02:35:18,509 --> 02:35:18,676
SECONDS.

3860
02:35:18,742 --> 02:35:19,877
CLEARLY DEFINED WHAT WE

3861
02:35:19,943 --> 02:35:21,645
CONSIDERED PERINATAL, WHICH

3862
02:35:21,712 --> 02:35:22,813
WOULD INCLUDE DURING PREGNANCY

3863
02:35:22,880 --> 02:35:25,916
AND LABOR AND DELIVERY AND THEN

3864
02:35:25,983 --> 02:35:27,184
POSTNATAL HIV TRANSMISSION FOR

3865
02:35:27,251 --> 02:35:28,886
THOSE THAT WOULD BE ACQUIRED

3866
02:35:28,952 --> 02:35:30,087
THROUGH THE BREASTFEEDING

3867
02:35:30,154 --> 02:35:32,056
PERIOD, WHICH IS OUTSIDE OF THE

3868
02:35:32,122 --> 02:35:33,757
PERINATAL TIMEFRAME.

3869
02:35:33,824 --> 02:35:38,128
NEXT SLIDE, PLEASE.

3870
02:35:38,195 --> 02:35:40,197
WE'VE ALSO UPDATED

3871
02:35:40,264 --> 02:35:45,736
RECOMMENDATIONS FOR THE AIV DRUG

3872
02:35:45,803 --> 02:35:46,970
MANAGEMENT DURING PREGNANCY FOR

3873
02:35:47,037 --> 02:35:48,639
PEOPLE TRYING TO CONCEIVE AND

3874
02:35:48,706 --> 02:35:51,275
THOSE ARE FOUND IN TABLE 6 AND

3875
02:35:51,341 --> 02:35:52,743
7.

3876
02:35:52,810 --> 02:35:56,980
AND WE UPDATED -- INSUFFICIENT

3877
02:35:57,047 --> 02:35:59,750
DATA TO RECOMMEND INJECTABLE

3878
02:35:59,817 --> 02:36:01,652
LONG-ACTING TREATMENT IN

3879
02:36:01,719 --> 02:36:04,788
PREGNANCY AND FOR INDIVIDUALS

3880
02:36:04,855 --> 02:36:07,024
WHO ARE ON LONG-ACTING THERAPY

3881
02:36:07,091 --> 02:36:09,393
FOR PrEP DURING PREGNANCY, THE

3882
02:36:09,460 --> 02:36:11,228
PANEL MADE SURE TO POINT OUT

3883
02:36:11,295 --> 02:36:12,429
THAT, REALLY TO DISCUSS THE

3884
02:36:12,496 --> 02:36:15,532
DECISION OF WHAT TO DO AND HOW

3885
02:36:15,599 --> 02:36:17,534
TO MANAGE INDIVIDUALS WHO BECOME

3886
02:36:17,601 --> 02:36:19,436
PREGNANT AND WHEN CONSIDERING

3887
02:36:19,503 --> 02:36:22,072
CHANGE TO EITHER ORAL REGIMEN

3888
02:36:22,139 --> 02:36:23,240
FOR INDIVIDUALS WHO ARE TRYING

3889
02:36:23,307 --> 02:36:26,643
TO CONCEIVE SO IT IS MORE OF A

3890
02:36:26,710 --> 02:36:27,644
PATIENT-CENTERED APPROACH IN

3891
02:36:27,711 --> 02:36:29,713
THEIR RECOMMENDATIONS.

3892
02:36:29,780 --> 02:36:34,985
NEXT SLIDE, PLEASE.

3893
02:36:35,052 --> 02:36:38,021
WE HAVE ALTERED OR CHANGED THE

3894
02:36:38,088 --> 02:36:40,390
RECOMMENDATION AS FOR PREFERRED

3895
02:36:40,457 --> 02:36:43,427
REGIMEN FOR TREATMENT FOR

3896
02:36:43,494 --> 02:36:45,562
PREGNANT PEOPLE WHO HAVE NEVER

3897
02:36:45,629 --> 02:36:50,200
RECEIVED ARV TO START WITH A

3898
02:36:50,267 --> 02:36:57,741
THREE-DRUG REGIMEN WITH DOLL TAG

3899
02:36:57,808 --> 02:36:59,777
VER-BASED REGIMENS.

3900
02:36:59,843 --> 02:37:01,245
WE CHANGED THE REGIMEN FROM

3901
02:37:01,311 --> 02:37:03,747
PREFERRED TO ALTERNATIVE FOR

3902
02:37:03,814 --> 02:37:08,352
INITIATION OF TREATMENT FOR

3903
02:37:08,418 --> 02:37:10,354
INDIVIDUALS DURING PREGNANCY

3904
02:37:10,420 --> 02:37:12,523
EXCEPT IN SITUATIONS WHERE THERE

3905
02:37:12,589 --> 02:37:19,997
IS A USE OF LONG-ACTING

3906
02:37:20,063 --> 02:37:22,299
TREATMENTS DUE TO CONCERNS WITH

3907
02:37:22,366 --> 02:37:24,968
THE RESISTANCE MUTATIONS, AS

3908
02:37:25,035 --> 02:37:30,207
ALICE MENTIONED EARLIER.

3909
02:37:30,274 --> 02:37:30,674
AND BIC TEGRA VEER IS

3910
02:37:30,741 --> 02:37:32,142
ALTERNATIVE TREATMENT FOR USE IN

3911
02:37:32,209 --> 02:37:33,210
PREGNANCY, INCLUDING FOR THOSE

3912
02:37:33,277 --> 02:37:35,445
INDIVIDUALS WITH HIV-2

3913
02:37:35,512 --> 02:37:35,779
INFECTION.

3914
02:37:35,846 --> 02:37:38,215
AND THAT IS A CHANGE FROM

3915
02:37:38,282 --> 02:37:43,086
INSUFFICIENT TO RECOMMENDED.

3916
02:37:43,153 --> 02:37:46,223
NEXT SLIDE, PLEASE.

3917
02:37:46,290 --> 02:37:49,893
SO WE ALSO UPDATED THE BULLETED

3918
02:37:49,960 --> 02:37:51,361
RECOMMENDATIONS AND THE TEXT TO

3919
02:37:51,428 --> 02:37:54,631
DEFINE LACK OF VIRAL SUPPRESSION

3920
02:37:54,698 --> 02:37:57,367
AND VIROLOGICAL FAILURE FOR

3921
02:37:57,434 --> 02:38:00,637
PREGNANT INDIVIDUALS FOR THOSE

3922
02:38:00,704 --> 02:38:02,840
WHO ARE NOT PREGNANT AND

3923
02:38:02,906 --> 02:38:04,308
CLARIFIED GUIDANCE ABOUT THE

3924
02:38:04,374 --> 02:38:05,576
EVALUATION AND MANAGEMENT WHEN

3925
02:38:05,642 --> 02:38:08,111
VIRAL SUPPRESSION IS NOT

3926
02:38:08,178 --> 02:38:09,379
ACHIEVED DURING PREGNANCY.

3927
02:38:09,446 --> 02:38:11,348
SO THAT IT IS CLEAR

3928
02:38:11,415 --> 02:38:14,418
RECOMMENDATIONS OF WHAT TO DO.

3929
02:38:14,484 --> 02:38:16,486
WE ALSO ADDED RECOMMENDATIONS

3930
02:38:16,553 --> 02:38:18,488
FOR VIRAL CO-INFECTION TESTING

3931
02:38:18,555 --> 02:38:22,392
IN INFANTS WHO ARE EXPOSED TO

3932
02:38:22,459 --> 02:38:27,564
HIV TO INCLUDE CONGENITAL,

3933
02:38:27,631 --> 02:38:28,866
HEPATITIS C AND THE B AND

3934
02:38:28,932 --> 02:38:32,836
PROVIDED LINKS ABOUT TESTING AND

3935
02:38:32,903 --> 02:38:35,105
CARE IN THOSE INDIVIDUALS IN OUR

3936
02:38:35,172 --> 02:38:37,341
SECTION RELATED TO INITIAL

3937
02:38:37,407 --> 02:38:40,410
POST-NATAL MANAGEMENT OF THE

3938
02:38:40,477 --> 02:38:42,746
NEONATES AND EXPOSED TO HIV.

3939
02:38:42,813 --> 02:38:44,681
AND WE HAVE UPDATED THE SAFETY

3940
02:38:44,748 --> 02:38:49,386
OF TOXICITY FOR INDIVIDUALS

3941
02:38:49,453 --> 02:38:50,854
ANTI-RETROVIRAL TREATMENTS TO

3942
02:38:50,921 --> 02:38:52,122
INCORPORATE NEW DRUGS, EACH

3943
02:38:52,189 --> 02:38:53,724
THOUGH THERE ARE NOT NECESSARILY

3944
02:38:53,790 --> 02:38:54,591
RECOMMENDED BUT JUST MAKE SURE

3945
02:38:54,658 --> 02:38:57,327
THAT WE HAVE INCLUDED THEM INTO

3946
02:38:57,394 --> 02:39:02,833
THE UPDATES FOR THE GUIDELINES.

3947
02:39:02,900 --> 02:39:04,668
AND THEN FINALLY TO MAKE AN

3948
02:39:04,735 --> 02:39:06,670
ANNOUNCEMENT ON BEHALF OF THE

3949
02:39:06,737 --> 02:39:11,875
PEDIATRIC PANEL IS THAT WE ARE

3950
02:39:11,942 --> 02:39:13,877
SOLICITING PANEL MEMBERS AS WELL

3951
02:39:13,944 --> 02:39:17,981
FOR THE PEDIATRIC PANEL.

3952
02:39:18,048 --> 02:39:21,351
THE APPLICATIONS ARE DUE NEXT

3953
02:39:21,418 --> 02:39:26,723
WEEK AND THE DETAILS ON THE

3954
02:39:26,790 --> 02:39:28,558
APPLICATION IS ON CLINICAL INFO

3955
02:39:28,625 --> 02:39:31,828
AND THE NEWS WEBSITE.

3956
02:39:31,895 --> 02:39:33,297
SO PLEASE ENCOURAGE PEOPLE TO

3957
02:39:33,363 --> 02:39:33,497
APPLY.

3958
02:39:33,563 --> 02:39:37,100
AND I WANT TO ACKNOWLEDGE OR

3959
02:39:37,167 --> 02:39:40,604
TAKE THE OPPORTUNITY TO

3960
02:39:40,671 --> 02:39:41,204
ACKNOWLEDGE AND THANK A MEMBER

3961
02:39:41,271 --> 02:39:43,974
OF OUR PANEL THAT A LONGSTANDING

3962
02:39:44,041 --> 02:39:46,276
MEMBER OF OUR PANEL, WHO HAS

3963
02:39:46,343 --> 02:39:47,110
REALLY MADE SIGNIFICANT

3964
02:39:47,177 --> 02:39:48,979
CONTRIBUTIONS AND HAS BEEN VERY

3965
02:39:49,046 --> 02:39:51,481
INSTRUMENTAL IN BOTH THE

3966
02:39:51,548 --> 02:39:52,449
PEDIATRIC AND THE PERINATAL

3967
02:39:52,516 --> 02:39:55,652
PANEL AND THAT IS DR. STORM.

3968
02:39:55,719 --> 02:39:58,221
AND SHE WILL BE RETIRING THIS

3969
02:39:58,288 --> 02:40:00,524
YEAR.

3970
02:40:00,590 --> 02:40:01,158
WE WILL SORELY MISS HER AND WE

3971
02:40:01,224 --> 02:40:07,197
JUST WANTED TO SAY THANK YOU.

3972
02:40:07,264 --> 02:40:15,806
>> THANK YOUAISETHYOU.

3973
02:40:15,872 --> 02:40:16,173
>> THANK YOU.

3974
02:40:16,239 --> 02:40:17,207
DR.IATES OVER TO YOU.

3975
02:40:17,274 --> 02:40:19,876
>> I'M FRANKLIN YATES, A MEDICAL

3976
02:40:19,943 --> 02:40:21,645
OFFICER WITH NICHD AND THE

3977
02:40:21,712 --> 02:40:25,215
PLEASED TO PRESENT UPDATES WITH

3978
02:40:25,282 --> 02:40:29,119
THE PEDIATRIC GUIDELINES FOR

3979
02:40:29,186 --> 02:40:31,621
2023.

3980
02:40:31,688 --> 02:40:32,689
NEXT SLIDE.

3981
02:40:32,756 --> 02:40:36,126
JUST TO ACKNOWLEDGE THERE HAVE

3982
02:40:36,193 --> 02:40:37,461
BEEN A COUPLE OF TRANSITIONS

3983
02:40:37,527 --> 02:40:41,565
THAT OCCURRED IN THE PAST YEAR.

3984
02:40:41,631 --> 02:40:46,003
FIRST AND FOREMOST, DR. BILL

3985
02:40:46,069 --> 02:40:47,037
KAPOGIANNIS, MY FRIEND AND

3986
02:40:47,104 --> 02:40:48,505
FORMER COLLEAGUE, HAS STEPPED

3987
02:40:48,572 --> 02:40:52,743
OUT OF THE ROLE OF EXECUTIVE

3988
02:40:52,809 --> 02:40:54,011
SECRETARY AND HAS MOVED ON,

3989
02:40:54,077 --> 02:40:56,980
ALTHOUGH WE ARE GRATEFUL THAT HE

3990
02:40:57,047 --> 02:40:58,548
IS -- REMAINS A PANEL MEMBER.

3991
02:40:58,615 --> 02:41:03,687
AND THEN ALSO DR. NESHEIM ALSO

3992
02:41:03,754 --> 02:41:05,589
TRANSITIONED OUT OF HIS ROLE.

3993
02:41:05,655 --> 02:41:08,258
AND WE ARE VERY GRATEFUL AND

3994
02:41:08,325 --> 02:41:10,660
THANKFUL FOR ALL OF HIS MANY

3995
02:41:10,727 --> 02:41:14,765
CONTRIBUTIONS IN A LONGSTANDING

3996
02:41:14,831 --> 02:41:14,998
MEMBER.

3997
02:41:15,065 --> 02:41:21,371
THIS SLIDE SERVES TO ILLUSTRATE

3998
02:41:21,438 --> 02:41:24,174
THAT THE CONSISTENCY AND THE

3999
02:41:24,241 --> 02:41:29,513
ROBUSTNESS OF THE LEADERSHIP OF

4000
02:41:29,579 --> 02:41:31,481
THE WEB PAGES, EVEN THROUGHOUT

4001
02:41:31,548 --> 02:41:38,321
THE COVID EPIDEMIC YEARS, AND

4002
02:41:38,388 --> 02:41:42,059
STILL HAVE AROUND THE SAME AS IN

4003
02:41:42,125 --> 02:41:42,259
2019.

4004
02:41:42,325 --> 02:41:47,097
NEXT SLIDE, PLEASE.

4005
02:41:47,164 --> 02:41:50,634
AND THIS SLIDE IS ILLUSTRATING

4006
02:41:50,700 --> 02:41:54,171
THE TOP 10 PAGE VIEWS AND

4007
02:41:54,237 --> 02:41:56,339
PERHAPS NOT UNEXPECTEDLY THE

4008
02:41:56,406 --> 02:42:00,744
MOST VIEWED PAGE IS THE WHAT'S

4009
02:42:00,811 --> 02:42:04,648
NOW SECTION IN THE GUIDELINES.

4010
02:42:04,714 --> 02:42:07,551
FOLLOWED BY THE RECOMMENDED

4011
02:42:07,617 --> 02:42:12,122
IMMUNIZATION SCHEDULE.

4012
02:42:12,189 --> 02:42:14,891
AND THEN SECTIONS OF PATHOGENS,

4013
02:42:14,958 --> 02:42:17,961
PCP, TOXO PLASMA AND

4014
02:42:18,028 --> 02:42:18,495
CYTOMEGALOVIRUS.

4015
02:42:18,562 --> 02:42:20,430
THESE DATA HAVEN'T REALLY

4016
02:42:20,497 --> 02:42:21,731
CHANGED MUCH OVER THE PAST FEW

4017
02:42:21,798 --> 02:42:23,633
YEARS.

4018
02:42:23,700 --> 02:42:27,337
NEXT SLIDE.

4019
02:42:27,404 --> 02:42:35,679
2023 WE PUBLISHED SEVERAL NEW

4020
02:42:35,745 --> 02:42:40,050
SECTIONS AND ABOUT FOUR NEW

4021
02:42:40,117 --> 02:42:40,951
APPENDICES.

4022
02:42:41,017 --> 02:42:42,586
FIRST THE INTRODUCTION WAS

4023
02:42:42,652 --> 02:42:46,223
COMPLETELY REWRITTEN AND NOW

4024
02:42:46,289 --> 02:42:48,258
SUMMARIZES KEY CHANGES THAT

4025
02:42:48,325 --> 02:42:50,293
RESULT FROM THE RESCOPING

4026
02:42:50,360 --> 02:42:55,599
CONSULTATION THAT OCCURRED IN

4027
02:42:55,665 --> 02:42:55,799
2021.

4028
02:42:55,866 --> 02:43:00,203
AND SOME OF THOSE IMPORTANT

4029
02:43:00,270 --> 02:43:02,272
CHANGES INCLUDE UPDATES TO THE

4030
02:43:02,339 --> 02:43:04,608
FREQUENCY WITH CERTAIN SECTIONS

4031
02:43:04,674 --> 02:43:05,275
WILL BE REVISED.

4032
02:43:05,342 --> 02:43:08,178
THEY WILL NOW BE REVISED ON AN

4033
02:43:08,245 --> 02:43:11,014
EITHER FOUR-YEAR SCHEDULE,

4034
02:43:11,081 --> 02:43:14,417
DEPENDING ON THE SECTION, AND

4035
02:43:14,484 --> 02:43:17,187
ALSO THE INTRODUCTION HIGHLIGHTS

4036
02:43:17,254 --> 02:43:21,791
TRANSITION TO THE NEW EVIDENCE

4037
02:43:21,858 --> 02:43:22,926
RATINGS SCHEME TO BE ALIGNED

4038
02:43:22,993 --> 02:43:27,197
WITH OTHER GUIDELINES.

4039
02:43:27,264 --> 02:43:31,334
THEY ALSO, IN SEPTEMBER,

4040
02:43:31,401 --> 02:43:33,370
PUBLISHED A UPDATE TO THE

4041
02:43:33,436 --> 02:43:36,640
CYTOMEGALOVIRUS SECTION AND A

4042
02:43:36,706 --> 02:43:39,376
KEY FINDING FROM THIS SECTION IS

4043
02:43:39,442 --> 02:43:43,280
THAT THERE IS NOW A UNIVERSAL

4044
02:43:43,346 --> 02:43:44,848
RECOMMENDATION TO TEST INFANTS

4045
02:43:44,915 --> 02:43:47,951
EXPOSED TO HIV FOR CONGENITAL

4046
02:43:48,018 --> 02:43:48,318
CMV.

4047
02:43:48,385 --> 02:43:54,457
WE ALSO PUBLISHED IN SEPTEMBER A

4048
02:43:54,524 --> 02:43:57,561
REVISED TB SECTION, AND ADDED

4049
02:43:57,627 --> 02:44:00,530
RECOMMENDATIONS FOR

4050
02:44:00,597 --> 02:44:01,097
INHIBITOR-BASED REGIMENS IN

4051
02:44:01,164 --> 02:44:02,065
CONTEXT OF TB DISEASE.

4052
02:44:02,132 --> 02:44:04,935
THERE IS ALSO NOW AN ADDED

4053
02:44:05,001 --> 02:44:05,602
RECOMMENDATION THAT SOME

4054
02:44:05,669 --> 02:44:07,103
CHILDREN OVER THE AGE OF TWO,

4055
02:44:07,170 --> 02:44:16,179
LIVING WITH HIV, CAN RECEIVE THE

4056
02:44:16,246 --> 02:44:20,383
LTBI TREATMENT REGIMEN.

4057
02:44:20,450 --> 02:44:23,553
WE HAVE A NUMBER OF SECTION

4058
02:44:23,620 --> 02:44:27,691
UPDATES COMING IN WENT TOY 24.

4059
02:44:27,757 --> 02:44:29,859
PROMISES TO BE A -- 2024 --

4060
02:44:29,926 --> 02:44:31,728
PROMISES TO BE A BUSY YEAR AND

4061
02:44:31,795 --> 02:44:33,230
CURRENTLY SLATED FOR PUBLICATION

4062
02:44:33,296 --> 02:44:35,198
IN THE EARLY STRING, IF NOT LATE

4063
02:44:35,265 --> 02:44:38,568
WINTER, WE HAVE HEPATITIS B

4064
02:44:38,635 --> 02:44:40,403
VIRUS SECTION.

4065
02:44:40,470 --> 02:44:42,205
THE HEP C VIRUS SECTION AND

4066
02:44:42,272 --> 02:44:44,374
SARS-COV-2 SECTION.

4067
02:44:44,441 --> 02:44:47,711
AND THEN ON TRACK FOR

4068
02:44:47,777 --> 02:44:49,246
PUBLICATION IN THE FALL, IS THE

4069
02:44:49,312 --> 02:44:52,115
SECTION ON VACCINE-PREVENTIBLE

4070
02:44:52,182 --> 02:44:53,250
DISEASES AS WELL AS BACTERIAL

4071
02:44:53,316 --> 02:44:59,089
INFECTIONS AND HPV SECTION.

4072
02:44:59,155 --> 02:45:06,496
I BELIEVE THAT IS MY LAST SLIDE.

4073
02:45:06,563 --> 02:45:06,863
>> THANK YOU.

4074
02:45:06,930 --> 02:45:10,734
COLLEAGUES, WE ARE NOW OPEN FOR

4075
02:45:10,800 --> 02:45:21,011
DISCUSSION.

4076
02:45:34,224 --> 02:45:36,693
ANY HANDS I'M NOT SEEING,

4077
02:45:36,760 --> 02:45:37,027
DR. HOLTZ?

4078
02:45:37,093 --> 02:45:43,133
HERE WE GO.

4079
02:45:43,199 --> 02:45:44,801
>> I SEE DR. AKE AND DR. JOHN

4080
02:45:44,868 --> 02:45:45,068
SLEASMAN.

4081
02:45:45,135 --> 02:45:47,804
>> I SEE THEM TOO NOW, THANK

4082
02:45:47,871 --> 02:45:49,706
YOU.

4083
02:45:49,773 --> 02:45:50,040
>> DR. AKE.

4084
02:45:50,106 --> 02:45:53,176
>> THANK YOU VERY MUCH, JOHN WAS

4085
02:45:53,243 --> 02:45:56,913
FIRST.

4086
02:45:56,980 --> 02:45:57,180
>> OKAY.

4087
02:45:57,247 --> 02:46:03,787
[ MULTIPLE SPEAKERS ]

4088
02:46:03,853 --> 02:46:04,354
>> THANK YOU VERY MUCH.

4089
02:46:04,421 --> 02:46:07,424
AND I GUESS I WOULD REITERATE

4090
02:46:07,490 --> 02:46:09,726
WHAT SOME OF THE DATA HAS SHOWN,

4091
02:46:09,793 --> 02:46:11,161
WHICH IS JUST HOW CONTINUOUSLY

4092
02:46:11,227 --> 02:46:13,963
THESE GUIDELINES CONTINUE ARE

4093
02:46:14,030 --> 02:46:14,197
USEFUL.

4094
02:46:14,264 --> 02:46:15,965
AND I WILL SAY THAT IT MIGHT BE

4095
02:46:16,032 --> 02:46:20,437
FOR SOME VERY CLINICALLY ACTIVE

4096
02:46:20,503 --> 02:46:23,773
PEOPLE WHO RUN INTO RARE

4097
02:46:23,840 --> 02:46:25,375
CIRCUMSTANCES, BUT WE HAPPEN TO

4098
02:46:25,442 --> 02:46:26,476
BE PART OF A REALLY DIVERSE

4099
02:46:26,543 --> 02:46:28,611
COMMUNITY OF PEOPLE WHO ARE

4100
02:46:28,678 --> 02:46:30,313
RESEARCHERS WHO, THEY MAY ONLY

4101
02:46:30,380 --> 02:46:33,350
SPEND TWO MONTHS A YEAR SEEING

4102
02:46:33,416 --> 02:46:34,651
PATIENTS.

4103
02:46:34,718 --> 02:46:37,053
AND I WOULD SAY IT'S EQUALLY IF

4104
02:46:37,120 --> 02:46:41,224
NOT MORE SO USEFUL FOR SUCH AN

4105
02:46:41,291 --> 02:46:44,327
UP-TO-DATE EXPERT,

4106
02:46:44,394 --> 02:46:45,528
EVIDENCE-DRIVEN RESOURCE TO BE

4107
02:46:45,595 --> 02:46:50,867
AVAILABLE FOR THOSE CLINICIANS

4108
02:46:50,934 --> 02:46:51,101
AS WELL.

4109
02:46:51,167 --> 02:46:53,870
I THINK IN MANY WAYS, THOSE WHO

4110
02:46:53,937 --> 02:46:54,971
SPEND SO MUCH TIME DEVELOPING

4111
02:46:55,038 --> 02:46:58,074
THESE GUIDELINES INFLUENCE THE

4112
02:46:58,141 --> 02:47:00,410
CARE FOR SO MANY, THEY ARE

4113
02:47:00,477 --> 02:47:01,778
UNSUNG HEROES IN OUR FIELD AND I

4114
02:47:01,845 --> 02:47:05,115
JUST WANT TO CONVEY THAT

4115
02:47:05,181 --> 02:47:05,882
APPRECIATION AND EXTEND MY THANK

4116
02:47:05,949 --> 02:47:08,451
YOU TO ALL OF THOSE INDIVIDUALS

4117
02:47:08,518 --> 02:47:09,986
WHO ARE LEAVING THE PANELS WE

4118
02:47:10,053 --> 02:47:10,787
HEARD ABOUT.

4119
02:47:10,854 --> 02:47:13,890
THEY PROBABLY DON'T HAVE A SENSE

4120
02:47:13,957 --> 02:47:16,526
FOR HOW MANY INDIVIDUAL PATIENTS

4121
02:47:16,593 --> 02:47:17,460
THEY'VE IMPACTED THE CARE OF AND

4122
02:47:17,527 --> 02:47:18,528
IMPROVED THE CARE OF.

4123
02:47:18,595 --> 02:47:21,698
BUT THEY HAVE.

4124
02:47:21,765 --> 02:47:25,368
AND SO, I WOULD JUST EXTEND THAT

4125
02:47:25,435 --> 02:47:32,442
CONGRATULATIONS.

4126
02:47:32,509 --> 02:47:36,179
>> THANK YOU, DR. AKE.

4127
02:47:36,246 --> 02:47:40,583
>> JOHN SLEASMAN.

4128
02:47:40,650 --> 02:47:44,721
>> MOSTLY ABOUT ARV USE IN

4129
02:47:44,788 --> 02:47:46,389
ADULTS AND PEDIATRICS.

4130
02:47:46,456 --> 02:47:47,957
BUT ONE OF THE THINGS THAT CAME

4131
02:47:48,024 --> 02:47:50,660
OUT OF THE LISTENING SESSIONS

4132
02:47:50,727 --> 02:47:52,695
AROUND THE COUNTRY, RURAL AND

4133
02:47:52,762 --> 02:47:55,231
UNDERSERVED AREAS LIKE

4134
02:47:55,298 --> 02:47:57,267
MISSISSIPPI IS IN WHILE HIV CARE

4135
02:47:57,333 --> 02:47:58,768
IS ADMINISTERED IN HEALTH

4136
02:47:58,835 --> 02:48:01,604
DEPARTMENTS AND/OR IN FAMILY

4137
02:48:01,671 --> 02:48:06,576
PRACTICE OFFICES OR BY

4138
02:48:06,643 --> 02:48:07,744
PHYSICIANS AND PROVIDERS WHO ARE

4139
02:48:07,811 --> 02:48:08,878
NOT HIV EXPERTS.

4140
02:48:08,945 --> 02:48:12,081
SO HAVING THESE GUIDELINES IS

4141
02:48:12,148 --> 02:48:12,415
ESSENTIAL.

4142
02:48:12,482 --> 02:48:14,284
AND I GUESS ONE OF THE QUESTIONS

4143
02:48:14,350 --> 02:48:16,886
IS, ARE WE DOING A GOOD JOB IN

4144
02:48:16,953 --> 02:48:19,489
GETTING THOSE FOLKS TO USE THE

4145
02:48:19,556 --> 02:48:22,826
GUIDELINES AS A PRIMARY SOURCE

4146
02:48:22,892 --> 02:48:23,293
FOR THE TREATMENT?

4147
02:48:23,359 --> 02:48:26,729
AND HOW ARE WE TRACKING THAT?

4148
02:48:26,796 --> 02:48:30,333
AND THEN THE SECOND THING IS,

4149
02:48:30,400 --> 02:48:35,672
MORE FOR DR.-- IS -- AND I ASKED

4150
02:48:35,738 --> 02:48:37,040
THIS QUESTION BEFORE.

4151
02:48:37,106 --> 02:48:40,043
IS THAT THE OI USE SEEMS VERY

4152
02:48:40,109 --> 02:48:43,980
HIGH SO I SUSPECT THAT PEOPLE

4153
02:48:44,047 --> 02:48:48,885
WHO HAVE A -- ARE SURFING OFF

4154
02:48:48,952 --> 02:48:51,421
THE HIV GUIDELINES IN ORDER --

4155
02:48:51,488 --> 02:48:53,923
FOR PATIENTS WHO DON'T HAVE HIV.

4156
02:48:53,990 --> 02:48:57,627
HOW DO WE DEAL WITH THAT IN

4157
02:48:57,694 --> 02:49:01,331
TERMS OF RECOMMENDATIONS?

4158
02:49:01,397 --> 02:49:03,233
>> MAYBE I CAN ANSWER THE

4159
02:49:03,299 --> 02:49:05,235
QUESTION FIRST ABOUT HOW DO WE

4160
02:49:05,301 --> 02:49:07,804
TRACK PEOPLE ARE USING THE

4161
02:49:07,871 --> 02:49:08,605
GUIDELINES.

4162
02:49:08,671 --> 02:49:09,806
NUMBER 1, I DON'T KNOW THE

4163
02:49:09,873 --> 02:49:10,874
ANSWER TO THE QUESTION.

4164
02:49:10,940 --> 02:49:14,911
BUT SECONDLY IS THE FACT THAT I

4165
02:49:14,978 --> 02:49:18,982
KNOW HRSA DEFINITELY THROUGH THE

4166
02:49:19,048 --> 02:49:19,616
RYAN WHITE PROGRAM AND -- HAVE

4167
02:49:19,682 --> 02:49:21,784
SOME WAYS OF TRACKING WHAT ARE

4168
02:49:21,851 --> 02:49:22,919
BEING USED.

4169
02:49:22,986 --> 02:49:25,922
AND PERIODICALLY, LAURA ACHIEVER

4170
02:49:25,989 --> 02:49:27,323
IS PART OF OUR GUIDELINES PANEL

4171
02:49:27,390 --> 02:49:29,058
MEMBER AND SHE IS EXTREMELY

4172
02:49:29,125 --> 02:49:31,194
HELPFUL IN GUIDING US WHENEVER

4173
02:49:31,261 --> 02:49:33,763
WE HAVE ANY QUESTIONS AS

4174
02:49:33,830 --> 02:49:34,831
RELATING TO HOW OUR GUIDELINES

4175
02:49:34,898 --> 02:49:37,467
BEING USED BY THE COMMUNITY.

4176
02:49:37,534 --> 02:49:38,668
>> INTERESTING THEN, ARE THEY

4177
02:49:38,735 --> 02:49:40,136
LOOKING AT HOW THEY ARE BEING

4178
02:49:40,203 --> 02:49:43,506
USED IN COMPARED TO THE

4179
02:49:43,573 --> 02:49:45,241
GUIDELINES AS A --

4180
02:49:45,308 --> 02:49:47,544
>> I CAN BRING IT UP TO HER

4181
02:49:47,610 --> 02:49:49,178
ATTENTION BECAUSE OFTENTIMES

4182
02:49:49,245 --> 02:49:50,647
WHEN WE ARE WRITING SOMETHING,

4183
02:49:50,713 --> 02:49:53,249
SOMETHING THAT SHE ALWAYS POINT

4184
02:49:53,316 --> 02:49:56,519
OUT IS THAT THEY WILL BE USING

4185
02:49:56,586 --> 02:49:58,721
IT AS THEIR MEASURE WHATEVER WE

4186
02:49:58,788 --> 02:49:58,988
RECOMMEND.

4187
02:49:59,055 --> 02:50:00,089
FOR INSTANCE, WHEN WE WERE

4188
02:50:00,156 --> 02:50:02,058
TRYING TO MAKE RECOMMENDATIONS,

4189
02:50:02,125 --> 02:50:03,960
HOW OFTEN DO WE GET VIRAL LOAD

4190
02:50:04,027 --> 02:50:05,495
AND CD4 COUNT?

4191
02:50:05,562 --> 02:50:07,797
THAT WILL BE ONE OF THE MEASURES

4192
02:50:07,864 --> 02:50:10,199
THAT WILL USE IN TERMS OF

4193
02:50:10,266 --> 02:50:11,901
FUNDING AND OTHER REASONS AS

4194
02:50:11,968 --> 02:50:12,535
WELL.

4195
02:50:12,602 --> 02:50:13,803
BUT THE OTHER WAY AROUND WOULD

4196
02:50:13,870 --> 02:50:15,872
BE TRYING TO SEE HOW THE

4197
02:50:15,939 --> 02:50:18,541
PRESCRIBING IS GOING ON IN

4198
02:50:18,608 --> 02:50:20,610
DIFFERENT PARTS OF THE COUNTRY

4199
02:50:20,677 --> 02:50:22,879
AND DIFFERENT PROGRAMS THAT WE

4200
02:50:22,946 --> 02:50:24,814
SEE FUNDING -- RECEIVE FUNDING.

4201
02:50:24,881 --> 02:50:26,182
>> MANY PROVIDERS ARE

4202
02:50:26,249 --> 02:50:28,251
CONSTRAINED BY WHAT'S AVAILABLE

4203
02:50:28,318 --> 02:50:28,885
IN THEIR STATE MEDICAID, WHICH

4204
02:50:28,952 --> 02:50:31,220
IS A REAL PROBLEM.

4205
02:50:31,287 --> 02:50:32,288
THAT'S A STORY FOR ANOTHER DAY.

4206
02:50:32,355 --> 02:50:33,456
>> I WANT TO ADD THAT SIMILAR

4207
02:50:33,523 --> 02:50:35,158
FOR THE PERINATAL GUIDELINES,

4208
02:50:35,224 --> 02:50:37,794
THERE IS MEMBERS OF THE

4209
02:50:37,860 --> 02:50:38,561
PERINATAL GUIDELINES THAT GO OUT

4210
02:50:38,628 --> 02:50:43,199
TO THE HRSA FQHCs AND DO

4211
02:50:43,266 --> 02:50:44,634
TRAINING AND/OR PRESENTATIONS ON

4212
02:50:44,701 --> 02:50:48,338
UPDATES RELATED TO TREATMENT IN

4213
02:50:48,404 --> 02:50:48,805
PREGNANT INDIVIDUALS.

4214
02:50:48,871 --> 02:50:56,379
AND THAT IS SUPPORTED BY HRSA AS

4215
02:50:56,446 --> 02:50:58,214
WELL.

4216
02:50:58,281 --> 02:51:00,516
>> I SEE DR. JONATHAN MERMIN AND

4217
02:51:00,583 --> 02:51:01,751
DR. ROHAN HAZRA.

4218
02:51:01,818 --> 02:51:02,118
>> THANK YOU.

4219
02:51:02,185 --> 02:51:07,123
I WANTED TO ALSO APPRECIATE THE

4220
02:51:07,190 --> 02:51:08,558
COLONEL'S COMMENTS ABOUT THESE

4221
02:51:08,625 --> 02:51:09,292
GUIDELINES.

4222
02:51:09,359 --> 02:51:12,061
THIS IS HARD AND REALLY

4223
02:51:12,128 --> 02:51:12,362
MEANINGFUL.

4224
02:51:12,428 --> 02:51:15,698
AND COMPLETELY THANKLESS.

4225
02:51:15,765 --> 02:51:18,601
SO HERE YOU GET SOME POSITIVE

4226
02:51:18,668 --> 02:51:20,703
REINFORCEMENT FOR SOME REALLY

4227
02:51:20,770 --> 02:51:21,137
HARD WORK HERE.

4228
02:51:21,204 --> 02:51:25,441
I HAD A QUESTION FOR DR. AMAZE

4229
02:51:25,508 --> 02:51:25,608
MAS.

4230
02:51:25,675 --> 02:51:35,184
YOU MEN MAZUR.YOU MENTIONED YOUG

4231
02:51:35,251 --> 02:51:36,119
ON -- SYPHILIS, WHICH ALSO KIND

4232
02:51:36,185 --> 02:51:41,524
OF IS COVERED IN CDC'S STI

4233
02:51:41,591 --> 02:51:45,662
GUIDELINES AND THE DRAFT

4234
02:51:45,728 --> 02:51:46,229
HOPEFULLY SOON-TO-BE FINAL.

4235
02:51:46,295 --> 02:51:48,131
AND I MENTION THERE IS DIFFERENT

4236
02:51:48,197 --> 02:51:49,499
PLACES IN THE GUIDELINES THAT

4237
02:51:49,565 --> 02:51:55,204
YOU'RE LEADING WHERE THERE ARE

4238
02:51:55,271 --> 02:51:56,739
OTHER GUIDANCE OUT THERE FROM

4239
02:51:56,806 --> 02:52:01,010
OTHER EITHER GOVERNMENT BODIES

4240
02:52:01,077 --> 02:52:04,681
OR PROFESSIONAL ORGANIZATIONS.

4241
02:52:04,747 --> 02:52:06,549
AND I'M WONDERING, I THINK THESE

4242
02:52:06,616 --> 02:52:07,884
GUIDELINES ARE GREAT EXAMPLES OF

4243
02:52:07,950 --> 02:52:09,218
LIVING GUIDELINES THAT KEEP

4244
02:52:09,285 --> 02:52:12,622
GETTING ADAPTED AS THINGS

4245
02:52:12,689 --> 02:52:13,389
CHANGE.

4246
02:52:13,456 --> 02:52:14,357
HOW HAVE YOU DEALT WITH THAT?

4247
02:52:14,424 --> 02:52:15,591
IS THERE A WAY OF LINKING TO

4248
02:52:15,658 --> 02:52:16,993
OTHER GUIDANCE AND SAYING WE

4249
02:52:17,060 --> 02:52:18,027
DEFER TO THESE?

4250
02:52:18,094 --> 02:52:20,396
BUT THIS IS THEIR MAIN,

4251
02:52:20,463 --> 02:52:21,764
CURRENTLY WHAT THEY ARE

4252
02:52:21,831 --> 02:52:22,031
COVERING?

4253
02:52:22,098 --> 02:52:24,801
WHAT HAPPENS IF YOU FEEL

4254
02:52:24,867 --> 02:52:26,469
DIFFERENTLY THAN WHAT THESE

4255
02:52:26,536 --> 02:52:28,705
OTHER GUIDELINES MAY SAY?

4256
02:52:28,771 --> 02:52:33,342
HOW DO YOU COPE WITH THAT?

4257
02:52:33,409 --> 02:52:34,343
>> YOU DON'T COUNT ON YOUR

4258
02:52:34,410 --> 02:52:36,345
FRIENDS TO ASK YOU IMPOSSIBLE

4259
02:52:36,412 --> 02:52:36,746
QUESTIONS.

4260
02:52:36,813 --> 02:52:38,181
SO THANK YOU FOR THAT.

4261
02:52:38,247 --> 02:52:40,316
WE WORK VERY CAREFULLY, AS YOU

4262
02:52:40,383 --> 02:52:42,351
KNOW WITH JOHN BROOKS, AND JOHN

4263
02:52:42,418 --> 02:52:44,520
TRIES TO MAKE SURE THAT WE

4264
02:52:44,587 --> 02:52:48,191
COORDINATE CERTAINLY WITH CDC

4265
02:52:48,257 --> 02:52:48,558
GUIDELINES.

4266
02:52:48,624 --> 02:52:49,525
WHEN YOU SAY DO WE DEFER TO

4267
02:52:49,592 --> 02:52:50,493
OTHER GUIDELINES, IT DEPENDS ON

4268
02:52:50,560 --> 02:52:52,695
WHO IS PUTTING OUT THE GUIDELINE

4269
02:52:52,762 --> 02:52:53,830
AND WHAT IS THE CONTENT.

4270
02:52:53,896 --> 02:52:58,267
BUT SINCE CDC AND ITSA ARE

4271
02:52:58,334 --> 02:53:00,369
SPONSORING, WE TRY TO HARMONIZE

4272
02:53:00,436 --> 02:53:00,737
OUR GUIDELINES.

4273
02:53:00,803 --> 02:53:02,972
AS YOU KNOW, THERE ARE CERTAIN

4274
02:53:03,039 --> 02:53:06,309
AREAS LIKE TB WHERE WE CAN'T

4275
02:53:06,375 --> 02:53:12,081
COME TO CONSENSUS BUT WE TRY IN

4276
02:53:12,148 --> 02:53:12,782
A COLLEGIAL WAY TO STATE THAT

4277
02:53:12,849 --> 02:53:13,883
THERE ARE DIFFERENCES OF

4278
02:53:13,950 --> 02:53:14,517
OPINIONS.

4279
02:53:14,584 --> 02:53:16,419
THIS IS OUR OPINION.

4280
02:53:16,486 --> 02:53:18,821
BUT CDC HAS A DIFFERENT OPINION.

4281
02:53:18,888 --> 02:53:20,223
THERE ARE NOT VERY MANY

4282
02:53:20,289 --> 02:53:21,858
SITUATIONS LIKE THAT.

4283
02:53:21,924 --> 02:53:24,260
AND PARTICULARLY WITH STDs, WE

4284
02:53:24,327 --> 02:53:28,264
RECOGNIZE THAT CDC HAS

4285
02:53:28,331 --> 02:53:29,132
HISTORICALLY ALWAYS BEEN THE

4286
02:53:29,198 --> 02:53:29,832
SOURCE OF GUIDELINES.

4287
02:53:29,899 --> 02:53:31,501
SO I THINK THAT IS AN AREA WHERE

4288
02:53:31,567 --> 02:53:35,071
WE ARE UNLIKELY TO HAVE

4289
02:53:35,138 --> 02:53:35,638
SOMETHING OTHER THAN A LINK.

4290
02:53:35,705 --> 02:53:36,506
BUT WE ALSO FEEL THAT PEOPLE

4291
02:53:36,572 --> 02:53:37,840
DON'T LIKE TO JUMP AROUND TOO

4292
02:53:37,907 --> 02:53:40,209
MUCH FROM ONE GUIDELINE TO

4293
02:53:40,276 --> 02:53:40,443
ANOTHER.

4294
02:53:40,510 --> 02:53:43,679
SO WE WILL PUT SOMETHING IN

4295
02:53:43,746 --> 02:53:44,814
THERE BUT I THINK I'M TRYING TO

4296
02:53:44,881 --> 02:53:46,249
THINK IF THERE IS ANY SITUATION

4297
02:53:46,315 --> 02:53:51,020
WITH STDs WHERE WE DIFFER FROM

4298
02:53:51,087 --> 02:53:51,187
CDC.

4299
02:53:51,254 --> 02:53:53,055
BECAUSE THEN IT GETS CONFUSING

4300
02:53:53,122 --> 02:53:54,791
FOR A CLINICIAN.

4301
02:53:54,857 --> 02:53:55,925
BUT I THINK MOST OF THE TIME

4302
02:53:55,992 --> 02:53:58,995
WHERE WE DISAGREE EVEN ABOUT TB,

4303
02:53:59,061 --> 02:54:05,668
IS SOMETHING RELATIVELY ESOTE

4304
02:54:05,735 --> 02:54:05,935
ESOTERIC.

4305
02:54:06,002 --> 02:54:07,203
>> ONE THING THAT IS SOMEWHAT

4306
02:54:07,270 --> 02:54:09,972
SIMILAR THAT IS THAT ONE THING

4307
02:54:10,039 --> 02:54:11,908
WE OFTENTIMES FIND DIFFICULT IS

4308
02:54:11,974 --> 02:54:13,576
THAT DIFFERENT GUIDELINES ARE

4309
02:54:13,643 --> 02:54:15,478
UPDATED AT DIFFERENT TIMES.

4310
02:54:15,545 --> 02:54:17,814
WHEN NEW INFORMATION BECOMES

4311
02:54:17,880 --> 02:54:19,715
AVAILABLE, YOU MAY HAVE ONE

4312
02:54:19,782 --> 02:54:20,349
GUIDELINE THAT DECIDES THEY ARE

4313
02:54:20,416 --> 02:54:22,618
GOING TO HAVE TO UPDATE BUT THE

4314
02:54:22,685 --> 02:54:23,319
OTHER IS NOT READY YET.

4315
02:54:23,386 --> 02:54:26,455
SO YOU WILL HAVE INFORMATION

4316
02:54:26,522 --> 02:54:27,089
FROM DIFFERENT GUIDELINES WHERE

4317
02:54:27,156 --> 02:54:28,658
THE CLINICIANS WILL GO TO ONE

4318
02:54:28,724 --> 02:54:30,927
PLACE AND SAY, NOW WHICH ONE AM

4319
02:54:30,993 --> 02:54:33,262
I GOING TO FOLLOW BECAUSE OF

4320
02:54:33,329 --> 02:54:34,697
THAT?

4321
02:54:34,764 --> 02:54:37,266
AND THAT IS UNAVOIDABLE AND WE

4322
02:54:37,333 --> 02:54:39,101
TRY TO DO THE BEST WE CAN TO

4323
02:54:39,168 --> 02:54:41,804
MAKE SURE WE WILL HAVE SOME

4324
02:54:41,871 --> 02:54:43,306
HARMONIZING OF SOME THESE

4325
02:54:43,372 --> 02:54:47,210
GUIDELINES THAT IS NEVER EASY TO

4326
02:54:47,276 --> 02:54:47,677
DO.

4327
02:54:47,743 --> 02:54:49,879
>> AND ONE COMMENT TO THAT.

4328
02:54:49,946 --> 02:54:53,983
I SUSPECT THAT ALL THE GUIDELINE

4329
02:54:54,050 --> 02:54:54,550
PANELS ARE GRATEFUL WITH THE

4330
02:54:54,617 --> 02:55:00,223
FACT THAT OAR PROVIDES

4331
02:55:00,289 --> 02:55:01,891
ADMINISTERS THE UPDATES.

4332
02:55:01,958 --> 02:55:02,692
PROFESSIONAL SOCIETIES STRUGGLE

4333
02:55:02,758 --> 02:55:04,894
WITH THIS ISSUE OF UPDATING

4334
02:55:04,961 --> 02:55:06,062
GUIDELINES AND SOME OF THEM, THE

4335
02:55:06,128 --> 02:55:07,530
GUIDELINES ARE LUCKY IF THEY ARE

4336
02:55:07,597 --> 02:55:09,432
UPDATED EVERY TWO OR THREE YEARS

4337
02:55:09,498 --> 02:55:11,000
AND SOMETIMES YOU'RE LOOKING AT

4338
02:55:11,067 --> 02:55:12,168
MORE THAN FIVE YEARS.

4339
02:55:12,235 --> 02:55:13,703
SO ONE OF THE STRENGTHS OF THESE

4340
02:55:13,769 --> 02:55:16,372
GUIDELINES IS THAT WE CAN UPDATE

4341
02:55:16,439 --> 02:55:18,474
NEW INFORMATION AND ON THE RARE

4342
02:55:18,541 --> 02:55:19,876
OCCASIONS WHERE WE HAVE WRONG

4343
02:55:19,942 --> 02:55:21,444
INFORMATION, WE CAN CORRECT IT.

4344
02:55:21,510 --> 02:55:24,814
AND AGAIN, THAT'S BECAUSE WE

4345
02:55:24,881 --> 02:55:27,984
HAVE SUPPORT THAT VERY FEW OTHER

4346
02:55:28,050 --> 02:55:28,684
GUIDELINES PANELS HAVE.

4347
02:55:28,751 --> 02:55:30,019
AND I THINK WE HAVE TO RECOGNIZE

4348
02:55:30,086 --> 02:55:31,721
THAT IS AN IMPORTANT PART OF THE

4349
02:55:31,787 --> 02:55:34,790
INVESTMENT, WHICH OAR HAS BEEN

4350
02:55:34,857 --> 02:55:35,825
WILLING TO MAKE.

4351
02:55:35,892 --> 02:55:37,159
>> THANK YOU.

4352
02:55:37,226 --> 02:55:39,428
WE HAVE ONE FINAL QUESTION FROM

4353
02:55:39,495 --> 02:55:40,763
DR. ROHAN HAZRA.

4354
02:55:40,830 --> 02:55:41,163
>> THANK YOU.

4355
02:55:41,230 --> 02:55:43,065
THIS IS JUST A COMMENT TO

4356
02:55:43,132 --> 02:55:44,567
DR. JOHN SLEASMAN'S QUESTION

4357
02:55:44,634 --> 02:55:46,469
ABOUT HOW THE GUIDELINES ARE

4358
02:55:46,535 --> 02:55:46,736
USED.

4359
02:55:46,802 --> 02:55:48,738
AND WE HEARD ABOUT THE FACTS

4360
02:55:48,804 --> 02:55:54,110
COHORT EARLIER THAT FOLLOWS

4361
02:55:54,176 --> 02:55:55,511
ACQUIRED IN CHILDREN AND YOUNG

4362
02:55:55,578 --> 02:55:58,481
ADULTS AND PERINATALLY-ACQUIRED

4363
02:55:58,547 --> 02:55:58,748
INFECTION.

4364
02:55:58,814 --> 02:56:00,016
BUT ALSO PREGNANT PEOPLE WITH

4365
02:56:00,082 --> 02:56:04,086
HIV AND FOLLOWING THEIR HIV

4366
02:56:04,153 --> 02:56:06,022
EXPOSURE IN UNINFECTED INFANTS

4367
02:56:06,088 --> 02:56:07,290
AND CHILDREN.

4368
02:56:07,356 --> 02:56:10,226
AND AN ANALYSIS LOOKED AT HOW

4369
02:56:10,293 --> 02:56:12,895
WELL THE -- HOW THE TREATMENTS

4370
02:56:12,962 --> 02:56:15,398
DURING PREGNANCY AND THE FACTS

4371
02:56:15,464 --> 02:56:16,299
COHORDE ALIGNED OR DIDN'T ALIGN

4372
02:56:16,365 --> 02:56:17,033
WITH THE GUIDELINES.

4373
02:56:17,099 --> 02:56:19,001
AND AT THAT TIME, ABOUT A THIRD

4374
02:56:19,068 --> 02:56:22,471
OF WOMEN WERE ON REGIMENS OF

4375
02:56:22,538 --> 02:56:23,673
INSUFFICIENT DATA TO RECOMMEND

4376
02:56:23,739 --> 02:56:25,942
OR NOT RECOMMENDED AT ALL.

4377
02:56:26,008 --> 02:56:28,344
I THINK IN PREGNANCY, THAT IS

4378
02:56:28,411 --> 02:56:30,980
PROBABLY SHOWING YOU THE LACK OF

4379
02:56:31,047 --> 02:56:34,483
CONVINCING DATA TO PUT CERTAIN

4380
02:56:34,550 --> 02:56:35,217
REGIMENS IN THE GUIDELINES AND

4381
02:56:35,284 --> 02:56:36,819
THESE ARE CLINICIANS THAT ARE

4382
02:56:36,886 --> 02:56:38,621
OUT FRONT IN FRONT OF THE

4383
02:56:38,688 --> 02:56:38,921
GUIDELINES.

4384
02:56:38,988 --> 02:56:41,590
AND I THINK IT'S AN AREA THAT OF

4385
02:56:41,657 --> 02:56:44,460
COURSE USE OF MEDICATIONS IN

4386
02:56:44,527 --> 02:56:45,995
PREGNANCY WE'RE ALWAYS GOING TO

4387
02:56:46,062 --> 02:56:47,430
BE FIGHTING AGAINST.

4388
02:56:47,496 --> 02:56:48,864
THAT IS ONE ANALYSIS THAT

4389
02:56:48,931 --> 02:56:50,166
CLEARLY SHOWED MISALIGNMENT

4390
02:56:50,232 --> 02:56:51,467
BETWEEN WHAT IS BEING DONE IN

4391
02:56:51,534 --> 02:56:55,538
PRACTICE VERSUS WHAT IS BEING

4392
02:56:55,604 --> 02:56:55,838
RECOMMENDED.

4393
02:56:55,905 --> 02:56:56,372
>> THANK YOU.

4394
02:56:56,439 --> 02:56:56,806
THANK YOU VERY MUCH.

4395
02:56:56,872 --> 02:57:01,210
THANK YOU ALL FOR SUCH A LIVELY

4396
02:57:01,277 --> 02:57:01,544
DISCUSSION.

4397
02:57:01,610 --> 02:57:03,813
AS WE BEGIN TO CLOSE OUR MEETING

4398
02:57:03,879 --> 02:57:07,850
FOR TODAY, THIS PARTICULAR TIME

4399
02:57:07,917 --> 02:57:13,022
HAS BEEN ALLOTTED FOR PUBLIC

4400
02:57:13,089 --> 02:57:13,255
COMMENT.

4401
02:57:13,322 --> 02:57:13,889
DR. HOLTZ, HAVE WE RECEIVED ANY

4402
02:57:13,956 --> 02:57:16,459
COMMENTS FOR TODAY'S MEETING?

4403
02:57:16,525 --> 02:57:17,660
>> THANK YOU DR. TURNBULL.

4404
02:57:17,727 --> 02:57:20,196
WE DO NOT HAVE ANY PUBLIC

4405
02:57:20,262 --> 02:57:26,736
COMMENTS FOR TODAY'S MEETING.

4406
02:57:26,802 --> 02:57:28,037
>> OKAY.

4407
02:57:28,104 --> 02:57:29,071
>> NO COMMENTS?

4408
02:57:29,138 --> 02:57:31,741
I JUST WANT TO QUICKLY NOTE FOR

4409
02:57:31,807 --> 02:57:33,009
OARAC MEMBERS TO KINDLY RETURN

4410
02:57:33,075 --> 02:57:36,012
YOUR CONFLICT OF INTEREST FORMS

4411
02:57:36,078 --> 02:57:36,645
AT THE CLOSE OF THE MEETING AND

4412
02:57:36,712 --> 02:57:37,780
PLEASE NOTE THE NEXT PUBLIC

4413
02:57:37,847 --> 02:57:42,885
MEETING IS ON THURSDAY, JUNE 20,

4414
02:57:42,952 --> 02:57:43,085
2024.

4415
02:57:43,152 --> 02:57:44,787
BEFORE I TURN THE MEETING BACK

4416
02:57:44,854 --> 02:57:47,857
TO DR. TURNBULL, I'D LIKE TO

4417
02:57:47,923 --> 02:57:49,258
THANK THE MEMBERS FOR YOUR

4418
02:57:49,325 --> 02:57:53,195
PARTICIPATION IN OAR'S ADVISORY

4419
02:57:53,262 --> 02:57:53,429
COUNCIL.

4420
02:57:53,496 --> 02:57:55,231
THIS IS A TRANSFORMATIONAL TIME

4421
02:57:55,297 --> 02:57:57,466
AND EVERYONE'S INPUT IS VITAL.

4422
02:57:57,533 --> 02:57:59,368
I WOULD LIKE TO THANK DR. FINSY

4423
02:57:59,435 --> 02:58:02,004
FOR HER LEADERSHIP, CAPTAN

4424
02:58:02,071 --> 02:58:04,040
GLENNSHAW FOR HER WILLINGNESS TO

4425
02:58:04,106 --> 02:58:07,176
STEP IN AS ACT WELL DEPUTY GOING

4426
02:58:07,243 --> 02:58:08,644
FORWARD AS WELL AS THANK ALL MY

4427
02:58:08,711 --> 02:58:10,646
FELLOW COLLEAGUES IN OAR AND THE

4428
02:58:10,713 --> 02:58:12,381
NIH AIDS EXECUTIVE COMMITTEE FOR

4429
02:58:12,448 --> 02:58:14,650
THE PRIVILEGE OF WORKING WITH

4430
02:58:14,717 --> 02:58:16,018
THEM FOR THE PAST FIVE YEARS.

4431
02:58:16,085 --> 02:58:18,821
AND MOST PARTICULARLY, MY FELLOW

4432
02:58:18,888 --> 02:58:20,089
STAFF THAT SUPPORT THIS

4433
02:58:20,156 --> 02:58:21,524
COUNCIL'S REGULAR MEETINGS AND

4434
02:58:21,590 --> 02:58:23,793
THE IMPORTANT ADVISORY

4435
02:58:23,859 --> 02:58:25,461
RESPONSIBILITIES TO THE NIH OAR

4436
02:58:25,528 --> 02:58:28,130
CODIFIED IN THE CHARTER.

4437
02:58:28,197 --> 02:58:31,100
DR. TURNBULL, OVER TO YOU FOR

4438
02:58:31,167 --> 02:58:31,467
CLOSING REMARKS.

4439
02:58:31,534 --> 02:58:33,235
AND THANK YOU AGAIN.

4440
02:58:33,302 --> 02:58:36,839
>> THANK YOU ALSO, TIM.

4441
02:58:36,906 --> 02:58:38,407
THANK YOU EVERYONE FOR A

4442
02:58:38,474 --> 02:58:40,476
FANTASTIC AND INFORMATIVE

4443
02:58:40,543 --> 02:58:42,945
MEETING TODAY.

4444
02:58:43,012 --> 02:58:44,713
WE APPRECIATE YOUR CONTINUED

4445
02:58:44,780 --> 02:58:45,948
FEEDBACK AND THE GREAT DIVERSITY

4446
02:58:46,015 --> 02:58:49,151
OF PERSPECTIVES AND INPUT.

4447
02:58:49,218 --> 02:58:51,320
TODAY'S MEETING IS NOW

4448
02:58:51,387 --> 02:58:51,587
ADJOURNED.

4449
02:58:51,654
THANK YOU ALL.